data_6j2y_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6j2y _Structure_validation_residue.Date_analyzed 2019-03-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.433 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.488 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.433 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.462 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.432 HG22 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.535 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.432 ' CD1' HG22 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB1' ' ND2' ' A' ' 74' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' MET . . . . . 0.479 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? . . . . . 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.359 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.432 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.495 ' ND2' ' HB1' ' A' ' 39' ' ' ALA . 8.0 p30 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.422 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.473 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.431 ' O ' HG21 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.628 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.411 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.411 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.471 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.477 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.471 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.531 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.531 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.535 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.496 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . 0.42 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.628 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.436 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.444 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . 0.479 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.42 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.49 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.488 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.426 ' HA ' HD22 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 . . . . . 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.547 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD12 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.521 HD12 ' CE3' ' A' ' 132' ' ' TRP . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' HG21 ' A' ' 167' ' ' THR . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm . . . . . 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.425 -1.7 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.559 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.442 ' CE1' HD12 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.559 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.518 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.474 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.431 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.446 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.603 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.468 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.609 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.609 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.501 ' O ' HG22 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.645 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.474 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.465 HG21 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.645 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.547 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.452 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.468 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . 0.422 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.443 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.409 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.468 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.405 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.461 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.477 HD12 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.461 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.423 ' CG1' HG23 ' A' ' 75' ' ' VAL . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? . . . . . 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.439 -1.02 0 N-CA-C 111.102 0.038 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.578 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.423 HG23 ' CG1' ' A' ' 36' ' ' VAL . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.458 ' O ' HG22 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.516 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . 0.542 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.402 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.431 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' MET . . . . . 0.542 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.56 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.56 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.663 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.403 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . 0.44 ' HZ2' ' HB3' ' A' ' 146' ' ' LYS . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' MET . . . . . 0.475 ' SD ' HD12 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.516 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.475 HD12 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.439 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.663 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.468 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.431 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.409 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.443 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.405 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 12' ' ' GLU . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.408 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.405 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.409 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.453 HG21 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.415 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.453 ' CD2' HG21 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.409 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.441 -0.917 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.534 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.503 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.426 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.52 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.514 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.462 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.514 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.462 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.509 ' HA ' ' CE2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.613 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.536 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.568 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.568 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.52 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.413 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.613 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.421 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 . . . . . 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.456 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.421 ' CG1' ' HE2' ' A' ' 148' ' ' MET . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.417 HD11 ' CE3' ' A' ' 132' ' ' TRP . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt . . . . . 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.43 -1.426 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.621 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.404 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.49 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.472 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.489 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.471 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 105' ' ' VAL . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.471 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.479 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.464 ' HZ3' ' CD ' ' A' ' 125' ' ' GLU . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.479 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.464 ' CD ' ' HZ3' ' A' ' 121' ' ' LYS . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.582 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.582 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.628 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.52 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.52 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' MET . . . . . 0.421 ' HE2' ' CG1' ' A' ' 13' ' ' VAL . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.489 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.43 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.628 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.456 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.404 ' CE1' HG21 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.419 ' HA ' ' HB2' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' HG23 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.435 HG22 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.506 HD12 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG22 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.407 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt . . . . . 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 . . . . . 0 N--CA 1.421 -1.913 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.418 HG23 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.504 ' O ' HG21 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.435 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.504 HG21 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.463 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.422 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.466 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' THR . . . . . 0.422 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.466 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.506 ' CE3' HD12 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.606 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.606 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.457 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.564 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.564 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.435 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.476 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.404 HG21 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.458 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.436 HG13 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . 0.435 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.458 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.506 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.574 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.417 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 19' ' ' LYS . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' MET . . . . . 0.432 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.4 mtp . . . . . 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.381 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.591 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.45 HG23 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.591 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.595 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.406 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.406 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.44 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.478 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.433 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.605 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.444 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.685 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.685 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.405 ' CE ' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.412 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.412 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.595 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.444 ' CD1' HD12 ' A' ' 140' ' ' LEU . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . 0.495 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.432 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.48 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.605 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.42 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . 0.436 ' CZ ' HG13 ' A' ' 3' ' ' VAL . 13.9 m-85 . . . . . 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.485 HG13 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.466 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.469 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . 0.401 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.479 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.422 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' MET . . . . . 0.598 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp . . . . . 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.42 -1.961 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.487 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.487 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.448 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.625 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.484 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . 0.484 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.511 ' HG ' ' CD2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.461 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.429 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.511 ' CD2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.412 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.634 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.634 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.589 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.421 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.625 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . 0.421 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.417 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.598 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.481 ' CZ ' ' HB3' ' A' ' 76' ' ' SER . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.589 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.466 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.421 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . 0.485 ' CE2' HG13 ' A' ' 3' ' ' VAL . 18.1 m-85 . . . . . 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.448 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.501 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . 0.402 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.557 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.426 HD13 ' CE3' ' A' ' 132' ' ' TRP . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.557 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.423 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.416 HG22 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.427 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . . . . . . . . . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.514 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.531 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.531 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.526 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.478 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.428 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.411 ' HG ' ' C ' ' A' ' 156' ' ' PHE . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.407 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.423 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.407 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.526 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.419 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.501 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . 0.448 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . 0.529 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.437 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.439 HG21 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.439 ' CD2' HG21 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 N--CA 1.436 -1.128 0 CA-C-O 119.422 -0.323 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.419 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.419 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.473 ' CE1' HD12 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.422 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.504 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . 0.435 ' O ' HG22 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.441 ' HA ' ' NE ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.486 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.447 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.504 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.682 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE1' ' HG3' ' A' ' 86' ' ' MET . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.504 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.504 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.422 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.437 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . 0.529 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . 0.429 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.427 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.477 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' MET . . . . . 0.407 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.456 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.437 -1.099 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.453 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HB2' ' OE2' ' A' ' 93' ' ' GLU . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.403 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.502 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.448 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.401 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.401 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.632 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.515 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . 0.416 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.566 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.41 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.566 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.502 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.409 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.572 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.632 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.427 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 . . . . . 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.482 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.402 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.61 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.42 ' O ' HG12 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.421 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.477 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.431 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 72.3 mtm . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.427 -1.582 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.533 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.533 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.41 ' HG3' ' HE2' ' A' ' 144' ' ' MET . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.438 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.594 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.404 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.406 ' O ' HD12 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.41 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . 0.439 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.439 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.429 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.429 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.658 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.468 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.41 ' HE2' ' HG3' ' A' ' 86' ' ' MET . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' SER . . . . . 0.42 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HE3' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.402 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.594 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.468 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.477 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.658 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.482 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 . . . . . 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . 0.478 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.422 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.506 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.426 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.471 HD13 ' CE3' ' A' ' 132' ' ' TRP . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.426 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.474 ' CG1' HG22 ' A' ' 75' ' ' VAL . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' MET . . . . . 0.451 ' HE2' ' SG ' ' A' ' 165' ' ' CYS . 25.1 mmt . . . . . 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.424 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.474 HG22 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' THR . . . . . 0.539 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.446 ' HG3' ' HE3' ' A' ' 144' ' ' MET . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.565 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.565 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.452 ' O ' HG22 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.543 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.421 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.522 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.602 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.602 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.601 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.474 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.539 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.446 ' HE3' ' HG3' ' A' ' 86' ' ' MET . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.588 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.588 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.422 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.543 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.525 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.451 ' SG ' ' HE2' ' A' ' 40' ' ' MET . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.451 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.601 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.506 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.522 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.478 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.452 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.497 ' O ' HG12 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.479 HG21 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 129' ' ' PHE . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.479 ' CD1' HG21 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 19' ' ' LYS . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' SER . . . . . 0.413 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 58.6 mtt . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.423 -1.79 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.406 ' HB ' ' ND2' ' A' ' 73' ' ' ASN . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.434 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.544 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.427 ' O ' HG22 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . 0.44 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.542 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.44 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . 0.438 ' O ' HG21 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.438 HG21 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.597 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.597 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.674 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.52 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.52 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.544 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' MET . . . . . 0.422 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . 0.632 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . 0.632 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.422 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.542 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.458 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.447 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.447 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.674 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.458 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.402 ' HA ' HD22 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.412 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.411 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.445 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.442 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . 0.43 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.45 HD13 ' CE3' ' A' ' 132' ' ' TRP . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.43 ' CD1' HG23 ' A' ' 20' ' ' ILE . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp . . . . . 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.416 ' CZ ' HD13 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG22 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.508 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.612 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . 0.404 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.495 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.612 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.509 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.509 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.614 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.585 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.585 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . 0.407 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.411 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.508 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.407 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.614 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.445 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.581 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 . . . . . 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.418 HG23 HG11 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.418 HG11 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.521 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . 0.407 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.481 HD12 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm . . . . . 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 . . . . . 0 C--O 1.242 0.701 0 N-CA-C 110.46 -0.2 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.485 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . 0.428 ' N ' HD21 ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.485 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.45 ' O ' HG22 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.565 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . 0.418 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.449 ' O ' HD11 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.612 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' A' ' 110' ' ' LYS . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.469 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.612 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.416 ' OE1' ' HB3' ' A' ' 121' ' ' LYS . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.528 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.528 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.417 ' O ' HG22 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.556 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.483 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.527 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.404 ' CE1' ' HG2' ' A' ' 136' ' ' LYS . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.556 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . 0.434 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 . . . . . 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' MET . . . . . 0.504 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . 0.449 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.554 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.409 ' HB2' HG23 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.45 ' CG1' HG23 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp . . . . . 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.435 -1.216 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.558 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.45 HG23 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.558 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.449 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' MET . . . . . 0.412 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.418 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.421 ' O ' HG22 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.59 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.554 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.43 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.553 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.553 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' MET . . . . . 0.443 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.499 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 . . . . . 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.441 ' O ' HG11 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' THR . . . . . 0.434 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.545 HD11 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.434 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . 0.436 ' HB2' HG23 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.441 HG11 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.424 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . 0.403 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.458 ' O ' HG22 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.435 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . 0.401 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . 0.563 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . 0.408 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.563 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.652 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.652 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.461 ' O ' HG22 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CE3' HD11 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.521 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.435 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . 0.412 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.41 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.496 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.433 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.632 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . 0.632 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.456 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.466 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.431 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.2 mtp . . . . . 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . 0.479 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 . . . . . 0 CA--C 1.504 -0.79 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.459 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . 0.466 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.571 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.561 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.442 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.409 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.561 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . 0.409 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.554 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . 0.427 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG21 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . 0.57 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.458 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.562 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . 0.402 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.571 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . 0.41 ' O ' ' HB ' ' A' ' 167' ' ' THR . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' THR . . . . . 0.41 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.458 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.433 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 . . . . . 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.434 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' LEU . . . . . 0.451 HD12 ' CE3' ' A' ' 132' ' ' TRP . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt . . . . . 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.307 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASN . . . . . 0.467 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' PHE . . . . . 0.464 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' TYR . . . . . 0.411 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' PHE . . . . . 0.46 ' O ' HG22 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' TRP . . . . . 0.466 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' LEU . . . . . 0.427 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' ALA . . . . . 0.418 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' VAL . . . . . 0.459 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' LYS . . . . . 0.459 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' PHE . . . . . 0.427 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' GLU . . . . . 0.406 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' ALA . . . . . 0.504 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' PHE . . . . . 0.504 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' VAL . . . . . 0.427 ' O ' HG22 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' TRP . . . . . 0.502 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.563 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' LEU . . . . . 0.466 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' SER . . . . . 0.417 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' PHE . . . . . 0.411 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' VAL . . . . . 0.502 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.434 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 175' ' ' TYR . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.433 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.488 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.433 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.462 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.432 HG22 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.535 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.432 ' CD1' HG22 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.495 ' HB1' ' ND2' ' A' ' 74' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.479 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? -93.94 109.52 21.24 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.403 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 35.6 m -113.62 153.84 15.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.403 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.88 115.41 5.95 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.252 0.549 . . . . 0.0 111.186 175.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 76.5 t -100.72 138.92 23.38 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 C-N-CA 124.495 1.118 . . . . 0.0 108.921 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.0 80.65 1.8 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 175.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.58 -31.88 9.12 Favored Glycine 0 N--CA 1.434 -1.461 0 C-N-CA 121.514 -0.374 . . . . 0.0 113.01 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.09 -51.1 4.51 Favored Glycine 0 C--O 1.243 0.69 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.741 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 63.69 36.54 10.68 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.236 1.014 . . . . 0.0 110.273 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mm -79.09 -52.88 14.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.686 -177.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -98.27 -39.91 8.6 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.645 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.7 mt -121.79 118.41 55.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.112 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.67 108.55 3.06 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 172.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 75.7 m -78.78 107.63 11.63 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.345 0.593 . . . . 0.0 112.091 -175.15 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.12 -68.72 1.65 Allowed Glycine 0 N--CA 1.433 -1.517 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.681 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 35.7 t30 64.24 84.94 0.14 Allowed 'General case' 0 C--O 1.242 0.675 0 C-N-CA 124.379 1.072 . . . . 0.0 111.084 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -136.19 144.15 44.79 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.667 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -89.93 121.42 32.02 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.295 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -87.68 111.94 3.78 Favored Glycine 0 N--CA 1.436 -1.323 0 C-N-CA 120.83 -0.7 . . . . 0.0 111.506 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.13 -36.52 4.14 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -81.57 136.13 35.57 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 128.98 -71.86 0.49 Allowed Glycine 0 N--CA 1.432 -1.628 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -156.57 179.64 9.07 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -109.78 -66.11 1.09 Allowed 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 118.177 0.444 . . . . 0.0 112.145 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -103.48 6.79 37.74 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -174.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.87 68.46 0.44 Allowed Glycine 0 C--N 1.302 -1.314 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 171.959 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -138.8 23.74 2.63 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -172.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -77.95 111.08 13.44 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.158 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -135.62 123.49 22.6 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.889 -173.8 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -116.49 18.74 15.0 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.626 0.727 . . . . 0.0 109.302 176.177 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.1 p -104.85 92.59 4.32 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.752 -176.001 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mm-40 -66.69 119.77 12.35 Favored 'General case' 0 CA--C 1.501 -0.929 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.673 176.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.403 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 32.4 mmtp -97.01 120.77 37.99 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.06 165.72 26.6 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.432 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.495 ' ND2' ' HB1' ' A' ' 39' ' ' ALA . 8.0 p30 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.422 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.473 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.473 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.431 ' O ' HG21 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.628 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.431 HG21 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.411 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.411 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.471 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.477 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.409 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.471 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.477 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.531 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.531 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.535 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.496 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 0.42 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.496 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . 0.479 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.628 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.436 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.444 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.444 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . 0.479 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.429 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.42 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.49 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.488 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.426 ' HA ' HD22 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -87.94 119.98 28.83 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 6.9 tt -170.36 -61.74 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -90.79 89.02 7.3 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.433 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -85.36 -58.43 2.68 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -100.48 101.16 12.04 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.492 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -155.7 164.04 39.11 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -178.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -145.43 90.89 2.06 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 175.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -87.88 107.6 18.77 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.753 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 177.934 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.422 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.547 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD12 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.521 HD12 ' CE3' ' A' ' 132' ' ' TRP . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.465 ' O ' HG21 ' A' ' 167' ' ' THR . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm -85.25 108.89 17.98 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.7 m -117.12 152.44 18.93 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -76.75 117.99 18.93 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.192 0.52 . . . . 0.0 110.177 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.0 t -109.41 112.55 40.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.16 161.3 54.29 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.92 86.36 0.56 Allowed Glycine 0 C--N 1.316 -0.578 0 N-CA-C 111.958 -0.457 . . . . 0.0 111.958 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.65 -19.45 59.94 Favored Glycine 0 N--CA 1.446 -0.643 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -77.77 101.21 6.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.541 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.3 mt -67.87 111.59 2.5 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.372 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -94.02 148.51 22.09 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 176.201 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.4 mm -66.03 -31.46 53.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 CA-C-O 121.39 0.614 . . . . 0.0 110.377 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.14 -46.59 1.07 Allowed Glycine 0 CA--C 1.48 -2.119 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 -176.932 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 49.0 t 179.34 -36.65 0.01 OUTLIER 'General case' 0 C--O 1.21 -1.015 0 C-N-CA 124.917 1.287 . . . . 0.0 107.615 176.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.02 0.87 26.99 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -163.87 150.9 12.01 Favored 'General case' 0 C--O 1.246 0.884 0 C-N-CA 124.191 0.996 . . . . 0.0 108.566 -178.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.36 152.44 18.59 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -104.8 -37.07 7.18 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 121.202 0.525 . . . . 0.0 111.038 -178.018 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.75 144.59 3.95 Favored Glycine 0 N--CA 1.432 -1.572 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 68.47 -121.23 12.59 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -176.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -170.35 140.55 1.87 Allowed 'General case' 0 C--N 1.313 -0.981 0 C-N-CA 124.03 0.932 . . . . 0.0 108.973 177.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.12 -27.83 17.26 Favored Glycine 0 C--N 1.311 -0.85 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 173.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -169.93 165.41 9.59 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -68.54 -64.97 0.76 Allowed 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 119.062 0.846 . . . . 0.0 111.553 -177.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.81 -16.9 15.8 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 119.395 -0.922 . . . . 0.0 112.312 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 74.38 55.97 5.35 Favored Glycine 0 CA--C 1.498 -1.015 0 N-CA-C 107.357 -2.297 . . . . 0.0 107.357 -173.367 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -59.05 -66.95 0.42 Allowed 'General case' 0 C--O 1.239 0.525 0 CA-C-N 114.497 -0.852 . . . . 0.0 112.699 -172.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -148.49 157.02 43.2 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -164.29 166.13 21.17 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 104.886 -2.264 . . . . 0.0 104.886 177.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 58.51 74.79 0.42 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 124.825 1.25 . . . . 0.0 113.926 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 59.2 m -87.63 95.13 9.94 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 -87.07 147.88 25.5 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.068 -173.648 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 63.4 mttp -96.68 120.48 37.09 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 167.264 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -138.59 171.39 14.43 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -170.466 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.559 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.442 ' CE1' HD12 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.559 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.518 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.408 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.518 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.474 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.431 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.446 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.603 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.468 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.446 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.609 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.609 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.501 ' O ' HG22 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.645 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.474 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.465 HG21 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.645 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.547 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.452 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.468 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . 0.422 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -84.93 122.54 29.34 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.5 tp 75.86 -83.23 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.806 0 C-N-CA 125.299 1.44 . . . . 0.0 110.292 -174.619 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 179.35 162.52 0.86 Allowed 'General case' 0 C--O 1.245 0.846 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -80.7 77.73 7.51 Favored 'General case' 0 C--O 1.216 -0.68 0 CA-C-O 122.224 1.011 . . . . 0.0 111.067 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -146.09 -171.49 3.72 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 114.435 -1.257 . . . . 0.0 107.761 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . 0.254 79.5 m-70 83.36 171.06 0.09 Allowed 'General case' 0 C--O 1.242 0.674 0 C-N-CA 125.589 1.556 . . . . 0.0 110.476 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -88.22 90.49 8.41 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -171.396 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -108.8 133.77 52.4 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 170.344 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 21.3 p80 . . . . . 0 C--N 1.29 -1.984 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 -177.285 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.443 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.409 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.468 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.405 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.461 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.477 HD12 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.461 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.423 ' CG1' HG23 ' A' ' 75' ' ' VAL . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.578 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? -95.85 121.17 37.3 Favored 'General case' 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.2 m -113.52 153.77 15.02 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.894 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -82.34 114.87 21.1 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.019 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.1 t -85.62 113.8 24.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 177.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 104.27 74.39 0.98 Allowed Glycine 0 N--CA 1.433 -1.527 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 -176.514 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.88 119.26 2.21 Favored Glycine 0 N--CA 1.433 -1.505 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.35 77.64 1.1 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.0 150.4 35.85 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.249 0.62 . . . . 0.0 111.773 -178.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.7 mt -91.42 128.05 43.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.492 -177.254 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.3 t70 72.02 8.83 6.02 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 125.593 1.557 . . . . 0.0 112.397 173.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 49.8 mm -89.18 -19.86 7.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.899 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.06 171.94 38.23 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.042 -0.981 . . . . 0.0 111.625 176.869 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 63.8 m 76.27 -46.16 0.53 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.473 1.509 . . . . 0.0 111.443 -176.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 146.66 96.81 0.19 Allowed Glycine 0 N--CA 1.432 -1.607 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -129.17 97.93 4.75 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -153.01 -56.31 0.12 Allowed 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 69.79 -55.54 0.59 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 126.343 1.857 . . . . 0.0 113.885 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 156.61 -138.06 5.76 Favored Glycine 0 N--CA 1.42 -2.368 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.842 178.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 97.04 -70.0 0.79 Allowed Glycine 0 N--CA 1.439 -1.159 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 -177.864 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -143.6 112.06 6.39 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.7 119.19 2.8 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -178.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -155.21 176.61 12.33 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -68.17 -36.76 80.13 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 177.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -123.8 121.57 35.77 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.67 176.295 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -133.94 -158.84 8.73 Favored Glycine 0 N--CA 1.437 -1.255 0 C-N-CA 120.709 -0.757 . . . . 0.0 111.515 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.3 -18.87 29.17 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 122.555 0.342 . . . . 0.0 110.506 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -64.84 132.8 50.44 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.479 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -69.46 129.46 39.78 Favored 'General case' 0 C--O 1.249 1.062 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.449 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.68 102.32 0.07 Allowed 'General case' 0 N--CA 1.44 -0.973 0 O-C-N 124.902 1.376 . . . . 0.0 113.006 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.7 p -124.61 147.37 48.53 Favored 'General case' 0 N--CA 1.412 -2.335 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 176.471 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 49.6 mt-30 -70.76 106.23 3.49 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.189 0.519 . . . . 0.0 110.709 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.9 mttp -113.98 120.56 41.07 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 176.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -154.57 171.54 19.27 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 123.255 0.347 . . . . 0.0 111.102 178.4 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.578 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.423 HG23 ' CG1' ' A' ' 36' ' ' VAL . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.423 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.458 ' O ' HG22 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.516 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.542 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.402 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.411 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.427 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.431 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' MET . . . . . 0.542 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.427 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.56 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.56 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.663 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.403 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.595 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.595 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . 0.44 ' HZ2' ' HB3' ' A' ' 146' ' ' LYS . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' MET . . . . . 0.475 ' SD ' HD12 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.516 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.475 HD12 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.439 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.412 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.663 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.468 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.431 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.409 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.443 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -92.01 144.6 25.28 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.4 tp 73.59 161.22 0.24 Allowed 'General case' 0 CA--C 1.547 0.848 0 O-C-N 124.589 1.18 . . . . 0.0 110.919 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . 0.419 ' CD ' ' H ' ' A' ' 183' ' ' HIS . 0.9 OUTLIER -77.4 173.87 11.46 Favored 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 176.12 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.419 ' H ' ' CD ' ' A' ' 182' ' ' GLU . 12.5 p-80 -75.89 8.29 3.24 Favored 'General case' 0 CA--C 1.549 0.941 0 O-C-N 121.181 -0.95 . . . . 0.0 112.124 -177.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -79.59 68.51 5.65 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.272 1.034 . . . . 0.0 109.684 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.0 t-80 -138.03 -4.41 1.73 Allowed 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.583 175.126 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 56.86 166.73 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 126.873 2.069 . . . . 0.0 113.232 -175.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -103.85 94.86 5.65 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.186 -1.006 . . . . 0.0 111.642 178.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 . . . . . 0 C--N 1.299 -1.59 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 174.432 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.405 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 12' ' ' GLU . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.408 ' H ' ' CG ' ' A' ' 11' ' ' ASP . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.405 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.409 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.453 HG21 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.415 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.453 ' CD2' HG21 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.413 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.409 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp -87.4 115.17 24.63 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.472 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 32.9 m -110.62 162.63 8.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -82.5 114.57 21.01 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.008 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -98.75 -89.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.663 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 93.98 163.12 36.0 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 178.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.85 -21.42 2.5 Favored Glycine 0 C--N 1.31 -0.886 0 N-CA-C 111.804 -0.518 . . . . 0.0 111.804 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 166.26 33.57 Favored Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.383 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 58.63 98.72 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.495 1.518 . . . . 0.0 112.933 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 41.9 mm -81.65 114.94 23.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -105.37 61.8 0.68 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-O 121.044 0.45 . . . . 0.0 110.404 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 73.1 mt 69.42 109.22 0.04 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.485 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.837 -177.206 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.88 -23.16 74.21 Favored Glycine 0 CA--C 1.519 0.288 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.334 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 25.7 m -83.55 1.33 42.55 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 122.946 0.498 . . . . 0.0 110.817 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.44 -5.19 88.83 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-N 116.483 -0.326 . . . . 0.0 112.492 -178.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -101.02 97.51 8.06 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 176.885 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.58 -56.41 2.18 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 177.517 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -131.24 113.88 14.37 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.36 153.73 6.13 Favored Glycine 0 N--CA 1.426 -1.997 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.703 -178.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.33 -60.44 0.59 Allowed Glycine 0 N--CA 1.429 -1.774 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 71.76 -58.05 0.59 Allowed 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 126.326 1.85 . . . . 0.0 112.456 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 139.29 138.88 3.71 Favored Glycine 0 N--CA 1.427 -1.953 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.43 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -146.11 152.08 38.71 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -89.47 -28.12 19.89 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -174.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -126.87 -38.57 2.03 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.389 -171.895 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.57 -31.19 34.02 Favored Glycine 0 N--CA 1.441 -1.012 0 CA-C-N 116.379 -0.373 . . . . 0.0 112.984 -174.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.33 97.3 2.46 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.576 0.703 . . . . 0.0 111.994 -177.28 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.02 -49.3 14.29 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -163.83 166.61 21.74 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 178.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.36 23.03 0.41 Allowed 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.089 0.555 . . . . 0.0 111.854 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.1 m -62.69 -64.49 0.91 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.618 1.167 . . . . 0.0 110.756 -178.08 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 97.9 mt-30 -100.62 141.98 32.73 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.381 -176.743 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 9.3 mtmp? -125.71 119.9 29.22 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 168.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 161.16 40.92 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -175.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.534 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.503 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.426 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.52 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.514 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.462 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.514 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.462 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.509 ' HA ' ' CE2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.509 ' CE2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.613 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.536 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.536 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.568 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.568 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.52 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.413 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.613 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.421 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.73 116.82 32.72 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 7.2 mp -90.11 87.6 6.94 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 170.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.85 147.42 48.86 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.181 -176.432 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.3 t60 70.34 103.52 0.06 Allowed 'General case' 0 CA--C 1.515 -0.393 0 C-N-CA 125.343 1.457 . . . . 0.0 108.107 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 34.5 p-80 -41.57 116.55 0.79 Allowed 'General case' 0 N--CA 1.475 0.81 0 O-C-N 124.691 1.245 . . . . 0.0 113.25 -176.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -86.6 94.99 9.61 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.91 97.6 6.33 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -101.03 137.53 39.27 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.288 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 . . . . . 0 N--CA 1.422 -1.843 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.985 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.456 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.421 ' CG1' ' HE2' ' A' ' 148' ' ' MET . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.417 HD11 ' CE3' ' A' ' 132' ' ' TRP . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.43 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.621 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt -88.24 112.54 22.9 Favored 'General case' 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 31.5 m -118.21 162.79 15.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.06 178.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -93.26 121.97 35.18 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.405 ' HB ' ' O ' ' A' ' 68' ' ' ALA . 61.7 t -70.78 -33.94 54.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.687 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.66 153.17 24.86 Favored Glycine 0 N--CA 1.424 -2.104 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.08 -39.87 0.67 Allowed Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.788 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.96 96.46 1.23 Allowed Glycine 0 N--CA 1.44 -1.099 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -45.89 104.81 0.05 Allowed 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 125.725 1.61 . . . . 0.0 112.717 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.3 mt 67.45 -51.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 125.566 1.546 . . . . 0.0 115.092 173.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -50.0 -45.61 51.95 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.151 1.38 . . . . 0.0 112.34 -177.169 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.6 mt -79.31 98.89 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.57 57.06 4.91 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 44.1 t -123.88 96.44 4.95 Favored 'General case' 0 N--CA 1.415 -2.221 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.67 -9.86 12.09 Favored Glycine 0 N--CA 1.435 -1.396 0 N-CA-C 109.851 -1.3 . . . . 0.0 109.851 174.033 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -94.29 112.2 23.98 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -130.76 157.94 41.48 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.957 -176.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -92.57 88.7 6.42 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 176.556 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.17 -53.55 4.78 Favored Glycine 0 CA--C 1.523 0.557 0 CA-C-N 116.059 -0.519 . . . . 0.0 112.365 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -175.53 118.98 0.69 Allowed Glycine 0 N--CA 1.428 -1.885 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -156.88 178.03 10.83 Favored 'General case' 0 C--O 1.245 0.828 0 N-CA-C 109.479 -0.564 . . . . 0.0 109.479 -178.516 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 127.57 163.29 11.36 Favored Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -178.715 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -72.44 -49.85 30.48 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 118.1 0.95 . . . . 0.0 108.867 -177.466 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -109.25 20.37 18.38 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 172.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 73.71 144.5 0.07 Allowed 'General case' 0 C--O 1.24 0.592 0 C-N-CA 125.549 1.54 . . . . 0.0 110.839 -169.8 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.24 63.04 0.39 Allowed Glycine 0 N--CA 1.434 -1.498 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.932 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.1 -38.72 63.76 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 178.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -135.53 150.45 49.75 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -90.9 81.16 5.72 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 118.9 -1.12 . . . . 0.0 110.912 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.405 ' O ' ' HB ' ' A' ' 43' ' ' VAL . . . -148.13 109.81 4.45 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 176.115 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.7 m -78.43 48.15 0.75 Allowed 'General case' 0 C--N 1.289 -2.065 0 CA-C-O 121.937 0.875 . . . . 0.0 111.014 -175.794 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -99.94 130.2 46.09 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -101.56 119.72 39.2 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 171.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.67 171.66 19.91 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -174.728 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.621 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.404 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.49 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.472 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.489 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.471 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . 0.404 ' O ' HG23 ' A' ' 105' ' ' VAL . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.471 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.404 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.479 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.464 ' HZ3' ' CD ' ' A' ' 125' ' ' GLU . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.479 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.464 ' CD ' ' HZ3' ' A' ' 121' ' ' LYS . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.582 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.582 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.628 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.41 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.52 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.52 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.472 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' MET . . . . . 0.421 ' HE2' ' CG1' ' A' ' 13' ' ' VAL . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.489 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.441 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.43 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.628 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.484 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.456 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -121.28 161.45 21.98 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.489 ' H ' HD23 ' A' ' 181' ' ' LEU . 1.3 pt? -97.07 112.89 24.46 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 174.082 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.51 -3.84 17.76 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -166.336 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.462 ' CE1' ' HB2' ' A' ' 186' ' ' HIS . 4.7 t-160 -80.89 -40.53 24.54 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.616 -1.234 . . . . 0.0 112.533 -169.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 53.7 59.8 4.08 Favored 'General case' 0 CA--C 1.549 0.926 0 O-C-N 124.05 0.844 . . . . 0.0 111.034 177.302 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 75.77 177.06 0.2 Allowed 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.543 1.537 . . . . 0.0 113.028 -178.106 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . 0.462 ' HB2' ' CE1' ' A' ' 183' ' ' HIS . 10.1 t-80 -165.78 101.79 0.68 Allowed 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 176.135 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -79.33 93.26 5.27 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.334 0.587 . . . . 0.0 110.637 -177.807 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 177.668 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.404 ' CE1' HG21 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.419 ' HA ' ' HB2' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.418 ' HB3' HG23 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.435 HG22 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.407 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.506 HD12 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG22 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.407 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt -85.2 135.44 33.95 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.6 m -122.4 141.08 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.312 0 CA-C-N 114.088 -1.414 . . . . 0.0 108.474 171.899 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -80.31 118.43 21.96 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 123.195 0.598 . . . . 0.0 109.741 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.47 129.91 68.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.24 93.46 1.77 Allowed Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 178.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -84.61 69.12 3.38 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 121.73 -0.271 . . . . 0.0 113.03 -177.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.27 99.69 2.23 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 174.177 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 70.96 161.75 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 125.993 1.717 . . . . 0.0 110.359 -175.123 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mt -77.3 -40.8 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 170.147 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -155.79 -59.7 0.1 Allowed 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.393 -2.077 . . . . 0.0 105.393 170.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 55.7 mt -139.6 94.35 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.869 0 N-CA-C 105.756 -1.942 . . . . 0.0 105.756 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 68.79 -132.03 26.36 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -172.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.8 t -104.55 -45.84 4.52 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.465 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.37 -76.51 0.22 Allowed Glycine 0 N--CA 1.437 -1.27 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.695 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -78.99 152.65 30.86 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 123.074 0.55 . . . . 0.0 110.018 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.2 -35.68 79.62 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.261 0.625 . . . . 0.0 112.543 -178.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -104.83 6.99 34.32 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.414 0.626 . . . . 0.0 109.957 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -94.07 138.58 14.12 Favored Glycine 0 N--CA 1.421 -2.327 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.072 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 151.7 -66.44 0.34 Allowed Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 57.93 -87.94 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.02 1.328 . . . . 0.0 113.11 178.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -109.86 1.41 30.26 Favored Glycine 0 C--O 1.224 -0.48 0 N-CA-C 112.086 -0.406 . . . . 0.0 112.086 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -117.92 16.23 14.28 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 177.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -78.08 -54.61 6.07 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.076 -173.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -83.77 101.79 11.85 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-O 121.535 0.683 . . . . 0.0 111.141 -174.027 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -172.6 57.99 0.16 Allowed Glycine 0 N--CA 1.418 -2.557 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -64.39 -53.29 50.88 Favored 'General case' 0 C--O 1.217 -0.637 0 O-C-N 124.112 0.537 . . . . 0.0 111.336 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -158.9 95.89 1.32 Allowed 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 121.092 0.472 . . . . 0.0 111.578 176.222 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -144.77 -177.95 5.77 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 177.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -136.3 44.43 2.42 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.577 0.703 . . . . 0.0 109.686 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.0 m -78.9 -3.59 45.5 Favored 'General case' 0 CA--C 1.558 1.283 0 CA-C-O 122.112 0.958 . . . . 0.0 109.189 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -97.98 111.64 23.88 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.625 -173.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -127.01 119.97 27.91 Favored 'General case' 0 C--N 1.281 -2.379 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 169.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -129.0 165.83 20.37 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -170.215 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.435 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.418 HG23 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.458 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.504 ' O ' HG21 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.435 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.504 HG21 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.476 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.476 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.463 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.463 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.458 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.422 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.466 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' THR . . . . . 0.422 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.466 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.506 ' CE3' HD12 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.606 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.606 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.457 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.564 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.564 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.419 ' HB2' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.435 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.476 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.404 HG21 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -86.96 102.45 14.39 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 80.6 mt -83.82 113.85 21.22 Favored 'General case' 0 N--CA 1.412 -2.361 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.701 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -59.27 -41.67 89.43 Favored 'General case' 0 C--N 1.316 -0.875 0 O-C-N 124.476 1.11 . . . . 0.0 108.41 178.545 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -118.32 102.08 8.68 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 114.999 -1.0 . . . . 0.0 108.956 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -81.49 79.9 7.98 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 174.309 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -106.0 117.38 33.89 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -177.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -80.99 103.99 11.19 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.538 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -90.7 88.52 7.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.262 -2.495 . . . . 0.0 104.262 169.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 . . . . . 0 C--N 1.31 -1.119 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 -171.162 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.458 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.436 HG13 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . 0.435 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.42 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.458 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.506 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.417 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.574 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.574 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.417 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.506 HG13 ' O ' ' A' ' 19' ' ' LYS . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.432 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.4 mtp -88.52 109.31 19.95 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.432 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 33.7 m -110.59 157.39 11.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 115.342 -0.845 . . . . 0.0 108.888 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -71.07 114.24 8.93 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.156 0.503 . . . . 0.0 110.319 176.373 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.29 -42.37 78.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 CA-C-N 114.497 -1.229 . . . . 0.0 110.322 -179.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.02 -78.19 1.16 Allowed Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -160.96 144.2 9.66 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.87 -28.45 0.47 Allowed Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.436 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.74 60.53 4.71 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.1 mt -146.2 101.4 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 174.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.1 t70 67.06 117.36 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 124.605 1.162 . . . . 0.0 113.423 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt 72.0 -38.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 125.026 1.33 . . . . 0.0 112.899 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.18 -9.57 64.02 Favored Glycine 0 CA--C 1.527 0.785 0 CA-C-N 116.421 -0.354 . . . . 0.0 113.839 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.2 m -92.39 -5.38 52.19 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 117.537 0.669 . . . . 0.0 110.89 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.82 96.0 1.93 Allowed Glycine 0 N--CA 1.433 -1.518 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 177.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -81.69 80.09 8.1 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.538 0.685 . . . . 0.0 109.4 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.28 23.99 7.49 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.204 -178.065 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -101.89 -62.25 1.28 Allowed 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 131.04 -71.96 0.49 Allowed Glycine 0 N--CA 1.428 -1.898 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 164.79 96.39 0.11 Allowed Glycine 0 N--CA 1.431 -1.687 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.35 94.41 4.85 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 122.492 0.317 . . . . 0.0 111.59 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 140.74 -123.33 2.33 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 121.045 -0.598 . . . . 0.0 111.854 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -160.78 -65.34 0.06 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -86.38 -48.25 8.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 122.227 1.013 . . . . 0.0 108.304 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.34 140.18 36.96 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 177.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -130.68 28.16 3.79 Favored Glycine 0 C--O 1.247 0.932 0 C-N-CA 119.636 -1.269 . . . . 0.0 114.936 -169.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -155.18 -152.26 0.39 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.339 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -127.58 171.74 11.37 Favored 'General case' 0 C--O 1.257 1.493 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -83.2 82.52 8.22 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.296 1.046 . . . . 0.0 109.916 -179.067 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 -47.48 0.07 Allowed 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 t -143.79 103.73 4.09 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.202 176.033 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 23.1 mm-40 -84.98 112.16 20.34 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.609 177.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.432 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 55.6 mttm -97.38 122.31 40.28 Favored 'General case' 0 C--N 1.292 -1.926 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.806 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.64 162.24 36.43 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.591 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.45 HG23 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.591 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.595 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.406 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.406 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.433 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.44 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.44 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.478 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.433 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.478 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.417 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.444 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.605 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.444 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.685 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.685 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.405 ' CE ' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.412 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.412 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.595 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.444 ' CD1' HD12 ' A' ' 140' ' ' LEU . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.495 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . 0.495 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.432 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.48 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.605 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.42 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . 0.435 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . 0.436 ' CZ ' HG13 ' A' ' 3' ' ' VAL . 13.9 m-85 -73.36 103.07 3.91 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -122.13 -47.23 2.16 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.46 -40.25 26.62 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.187 176.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -80.17 118.48 21.9 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.146 176.765 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 90.3 m-70 -115.48 130.49 56.9 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.898 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 19.3 m-70 -97.41 158.43 15.48 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.56 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 64.2 t60 -74.58 112.55 10.88 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.24 0.543 . . . . 0.0 110.259 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -88.48 120.94 30.33 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 . . . . . 0 N--CA 1.485 1.323 0 C-N-CA 124.718 1.207 . . . . 0.0 110.246 -175.459 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.485 HG13 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.466 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.438 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.469 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.438 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . 0.401 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.479 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.422 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.598 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp -85.64 109.4 18.54 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.64 145.12 17.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.77 125.48 34.9 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.594 0.711 . . . . 0.0 111.627 -177.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.5 t -96.96 98.41 7.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.578 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.77 130.03 12.59 Favored Glycine 0 N--CA 1.438 -1.214 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.04 -146.05 40.65 Favored Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -176.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.63 -53.53 4.83 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 117.065 0.432 . . . . 0.0 113.196 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.14 71.41 0.58 Allowed 'General case' 0 CA--C 1.497 -1.075 0 C-N-CA 124.395 1.078 . . . . 0.0 111.953 -176.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -108.61 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.232 -178.525 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.4 t70 63.13 133.71 0.01 OUTLIER 'General case' 0 C--O 1.251 1.154 0 C-N-CA 124.834 1.254 . . . . 0.0 111.671 -174.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 38.7 mm -80.57 75.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 122.155 0.979 . . . . 0.0 109.898 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -158.55 20.12 0.32 Allowed Glycine 0 C--N 1.3 -1.437 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 175.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 81.3 m -87.11 112.66 22.14 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.59 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.13 -63.74 0.62 Allowed Glycine 0 N--CA 1.433 -1.532 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 178.624 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -92.76 89.25 6.55 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -90.85 109.86 21.08 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -74.74 -45.91 40.93 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.606 -178.054 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.52 88.76 1.34 Allowed Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.812 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -83.13 154.25 31.6 Favored Glycine 0 N--CA 1.436 -1.364 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 178.235 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.19 127.76 33.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.98 -71.74 2.35 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -149.47 137.59 20.57 Favored 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 122.707 0.403 . . . . 0.0 110.173 -177.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -81.68 77.73 8.49 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 123.174 0.59 . . . . 0.0 109.618 175.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -33.27 107.17 0.04 OUTLIER 'General case' 0 C--O 1.25 1.127 0 C-N-CA 125.32 1.448 . . . . 0.0 114.091 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -120.54 -98.22 1.65 Allowed Glycine 0 N--CA 1.432 -1.629 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.678 179.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -163.48 177.91 8.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.164 0.507 . . . . 0.0 111.319 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -139.75 156.03 47.0 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 105.408 -2.071 . . . . 0.0 105.408 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.9 t70 76.45 -26.37 0.19 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 124.667 1.187 . . . . 0.0 112.829 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 64.47 85.49 0.14 Allowed 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 124.938 1.295 . . . . 0.0 110.668 179.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' THR . . . . . 0.437 ' O ' ' HG3' ' A' ' 71' ' ' LYS . 14.2 t -120.3 23.81 10.72 Favored 'General case' 0 C--N 1.297 -1.706 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.681 -175.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -45.4 117.29 1.37 Allowed 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 126.432 1.893 . . . . 0.0 111.519 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.437 ' HG3' ' O ' ' A' ' 69' ' ' THR . 62.7 mttp -112.52 120.99 43.52 Favored 'General case' 0 C--N 1.294 -1.839 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.901 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.4 165.72 24.52 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.487 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.487 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.448 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.625 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.484 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . 0.484 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.511 ' HG ' ' CD2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.461 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.448 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.461 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.429 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.511 ' CD2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.412 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.429 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.634 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.634 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.589 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.421 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.625 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . 0.421 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.417 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.598 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.481 ' CZ ' ' HB3' ' A' ' 76' ' ' SER . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.589 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.466 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.421 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . 0.485 ' CE2' HG13 ' A' ' 3' ' ' VAL . 18.1 m-85 -86.94 126.85 34.97 Favored 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -87.48 178.28 6.85 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.788 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -94.6 146.5 24.09 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.657 -0.702 . . . . 0.0 111.848 -177.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -119.56 120.54 37.04 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.586 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -102.57 -39.45 7.08 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.314 -175.95 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -72.43 -32.97 66.76 Favored 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 11.5 t60 -91.73 110.76 22.1 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 171.576 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -88.0 -178.29 5.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.196 -173.516 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 46.6 m80 . . . . . 0 C--N 1.306 -1.298 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 177.467 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.448 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.501 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . 0.402 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.557 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.426 HD13 ' CE3' ' A' ' 132' ' ' TRP . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.557 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.423 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm -114.16 146.95 39.64 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 24.7 m -132.63 167.68 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.336 175.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -75.59 118.35 18.35 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.406 0.622 . . . . 0.0 110.761 -179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 68.3 t -100.6 132.05 47.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -116.57 -133.1 5.07 Favored Glycine 0 N--CA 1.431 -1.635 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.05 -60.98 1.05 Allowed Glycine 0 N--CA 1.434 -1.476 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.36 -35.83 2.84 Favored Glycine 0 N--CA 1.438 -1.192 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 70.49 19.51 6.25 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 125.034 1.334 . . . . 0.0 111.241 176.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 62.7 mt -101.88 106.0 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.911 -177.191 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.6 t70 70.86 -46.65 0.64 Allowed 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 125.744 1.617 . . . . 0.0 115.039 174.396 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt -67.35 121.47 16.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 123.044 0.538 . . . . 0.0 110.157 -178.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.27 -162.36 18.67 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.8 m 71.41 -30.73 0.21 Allowed 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 125.999 1.72 . . . . 0.0 113.576 178.024 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.3 -14.25 82.74 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 176.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -78.87 132.84 36.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 72.07 -44.73 0.6 Allowed 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.436 1.495 . . . . 0.0 113.922 177.098 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -82.91 102.53 11.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.075 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -125.79 91.21 0.39 Allowed Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 155.73 66.29 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.211 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -119.11 19.22 12.97 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 121.831 0.824 . . . . 0.0 109.452 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.38 -70.6 0.21 Allowed Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 106.698 -2.561 . . . . 0.0 106.698 -174.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 58.45 26.57 14.36 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.717 1.207 . . . . 0.0 111.762 172.536 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -71.31 -33.56 69.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.04 -176.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -96.54 1.71 51.65 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.71 -178.955 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -107.46 -64.09 0.59 Allowed Glycine 0 N--CA 1.428 -1.873 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.865 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.08 90.39 3.32 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.06 0.457 . . . . 0.0 111.46 -175.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -99.22 -14.28 19.36 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 173.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -140.97 128.75 21.65 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 176.406 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -76.48 110.19 10.82 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 35.2 m 72.17 91.62 0.09 Allowed 'General case' 0 C--O 1.24 0.559 0 C-N-CA 124.726 1.21 . . . . 0.0 109.612 -174.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.9 mp0 -75.74 150.38 37.83 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.046 -177.505 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.478 ' HD2' ' N ' ' A' ' 71' ' ' LYS . 6.0 mptt -116.57 121.46 41.82 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -128.19 172.73 10.74 Favored 'General case' 0 C--N 1.281 -2.413 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.416 HG22 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.427 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . . . . . . . . . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.427 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.514 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.419 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.531 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.531 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.526 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.445 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.478 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.478 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . . . . . . . . . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.428 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.411 ' HG ' ' C ' ' A' ' 156' ' ' PHE . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.407 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.423 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.407 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.526 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.419 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.501 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.448 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -113.13 102.81 10.73 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 1.5 pt? -100.44 -17.26 17.26 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 169.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 68.27 -7.81 0.64 Allowed 'General case' 0 C--N 1.351 0.652 0 C-N-CA 127.308 2.243 . . . . 0.0 113.596 176.947 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 61.65 59.03 1.89 Allowed 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 123.848 0.859 . . . . 0.0 110.213 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -79.99 94.68 5.96 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.392 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.8 t60 -134.26 84.5 2.12 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -83.45 110.84 18.51 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.756 -0.657 . . . . 0.0 112.208 -175.571 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . 0.421 ' O ' ' HB2' ' A' ' 188' ' ' HIS . 61.4 t60 -109.39 90.31 3.26 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 176.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . 0.421 ' HB2' ' O ' ' A' ' 187' ' ' HIS . 6.0 t60 . . . . . 0 N--CA 1.484 1.239 0 C-N-CA 126.545 1.938 . . . . 0.0 106.029 174.515 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . 0.529 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.437 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.473 HD12 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.439 HG21 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.422 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.439 ' CD2' HG21 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm -93.67 128.86 40.07 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.9 m -122.54 167.82 15.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.25 113.96 4.97 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.903 0.752 . . . . 0.0 110.633 173.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.0 t -109.01 97.44 5.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 174.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -104.1 169.35 17.6 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 115.119 -0.946 . . . . 0.0 113.042 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.93 63.78 3.78 Favored Glycine 0 N--CA 1.434 -1.442 0 CA-C-N 115.42 -0.39 . . . . 0.0 112.488 176.924 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.05 107.36 3.15 Favored Glycine 0 N--CA 1.421 -2.312 0 N-CA-C 107.94 -2.064 . . . . 0.0 107.94 176.016 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -60.58 126.12 26.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -175.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.4 mm -88.81 74.69 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 105.147 -2.168 . . . . 0.0 105.147 170.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.0 -40.03 10.32 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 113.333 -1.758 . . . . 0.0 109.262 -176.047 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt 61.37 82.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.772 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.63 129.07 4.87 Favored Glycine 0 CA--C 1.488 -1.628 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 72.5 m 60.32 21.79 11.28 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.933 0.893 . . . . 0.0 111.074 -176.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.89 157.4 25.88 Favored Glycine 0 N--CA 1.428 -1.886 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 71.83 6.35 5.61 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 125.464 1.506 . . . . 0.0 112.994 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.97 -49.95 5.32 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 175.115 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -126.44 -63.46 1.09 Allowed 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.946 -1.025 . . . . 0.0 108.236 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.0 -162.84 38.69 Favored Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.522 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -85.42 174.74 49.0 Favored Glycine 0 C--N 1.311 -0.813 0 C-N-CA 121.671 -0.299 . . . . 0.0 113.008 -176.195 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -137.55 -178.76 5.37 Favored 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.23 -110.02 3.39 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -164.47 100.68 0.82 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -87.21 -31.3 20.39 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.051 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -170.57 74.58 0.07 Allowed 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.49 -76.36 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.778 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 175.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.57 93.21 4.18 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.44 0.638 . . . . 0.0 109.403 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -88.2 115.94 26.04 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.685 -179.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -132.88 141.89 48.64 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.239 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.37 30.18 0.69 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.562 0.539 . . . . 0.0 109.939 -177.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 31.1 m -69.5 -35.8 75.87 Favored 'General case' 0 CA--C 1.558 1.288 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -176.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -100.32 119.69 38.8 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 122.021 -0.424 . . . . 0.0 110.035 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -105.54 120.39 41.51 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 171.313 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -154.6 171.56 19.26 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.21 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.419 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.419 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.473 ' CE1' HD12 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.422 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.504 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . 0.435 ' O ' HG22 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.441 ' HA ' ' NE ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.435 HG22 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.486 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.486 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.447 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.437 ' O ' HG22 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.447 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.504 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.682 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.682 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE1' ' HG3' ' A' ' 86' ' ' MET . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.504 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.504 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.422 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.437 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . 0.529 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 -68.41 117.64 10.45 Favored 'General case' 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 56.1 tp 71.11 -73.63 0.1 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 126.029 1.732 . . . . 0.0 111.127 -177.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 52.09 74.61 0.26 Allowed 'General case' 0 C--O 1.24 0.577 0 CA-C-O 122.56 1.171 . . . . 0.0 110.942 -175.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.6 t60 -149.41 101.5 3.11 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.8 t60 67.15 19.41 10.39 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.41 1.084 . . . . 0.0 108.553 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 63.83 -78.26 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.173 1.389 . . . . 0.0 109.887 -172.028 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 1.9 m80 166.16 -79.13 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 128.238 2.615 . . . . 0.0 107.718 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -107.4 90.94 3.45 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 . . . . . 0 C--O 1.246 0.899 0 C-N-CA 124.743 1.217 . . . . 0.0 110.497 -176.718 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.429 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.427 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.429 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.477 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.406 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' MET . . . . . 0.407 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . 0.443 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.406 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.456 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt -79.14 140.81 37.69 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.8 m -136.28 159.81 38.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 172.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.78 140.51 36.87 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.4 t -63.01 -43.72 99.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.135 0.493 . . . . 0.0 109.779 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 111.84 158.87 14.79 Favored Glycine 0 N--CA 1.426 -1.975 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.377 177.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.9 -170.97 23.27 Favored Glycine 0 N--CA 1.424 -2.148 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -177.86 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 65.07 -155.18 49.21 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.494 ' HB2' ' CD1' ' A' ' 50' ' ' ILE . 9.2 m-20 -119.73 -28.55 5.22 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 176.503 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 71.6 mt 73.76 -29.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.214 0 C-N-CA 124.74 1.216 . . . . 0.0 112.742 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . 0.403 ' H ' ' C ' ' A' ' 47' ' ' ASP . 38.9 m-20 -71.66 -3.46 21.79 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 123.911 0.884 . . . . 0.0 112.707 -178.876 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.494 ' CD1' ' HB2' ' A' ' 47' ' ' ASP . 2.6 mp -78.66 115.14 20.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.57 -129.31 9.21 Favored Glycine 0 N--CA 1.422 -2.288 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.444 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.0 m -126.98 132.54 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -176.89 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -71.08 -15.06 74.14 Favored Glycine 0 C--O 1.222 -0.619 0 N-CA-C 114.499 0.56 . . . . 0.0 114.499 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 46.0 m-80 -100.5 -0.22 38.31 Favored 'General case' 0 C--N 1.311 -1.099 0 O-C-N 122.012 -0.699 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.51 125.65 42.32 Favored 'General case' 0 N--CA 1.434 -1.269 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -138.71 178.49 7.11 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.74 -117.44 1.07 Allowed Glycine 0 N--CA 1.426 -2.01 0 O-C-N 123.888 0.743 . . . . 0.0 112.498 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.81 22.95 57.07 Favored Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -174.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 40.17 0.14 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 148.42 -76.19 0.26 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -176.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -87.76 88.24 7.6 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -86.85 -58.81 2.46 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.724 -1.125 . . . . 0.0 108.5 -176.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -103.48 35.5 2.57 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.618 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -162.5 -171.81 29.14 Favored Glycine 0 N--CA 1.43 -1.761 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -171.8 -172.35 1.0 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -178.869 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -100.32 3.82 43.63 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.595 1.188 . . . . 0.0 109.92 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 68' ' ' ALA . 21.4 t70 -141.06 -161.16 1.17 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.462 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.423 ' H ' ' CG ' ' A' ' 67' ' ' ASP . . . -119.28 33.52 5.61 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-O 122.17 0.986 . . . . 0.0 109.006 -179.636 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 m -78.0 2.09 18.77 Favored 'General case' 0 CA--C 1.577 1.989 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.21 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 6.1 mp0 -47.71 125.41 8.55 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 125.719 1.608 . . . . 0.0 111.764 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -105.48 128.06 53.35 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.36 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -138.07 159.78 41.12 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -178.182 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.453 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.453 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.405 ' HB2' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.444 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HB2' ' OE2' ' A' ' 93' ' ' GLU . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.403 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.502 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.448 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.401 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.448 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.401 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.632 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.515 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 0.416 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.572 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.566 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . 0.405 ' HB2' ' HB2' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.41 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.566 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.502 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.409 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.572 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.472 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.632 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.427 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -117.64 157.48 26.35 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -148.89 154.76 39.92 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.96 106.98 10.17 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -147.03 -10.47 0.44 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.186 -176.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -143.25 23.09 1.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 123.119 0.567 . . . . 0.0 110.895 178.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.7 t60 -119.66 57.57 0.91 Allowed 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -104.61 147.94 27.08 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.125 178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 1.4 p-80 -105.43 176.69 5.08 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.286 0.565 . . . . 0.0 112.379 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 t60 . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 175.536 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.482 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.402 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.61 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.42 ' O ' HG12 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.421 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.477 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.431 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.489 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 72.3 mtm -87.45 128.99 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.2 m -121.28 165.46 16.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.961 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.08 114.82 7.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 124.143 0.902 . . . . 0.0 111.482 179.253 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.1 t -82.36 -48.31 18.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 158.43 -156.57 27.54 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.21 119.9 6.46 Favored Glycine 0 N--CA 1.429 -1.777 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -103.01 -172.66 26.37 Favored Glycine 0 C--N 1.302 -1.309 0 N-CA-C 110.741 -0.943 . . . . 0.0 110.741 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -88.55 -54.93 3.93 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 117.481 0.64 . . . . 0.0 111.712 -176.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.1 mt -92.11 79.35 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.454 -173.048 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.7 t70 177.15 114.44 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 173.306 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -115.31 92.31 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.185 -174.242 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.2 -81.1 0.82 Allowed Glycine 0 C--O 1.239 0.418 0 CA-C-N 115.431 -0.804 . . . . 0.0 113.381 176.513 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 39.6 m 66.21 179.33 0.21 Allowed 'General case' 0 C--O 1.254 1.33 0 C-N-CA 125.682 1.593 . . . . 0.0 111.834 178.21 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.41 70.7 2.92 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 107.949 -2.061 . . . . 0.0 107.949 173.512 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -121.68 135.17 54.97 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 123.864 0.865 . . . . 0.0 110.254 -169.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.21 121.68 27.41 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 67.7 m-85 -93.19 6.36 48.29 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.871 0.367 . . . . 0.0 111.498 -176.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -134.27 120.06 2.37 Favored Glycine 0 N--CA 1.439 -1.107 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 177.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -116.8 -105.32 2.4 Favored Glycine 0 N--CA 1.436 -1.307 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.262 -177.889 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -127.13 -19.76 4.28 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.083 0.468 . . . . 0.0 110.985 -178.799 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -163.33 43.43 0.33 Allowed Glycine 0 CA--C 1.484 -1.874 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.45 14.94 16.78 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 113.856 -1.172 . . . . 0.0 108.906 -172.018 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -59.8 -54.68 43.4 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.168 -174.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -119.54 29.23 7.72 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.516 -174.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -61.42 -45.93 95.4 Favored Glycine 0 C--N 1.337 0.636 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 176.496 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -177.67 158.36 1.33 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 125.719 1.607 . . . . 0.0 106.688 175.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -96.55 66.45 2.34 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 122.002 0.906 . . . . 0.0 110.483 179.273 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.8 t70 156.21 81.97 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 129.048 2.939 . . . . 0.0 104.967 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . 0.416 ' O ' ' HE3' ' A' ' 71' ' ' LYS . . . -87.24 72.81 9.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.012 -177.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -87.04 -43.57 12.22 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.799 -179.287 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -85.1 122.33 29.16 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.5 0.667 . . . . 0.0 112.083 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.489 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 2.2 mptm? -120.66 143.26 48.79 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.074 176.881 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.65 160.35 43.17 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 176.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.533 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.533 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.42 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.41 ' HG3' ' HE2' ' A' ' 144' ' ' MET . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.438 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.594 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.404 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.406 ' O ' HD12 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.41 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . 0.439 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.439 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.41 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.429 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.429 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.658 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.468 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.41 ' HE2' ' HG3' ' A' ' 86' ' ' MET . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' SER . . . . . 0.42 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.404 ' HA ' ' HE3' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.402 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.594 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.468 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.439 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.477 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.658 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.482 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -107.45 143.42 35.83 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -95.92 -29.32 14.24 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.311 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.0 pm0 -77.35 156.14 31.46 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-N 114.366 -1.288 . . . . 0.0 108.854 176.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -117.88 129.56 55.71 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -87.66 12.27 13.08 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 122.163 0.982 . . . . 0.0 110.699 -178.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -122.99 86.38 2.57 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 172.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.4 t60 -119.75 -10.89 9.47 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.571 -170.038 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -71.53 129.29 38.4 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 12.8 p80 . . . . . 0 C--N 1.31 -1.151 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.858 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . 0.478 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.422 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.506 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.426 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.471 HD13 ' CE3' ' A' ' 132' ' ' TRP . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.426 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.474 ' CG1' HG22 ' A' ' 75' ' ' VAL . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.451 ' HE2' ' SG ' ' A' ' 165' ' ' CYS . 25.1 mmt -84.23 116.71 23.1 Favored 'General case' 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.84 154.2 24.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.111 177.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.19 133.12 36.71 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.453 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.0 t -65.99 97.93 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.834 0 CA-C-O 121.514 0.673 . . . . 0.0 111.554 -178.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -160.86 84.12 0.12 Allowed Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 108.404 -1.878 . . . . 0.0 108.404 176.837 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.03 154.87 16.89 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.955 -175.173 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 151.57 -158.27 27.65 Favored Glycine 0 N--CA 1.431 -1.667 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -75.79 122.45 24.08 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp 66.23 69.01 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-O 123.019 1.39 . . . . 0.0 107.841 -171.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -96.32 177.84 5.57 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.498 -1.683 . . . . 0.0 111.551 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.61 90.7 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.017 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 176.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -168.78 178.75 42.01 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.1 m 68.64 -65.19 0.28 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 125.077 1.351 . . . . 0.0 111.083 -177.352 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -101.88 63.67 0.49 Allowed Glycine 0 CA--C 1.493 -1.343 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 175.741 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -54.83 -50.58 68.25 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 125.946 1.699 . . . . 0.0 111.7 -173.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.77 -39.64 2.95 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.325 -178.898 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 59.1 m-85 -126.74 138.9 53.45 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 80.01 39.6 16.16 Favored Glycine 0 C--N 1.31 -0.896 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.19 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.7 -44.57 0.21 Allowed Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.356 -0.925 . . . . 0.0 112.449 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -93.72 92.62 7.57 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 122.642 -0.328 . . . . 0.0 111.146 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -107.41 -146.17 12.64 Favored Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -89.65 60.81 5.23 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 122.724 1.25 . . . . 0.0 110.765 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -108.81 -48.92 3.22 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.105 -177.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 63.39 70.55 0.53 Allowed 'General case' 0 C--O 1.241 0.621 0 O-C-N 124.267 0.98 . . . . 0.0 111.37 -172.08 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -111.72 128.19 8.5 Favored Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 176.103 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 72.6 -43.06 0.55 Allowed 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 125.235 1.414 . . . . 0.0 112.796 -177.604 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -76.84 102.25 6.24 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -150.91 -63.27 0.19 Allowed 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.19 82.63 1.26 Allowed 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 107.977 -1.119 . . . . 0.0 107.977 171.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 15.2 t -143.9 170.97 14.9 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -77.54 149.35 34.92 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -118.64 121.2 39.6 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 174.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.48 171.55 14.32 Favored 'General case' 0 C--N 1.285 -2.214 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.693 -170.902 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.474 HG22 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' THR . . . . . 0.539 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.446 ' HG3' ' HE3' ' A' ' 144' ' ' MET . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.565 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.565 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.452 ' O ' HG22 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.543 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.452 HG22 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.421 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.507 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.421 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.522 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.602 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.602 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.601 ' CZ3' HG11 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . 0.474 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.474 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.539 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.446 ' HE3' ' HG3' ' A' ' 86' ' ' MET . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.588 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.588 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.422 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.543 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.525 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.451 ' SG ' ' HE2' ' A' ' 40' ' ' MET . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.451 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.601 HG11 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.506 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.522 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.478 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . 0.486 ' HB2' ' CE1' ' A' ' 183' ' ' HIS . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -87.56 103.1 15.23 Favored 'General case' 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.585 ' HB3' ' CE1' ' A' ' 183' ' ' HIS . 45.2 tp 170.4 163.56 0.07 Allowed 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 177.08 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -58.76 -49.87 76.03 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 118.366 0.53 . . . . 0.0 112.23 -177.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . 0.585 ' CE1' ' HB3' ' A' ' 181' ' ' LEU . 73.7 m80 57.92 50.76 9.87 Favored 'General case' 0 N--CA 1.481 1.082 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.417 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -72.67 -10.7 60.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 113.702 -1.59 . . . . 0.0 112.978 -169.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 9.5 p-80 -55.47 113.03 1.26 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.611 0.719 . . . . 0.0 111.096 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 17.8 p-80 -100.06 -25.51 14.28 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.7 -175.586 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -109.49 144.52 37.63 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 30.6 m80 . . . . . 0 C--N 1.295 -1.791 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.542 174.116 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.452 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.458 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.497 ' O ' HG12 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.479 HG21 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.412 HD12 ' HA ' ' A' ' 129' ' ' PHE . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.479 ' CD1' HG21 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.497 HG12 ' O ' ' A' ' 19' ' ' LYS . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' SER . . . . . 0.413 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.402 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 58.6 mtt -81.67 150.28 28.11 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.5 m -131.96 148.54 32.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 113.739 -1.573 . . . . 0.0 107.444 172.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.33 114.59 12.88 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 121.287 0.565 . . . . 0.0 110.66 178.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 56.8 t -113.93 140.98 31.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -79.41 128.76 8.72 Favored Glycine 0 N--CA 1.43 -1.735 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 174.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.64 43.98 1.31 Allowed Glycine 0 C--N 1.301 -1.389 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.046 -175.676 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 77.78 -128.11 8.66 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.131 178.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -83.25 -37.31 23.71 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.829 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.1 mt 75.05 -48.88 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 125.939 1.695 . . . . 0.0 112.806 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 72.09 -65.2 0.36 Allowed 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 125.648 1.579 . . . . 0.0 113.451 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 46.0 mm 68.76 99.11 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.713 1.205 . . . . 0.0 111.459 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.2 131.33 8.12 Favored Glycine 0 N--CA 1.423 -2.223 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 177.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 61.8 m -67.53 117.37 9.39 Favored 'General case' 0 C--O 1.25 1.112 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.6 63.14 4.26 Favored Glycine 0 N--CA 1.44 -1.077 0 CA-C-N 115.602 -0.727 . . . . 0.0 113.649 -174.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -65.54 -36.66 84.47 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 123.338 0.655 . . . . 0.0 110.091 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 -10.3 59.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.658 -177.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -94.12 -26.05 16.88 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.98 -76.56 1.51 Allowed Glycine 0 N--CA 1.435 -1.413 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -178.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.35 70.96 0.28 Allowed Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.32 120.56 24.54 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 100.4 83.6 1.75 Allowed Glycine 0 N--CA 1.422 -2.282 0 N-CA-C 108.081 -2.007 . . . . 0.0 108.081 -174.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -64.81 -47.96 76.13 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.47 0.708 . . . . 0.0 111.046 -174.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -81.89 -18.43 43.76 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.289 177.927 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 62.02 79.87 0.24 Allowed 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.455 1.502 . . . . 0.0 111.223 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -153.25 -91.39 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.371 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 58.71 -165.59 0.18 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.645 1.178 . . . . 0.0 111.947 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -162.8 147.86 11.91 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.936 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -90.83 -22.15 21.12 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -101.38 -39.0 7.78 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.21 -175.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 24.8 p -128.91 174.34 9.59 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.382 -178.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -100.55 112.74 25.15 Favored 'General case' 0 N--CA 1.411 -2.376 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 171.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.402 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 49.9 mtmt -96.31 120.73 37.14 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.712 179.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.05 165.82 24.16 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -176.467 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.434 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.406 ' HB ' ' ND2' ' A' ' 73' ' ' ASN . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.434 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.544 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.427 ' O ' HG22 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . 0.44 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.542 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.44 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . 0.438 ' O ' HG21 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.438 HG21 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.597 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.597 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.674 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.425 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.52 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.52 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.544 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' MET . . . . . 0.422 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . 0.632 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . 0.632 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.422 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.542 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.458 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.447 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.447 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.674 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.458 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.402 ' HA ' HD22 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.412 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . 0.452 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -89.83 150.14 22.36 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 90.8 mt 81.22 8.94 1.03 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.018 1.727 . . . . 0.0 110.273 -174.104 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -90.0 -176.07 4.78 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.457 176.433 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -94.61 19.65 9.58 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -170.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.6 t-80 -125.42 29.79 5.95 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.906 -1.886 . . . . 0.0 105.906 175.614 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 17.1 t-160 -86.77 74.34 9.82 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.426 -173.049 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -104.48 -2.05 25.82 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 172.294 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -88.4 176.87 7.0 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.676 178.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 75.6 t60 . . . . . 0 C--N 1.311 -1.08 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.211 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.411 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.445 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.442 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . 0.43 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.532 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.532 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.45 HD13 ' CE3' ' A' ' 132' ' ' TRP . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.43 ' CD1' HG23 ' A' ' 20' ' ' ILE . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp -83.74 117.02 22.96 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.1 m -110.69 168.92 4.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.61 121.81 22.18 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 123.783 0.677 . . . . 0.0 110.839 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.7 t -111.37 94.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.25 150.25 18.53 Favored Glycine 0 N--CA 1.42 -2.422 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.7 83.74 1.34 Allowed Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.163 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.19 20.25 26.82 Favored Glycine 0 C--O 1.228 -0.258 0 C-N-CA 121.935 -0.174 . . . . 0.0 113.002 -176.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -56.86 -45.75 82.24 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.901 1.28 . . . . 0.0 109.62 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -124.12 105.49 15.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.866 -2.272 . . . . 0.0 104.866 173.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -144.48 150.02 36.92 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 121.229 -0.188 . . . . 0.0 110.873 -175.023 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.6 mp -88.21 93.71 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.107 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -133.51 -120.82 2.14 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 178.373 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 40.2 m -114.99 -6.67 12.55 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.165 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.08 -68.2 3.25 Favored Glycine 0 N--CA 1.443 -0.899 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -175.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -154.45 105.76 2.68 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.182 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.44 -72.8 0.26 Allowed 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.483 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -99.58 -7.81 25.35 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.75 0.786 . . . . 0.0 109.09 177.497 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.93 -100.77 0.29 Allowed Glycine 0 N--CA 1.426 -1.99 0 N-CA-C 107.439 -2.264 . . . . 0.0 107.439 -177.273 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -86.67 -28.02 27.87 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 173.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.45 133.24 36.53 Favored 'General case' 0 C--O 1.255 1.373 0 CA-C-N 115.29 -0.455 . . . . 0.0 109.838 178.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 165.18 -134.46 3.33 Favored Glycine 0 N--CA 1.424 -2.141 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -148.58 29.03 0.86 Allowed 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.685 1.231 . . . . 0.0 109.117 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -86.56 74.8 9.82 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.518 0.932 . . . . 0.0 113.518 -176.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -177.19 68.78 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.446 1.499 . . . . 0.0 107.955 173.715 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -97.89 -67.79 0.92 Allowed Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 70.37 -57.37 0.58 Allowed 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 126.006 1.723 . . . . 0.0 113.238 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -168.54 -159.55 0.26 Allowed 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 103.715 -2.698 . . . . 0.0 103.715 -177.261 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -77.62 -28.86 51.54 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 119.208 0.913 . . . . 0.0 110.086 175.411 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -176.69 140.05 0.33 Allowed 'General case' 0 CA--C 1.507 -0.702 0 O-C-N 124.818 1.324 . . . . 0.0 109.017 175.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 23.9 m -94.25 -71.23 0.67 Allowed 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 105.404 -2.072 . . . . 0.0 105.404 170.586 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 27.7 mp0 -102.79 174.37 5.91 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 168.367 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.69 141.3 48.53 Favored 'General case' 0 CA--C 1.486 -1.519 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 168.087 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.71 165.76 35.56 Favored 'General case' 0 C--N 1.285 -2.232 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.416 ' CZ ' HD13 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG22 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.508 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.437 HG22 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . 0.463 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . 0.463 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.612 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.404 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.419 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.495 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.612 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.509 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.509 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.614 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.585 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.585 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . 0.407 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.411 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.508 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.407 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.614 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.445 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.581 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.88 133.9 33.58 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 49.1 tp 55.47 68.3 0.88 Allowed 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.638 1.211 . . . . 0.0 111.392 178.858 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -73.56 -32.92 64.42 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.649 0.738 . . . . 0.0 109.487 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -82.76 76.13 9.62 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.529 178.554 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 23.5 p-80 -126.56 100.57 6.29 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.747 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -122.01 -84.82 0.66 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.807 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -105.15 -40.68 5.79 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -100.65 137.5 38.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.418 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 12.0 p80 . . . . . 0 C--N 1.289 -2.051 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 173.439 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.418 HG23 HG11 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.418 HG11 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.521 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.521 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . 0.407 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.481 HD12 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm -100.98 119.2 38.39 Favored 'General case' 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.4 m -117.04 141.39 35.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -61.54 125.41 23.68 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.102 0.477 . . . . 0.0 111.224 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 41.0 t -69.97 -36.29 68.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -88.6 65.64 3.29 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 178.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -177.77 35.49 0.08 OUTLIER Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -130.09 19.7 5.14 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 121.367 -0.444 . . . . 0.0 112.04 -177.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -89.51 86.97 6.89 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 49.6 mm 68.28 110.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -174.296 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -80.82 73.37 7.82 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -169.443 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.0 mp -136.73 83.67 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 103.924 -2.621 . . . . 0.0 103.924 166.736 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.43 47.4 0.8 Allowed Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -177.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 56' ' ' PHE . 58.9 m -78.29 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.642 -0.779 . . . . 0.0 110.069 -178.627 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.77 156.61 25.38 Favored Glycine 0 N--CA 1.437 -1.233 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -173.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -71.34 -35.84 71.33 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 117.256 0.528 . . . . 0.0 112.311 -173.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.95 5.85 50.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.936 0.398 . . . . 0.0 111.431 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . 0.461 ' CZ ' ' HA2' ' A' ' 64' ' ' GLY . 72.3 m-85 -115.41 74.89 0.91 Allowed 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 119.736 -0.786 . . . . 0.0 112.518 -176.253 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -121.65 61.57 0.54 Allowed Glycine 0 C--N 1.3 -1.467 0 N-CA-C 108.633 -1.787 . . . . 0.0 108.633 174.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.29 -39.61 1.52 Allowed Glycine 0 N--CA 1.439 -1.127 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -176.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.66 -67.68 0.45 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 120.679 0.276 . . . . 0.0 110.554 178.3 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.11 -71.02 1.96 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.511 175.47 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . 0.491 ' CG ' ' H ' ' A' ' 62' ' ' ASP . 21.8 t70 63.42 -164.29 0.25 Allowed 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 124.085 0.954 . . . . 0.0 108.65 -176.23 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . 0.491 ' H ' ' CG ' ' A' ' 61' ' ' ASP . 37.3 t70 -85.49 -30.28 23.58 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 176.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -163.44 -53.32 0.04 OUTLIER 'General case' 0 C--O 1.236 0.39 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.644 174.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . 0.461 ' HA2' ' CZ ' ' A' ' 56' ' ' PHE . . . -140.38 -66.19 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.642 -178.292 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -161.51 25.69 0.13 Allowed 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.309 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -151.07 175.57 11.98 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.296 -168.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -92.86 112.35 24.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -84.56 -70.74 0.55 Allowed 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -175.314 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.8 p -134.65 179.99 5.95 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.557 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -65.69 148.92 50.97 Favored 'General case' 0 CA--C 1.511 -0.53 0 O-C-N 123.27 0.356 . . . . 0.0 110.398 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -113.72 143.84 43.94 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.784 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -132.49 172.39 12.55 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 123.875 0.87 . . . . 0.0 110.46 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.485 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . 0.428 ' N ' HD21 ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.485 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.527 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.45 ' O ' HG22 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.565 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.45 HG22 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . 0.418 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.449 ' O ' HD11 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.612 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . 0.463 ' HZ1' ' HB3' ' A' ' 110' ' ' LYS . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.469 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.612 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.416 ' OE1' ' HB3' ' A' ' 121' ' ' LYS . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.528 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.528 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.417 ' O ' HG22 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.556 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.483 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.417 HG22 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.527 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.565 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.431 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.404 ' CE1' ' HG2' ' A' ' 136' ' ' LYS . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.556 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.434 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . 0.434 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -92.28 138.1 31.8 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 37.3 tp 76.14 -18.58 0.46 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.12 1.768 . . . . 0.0 112.726 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . 0.475 ' HA ' ' OE1' ' A' ' 182' ' ' GLU . 2.8 mm-40 -96.31 141.53 29.53 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 114.411 1.264 . . . . 0.0 114.411 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -134.21 16.11 3.79 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 176.291 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 74.48 -42.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 126.539 1.936 . . . . 0.0 110.082 -173.429 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 43.7 t60 -88.39 110.54 20.89 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 170.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 22.4 t60 -101.08 101.86 12.71 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 120.936 0.398 . . . . 0.0 110.341 -176.218 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -81.4 109.47 15.92 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 80.1 t60 . . . . . 0 C--N 1.298 -1.67 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.712 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.504 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . 0.504 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . 0.449 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.497 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.497 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.554 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.409 ' HB2' HG23 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.45 ' CG1' HG23 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.471 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp -95.29 112.57 24.26 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -111.11 160.33 10.45 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.073 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.91 126.76 31.16 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -73.97 -37.71 48.1 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.644 0.735 . . . . 0.0 109.155 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 107.97 122.71 4.8 Favored Glycine 0 N--CA 1.43 -1.726 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.862 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.66 137.62 9.78 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -176.586 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.19 174.52 16.91 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . 0.595 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 1.8 m-20 -76.15 0.01 20.45 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 114.055 1.131 . . . . 0.0 114.055 -174.65 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.8 mt -78.81 -22.88 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 172.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -107.5 -64.93 1.15 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . 0.595 ' O ' ' HA ' ' A' ' 47' ' ' ASP . 41.8 mm -94.78 107.22 19.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -178.55 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.63 72.22 2.81 Favored Glycine 0 C--N 1.307 -1.076 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.0 t -82.35 -35.42 27.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 -178.153 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.67 127.69 9.33 Favored Glycine 0 N--CA 1.42 -2.395 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -136.38 98.09 3.74 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.209 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.99 164.06 38.68 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.14 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -73.76 117.85 16.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 176.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.35 62.22 0.67 Allowed Glycine 0 N--CA 1.42 -2.43 0 N-CA-C 108.571 -1.812 . . . . 0.0 108.571 -173.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -77.83 -29.3 55.03 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 64.86 82.69 0.18 Allowed 'General case' 0 C--O 1.249 1.035 0 C-N-CA 125.094 1.358 . . . . 0.0 111.746 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -89.18 89.02 1.54 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -69.68 150.13 47.32 Favored 'General case' 0 C--O 1.245 0.834 0 CA-C-O 120.939 0.4 . . . . 0.0 110.132 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -78.44 -38.94 40.1 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.012 -177.163 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.93 139.66 47.24 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-O 121.134 0.492 . . . . 0.0 111.087 -176.665 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 173.13 85.58 0.06 OUTLIER Glycine 0 N--CA 1.422 -2.288 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -178.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.55 -22.89 56.65 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.505 0.669 . . . . 0.0 109.74 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.9 100.34 11.54 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.304 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -85.17 68.9 10.68 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-O 121.705 0.764 . . . . 0.0 110.683 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -158.94 73.42 0.61 Allowed 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 114.577 -1.192 . . . . 0.0 107.815 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 10.9 m -74.92 -24.75 58.56 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.345 -176.918 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -78.63 124.23 27.95 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.674 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -126.86 121.2 31.18 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 173.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -136.87 159.12 42.81 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -173.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.558 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.45 HG23 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.558 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.449 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' MET . . . . . 0.412 ' HG3' ' HE1' ' A' ' 144' ' ' MET . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.418 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.421 ' O ' HG22 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.421 HG22 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . 0.419 ' O ' HD12 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.4 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.59 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.59 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.554 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.43 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.553 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.553 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' MET . . . . . 0.443 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' MET . . . . . 0.443 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.499 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . . . . . . . . . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -93.37 102.67 14.92 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -84.67 -28.14 26.61 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.638 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.59 -179.39 6.41 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 175.332 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.7 t-160 -68.5 -72.92 0.16 Allowed 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 118.421 0.555 . . . . 0.0 110.935 -173.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -157.22 131.54 8.46 Favored 'General case' 0 CA--C 1.493 -1.215 0 C-N-CA 124.091 0.956 . . . . 0.0 109.689 178.019 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 33.1 m80 -78.18 120.15 22.57 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -77.56 146.49 36.24 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 175.607 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 -75.39 90.8 2.69 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.989 -174.372 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 33.3 m170 . . . . . 0 CA--C 1.501 -0.921 0 C-N-CA 125.679 1.592 . . . . 0.0 111.441 -179.306 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.441 ' O ' HG11 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' THR . . . . . 0.434 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.545 HD11 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.434 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . 0.436 ' HB2' HG23 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.441 HG11 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 60.3 mtt -79.81 129.01 34.12 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.3 m -118.46 144.85 25.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 175.901 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -78.98 124.07 27.9 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -74.57 96.61 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.345 -175.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -110.66 15.33 29.35 Favored Glycine 0 C--N 1.309 -0.933 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 169.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.6 -21.2 11.36 Favored Glycine 0 C--N 1.341 0.826 0 CA-C-N 113.88 -1.16 . . . . 0.0 113.376 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 101.49 5.33 52.0 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -172.744 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.15 76.61 6.08 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.0 mm 73.68 138.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 124.637 1.175 . . . . 0.0 109.879 -175.16 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.21 121.16 29.28 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.4 mp -84.4 79.65 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.791 0 CA-C-O 122.572 1.177 . . . . 0.0 110.106 -177.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -155.91 112.63 0.53 Allowed Glycine 0 N--CA 1.417 -2.606 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 58.4 m -93.46 11.37 28.74 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.998 0.428 . . . . 0.0 110.611 -178.087 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.46 -41.74 0.17 Allowed Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.799 -179.58 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -153.59 162.42 41.28 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -53.97 -40.15 66.62 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 123.702 0.801 . . . . 0.0 111.187 176.763 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -88.67 98.86 11.91 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.958 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.64 171.61 13.92 Favored Glycine 0 C--N 1.311 -0.852 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 106.09 123.19 5.1 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.128 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -98.24 -21.75 16.52 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.326 0.584 . . . . 0.0 110.411 -176.403 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 96.37 37.12 4.92 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -178.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -95.82 -75.01 0.54 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.891 0.377 . . . . 0.0 111.081 -177.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -108.78 -35.39 6.41 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.462 -178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -34.06 89.58 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 128.107 2.563 . . . . 0.0 114.142 -174.347 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -101.33 -22.02 10.98 Favored Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 178.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 69.95 6.71 Favored 'General case' 0 N--CA 1.427 -1.577 0 CA-C-O 121.51 0.672 . . . . 0.0 110.127 178.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -103.54 93.35 4.89 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 106.244 -1.761 . . . . 0.0 106.244 173.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -112.89 154.96 25.52 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.211 -170.929 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -68.29 93.35 0.46 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.457 0.646 . . . . 0.0 110.661 179.583 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 m -69.24 145.29 53.27 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.821 -178.111 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.65 135.0 38.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -120.58 130.74 54.32 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -128.37 160.1 33.29 Favored 'General case' 0 C--N 1.284 -2.254 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 175.727 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.424 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.403 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . 0.403 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.458 ' O ' HG22 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.435 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.458 HG22 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . 0.401 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . 0.563 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . 0.408 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.563 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.652 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.652 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.461 ' O ' HG22 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CE3' HD11 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.461 HG22 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.521 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.521 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.435 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . 0.412 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.412 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.41 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.496 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -103.17 105.42 15.71 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.1 37.92 1.77 Allowed 'General case' 0 C--N 1.295 -1.79 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.11 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -149.47 121.79 8.42 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-N 114.084 -1.417 . . . . 0.0 107.702 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.1 m-70 -82.63 118.88 23.63 Favored 'General case' 0 CA--C 1.49 -1.344 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 173.922 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -81.0 110.6 16.69 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.736 -177.448 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 57.5 t60 -161.65 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.998 -174.358 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -99.46 123.29 43.61 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -96.3 144.43 26.48 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -178.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 79.7 t60 . . . . . 0 C--N 1.295 -1.778 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 174.234 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.433 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.632 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . 0.632 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.456 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.466 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.431 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.459 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' MET . . . . . 0.418 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 89.2 mtp -89.58 123.97 34.13 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 24.3 m -110.18 155.46 11.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.627 178.681 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . 0.417 ' HA ' ' HG2' ' A' ' 71' ' ' LYS . . . -90.46 116.73 28.61 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -172.474 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.99 100.94 11.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 172.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -100.29 142.71 16.0 Favored Glycine 0 CA--C 1.494 -1.249 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.294 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 92.5 -50.37 2.66 Favored Glycine 0 N--CA 1.436 -1.361 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.23 91.78 0.74 Allowed Glycine 0 CA--C 1.493 -1.339 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 -178.812 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 34.5 m-20 -101.14 103.02 14.07 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -175.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 45.0 mm -99.97 90.44 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 175.393 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 66.78 34.81 5.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 124.034 0.834 . . . . 0.0 110.538 -174.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 2.1 mp 73.6 107.13 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.587 1.155 . . . . 0.0 110.203 -177.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 169.87 42.77 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.803 -176.888 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 26.1 p -162.98 -45.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 123.461 0.705 . . . . 0.0 109.167 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.18 41.9 0.79 Allowed Glycine 0 N--CA 1.435 -1.41 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -83.69 96.32 8.66 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.08 89.25 3.08 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 63.87 23.63 13.44 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.652 1.181 . . . . 0.0 111.623 -179.587 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 155.41 170.38 20.86 Favored Glycine 0 N--CA 1.432 -1.576 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -178.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.78 -87.52 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.241 -0.981 . . . . 0.0 112.874 -179.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -90.93 157.4 17.33 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.23 0.538 . . . . 0.0 112.054 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.14 149.68 21.7 Favored Glycine 0 N--CA 1.434 -1.435 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 177.912 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -95.58 15.74 19.04 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 117.44 0.62 . . . . 0.0 110.652 -175.273 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -94.94 15.79 17.79 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.427 0.691 . . . . 0.0 110.532 -179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -139.16 147.67 42.17 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.48 82.82 1.1 Allowed Glycine 0 N--CA 1.422 -2.264 0 C-N-CA 120.395 -0.907 . . . . 0.0 113.322 175.73 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.49 -44.59 70.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 174.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -88.19 -57.29 2.98 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 174.456 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 179.18 161.29 0.75 Allowed 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 125.769 1.628 . . . . 0.0 106.834 177.103 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -118.6 26.77 9.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 121.594 0.711 . . . . 0.0 109.755 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.9 p -119.46 177.02 5.08 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.125 -173.853 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -100.62 117.92 35.72 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 170.653 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . 0.418 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 60.4 mtpt -111.93 121.84 46.14 Favored 'General case' 0 C--N 1.292 -1.926 0 C-N-CA 119.717 -0.793 . . . . 0.0 112.43 -174.856 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . 0.479 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 -130.36 171.08 13.34 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.793 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.459 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . 0.466 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.571 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.561 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.442 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.442 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.409 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.561 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . 0.409 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.554 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . 0.427 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG21 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . 0.57 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.458 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.441 HG21 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.562 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.562 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . 0.402 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.571 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . 0.41 ' O ' ' HB ' ' A' ' 167' ' ' THR . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.479 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' THR . . . . . 0.41 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.458 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.433 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . . . . . . . . . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -95.42 114.41 26.18 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -86.65 178.32 7.08 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.02 121.49 15.25 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 2.4 p80 -129.38 98.05 4.75 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 121.997 0.903 . . . . 0.0 113.359 -175.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 20.2 m80 -114.96 113.54 24.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 170.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 28.2 t-80 -82.13 96.79 7.91 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -176.712 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -131.58 -47.62 0.97 Allowed 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.9 -177.117 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -109.29 100.83 9.89 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.475 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--N 1.295 -1.773 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 174.622 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.434 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' LEU . . . . . 0.451 HD12 ' CE3' ' A' ' 132' ' ' TRP . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' VAL . . . . . 0.411 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.421 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt -85.52 136.74 33.29 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.3 m -123.22 169.31 14.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 175.458 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.19 114.03 24.41 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.247 0.546 . . . . 0.0 109.786 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.4 t -103.47 144.72 13.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -179.07 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 156.6 -53.05 0.41 Allowed Glycine 0 N--CA 1.432 -1.619 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.58 -89.21 1.4 Allowed Glycine 0 CA--C 1.495 -1.157 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -157.51 155.73 26.66 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.48 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.27 -25.19 29.54 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 116.784 0.292 . . . . 0.0 110.492 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.2 mt 61.08 51.28 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 122.983 1.373 . . . . 0.0 107.934 -178.934 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 23.6 t70 70.65 -85.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 113.394 -1.73 . . . . 0.0 111.474 -175.651 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.9 mt 38.41 58.31 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.483 0 C-N-CA 125.344 1.458 . . . . 0.0 111.178 -172.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.15 72.53 2.73 Favored Glycine 0 CA--C 1.496 -1.13 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.499 178.772 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 80.0 m -110.29 113.62 26.43 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.719 0.295 . . . . 0.0 110.544 -177.231 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.96 93.51 1.51 Allowed Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 175.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 33.1 p30 -62.74 152.09 36.68 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.95 126.84 45.0 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.456 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 60.2 m-85 63.94 -74.77 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.934 1.693 . . . . 0.0 113.836 178.162 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -173.83 167.31 39.8 Favored Glycine 0 N--CA 1.435 -1.371 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.148 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 156.64 -140.11 6.97 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.662 179.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -99.61 106.15 18.08 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.148 0.499 . . . . 0.0 110.437 -178.625 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.92 25.99 3.86 Favored Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 67.64 145.1 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 125.279 1.432 . . . . 0.0 114.379 -179.329 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -84.54 -25.41 28.77 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.034 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -81.13 99.77 8.7 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -149.84 162.99 29.3 Favored Glycine 0 N--CA 1.422 -2.243 0 C-N-CA 119.745 -1.217 . . . . 0.0 112.098 -177.606 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.02 24.93 1.68 Allowed 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 123.373 0.669 . . . . 0.0 110.23 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -57.3 -35.63 70.07 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.84 1.256 . . . . 0.0 111.084 -178.322 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -70.51 -64.53 0.88 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 177.58 -51.93 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 105.199 -2.148 . . . . 0.0 105.199 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 8.5 m -153.64 157.11 39.12 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 103.971 -2.603 . . . . 0.0 103.971 174.826 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 62.9 mt-30 -87.62 119.06 27.54 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 119.221 0.919 . . . . 0.0 109.421 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -110.36 121.15 44.61 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.491 173.75 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.14 162.21 40.89 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASN . . . . . 0.467 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' SER . . . . . 0.464 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' PHE . . . . . 0.464 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' TYR . . . . . 0.411 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' PHE . . . . . 0.46 ' O ' HG22 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' TRP . . . . . 0.466 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' VAL . . . . . 0.46 HG22 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' LEU . . . . . 0.427 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . 0.418 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' VAL . . . . . 0.459 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.418 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' LYS . . . . . 0.459 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' PHE . . . . . 0.427 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' GLU . . . . . 0.406 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' ALA . . . . . 0.504 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' PHE . . . . . 0.504 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' VAL . . . . . 0.427 ' O ' HG22 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' TRP . . . . . 0.502 ' CZ3' HG12 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' LEU . . . . . 0.456 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' VAL . . . . . 0.427 HG22 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.563 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' LEU . . . . . 0.563 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' LEU . . . . . 0.466 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' SER . . . . . 0.417 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' PHE . . . . . 0.411 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' VAL . . . . . 0.502 HG12 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.434 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 175' ' ' TYR . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.75 161.47 18.68 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' LEU . . . . . 0.475 HD13 ' O ' ' A' ' 181' ' ' LEU . 3.9 pp -110.5 114.17 27.37 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 174.454 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.45 119.26 30.58 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -177.708 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -127.63 11.59 6.77 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.588 -174.664 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -88.34 104.65 16.96 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.865 -0.522 . . . . 0.0 110.144 -178.652 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 61.5 m-70 59.22 77.52 0.3 Allowed 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.392 1.077 . . . . 0.0 112.867 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -148.71 117.06 6.49 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -77.08 94.59 4.06 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.422 -1.858 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.642 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.423 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.423 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.478 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.443 HG23 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.423 HG22 ' HB2' ' A' ' 35' ' ' GLU . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.423 ' HB2' HG22 ' A' ' 23' ' ' VAL . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' MET . . . . . 0.49 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? . . . . . 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.359 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.439 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.521 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.429 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.521 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.441 ' O ' HG23 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.639 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.402 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.478 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.501 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.478 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.501 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.546 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.508 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.442 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.639 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.515 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.462 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.462 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 164' ' ' HIS . . . . . 0.49 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.439 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.453 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.526 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 . . . . . 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.53 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.459 HD11 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.467 ' HA ' ' HB2' ' A' ' 35' ' ' GLU . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.507 HG12 HD12 ' A' ' 33' ' ' LEU . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 171' ' ' VAL . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.519 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.539 HG13 HG21 ' A' ' 75' ' ' VAL . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm . . . . . 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.425 -1.7 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.539 HG21 HG13 ' A' ' 36' ' ' VAL . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.588 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.459 ' CE1' HD11 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.588 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . 0.539 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.539 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.451 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.613 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.613 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.621 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.621 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.708 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.425 ' HB3' HD23 ' A' ' 140' ' ' LEU . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.519 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.571 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.45 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.437 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.627 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.471 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' GLU . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.498 HD13 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.471 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' A' ' 23' ' ' VAL . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? . . . . . 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.439 -1.02 0 N-CA-C 111.102 0.038 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.598 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.627 HG22 ' HB3' ' A' ' 18' ' ' LEU . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.426 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.527 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' LYS . . . . . 0.557 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.406 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.416 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.427 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.443 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' MET . . . . . 0.557 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.604 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.604 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.479 ' SD ' HD11 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.527 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.479 HD11 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.562 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.426 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.445 ' HA ' HD23 ' A' ' 33' ' ' LEU . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.413 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.437 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.466 ' HB2' ' HG3' ' A' ' 176' ' ' LYS . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG23 HD12 ' A' ' 18' ' ' LEU . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.4 HD12 HG23 ' A' ' 14' ' ' VAL . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.467 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.509 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 171' ' ' VAL . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.459 ' CD2' HG23 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.553 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.441 -0.917 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.51 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.479 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.436 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.53 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.466 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.532 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.509 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.625 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.546 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.57 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.57 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.53 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.625 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.502 ' HA ' HD23 ' A' ' 33' ' ' LEU . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.406 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.437 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG3' ' HB2' ' A' ' 5' ' ' LYS . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 . . . . . 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.468 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.526 HD11 ' HA ' ' A' ' 101' ' ' TYR . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.43 ' HB2' ' HE2' ' A' ' 148' ' ' MET . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.411 HG23 HG12 ' A' ' 14' ' ' VAL . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.411 HG12 HG23 ' A' ' 13' ' ' VAL . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' HG22 ' A' ' 75' ' ' VAL . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.453 HG12 HD12 ' A' ' 33' ' ' LEU . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 HG12 ' A' ' 30' ' ' VAL . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 170' ' ' TYR . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt . . . . . 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.43 -1.426 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.626 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 18' ' ' LEU . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.495 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.498 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 94' ' ' PHE . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.461 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.526 ' HA ' HD11 ' A' ' 8' ' ' ILE . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.406 HG12 ' HB2' ' A' ' 118' ' ' ASP . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.405 HG12 ' O ' ' A' ' 115' ' ' ALA . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.447 ' HB3' ' HZ3' ' A' ' 121' ' ' LYS . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.596 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' THR . . . . . 0.443 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.596 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 128' ' ' THR . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.64 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.403 ' HA ' HD12 ' A' ' 140' ' ' LEU . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.43 ' HE2' ' HB2' ' A' ' 11' ' ' ASP . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.498 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.64 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.417 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.468 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CE1' HG22 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HA ' ' A' ' 101' ' ' TYR . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.427 ' HA ' ' HB1' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.635 ' HB3' ' HE3' ' A' ' 148' ' ' MET . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HB3' HG22 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.523 HD13 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.444 ' CD2' HG23 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.522 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.401 ' CG1' HG21 ' A' ' 75' ' ' VAL . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt . . . . . 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 . . . . . 0 N--CA 1.421 -1.913 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.502 HG22 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.47 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.513 ' O ' HG23 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.413 ' HA ' HD11 ' A' ' 8' ' ' ILE . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.478 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.464 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.464 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.426 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.474 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.523 ' CE3' HD13 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.615 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.615 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.47 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.635 ' HE3' ' HB3' ' A' ' 11' ' ' ASP . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.575 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.575 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HB1' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.489 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.507 HG12 ' H ' ' A' ' 174' ' ' GLY . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.507 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.417 HG22 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.468 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' TYR . . . . . 0.433 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.46 HD13 HG13 ' A' ' 75' ' ' VAL . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.424 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.428 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.555 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' MET . . . . . 0.447 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.4 mtp . . . . . 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.381 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.599 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.599 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HB2' ' A' ' 82' ' ' ALA . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 78' ' ' PRO . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.423 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.454 ' HG ' ' CZ ' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 118' ' ' ASP . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.457 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.457 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.489 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.454 ' CZ ' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.433 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.631 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.696 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.696 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' ALA . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.422 ' HB3' ' HE2' ' A' ' 144' ' ' MET . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.443 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.506 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.447 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.631 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.428 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 174' ' ' GLY . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.496 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' VAL . . . . . 0.433 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 180' ' ' PHE . . . . . 0.444 ' CZ ' HG11 ' A' ' 3' ' ' VAL . 13.9 m-85 . . . . . 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.412 ' CG2' ' HA ' ' A' ' 152' ' ' ALA . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HB3' HG22 ' A' ' 75' ' ' VAL . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.488 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.44 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.409 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.515 HD23 ' HA ' ' A' ' 171' ' ' VAL . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.441 ' HB2' HG22 ' A' ' 23' ' ' VAL . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.536 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.449 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' MET . . . . . 0.603 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp . . . . . 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.42 -1.961 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.491 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.467 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.498 ' HB3' ' CZ ' ' A' ' 168' ' ' PHE . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.447 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.447 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.45 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.479 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.635 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.485 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.513 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.432 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.513 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.417 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.645 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.645 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.62 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.629 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.433 ' HA ' HD12 ' A' ' 140' ' ' LEU . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.629 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.4 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CG2' ' A' ' 8' ' ' ILE . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.635 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.4 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.519 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.603 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.536 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.62 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.471 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.515 ' HA ' HD23 ' A' ' 33' ' ' LEU . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.424 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.456 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 3' ' ' VAL . 18.1 m-85 . . . . . 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.516 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.436 HD11 ' HA ' ' A' ' 101' ' ' TYR . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.454 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.476 HG12 HD12 ' A' ' 33' ' ' LEU . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLY . . . . . 0.406 ' HA2' ' OG ' ' A' ' 173' ' ' SER . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 171' ' ' VAL . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.562 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.43 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.434 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.409 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' ASP . . . . . 0.424 ' HA ' ' HB3' ' A' ' 103' ' ' ARG . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.436 ' HA ' HD11 ' A' ' 8' ' ' ILE . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 101' ' ' TYR . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' VAL . . . . . 0.442 HG12 ' HB2' ' A' ' 118' ' ' ASP . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.431 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.442 ' HB2' HG12 ' A' ' 114' ' ' VAL . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.604 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.441 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.538 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.538 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.489 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.48 ' HB2' ' HB3' ' A' ' 152' ' ' ALA . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 149' ' ' ASN . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.409 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.5 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.404 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.404 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.545 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 174' ' ' GLY . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.4 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.441 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.516 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.45 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.489 HD11 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HB2' HD21 ' A' ' 74' ' ' ASN . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.448 HG23 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.51 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.448 ' CD2' HG23 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 N--CA 1.436 -1.128 0 CA-C-O 119.422 -0.323 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.424 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.431 HD21 ' HB2' ' A' ' 19' ' ' LYS . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.405 HG22 ' HB3' ' A' ' 18' ' ' LEU . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.489 ' CE1' HD11 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.515 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.436 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.49 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.615 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.615 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.515 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.515 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.424 ' HB3' HD13 ' A' ' 140' ' ' LEU . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.51 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.484 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 180' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.481 HG22 ' HA ' ' A' ' 152' ' ' ALA . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.43 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.467 HG23 HD12 ' A' ' 18' ' ' LEU . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.467 HD12 HG23 ' A' ' 14' ' ' VAL . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' MET . . . . . 0.419 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' GLU . . . . . 0.457 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 171' ' ' VAL . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.437 -1.099 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.462 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.462 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.443 ' CE1' HD11 ' A' ' 18' ' ' LEU . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.514 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.46 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.46 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.415 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.415 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.583 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.583 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.653 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.435 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.556 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' LYS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.405 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.556 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.481 ' HA ' HG22 ' A' ' 8' ' ' ILE . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.514 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.539 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.541 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.653 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.43 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 174' ' ' GLY . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.482 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 . . . . . 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.497 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.405 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.427 ' O ' HG13 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 33' ' ' LEU . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.549 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 72.3 mtm . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.427 -1.582 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.544 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.544 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.437 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.414 ' O ' HD13 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.416 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.433 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.416 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.451 ' HA ' HD11 ' A' ' 33' ' ' LEU . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.672 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.627 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.627 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 155' ' ' ILE . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE2' ' HA ' ' A' ' 150' ' ' PRO . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 145' ' ' SER . . . . . 0.441 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.519 ' HA ' ' HE2' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.405 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' PHE . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.468 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.549 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.672 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.611 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 174' ' ' GLY . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.435 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.497 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 . . . . . 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.502 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 101' ' ' TYR . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.424 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.514 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 75' ' ' VAL . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.435 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.511 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.501 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.411 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 25.1 mmt . . . . . 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.424 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' THR . . . . . 0.532 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ALA . . . . . 0.412 ' HB2' ' CE1' ' A' ' 143' ' ' PHE . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.572 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.572 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.464 ' O ' HG23 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.556 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.437 ' HA ' HD11 ' A' ' 8' ' ' ILE . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.447 HG13 ' HA3' ' A' ' 174' ' ' GLY . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.435 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.647 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.492 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.475 ' HB3' HD11 ' A' ' 154' ' ' LEU . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.532 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.494 ' HE3' ' HA ' ' A' ' 150' ' ' PRO . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.584 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.584 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.424 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.556 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CD2' HD13 ' A' ' 140' ' ' LEU . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.531 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.501 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.647 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.514 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.511 ' HA ' HD23 ' A' ' 33' ' ' LEU . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.538 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.471 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.502 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.466 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.493 HD13 HG13 ' A' ' 75' ' ' VAL . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' CG1' HD12 ' A' ' 33' ' ' LEU . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.577 HD23 ' HA ' ' A' ' 171' ' ' VAL . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.49 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 75' ' ' VAL . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' SER . . . . . 0.474 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 58.6 mtt . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.423 -1.79 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.437 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 36' ' ' VAL . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.462 ' HA ' ' CD1' ' A' ' 83' ' ' TYR . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.551 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.463 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.555 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.463 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.452 ' O ' HG23 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 105' ' ' VAL . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.407 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.687 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.53 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.437 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ASN . . . . . 0.636 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' PRO . . . . . 0.636 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.437 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.555 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.579 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.474 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.687 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.577 ' HA ' HD23 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.441 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.419 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.414 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.506 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 36' ' ' VAL . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 171' ' ' VAL . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.472 ' HD2' ' HB2' ' A' ' 172' ' ' LYS . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp . . . . . 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.431 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.424 ' CZ ' HD11 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.446 ' O ' HG23 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.523 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' VAL . . . . . 0.461 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG13 ' HA2' ' A' ' 174' ' ' GLY . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.623 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.503 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.623 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.503 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.518 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.518 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 134' ' ' VAL . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.633 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 130' ' ' VAL . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.599 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' PHE . . . . . 0.459 ' HB3' HD11 ' A' ' 154' ' ' LEU . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' LYS . . . . . 0.417 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.523 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.502 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HD2' HG21 ' A' ' 167' ' ' THR . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 160' ' ' LYS . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.633 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.498 ' HA ' HD23 ' A' ' 33' ' ' LEU . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 172' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 34' ' ' PHE . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.607 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 105' ' ' VAL . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 . . . . . 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.411 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ASP . . . . . 0.401 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 101' ' ' TYR . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLU . . . . . 0.411 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.464 HG12 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 20' ' ' ILE . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ILE . . . . . 0.441 HD12 ' HA ' ' A' ' 16' ' ' ASP . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.475 HD13 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.434 HG11 HG21 ' A' ' 75' ' ' VAL . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm . . . . . 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 . . . . . 0 C--O 1.242 0.701 0 N-CA-C 110.46 -0.2 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.482 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ASN . . . . . 0.419 HD22 ' N ' ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 36' ' ' VAL . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.534 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.459 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HD3' ' HA ' ' A' ' 95' ' ' LYS . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' LYS . . . . . 0.413 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.417 ' HA ' HD11 ' A' ' 8' ' ' ILE . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.445 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.635 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.635 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.43 ' OE2' ' HB2' ' A' ' 31' ' ' PRO . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.426 ' O ' HG23 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.569 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.612 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.534 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.423 ' HB3' HD23 ' A' ' 140' ' ' LEU . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.569 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.416 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 . . . . . 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' MET . . . . . 0.494 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.55 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.457 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.588 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.473 ' HB2' HG22 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.469 ' CG1' HG21 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp . . . . . 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.435 -1.216 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.564 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.469 HG21 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.564 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.415 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.457 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.428 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.428 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.43 ' O ' HG23 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.493 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.409 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.404 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.588 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.56 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' MET . . . . . 0.537 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.493 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.434 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.55 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.501 ' HA ' HD23 ' A' ' 33' ' ' LEU . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 . . . . . 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD2' HG21 ' A' ' 178' ' ' VAL . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 13' ' ' VAL . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.566 HG22 ' HB2' ' A' ' 35' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLU . . . . . 0.566 ' HB2' HG22 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLU . . . . . 0.416 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' GLU . . . . . 0.481 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' ASP . . . . . 0.579 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.579 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.666 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.666 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.427 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.49 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.501 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.403 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' VAL . . . . . 0.417 HG21 ' HD2' ' A' ' 5' ' ' LYS . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.435 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' LYS . . . . . 0.49 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.643 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' GLU . . . . . 0.643 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.474 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.2 mtp . . . . . 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 . . . . . 0 CA--C 1.504 -0.79 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.8 p-10 -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.582 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.454 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.581 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.553 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.556 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.556 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.451 ' O ' HG23 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.474 ' CE3' HD13 ' A' ' 33' ' ' LEU . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' TYR . . . . . 0.487 ' HA ' HD12 ' A' ' 140' ' ' LEU . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.582 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.425 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' SER . . . . . 0.432 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.403 ' HB3' HD23 ' A' ' 140' ' ' LEU . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.478 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' THR . . . . . 0.419 HG23 ' HA ' ' A' ' 37' ' ' ASP . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.438 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.474 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.435 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 174' ' ' GLY . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.439 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 . . . . . 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.473 ' HB3' ' HB1' ' A' ' 152' ' ' ALA . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.432 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' LEU . . . . . 0.427 ' HB3' HG22 ' A' ' 75' ' ' VAL . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt . . . . . 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.307 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 ' HB3' ' A' ' 18' ' ' LEU . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' SER . . . . . 0.477 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' PHE . . . . . 0.477 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' PHE . . . . . 0.468 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' TYR . . . . . 0.43 ' O ' HG23 ' A' ' 105' ' ' VAL . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 101' ' ' TYR . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' LEU . . . . . 0.437 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 115' ' ' ALA . . . . . 0.433 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' VAL . . . . . 0.465 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 120' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 122' ' ' PHE . . . . . 0.437 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' PHE . . . . . 0.527 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 132' ' ' TRP . . . . . 0.52 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 134' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.577 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.473 ' HB1' ' HB3' ' A' ' 9' ' ' SER . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' TYR . . . . . 0.4 ' HB3' HD23 ' A' ' 140' ' ' LEU . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' PHE . . . . . 0.464 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 169' ' ' VAL . . . . . 0.52 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.432 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 174' ' ' GLY . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.529 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.423 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.423 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.478 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.443 HG23 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.423 HG22 ' HB2' ' A' ' 35' ' ' GLU . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.423 ' HB2' HG22 ' A' ' 23' ' ' VAL . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.418 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.49 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? -93.94 109.52 21.24 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 35.6 m -113.62 153.84 15.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.403 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.88 115.41 5.95 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.252 0.549 . . . . 0.0 111.186 175.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 76.5 t -100.72 138.92 23.38 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 C-N-CA 124.495 1.118 . . . . 0.0 108.921 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.0 80.65 1.8 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 175.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.58 -31.88 9.12 Favored Glycine 0 N--CA 1.434 -1.461 0 C-N-CA 121.514 -0.374 . . . . 0.0 113.01 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.09 -51.1 4.51 Favored Glycine 0 C--O 1.243 0.69 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.741 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 63.69 36.54 10.68 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.236 1.014 . . . . 0.0 110.273 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mm -79.09 -52.88 14.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.686 -177.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -98.27 -39.91 8.6 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.645 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.7 mt -121.79 118.41 55.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.112 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.67 108.55 3.06 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 172.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 75.7 m -78.78 107.63 11.63 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.345 0.593 . . . . 0.0 112.091 -175.15 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.12 -68.72 1.65 Allowed Glycine 0 N--CA 1.433 -1.517 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.681 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 35.7 t30 64.24 84.94 0.14 Allowed 'General case' 0 C--O 1.242 0.675 0 C-N-CA 124.379 1.072 . . . . 0.0 111.084 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -136.19 144.15 44.79 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.667 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -89.93 121.42 32.02 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.295 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -87.68 111.94 3.78 Favored Glycine 0 N--CA 1.436 -1.323 0 C-N-CA 120.83 -0.7 . . . . 0.0 111.506 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.13 -36.52 4.14 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -81.57 136.13 35.57 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 128.98 -71.86 0.49 Allowed Glycine 0 N--CA 1.432 -1.628 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -156.57 179.64 9.07 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -109.78 -66.11 1.09 Allowed 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 118.177 0.444 . . . . 0.0 112.145 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -103.48 6.79 37.74 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -174.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.87 68.46 0.44 Allowed Glycine 0 C--N 1.302 -1.314 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 171.959 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -138.8 23.74 2.63 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -172.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -77.95 111.08 13.44 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.158 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -135.62 123.49 22.6 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.889 -173.8 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -116.49 18.74 15.0 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.626 0.727 . . . . 0.0 109.302 176.177 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.1 p -104.85 92.59 4.32 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.752 -176.001 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mm-40 -66.69 119.77 12.35 Favored 'General case' 0 CA--C 1.501 -0.929 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.673 176.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.43 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 32.4 mmtp -97.01 120.77 37.99 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.06 165.72 26.6 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.439 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.521 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.429 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.521 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.441 ' O ' HG23 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.639 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.402 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.478 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.501 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.478 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.501 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.546 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.508 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.442 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.639 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.515 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.462 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.462 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 164' ' ' HIS . . . . . 0.49 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.439 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.453 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.526 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -87.94 119.98 28.83 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 6.9 tt -170.36 -61.74 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -90.79 89.02 7.3 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.433 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -85.36 -58.43 2.68 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -100.48 101.16 12.04 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.492 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -155.7 164.04 39.11 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -178.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -145.43 90.89 2.06 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 175.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -87.88 107.6 18.77 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.753 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 177.934 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.53 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.459 HD11 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.467 ' HA ' ' HB2' ' A' ' 35' ' ' GLU . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.507 HG12 HD12 ' A' ' 33' ' ' LEU . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 171' ' ' VAL . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.519 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.539 HG13 HG21 ' A' ' 75' ' ' VAL . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm -85.25 108.89 17.98 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 35.7 m -117.12 152.44 18.93 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -76.75 117.99 18.93 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.192 0.52 . . . . 0.0 110.177 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.0 t -109.41 112.55 40.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.16 161.3 54.29 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.92 86.36 0.56 Allowed Glycine 0 C--N 1.316 -0.578 0 N-CA-C 111.958 -0.457 . . . . 0.0 111.958 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.65 -19.45 59.94 Favored Glycine 0 N--CA 1.446 -0.643 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -77.77 101.21 6.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.541 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.3 mt -67.87 111.59 2.5 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.372 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -94.02 148.51 22.09 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 176.201 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.4 mm -66.03 -31.46 53.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 CA-C-O 121.39 0.614 . . . . 0.0 110.377 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.14 -46.59 1.07 Allowed Glycine 0 CA--C 1.48 -2.119 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 -176.932 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 49.0 t 179.34 -36.65 0.01 OUTLIER 'General case' 0 C--O 1.21 -1.015 0 C-N-CA 124.917 1.287 . . . . 0.0 107.615 176.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.02 0.87 26.99 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 3.3 p-10 -163.87 150.9 12.01 Favored 'General case' 0 C--O 1.246 0.884 0 C-N-CA 124.191 0.996 . . . . 0.0 108.566 -178.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.36 152.44 18.59 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -104.8 -37.07 7.18 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 121.202 0.525 . . . . 0.0 111.038 -178.018 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.75 144.59 3.95 Favored Glycine 0 N--CA 1.432 -1.572 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 68.47 -121.23 12.59 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -176.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -170.35 140.55 1.87 Allowed 'General case' 0 C--N 1.313 -0.981 0 C-N-CA 124.03 0.932 . . . . 0.0 108.973 177.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.12 -27.83 17.26 Favored Glycine 0 C--N 1.311 -0.85 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 173.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -169.93 165.41 9.59 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -68.54 -64.97 0.76 Allowed 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 119.062 0.846 . . . . 0.0 111.553 -177.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.81 -16.9 15.8 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 119.395 -0.922 . . . . 0.0 112.312 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 74.38 55.97 5.35 Favored Glycine 0 CA--C 1.498 -1.015 0 N-CA-C 107.357 -2.297 . . . . 0.0 107.357 -173.367 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -59.05 -66.95 0.42 Allowed 'General case' 0 C--O 1.239 0.525 0 CA-C-N 114.497 -0.852 . . . . 0.0 112.699 -172.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -148.49 157.02 43.2 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -164.29 166.13 21.17 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 104.886 -2.264 . . . . 0.0 104.886 177.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 58.51 74.79 0.42 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 124.825 1.25 . . . . 0.0 113.926 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 59.2 m -87.63 95.13 9.94 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 80.8 mt-30 -87.07 147.88 25.5 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.068 -173.648 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 63.4 mttp -96.68 120.48 37.09 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 167.264 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -138.59 171.39 14.43 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -170.466 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.539 HG21 HG13 ' A' ' 36' ' ' VAL . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.588 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.459 ' CE1' HD11 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.588 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.539 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.539 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.451 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.613 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.613 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.621 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.621 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.708 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.425 ' HB3' HD23 ' A' ' 140' ' ' LEU . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.519 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.571 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.45 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -84.93 122.54 29.34 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.5 tp 75.86 -83.23 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.806 0 C-N-CA 125.299 1.44 . . . . 0.0 110.292 -174.619 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 179.35 162.52 0.86 Allowed 'General case' 0 C--O 1.245 0.846 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -80.7 77.73 7.51 Favored 'General case' 0 C--O 1.216 -0.68 0 CA-C-O 122.224 1.011 . . . . 0.0 111.067 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -146.09 -171.49 3.72 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 114.435 -1.257 . . . . 0.0 107.761 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . 0.254 79.5 m-70 83.36 171.06 0.09 Allowed 'General case' 0 C--O 1.242 0.674 0 C-N-CA 125.589 1.556 . . . . 0.0 110.476 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -88.22 90.49 8.41 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -171.396 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -108.8 133.77 52.4 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 170.344 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 21.3 p80 . . . . . 0 C--N 1.29 -1.984 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 -177.285 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.437 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.627 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.471 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' GLU . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.498 HD13 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.471 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' A' ' 23' ' ' VAL . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? -95.85 121.17 37.3 Favored 'General case' 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.2 m -113.52 153.77 15.02 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.894 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -82.34 114.87 21.1 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.019 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.1 t -85.62 113.8 24.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 177.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 104.27 74.39 0.98 Allowed Glycine 0 N--CA 1.433 -1.527 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 -176.514 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.88 119.26 2.21 Favored Glycine 0 N--CA 1.433 -1.505 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.35 77.64 1.1 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.0 150.4 35.85 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.249 0.62 . . . . 0.0 111.773 -178.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.7 mt -91.42 128.05 43.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.492 -177.254 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.3 t70 72.02 8.83 6.02 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 125.593 1.557 . . . . 0.0 112.397 173.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 49.8 mm -89.18 -19.86 7.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.899 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.06 171.94 38.23 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.042 -0.981 . . . . 0.0 111.625 176.869 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 63.8 m 76.27 -46.16 0.53 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.473 1.509 . . . . 0.0 111.443 -176.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 146.66 96.81 0.19 Allowed Glycine 0 N--CA 1.432 -1.607 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -129.17 97.93 4.75 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -153.01 -56.31 0.12 Allowed 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 69.79 -55.54 0.59 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 126.343 1.857 . . . . 0.0 113.885 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 156.61 -138.06 5.76 Favored Glycine 0 N--CA 1.42 -2.368 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.842 178.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 97.04 -70.0 0.79 Allowed Glycine 0 N--CA 1.439 -1.159 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 -177.864 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -143.6 112.06 6.39 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.7 119.19 2.8 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -178.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -155.21 176.61 12.33 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -68.17 -36.76 80.13 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 177.292 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -123.8 121.57 35.77 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.67 176.295 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -133.94 -158.84 8.73 Favored Glycine 0 N--CA 1.437 -1.255 0 C-N-CA 120.709 -0.757 . . . . 0.0 111.515 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.3 -18.87 29.17 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 122.555 0.342 . . . . 0.0 110.506 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -64.84 132.8 50.44 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.479 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -69.46 129.46 39.78 Favored 'General case' 0 C--O 1.249 1.062 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.449 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.68 102.32 0.07 Allowed 'General case' 0 N--CA 1.44 -0.973 0 O-C-N 124.902 1.376 . . . . 0.0 113.006 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.7 p -124.61 147.37 48.53 Favored 'General case' 0 N--CA 1.412 -2.335 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 176.471 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 49.6 mt-30 -70.76 106.23 3.49 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.189 0.519 . . . . 0.0 110.709 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.9 mttp -113.98 120.56 41.07 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 176.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -154.57 171.54 19.27 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 123.255 0.347 . . . . 0.0 111.102 178.4 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.598 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.627 HG22 ' HB3' ' A' ' 18' ' ' LEU . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.426 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.527 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.557 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.406 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.416 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.427 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.443 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' MET . . . . . 0.557 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.604 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.604 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.479 ' SD ' HD11 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.527 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.479 HD11 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.562 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.426 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.445 ' HA ' HD23 ' A' ' 33' ' ' LEU . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.413 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.437 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -92.01 144.6 25.28 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.4 tp 73.59 161.22 0.24 Allowed 'General case' 0 CA--C 1.547 0.848 0 O-C-N 124.589 1.18 . . . . 0.0 110.919 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 183' ' ' HIS . 0.9 OUTLIER -77.4 173.87 11.46 Favored 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 176.12 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.411 ' H ' ' CD ' ' A' ' 182' ' ' GLU . 12.5 p-80 -75.89 8.29 3.24 Favored 'General case' 0 CA--C 1.549 0.941 0 O-C-N 121.181 -0.95 . . . . 0.0 112.124 -177.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -79.59 68.51 5.65 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.272 1.034 . . . . 0.0 109.684 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.0 t-80 -138.03 -4.41 1.73 Allowed 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.583 175.126 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 56.86 166.73 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 126.873 2.069 . . . . 0.0 113.232 -175.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -103.85 94.86 5.65 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.186 -1.006 . . . . 0.0 111.642 178.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 . . . . . 0 C--N 1.299 -1.59 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 174.432 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.466 ' HB2' ' HG3' ' A' ' 176' ' ' LYS . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG23 HD12 ' A' ' 18' ' ' LEU . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.4 HD12 HG23 ' A' ' 14' ' ' VAL . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.467 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.509 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 171' ' ' VAL . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.459 ' CD2' HG23 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.553 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp -87.4 115.17 24.63 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 32.9 m -110.62 162.63 8.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 70' ' ' GLN . . . -82.5 114.57 21.01 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -98.75 -89.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.663 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 70' ' ' GLN . . . 93.98 163.12 36.0 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 178.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.85 -21.42 2.5 Favored Glycine 0 C--N 1.31 -0.886 0 N-CA-C 111.804 -0.518 . . . . 0.0 111.804 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 166.26 33.57 Favored Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.383 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 58.63 98.72 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.495 1.518 . . . . 0.0 112.933 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 41.9 mm -81.65 114.94 23.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -105.37 61.8 0.68 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-O 121.044 0.45 . . . . 0.0 110.404 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 73.1 mt 69.42 109.22 0.04 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.485 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.837 -177.206 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.88 -23.16 74.21 Favored Glycine 0 CA--C 1.519 0.288 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.334 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 25.7 m -83.55 1.33 42.55 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 122.946 0.498 . . . . 0.0 110.817 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.44 -5.19 88.83 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-N 116.483 -0.326 . . . . 0.0 112.492 -178.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -101.02 97.51 8.06 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 176.885 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.58 -56.41 2.18 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 177.517 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -131.24 113.88 14.37 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.36 153.73 6.13 Favored Glycine 0 N--CA 1.426 -1.997 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.703 -178.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.33 -60.44 0.59 Allowed Glycine 0 N--CA 1.429 -1.774 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 71.76 -58.05 0.59 Allowed 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 126.326 1.85 . . . . 0.0 112.456 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 139.29 138.88 3.71 Favored Glycine 0 N--CA 1.427 -1.953 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.43 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -146.11 152.08 38.71 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -89.47 -28.12 19.89 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -174.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -126.87 -38.57 2.03 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.389 -171.895 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.57 -31.19 34.02 Favored Glycine 0 N--CA 1.441 -1.012 0 CA-C-N 116.379 -0.373 . . . . 0.0 112.984 -174.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.33 97.3 2.46 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.576 0.703 . . . . 0.0 111.994 -177.28 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.02 -49.3 14.29 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -163.83 166.61 21.74 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 178.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.36 23.03 0.41 Allowed 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.089 0.555 . . . . 0.0 111.854 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.1 m -62.69 -64.49 0.91 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.618 1.167 . . . . 0.0 110.756 -178.08 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.496 ' HB2' ' H ' ' A' ' 44' ' ' GLY . 97.9 mt-30 -100.62 141.98 32.73 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.381 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 9.3 mtmp? -125.71 119.9 29.22 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 168.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 161.16 40.92 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -175.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.51 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.479 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.436 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.53 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.466 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.532 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.509 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.625 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.546 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.57 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.57 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.53 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.625 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.502 ' HA ' HD23 ' A' ' 33' ' ' LEU . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.406 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.437 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG3' ' HB2' ' A' ' 5' ' ' LYS . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.73 116.82 32.72 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 7.2 mp -90.11 87.6 6.94 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 170.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.85 147.42 48.86 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.181 -176.432 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.3 t60 70.34 103.52 0.06 Allowed 'General case' 0 CA--C 1.515 -0.393 0 C-N-CA 125.343 1.457 . . . . 0.0 108.107 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 34.5 p-80 -41.57 116.55 0.79 Allowed 'General case' 0 N--CA 1.475 0.81 0 O-C-N 124.691 1.245 . . . . 0.0 113.25 -176.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -86.6 94.99 9.61 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.91 97.6 6.33 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -101.03 137.53 39.27 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.288 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 . . . . . 0 N--CA 1.422 -1.843 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.985 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.468 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.526 HD11 ' HA ' ' A' ' 101' ' ' TYR . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.43 ' HB2' ' HE2' ' A' ' 148' ' ' MET . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.411 HG23 HG12 ' A' ' 14' ' ' VAL . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.411 HG12 HG23 ' A' ' 13' ' ' VAL . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' HG22 ' A' ' 75' ' ' VAL . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.453 HG12 HD12 ' A' ' 33' ' ' LEU . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 HG12 ' A' ' 30' ' ' VAL . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 170' ' ' TYR . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt -88.24 112.54 22.9 Favored 'General case' 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 31.5 m -118.21 162.79 15.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.06 178.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -93.26 121.97 35.18 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.419 ' HB ' ' O ' ' A' ' 68' ' ' ALA . 61.7 t -70.78 -33.94 54.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.687 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.66 153.17 24.86 Favored Glycine 0 N--CA 1.424 -2.104 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.08 -39.87 0.67 Allowed Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.788 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.96 96.46 1.23 Allowed Glycine 0 N--CA 1.44 -1.099 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -45.89 104.81 0.05 Allowed 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 125.725 1.61 . . . . 0.0 112.717 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.3 mt 67.45 -51.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 125.566 1.546 . . . . 0.0 115.092 173.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -50.0 -45.61 51.95 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.151 1.38 . . . . 0.0 112.34 -177.169 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.6 mt -79.31 98.89 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.57 57.06 4.91 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 44.1 t -123.88 96.44 4.95 Favored 'General case' 0 N--CA 1.415 -2.221 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.67 -9.86 12.09 Favored Glycine 0 N--CA 1.435 -1.396 0 N-CA-C 109.851 -1.3 . . . . 0.0 109.851 174.033 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -94.29 112.2 23.98 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -130.76 157.94 41.48 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.957 -176.193 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -92.57 88.7 6.42 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 176.556 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.17 -53.55 4.78 Favored Glycine 0 CA--C 1.523 0.557 0 CA-C-N 116.059 -0.519 . . . . 0.0 112.365 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -175.53 118.98 0.69 Allowed Glycine 0 N--CA 1.428 -1.885 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -156.88 178.03 10.83 Favored 'General case' 0 C--O 1.245 0.828 0 N-CA-C 109.479 -0.564 . . . . 0.0 109.479 -178.516 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 127.57 163.29 11.36 Favored Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -178.715 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -72.44 -49.85 30.48 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 118.1 0.95 . . . . 0.0 108.867 -177.466 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -109.25 20.37 18.38 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 172.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 73.71 144.5 0.07 Allowed 'General case' 0 C--O 1.24 0.592 0 C-N-CA 125.549 1.54 . . . . 0.0 110.839 -169.8 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.24 63.04 0.39 Allowed Glycine 0 N--CA 1.434 -1.498 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.932 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.1 -38.72 63.76 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 178.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -135.53 150.45 49.75 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -90.9 81.16 5.72 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 118.9 -1.12 . . . . 0.0 110.912 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 43' ' ' VAL . . . -148.13 109.81 4.45 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 176.115 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.7 m -78.43 48.15 0.75 Allowed 'General case' 0 C--N 1.289 -2.065 0 CA-C-O 121.937 0.875 . . . . 0.0 111.014 -175.794 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -99.94 130.2 46.09 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -101.56 119.72 39.2 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 171.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.67 171.66 19.91 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -174.728 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.626 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 18' ' ' LEU . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.495 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.498 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 94' ' ' PHE . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.461 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.526 ' HA ' HD11 ' A' ' 8' ' ' ILE . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.406 HG12 ' HB2' ' A' ' 118' ' ' ASP . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.405 HG12 ' O ' ' A' ' 115' ' ' ALA . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.447 ' HB3' ' HZ3' ' A' ' 121' ' ' LYS . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.596 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' THR . . . . . 0.443 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.596 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 128' ' ' THR . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.64 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.403 ' HA ' HD12 ' A' ' 140' ' ' LEU . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.43 ' HE2' ' HB2' ' A' ' 11' ' ' ASP . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.498 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.64 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.417 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.468 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -121.28 161.45 21.98 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.651 ' H ' HD23 ' A' ' 181' ' ' LEU . 1.3 pt? -97.07 112.89 24.46 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 174.082 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.51 -3.84 17.76 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -166.336 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.0 t60 -80.89 -40.53 24.54 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.616 -1.234 . . . . 0.0 112.533 -169.088 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 53.7 59.8 4.08 Favored 'General case' 0 CA--C 1.549 0.926 0 O-C-N 124.05 0.844 . . . . 0.0 111.034 177.302 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 75.77 177.06 0.2 Allowed 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.543 1.537 . . . . 0.0 113.028 -178.106 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 10.1 t-80 -165.78 101.79 0.68 Allowed 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 176.135 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -79.33 93.26 5.27 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.334 0.587 . . . . 0.0 110.637 -177.807 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 177.668 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CE1' HG22 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HA ' ' A' ' 101' ' ' TYR . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.427 ' HA ' ' HB1' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.635 ' HB3' ' HE3' ' A' ' 148' ' ' MET . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HB3' HG22 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.523 HD13 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.444 ' CD2' HG23 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.522 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.401 ' CG1' HG21 ' A' ' 75' ' ' VAL . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt -85.2 135.44 33.95 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.6 m -122.4 141.08 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.312 0 CA-C-N 114.088 -1.414 . . . . 0.0 108.474 171.899 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -80.31 118.43 21.96 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 123.195 0.598 . . . . 0.0 109.741 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.47 129.91 68.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.24 93.46 1.77 Allowed Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 178.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -84.61 69.12 3.38 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 121.73 -0.271 . . . . 0.0 113.03 -177.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.27 99.69 2.23 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 174.177 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 70.96 161.75 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 125.993 1.717 . . . . 0.0 110.359 -175.123 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mt -77.3 -40.8 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 170.147 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -155.79 -59.7 0.1 Allowed 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.393 -2.077 . . . . 0.0 105.393 170.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 55.7 mt -139.6 94.35 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.869 0 N-CA-C 105.756 -1.942 . . . . 0.0 105.756 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 68.79 -132.03 26.36 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -172.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.8 t -104.55 -45.84 4.52 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.465 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.37 -76.51 0.22 Allowed Glycine 0 N--CA 1.437 -1.27 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.695 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -78.99 152.65 30.86 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 123.074 0.55 . . . . 0.0 110.018 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.2 -35.68 79.62 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.261 0.625 . . . . 0.0 112.543 -178.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -104.83 6.99 34.32 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.414 0.626 . . . . 0.0 109.957 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -94.07 138.58 14.12 Favored Glycine 0 N--CA 1.421 -2.327 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.072 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 151.7 -66.44 0.34 Allowed Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 57.93 -87.94 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.02 1.328 . . . . 0.0 113.11 178.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -109.86 1.41 30.26 Favored Glycine 0 C--O 1.224 -0.48 0 N-CA-C 112.086 -0.406 . . . . 0.0 112.086 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -117.92 16.23 14.28 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 177.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -78.08 -54.61 6.07 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.076 -173.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -83.77 101.79 11.85 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-O 121.535 0.683 . . . . 0.0 111.141 -174.027 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -172.6 57.99 0.16 Allowed Glycine 0 N--CA 1.418 -2.557 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -64.39 -53.29 50.88 Favored 'General case' 0 C--O 1.217 -0.637 0 O-C-N 124.112 0.537 . . . . 0.0 111.336 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -158.9 95.89 1.32 Allowed 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 121.092 0.472 . . . . 0.0 111.578 176.222 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -144.77 -177.95 5.77 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 177.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -136.3 44.43 2.42 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.577 0.703 . . . . 0.0 109.686 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.0 m -78.9 -3.59 45.5 Favored 'General case' 0 CA--C 1.558 1.283 0 CA-C-O 122.112 0.958 . . . . 0.0 109.189 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -97.98 111.64 23.88 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.625 -173.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -127.01 119.97 27.91 Favored 'General case' 0 C--N 1.281 -2.379 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 169.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -129.0 165.83 20.37 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -170.215 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 23.5 p-10 -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.502 HG22 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.47 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.513 ' O ' HG23 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.413 ' HA ' HD11 ' A' ' 8' ' ' ILE . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.478 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.464 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.464 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.426 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.474 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.523 ' CE3' HD13 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.615 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.615 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.47 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.635 ' HE3' ' HB3' ' A' ' 11' ' ' ASP . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.575 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.575 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HB1' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.489 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.507 HG12 ' H ' ' A' ' 174' ' ' GLY . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.507 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.417 HG22 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -86.96 102.45 14.39 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 80.6 mt -83.82 113.85 21.22 Favored 'General case' 0 N--CA 1.412 -2.361 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.701 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -59.27 -41.67 89.43 Favored 'General case' 0 C--N 1.316 -0.875 0 O-C-N 124.476 1.11 . . . . 0.0 108.41 178.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -118.32 102.08 8.68 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 114.999 -1.0 . . . . 0.0 108.956 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -81.49 79.9 7.98 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 174.309 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -106.0 117.38 33.89 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -177.328 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -80.99 103.99 11.19 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.538 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -90.7 88.52 7.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.262 -2.495 . . . . 0.0 104.262 169.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 . . . . . 0 C--N 1.31 -1.119 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 -171.162 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.468 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' TYR . . . . . 0.433 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.46 HD13 HG13 ' A' ' 75' ' ' VAL . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.424 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.428 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.555 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.47 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 80.4 mtp -88.52 109.31 19.95 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.439 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 33.7 m -110.59 157.39 11.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 115.342 -0.845 . . . . 0.0 108.888 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.407 ' HA ' ' O ' ' A' ' 70' ' ' GLN . . . -71.07 114.24 8.93 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.156 0.503 . . . . 0.0 110.319 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.29 -42.37 78.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 CA-C-N 114.497 -1.229 . . . . 0.0 110.322 -179.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.02 -78.19 1.16 Allowed Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -160.96 144.2 9.66 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.87 -28.45 0.47 Allowed Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.436 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.74 60.53 4.71 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.1 mt -146.2 101.4 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 174.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.1 t70 67.06 117.36 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 124.605 1.162 . . . . 0.0 113.423 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt 72.0 -38.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 125.026 1.33 . . . . 0.0 112.899 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.18 -9.57 64.02 Favored Glycine 0 CA--C 1.527 0.785 0 CA-C-N 116.421 -0.354 . . . . 0.0 113.839 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.2 m -92.39 -5.38 52.19 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 117.537 0.669 . . . . 0.0 110.89 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.82 96.0 1.93 Allowed Glycine 0 N--CA 1.433 -1.518 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 177.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -81.69 80.09 8.1 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.538 0.685 . . . . 0.0 109.4 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.28 23.99 7.49 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.204 -178.065 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -101.89 -62.25 1.28 Allowed 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 131.04 -71.96 0.49 Allowed Glycine 0 N--CA 1.428 -1.898 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 164.79 96.39 0.11 Allowed Glycine 0 N--CA 1.431 -1.687 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.35 94.41 4.85 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 122.492 0.317 . . . . 0.0 111.59 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 140.74 -123.33 2.33 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 121.045 -0.598 . . . . 0.0 111.854 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -160.78 -65.34 0.06 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -86.38 -48.25 8.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 122.227 1.013 . . . . 0.0 108.304 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.34 140.18 36.96 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 177.155 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -130.68 28.16 3.79 Favored Glycine 0 C--O 1.247 0.932 0 C-N-CA 119.636 -1.269 . . . . 0.0 114.936 -169.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -155.18 -152.26 0.39 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.339 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -127.58 171.74 11.37 Favored 'General case' 0 C--O 1.257 1.493 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -83.2 82.52 8.22 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.296 1.046 . . . . 0.0 109.916 -179.067 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 -47.48 0.07 Allowed 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 t -143.79 103.73 4.09 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.202 176.033 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' ALA . 23.1 mm-40 -84.98 112.16 20.34 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.609 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.47 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 55.6 mttm -97.38 122.31 40.28 Favored 'General case' 0 C--N 1.292 -1.926 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.806 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.64 162.24 36.43 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.599 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.599 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HB2' ' A' ' 82' ' ' ALA . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 78' ' ' PRO . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.423 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.454 ' HG ' ' CZ ' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 118' ' ' ASP . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.457 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.457 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.489 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.454 ' CZ ' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.433 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.631 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.696 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.696 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' ALA . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.422 ' HB3' ' HE2' ' A' ' 144' ' ' MET . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.443 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.506 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.447 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.631 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.428 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 174' ' ' GLY . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.496 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' VAL . . . . . 0.433 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 180' ' ' PHE . . . . . 0.444 ' CZ ' HG11 ' A' ' 3' ' ' VAL . 13.9 m-85 -73.36 103.07 3.91 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -122.13 -47.23 2.16 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.46 -40.25 26.62 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.187 176.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -80.17 118.48 21.9 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.146 176.765 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 90.3 m-70 -115.48 130.49 56.9 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.898 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 19.3 m-70 -97.41 158.43 15.48 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.56 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 64.2 t60 -74.58 112.55 10.88 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.24 0.543 . . . . 0.0 110.259 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -88.48 120.94 30.33 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 . . . . . 0 N--CA 1.485 1.323 0 C-N-CA 124.718 1.207 . . . . 0.0 110.246 -175.459 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.412 ' CG2' ' HA ' ' A' ' 152' ' ' ALA . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HB3' HG22 ' A' ' 75' ' ' VAL . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.488 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.44 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.409 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.515 HD23 ' HA ' ' A' ' 171' ' ' VAL . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.441 ' HB2' HG22 ' A' ' 23' ' ' VAL . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.536 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.449 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.603 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp -85.64 109.4 18.54 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.64 145.12 17.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.77 125.48 34.9 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.594 0.711 . . . . 0.0 111.627 -177.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.5 t -96.96 98.41 7.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.578 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.77 130.03 12.59 Favored Glycine 0 N--CA 1.438 -1.214 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.04 -146.05 40.65 Favored Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -176.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.63 -53.53 4.83 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 117.065 0.432 . . . . 0.0 113.196 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.14 71.41 0.58 Allowed 'General case' 0 CA--C 1.497 -1.075 0 C-N-CA 124.395 1.078 . . . . 0.0 111.953 -176.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -108.61 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.232 -178.525 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.4 t70 63.13 133.71 0.01 OUTLIER 'General case' 0 C--O 1.251 1.154 0 C-N-CA 124.834 1.254 . . . . 0.0 111.671 -174.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 38.7 mm -80.57 75.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 122.155 0.979 . . . . 0.0 109.898 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -158.55 20.12 0.32 Allowed Glycine 0 C--N 1.3 -1.437 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 175.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 81.3 m -87.11 112.66 22.14 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.59 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.13 -63.74 0.62 Allowed Glycine 0 N--CA 1.433 -1.532 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 178.624 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -92.76 89.25 6.55 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -90.85 109.86 21.08 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -74.74 -45.91 40.93 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.606 -178.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.52 88.76 1.34 Allowed Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.812 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -83.13 154.25 31.6 Favored Glycine 0 N--CA 1.436 -1.364 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 178.235 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.19 127.76 33.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.98 -71.74 2.35 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -149.47 137.59 20.57 Favored 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 122.707 0.403 . . . . 0.0 110.173 -177.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -81.68 77.73 8.49 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 123.174 0.59 . . . . 0.0 109.618 175.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -33.27 107.17 0.04 OUTLIER 'General case' 0 C--O 1.25 1.127 0 C-N-CA 125.32 1.448 . . . . 0.0 114.091 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -120.54 -98.22 1.65 Allowed Glycine 0 N--CA 1.432 -1.629 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.678 179.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -163.48 177.91 8.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.164 0.507 . . . . 0.0 111.319 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -139.75 156.03 47.0 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 105.408 -2.071 . . . . 0.0 105.408 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.9 t70 76.45 -26.37 0.19 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 124.667 1.187 . . . . 0.0 112.829 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 64.47 85.49 0.14 Allowed 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 124.938 1.295 . . . . 0.0 110.668 179.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' THR . . . . . 0.452 ' O ' ' HG3' ' A' ' 71' ' ' LYS . 14.2 t -120.3 23.81 10.72 Favored 'General case' 0 C--N 1.297 -1.706 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.681 -175.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -45.4 117.29 1.37 Allowed 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 126.432 1.893 . . . . 0.0 111.519 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HG3' ' O ' ' A' ' 69' ' ' THR . 62.7 mttp -112.52 120.99 43.52 Favored 'General case' 0 C--N 1.294 -1.839 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.901 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.4 165.72 24.52 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.491 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.467 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.498 ' HB3' ' CZ ' ' A' ' 168' ' ' PHE . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.447 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.447 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.45 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.479 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.635 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.485 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.513 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.432 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.513 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.417 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.645 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.645 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.62 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.629 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.433 ' HA ' HD12 ' A' ' 140' ' ' LEU . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.629 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.4 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CG2' ' A' ' 8' ' ' ILE . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.635 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.4 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.519 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.603 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.536 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.62 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.471 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.515 ' HA ' HD23 ' A' ' 33' ' ' LEU . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.424 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.456 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 3' ' ' VAL . 18.1 m-85 -86.94 126.85 34.97 Favored 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -87.48 178.28 6.85 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.788 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -94.6 146.5 24.09 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.657 -0.702 . . . . 0.0 111.848 -177.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -119.56 120.54 37.04 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.586 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -102.57 -39.45 7.08 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.314 -175.95 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -72.43 -32.97 66.76 Favored 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 11.5 t60 -91.73 110.76 22.1 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 171.576 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -88.0 -178.29 5.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.196 -173.516 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 46.6 m80 . . . . . 0 C--N 1.306 -1.298 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 177.467 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.516 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.436 HD11 ' HA ' ' A' ' 101' ' ' TYR . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.454 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.476 HG12 HD12 ' A' ' 33' ' ' LEU . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLY . . . . . 0.406 ' HA2' ' OG ' ' A' ' 173' ' ' SER . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 171' ' ' VAL . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.562 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm -114.16 146.95 39.64 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 74' ' ' ASN . 24.7 m -132.63 167.68 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.336 175.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -75.59 118.35 18.35 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.406 0.622 . . . . 0.0 110.761 -179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 68.3 t -100.6 132.05 47.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -116.57 -133.1 5.07 Favored Glycine 0 N--CA 1.431 -1.635 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.05 -60.98 1.05 Allowed Glycine 0 N--CA 1.434 -1.476 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.36 -35.83 2.84 Favored Glycine 0 N--CA 1.438 -1.192 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 70.49 19.51 6.25 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 125.034 1.334 . . . . 0.0 111.241 176.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 62.7 mt -101.88 106.0 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.911 -177.191 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.6 t70 70.86 -46.65 0.64 Allowed 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 125.744 1.617 . . . . 0.0 115.039 174.396 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt -67.35 121.47 16.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 123.044 0.538 . . . . 0.0 110.157 -178.474 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.27 -162.36 18.67 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.8 m 71.41 -30.73 0.21 Allowed 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 125.999 1.72 . . . . 0.0 113.576 178.024 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.3 -14.25 82.74 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 176.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -78.87 132.84 36.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 72.07 -44.73 0.6 Allowed 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.436 1.495 . . . . 0.0 113.922 177.098 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -82.91 102.53 11.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.075 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -125.79 91.21 0.39 Allowed Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 155.73 66.29 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.211 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -119.11 19.22 12.97 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 121.831 0.824 . . . . 0.0 109.452 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.38 -70.6 0.21 Allowed Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 106.698 -2.561 . . . . 0.0 106.698 -174.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 58.45 26.57 14.36 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.717 1.207 . . . . 0.0 111.762 172.536 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -71.31 -33.56 69.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.04 -176.777 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.421 ' CD ' ' H ' ' A' ' 63' ' ' GLU . 0.0 OUTLIER -96.54 1.71 51.65 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.71 -178.955 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -107.46 -64.09 0.59 Allowed Glycine 0 N--CA 1.428 -1.873 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.865 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.08 90.39 3.32 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.06 0.457 . . . . 0.0 111.46 -175.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -99.22 -14.28 19.36 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 173.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -140.97 128.75 21.65 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 176.406 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -76.48 110.19 10.82 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 35.2 m 72.17 91.62 0.09 Allowed 'General case' 0 C--O 1.24 0.559 0 C-N-CA 124.726 1.21 . . . . 0.0 109.612 -174.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.9 mp0 -75.74 150.38 37.83 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.046 -177.505 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.463 ' HD2' ' N ' ' A' ' 71' ' ' LYS . 6.0 mptt -116.57 121.46 41.82 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -128.19 172.73 10.74 Favored 'General case' 0 C--N 1.281 -2.413 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.466 ' HA ' HG22 ' A' ' 41' ' ' VAL . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.43 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.434 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.409 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' ASP . . . . . 0.424 ' HA ' ' HB3' ' A' ' 103' ' ' ARG . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.436 ' HA ' HD11 ' A' ' 8' ' ' ILE . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 101' ' ' TYR . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . 0.442 HG12 ' HB2' ' A' ' 118' ' ' ASP . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.431 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.442 ' HB2' HG12 ' A' ' 114' ' ' VAL . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.604 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.441 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.538 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.538 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.489 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.48 ' HB2' ' HB3' ' A' ' 152' ' ' ALA . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 149' ' ' ASN . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.409 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.5 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.404 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.404 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.545 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 174' ' ' GLY . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.4 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.441 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.516 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -113.13 102.81 10.73 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 181' ' ' LEU . 1.5 pt? -100.44 -17.26 17.26 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 68.27 -7.81 0.64 Allowed 'General case' 0 C--N 1.351 0.652 0 C-N-CA 127.308 2.243 . . . . 0.0 113.596 176.947 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 61.65 59.03 1.89 Allowed 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 123.848 0.859 . . . . 0.0 110.213 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -79.99 94.68 5.96 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.392 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.8 t60 -134.26 84.5 2.12 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -83.45 110.84 18.51 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.756 -0.657 . . . . 0.0 112.208 -175.571 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 188' ' ' HIS . 61.4 t60 -109.39 90.31 3.26 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 176.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 188' ' ' HIS . . . . . 0.436 ' HB2' ' O ' ' A' ' 187' ' ' HIS . 6.0 t60 . . . . . 0 N--CA 1.484 1.239 0 C-N-CA 126.545 1.938 . . . . 0.0 106.029 174.515 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.45 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.489 HD11 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HB2' HD21 ' A' ' 74' ' ' ASN . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.448 HG23 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.51 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.448 ' CD2' HG23 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm -93.67 128.86 40.07 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.9 m -122.54 167.82 15.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.25 113.96 4.97 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.903 0.752 . . . . 0.0 110.633 173.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.0 t -109.01 97.44 5.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 174.201 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -104.1 169.35 17.6 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 115.119 -0.946 . . . . 0.0 113.042 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.93 63.78 3.78 Favored Glycine 0 N--CA 1.434 -1.442 0 CA-C-N 115.42 -0.39 . . . . 0.0 112.488 176.924 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.05 107.36 3.15 Favored Glycine 0 N--CA 1.421 -2.312 0 N-CA-C 107.94 -2.064 . . . . 0.0 107.94 176.016 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -60.58 126.12 26.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -175.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.4 mm -88.81 74.69 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 105.147 -2.168 . . . . 0.0 105.147 170.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.0 -40.03 10.32 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 113.333 -1.758 . . . . 0.0 109.262 -176.047 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt 61.37 82.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.772 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.63 129.07 4.87 Favored Glycine 0 CA--C 1.488 -1.628 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 72.5 m 60.32 21.79 11.28 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.933 0.893 . . . . 0.0 111.074 -176.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.89 157.4 25.88 Favored Glycine 0 N--CA 1.428 -1.886 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 71.83 6.35 5.61 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 125.464 1.506 . . . . 0.0 112.994 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.97 -49.95 5.32 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 175.115 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -126.44 -63.46 1.09 Allowed 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.946 -1.025 . . . . 0.0 108.236 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.0 -162.84 38.69 Favored Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.522 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -85.42 174.74 49.0 Favored Glycine 0 C--N 1.311 -0.813 0 C-N-CA 121.671 -0.299 . . . . 0.0 113.008 -176.195 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -137.55 -178.76 5.37 Favored 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.23 -110.02 3.39 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -164.47 100.68 0.82 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -87.21 -31.3 20.39 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.051 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -170.57 74.58 0.07 Allowed 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.49 -76.36 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.778 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 175.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.57 93.21 4.18 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.44 0.638 . . . . 0.0 109.403 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -88.2 115.94 26.04 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.685 -179.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -132.88 141.89 48.64 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.239 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.37 30.18 0.69 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.562 0.539 . . . . 0.0 109.939 -177.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 31.1 m -69.5 -35.8 75.87 Favored 'General case' 0 CA--C 1.558 1.288 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -176.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -100.32 119.69 38.8 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 122.021 -0.424 . . . . 0.0 110.035 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -105.54 120.39 41.51 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 171.313 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -154.6 171.56 19.26 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.21 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.424 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.431 HD21 ' HB2' ' A' ' 19' ' ' LYS . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.405 HG22 ' HB3' ' A' ' 18' ' ' LEU . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.489 ' CE1' HD11 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.515 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.436 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.49 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.615 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.615 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.515 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.515 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.424 ' HB3' HD13 ' A' ' 140' ' ' LEU . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.51 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.484 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 180' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 -68.41 117.64 10.45 Favored 'General case' 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 56.1 tp 71.11 -73.63 0.1 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 126.029 1.732 . . . . 0.0 111.127 -177.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 52.09 74.61 0.26 Allowed 'General case' 0 C--O 1.24 0.577 0 CA-C-O 122.56 1.171 . . . . 0.0 110.942 -175.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.6 t60 -149.41 101.5 3.11 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.8 t60 67.15 19.41 10.39 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.41 1.084 . . . . 0.0 108.553 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 63.83 -78.26 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.173 1.389 . . . . 0.0 109.887 -172.028 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 1.9 m80 166.16 -79.13 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 128.238 2.615 . . . . 0.0 107.718 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -107.4 90.94 3.45 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 . . . . . 0 C--O 1.246 0.899 0 C-N-CA 124.743 1.217 . . . . 0.0 110.497 -176.718 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.481 HG22 ' HA ' ' A' ' 152' ' ' ALA . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.43 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.467 HG23 HD12 ' A' ' 18' ' ' LEU . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.467 HD12 HG23 ' A' ' 14' ' ' VAL . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' MET . . . . . 0.419 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' GLU . . . . . 0.457 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 171' ' ' VAL . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt -79.14 140.81 37.69 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.8 m -136.28 159.81 38.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 172.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.78 140.51 36.87 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.4 t -63.01 -43.72 99.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.135 0.493 . . . . 0.0 109.779 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 111.84 158.87 14.79 Favored Glycine 0 N--CA 1.426 -1.975 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.377 177.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.9 -170.97 23.27 Favored Glycine 0 N--CA 1.424 -2.148 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -177.86 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 65.07 -155.18 49.21 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.509 ' HB2' ' CD1' ' A' ' 50' ' ' ILE . 9.2 m-20 -119.73 -28.55 5.22 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 176.503 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 71.6 mt 73.76 -29.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.214 0 C-N-CA 124.74 1.216 . . . . 0.0 112.742 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -71.66 -3.46 21.79 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 123.911 0.884 . . . . 0.0 112.707 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.509 ' CD1' ' HB2' ' A' ' 47' ' ' ASP . 2.6 mp -78.66 115.14 20.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.57 -129.31 9.21 Favored Glycine 0 N--CA 1.422 -2.288 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.444 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.0 m -126.98 132.54 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -176.89 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -71.08 -15.06 74.14 Favored Glycine 0 C--O 1.222 -0.619 0 N-CA-C 114.499 0.56 . . . . 0.0 114.499 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 46.0 m-80 -100.5 -0.22 38.31 Favored 'General case' 0 C--N 1.311 -1.099 0 O-C-N 122.012 -0.699 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.51 125.65 42.32 Favored 'General case' 0 N--CA 1.434 -1.269 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -138.71 178.49 7.11 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.74 -117.44 1.07 Allowed Glycine 0 N--CA 1.426 -2.01 0 O-C-N 123.888 0.743 . . . . 0.0 112.498 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.81 22.95 57.07 Favored Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -174.539 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 40.17 0.14 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 148.42 -76.19 0.26 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -176.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -87.76 88.24 7.6 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -86.85 -58.81 2.46 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.724 -1.125 . . . . 0.0 108.5 -176.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -103.48 35.5 2.57 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.618 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -162.5 -171.81 29.14 Favored Glycine 0 N--CA 1.43 -1.761 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -171.8 -172.35 1.0 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -178.869 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -100.32 3.82 43.63 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.595 1.188 . . . . 0.0 109.92 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -141.06 -161.16 1.17 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.462 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -119.28 33.52 5.61 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-O 122.17 0.986 . . . . 0.0 109.006 -179.636 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 m -78.0 2.09 18.77 Favored 'General case' 0 CA--C 1.577 1.989 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.21 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 6.1 mp0 -47.71 125.41 8.55 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 125.719 1.608 . . . . 0.0 111.764 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -105.48 128.06 53.35 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.36 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -138.07 159.78 41.12 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -178.182 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.462 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.462 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.443 ' CE1' HD11 ' A' ' 18' ' ' LEU . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.514 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.46 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.46 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.415 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.415 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.583 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.583 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.653 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.435 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.556 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' LYS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.405 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.556 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.481 ' HA ' HG22 ' A' ' 8' ' ' ILE . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.514 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.539 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.541 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.653 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.43 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 174' ' ' GLY . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.482 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -117.64 157.48 26.35 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -148.89 154.76 39.92 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.96 106.98 10.17 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -147.03 -10.47 0.44 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.186 -176.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -143.25 23.09 1.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 123.119 0.567 . . . . 0.0 110.895 178.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.7 t60 -119.66 57.57 0.91 Allowed 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -104.61 147.94 27.08 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.125 178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 1.4 p-80 -105.43 176.69 5.08 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.286 0.565 . . . . 0.0 112.379 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 t60 . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 175.536 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.497 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.405 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.427 ' O ' HG13 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 33' ' ' LEU . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.549 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.532 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 72.3 mtm -87.45 128.99 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.2 m -121.28 165.46 16.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.961 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.08 114.82 7.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 124.143 0.902 . . . . 0.0 111.482 179.253 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.1 t -82.36 -48.31 18.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 158.43 -156.57 27.54 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.21 119.9 6.46 Favored Glycine 0 N--CA 1.429 -1.777 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -103.01 -172.66 26.37 Favored Glycine 0 C--N 1.302 -1.309 0 N-CA-C 110.741 -0.943 . . . . 0.0 110.741 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -88.55 -54.93 3.93 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 117.481 0.64 . . . . 0.0 111.712 -176.87 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.1 mt -92.11 79.35 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.454 -173.048 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.7 t70 177.15 114.44 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 173.306 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -115.31 92.31 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.185 -174.242 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.2 -81.1 0.82 Allowed Glycine 0 C--O 1.239 0.418 0 CA-C-N 115.431 -0.804 . . . . 0.0 113.381 176.513 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 39.6 m 66.21 179.33 0.21 Allowed 'General case' 0 C--O 1.254 1.33 0 C-N-CA 125.682 1.593 . . . . 0.0 111.834 178.21 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.41 70.7 2.92 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 107.949 -2.061 . . . . 0.0 107.949 173.512 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -121.68 135.17 54.97 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 123.864 0.865 . . . . 0.0 110.254 -169.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.21 121.68 27.41 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 67.7 m-85 -93.19 6.36 48.29 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.871 0.367 . . . . 0.0 111.498 -176.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -134.27 120.06 2.37 Favored Glycine 0 N--CA 1.439 -1.107 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 177.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -116.8 -105.32 2.4 Favored Glycine 0 N--CA 1.436 -1.307 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.262 -177.889 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -127.13 -19.76 4.28 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.083 0.468 . . . . 0.0 110.985 -178.799 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -163.33 43.43 0.33 Allowed Glycine 0 CA--C 1.484 -1.874 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.45 14.94 16.78 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 113.856 -1.172 . . . . 0.0 108.906 -172.018 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -59.8 -54.68 43.4 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.168 -174.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -119.54 29.23 7.72 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.516 -174.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -61.42 -45.93 95.4 Favored Glycine 0 C--N 1.337 0.636 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 176.496 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -177.67 158.36 1.33 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 125.719 1.607 . . . . 0.0 106.688 175.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -96.55 66.45 2.34 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 122.002 0.906 . . . . 0.0 110.483 179.273 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.8 t70 156.21 81.97 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 129.048 2.939 . . . . 0.0 104.967 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ALA . . . . . 0.423 ' O ' ' HE3' ' A' ' 71' ' ' LYS . . . -87.24 72.81 9.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.012 -177.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -87.04 -43.57 12.22 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.799 -179.287 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -85.1 122.33 29.16 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.5 0.667 . . . . 0.0 112.083 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.532 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 2.2 mptm? -120.66 143.26 48.79 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.074 176.881 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.65 160.35 43.17 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 176.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.544 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.544 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.437 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.414 ' O ' HD13 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.416 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.433 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.416 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.451 ' HA ' HD11 ' A' ' 33' ' ' LEU . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.672 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.627 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.627 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 155' ' ' ILE . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE2' ' HA ' ' A' ' 150' ' ' PRO . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 145' ' ' SER . . . . . 0.441 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.519 ' HA ' ' HE2' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.405 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' PHE . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.468 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.549 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.672 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.611 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 174' ' ' GLY . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.435 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.497 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -107.45 143.42 35.83 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -95.92 -29.32 14.24 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.311 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.0 pm0 -77.35 156.14 31.46 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-N 114.366 -1.288 . . . . 0.0 108.854 176.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -117.88 129.56 55.71 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -87.66 12.27 13.08 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 122.163 0.982 . . . . 0.0 110.699 -178.3 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -122.99 86.38 2.57 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 172.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.4 t60 -119.75 -10.89 9.47 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.571 -170.038 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -71.53 129.29 38.4 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 52.1 p-80 . . . . . 0 C--N 1.31 -1.151 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.858 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.502 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 101' ' ' TYR . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.424 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.514 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 75' ' ' VAL . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.435 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.511 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.501 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.411 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 25.1 mmt -84.23 116.71 23.1 Favored 'General case' 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.84 154.2 24.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.111 177.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.19 133.12 36.71 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.453 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.0 t -65.99 97.93 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.834 0 CA-C-O 121.514 0.673 . . . . 0.0 111.554 -178.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -160.86 84.12 0.12 Allowed Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 108.404 -1.878 . . . . 0.0 108.404 176.837 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.03 154.87 16.89 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.955 -175.173 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 151.57 -158.27 27.65 Favored Glycine 0 N--CA 1.431 -1.667 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -75.79 122.45 24.08 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp 66.23 69.01 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-O 123.019 1.39 . . . . 0.0 107.841 -171.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -96.32 177.84 5.57 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.498 -1.683 . . . . 0.0 111.551 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.61 90.7 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.017 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 176.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -168.78 178.75 42.01 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.1 m 68.64 -65.19 0.28 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 125.077 1.351 . . . . 0.0 111.083 -177.352 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -101.88 63.67 0.49 Allowed Glycine 0 CA--C 1.493 -1.343 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 175.741 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -54.83 -50.58 68.25 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 125.946 1.699 . . . . 0.0 111.7 -173.272 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.77 -39.64 2.95 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.325 -178.898 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 59.1 m-85 -126.74 138.9 53.45 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 80.01 39.6 16.16 Favored Glycine 0 C--N 1.31 -0.896 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.19 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.7 -44.57 0.21 Allowed Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.356 -0.925 . . . . 0.0 112.449 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -93.72 92.62 7.57 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 122.642 -0.328 . . . . 0.0 111.146 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -107.41 -146.17 12.64 Favored Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -89.65 60.81 5.23 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 122.724 1.25 . . . . 0.0 110.765 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -108.81 -48.92 3.22 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.105 -177.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 63.39 70.55 0.53 Allowed 'General case' 0 C--O 1.241 0.621 0 O-C-N 124.267 0.98 . . . . 0.0 111.37 -172.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -111.72 128.19 8.5 Favored Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 176.103 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 72.6 -43.06 0.55 Allowed 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 125.235 1.414 . . . . 0.0 112.796 -177.604 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -76.84 102.25 6.24 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -150.91 -63.27 0.19 Allowed 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.19 82.63 1.26 Allowed 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 107.977 -1.119 . . . . 0.0 107.977 171.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 15.2 t -143.9 170.97 14.9 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -77.54 149.35 34.92 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -118.64 121.2 39.6 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 174.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.48 171.55 14.32 Favored 'General case' 0 C--N 1.285 -2.214 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.693 -170.902 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' THR . . . . . 0.532 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ALA . . . . . 0.412 ' HB2' ' CE1' ' A' ' 143' ' ' PHE . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.572 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.572 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.464 ' O ' HG23 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.556 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.437 ' HA ' HD11 ' A' ' 8' ' ' ILE . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.447 HG13 ' HA3' ' A' ' 174' ' ' GLY . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.435 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.647 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.492 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.475 ' HB3' HD11 ' A' ' 154' ' ' LEU . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.532 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.494 ' HE3' ' HA ' ' A' ' 150' ' ' PRO . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.584 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.584 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.424 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.556 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CD2' HD13 ' A' ' 140' ' ' LEU . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.531 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.501 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.647 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.514 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.511 ' HA ' HD23 ' A' ' 33' ' ' LEU . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.538 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.471 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.502 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 179' ' ' LYS . . . . . 0.489 ' HB2' ' CE1' ' A' ' 183' ' ' HIS . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -87.56 103.1 15.23 Favored 'General case' 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.593 ' HB3' ' CE1' ' A' ' 183' ' ' HIS . 45.2 tp 170.4 163.56 0.07 Allowed 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 177.08 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -58.76 -49.87 76.03 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 118.366 0.53 . . . . 0.0 112.23 -177.371 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 181' ' ' LEU . 73.7 m80 57.92 50.76 9.87 Favored 'General case' 0 N--CA 1.481 1.082 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.417 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -72.67 -10.7 60.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 113.702 -1.59 . . . . 0.0 112.978 -169.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 9.5 p-80 -55.47 113.03 1.26 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.611 0.719 . . . . 0.0 111.096 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 17.8 p-80 -100.06 -25.51 14.28 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.7 -175.586 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -109.49 144.52 37.63 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 30.6 m80 . . . . . 0 C--N 1.295 -1.791 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.542 174.116 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.466 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.493 HD13 HG13 ' A' ' 75' ' ' VAL . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' CG1' HD12 ' A' ' 33' ' ' LEU . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD23 ' HA ' ' A' ' 171' ' ' VAL . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.49 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 75' ' ' VAL . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' SER . . . . . 0.474 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.441 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 58.6 mtt -81.67 150.28 28.11 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.5 m -131.96 148.54 32.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 113.739 -1.573 . . . . 0.0 107.444 172.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.454 ' HA ' ' HG2' ' A' ' 71' ' ' LYS . . . -74.33 114.59 12.88 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 121.287 0.565 . . . . 0.0 110.66 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 56.8 t -113.93 140.98 31.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -79.41 128.76 8.72 Favored Glycine 0 N--CA 1.43 -1.735 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 174.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.64 43.98 1.31 Allowed Glycine 0 C--N 1.301 -1.389 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.046 -175.676 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 77.78 -128.11 8.66 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.131 178.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -83.25 -37.31 23.71 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.829 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.1 mt 75.05 -48.88 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 125.939 1.695 . . . . 0.0 112.806 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 72.09 -65.2 0.36 Allowed 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 125.648 1.579 . . . . 0.0 113.451 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 46.0 mm 68.76 99.11 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.713 1.205 . . . . 0.0 111.459 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.2 131.33 8.12 Favored Glycine 0 N--CA 1.423 -2.223 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 177.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 61.8 m -67.53 117.37 9.39 Favored 'General case' 0 C--O 1.25 1.112 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.6 63.14 4.26 Favored Glycine 0 N--CA 1.44 -1.077 0 CA-C-N 115.602 -0.727 . . . . 0.0 113.649 -174.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -65.54 -36.66 84.47 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 123.338 0.655 . . . . 0.0 110.091 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 -10.3 59.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.658 -177.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -94.12 -26.05 16.88 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.98 -76.56 1.51 Allowed Glycine 0 N--CA 1.435 -1.413 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -178.505 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.35 70.96 0.28 Allowed Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.32 120.56 24.54 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 100.4 83.6 1.75 Allowed Glycine 0 N--CA 1.422 -2.282 0 N-CA-C 108.081 -2.007 . . . . 0.0 108.081 -174.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -64.81 -47.96 76.13 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.47 0.708 . . . . 0.0 111.046 -174.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -81.89 -18.43 43.76 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.289 177.927 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 62.02 79.87 0.24 Allowed 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.455 1.502 . . . . 0.0 111.223 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -153.25 -91.39 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.371 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 58.71 -165.59 0.18 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.645 1.178 . . . . 0.0 111.947 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -162.8 147.86 11.91 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.936 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -90.83 -22.15 21.12 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -101.38 -39.0 7.78 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.21 -175.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 24.8 p -128.91 174.34 9.59 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.382 -178.278 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -100.55 112.74 25.15 Favored 'General case' 0 N--CA 1.411 -2.376 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 171.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.454 ' HG2' ' HA ' ' A' ' 42' ' ' ALA . 49.9 mtmt -96.31 120.73 37.14 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.712 179.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.05 165.82 24.16 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -176.467 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.437 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 36' ' ' VAL . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.462 ' HA ' ' CD1' ' A' ' 83' ' ' TYR . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.551 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.463 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.555 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.463 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.452 ' O ' HG23 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 105' ' ' VAL . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.407 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.687 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.53 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.437 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ASN . . . . . 0.636 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' PRO . . . . . 0.636 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.437 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.555 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.579 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.474 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.687 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.577 ' HA ' HD23 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.441 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.419 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -89.83 150.14 22.36 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 90.8 mt 81.22 8.94 1.03 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.018 1.727 . . . . 0.0 110.273 -174.104 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -90.0 -176.07 4.78 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.457 176.433 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -94.61 19.65 9.58 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -170.985 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.6 t-80 -125.42 29.79 5.95 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.906 -1.886 . . . . 0.0 105.906 175.614 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 17.1 t-160 -86.77 74.34 9.82 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.426 -173.049 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -104.48 -2.05 25.82 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 172.294 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -88.4 176.87 7.0 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.676 178.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 75.6 t60 . . . . . 0 C--N 1.311 -1.08 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.211 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.414 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.506 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 36' ' ' VAL . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 171' ' ' VAL . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.472 ' HD2' ' HB2' ' A' ' 172' ' ' LYS . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp -83.74 117.02 22.96 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.1 m -110.69 168.92 4.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.61 121.81 22.18 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 123.783 0.677 . . . . 0.0 110.839 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.7 t -111.37 94.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.25 150.25 18.53 Favored Glycine 0 N--CA 1.42 -2.422 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.7 83.74 1.34 Allowed Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.163 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.19 20.25 26.82 Favored Glycine 0 C--O 1.228 -0.258 0 C-N-CA 121.935 -0.174 . . . . 0.0 113.002 -176.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -56.86 -45.75 82.24 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.901 1.28 . . . . 0.0 109.62 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -124.12 105.49 15.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.866 -2.272 . . . . 0.0 104.866 173.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -144.48 150.02 36.92 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 121.229 -0.188 . . . . 0.0 110.873 -175.023 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.6 mp -88.21 93.71 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.107 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -133.51 -120.82 2.14 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 178.373 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 40.2 m -114.99 -6.67 12.55 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.165 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.08 -68.2 3.25 Favored Glycine 0 N--CA 1.443 -0.899 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -175.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -154.45 105.76 2.68 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.182 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.44 -72.8 0.26 Allowed 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.483 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -99.58 -7.81 25.35 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.75 0.786 . . . . 0.0 109.09 177.497 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.93 -100.77 0.29 Allowed Glycine 0 N--CA 1.426 -1.99 0 N-CA-C 107.439 -2.264 . . . . 0.0 107.439 -177.273 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -86.67 -28.02 27.87 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 173.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.45 133.24 36.53 Favored 'General case' 0 C--O 1.255 1.373 0 CA-C-N 115.29 -0.455 . . . . 0.0 109.838 178.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 165.18 -134.46 3.33 Favored Glycine 0 N--CA 1.424 -2.141 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -148.58 29.03 0.86 Allowed 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.685 1.231 . . . . 0.0 109.117 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -86.56 74.8 9.82 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.518 0.932 . . . . 0.0 113.518 -176.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -177.19 68.78 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.446 1.499 . . . . 0.0 107.955 173.715 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -97.89 -67.79 0.92 Allowed Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 70.37 -57.37 0.58 Allowed 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 126.006 1.723 . . . . 0.0 113.238 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -168.54 -159.55 0.26 Allowed 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 103.715 -2.698 . . . . 0.0 103.715 -177.261 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -77.62 -28.86 51.54 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 119.208 0.913 . . . . 0.0 110.086 175.411 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -176.69 140.05 0.33 Allowed 'General case' 0 CA--C 1.507 -0.702 0 O-C-N 124.818 1.324 . . . . 0.0 109.017 175.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 23.9 m -94.25 -71.23 0.67 Allowed 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 105.404 -2.072 . . . . 0.0 105.404 170.586 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 27.7 mp0 -102.79 174.37 5.91 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 168.367 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.69 141.3 48.53 Favored 'General case' 0 CA--C 1.486 -1.519 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 168.087 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.71 165.76 35.56 Favored 'General case' 0 C--N 1.285 -2.232 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.431 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.424 ' CZ ' HD11 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.446 ' O ' HG23 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.523 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' VAL . . . . . 0.461 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG13 ' HA2' ' A' ' 174' ' ' GLY . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.623 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.503 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.623 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.503 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.518 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.518 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 134' ' ' VAL . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.633 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 130' ' ' VAL . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.599 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' PHE . . . . . 0.459 ' HB3' HD11 ' A' ' 154' ' ' LEU . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' LYS . . . . . 0.417 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.523 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.502 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HD2' HG21 ' A' ' 167' ' ' THR . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 160' ' ' LYS . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.633 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.498 ' HA ' HD23 ' A' ' 33' ' ' LEU . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 172' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 34' ' ' PHE . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.607 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 105' ' ' VAL . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.88 133.9 33.58 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 49.1 tp 55.47 68.3 0.88 Allowed 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.638 1.211 . . . . 0.0 111.392 178.858 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -73.56 -32.92 64.42 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.649 0.738 . . . . 0.0 109.487 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -82.76 76.13 9.62 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.529 178.554 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 23.5 p-80 -126.56 100.57 6.29 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.747 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -122.01 -84.82 0.66 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.807 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -105.15 -40.68 5.79 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -100.65 137.5 38.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.418 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 12.0 p80 . . . . . 0 C--N 1.289 -2.051 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 173.439 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.411 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ASP . . . . . 0.401 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 101' ' ' TYR . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.411 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.464 HG12 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 20' ' ' ILE . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ILE . . . . . 0.441 HD12 ' HA ' ' A' ' 16' ' ' ASP . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.475 HD13 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.434 HG11 HG21 ' A' ' 75' ' ' VAL . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm -100.98 119.2 38.39 Favored 'General case' 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.4 m -117.04 141.39 35.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -61.54 125.41 23.68 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.102 0.477 . . . . 0.0 111.224 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 41.0 t -69.97 -36.29 68.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -88.6 65.64 3.29 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 178.318 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -177.77 35.49 0.08 OUTLIER Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -130.09 19.7 5.14 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 121.367 -0.444 . . . . 0.0 112.04 -177.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -89.51 86.97 6.89 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 49.6 mm 68.28 110.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -174.296 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -80.82 73.37 7.82 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -169.443 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.0 mp -136.73 83.67 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 103.924 -2.621 . . . . 0.0 103.924 166.736 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.43 47.4 0.8 Allowed Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -177.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' CYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 56' ' ' PHE . 58.9 m -78.29 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.642 -0.779 . . . . 0.0 110.069 -178.627 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.77 156.61 25.38 Favored Glycine 0 N--CA 1.437 -1.233 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -173.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -71.34 -35.84 71.33 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 117.256 0.528 . . . . 0.0 112.311 -173.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.95 5.85 50.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.936 0.398 . . . . 0.0 111.431 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PHE . . . . . 0.473 ' CZ ' ' HA2' ' A' ' 64' ' ' GLY . 72.3 m-85 -115.41 74.89 0.91 Allowed 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 119.736 -0.786 . . . . 0.0 112.518 -176.253 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -121.65 61.57 0.54 Allowed Glycine 0 C--N 1.3 -1.467 0 N-CA-C 108.633 -1.787 . . . . 0.0 108.633 174.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.29 -39.61 1.52 Allowed Glycine 0 N--CA 1.439 -1.127 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -176.682 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.66 -67.68 0.45 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 120.679 0.276 . . . . 0.0 110.554 178.3 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.11 -71.02 1.96 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.511 175.47 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 62' ' ' ASP . 21.8 t70 63.42 -164.29 0.25 Allowed 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 124.085 0.954 . . . . 0.0 108.65 -176.23 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASP . . . . . 0.453 ' H ' ' CG ' ' A' ' 61' ' ' ASP . 37.3 t70 -85.49 -30.28 23.58 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 176.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -163.44 -53.32 0.04 OUTLIER 'General case' 0 C--O 1.236 0.39 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.644 174.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLY . . . . . 0.473 ' HA2' ' CZ ' ' A' ' 56' ' ' PHE . . . -140.38 -66.19 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.642 -178.292 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -161.51 25.69 0.13 Allowed 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.309 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -151.07 175.57 11.98 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.296 -168.965 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -92.86 112.35 24.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -84.56 -70.74 0.55 Allowed 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -175.314 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.8 p -134.65 179.99 5.95 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.557 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -65.69 148.92 50.97 Favored 'General case' 0 CA--C 1.511 -0.53 0 O-C-N 123.27 0.356 . . . . 0.0 110.398 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -113.72 143.84 43.94 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.784 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -132.49 172.39 12.55 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 123.875 0.87 . . . . 0.0 110.46 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.482 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ASN . . . . . 0.419 HD22 ' N ' ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 36' ' ' VAL . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.534 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.459 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HD3' ' HA ' ' A' ' 95' ' ' LYS . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' LYS . . . . . 0.413 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.417 ' HA ' HD11 ' A' ' 8' ' ' ILE . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.445 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.635 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.635 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.43 ' OE2' ' HB2' ' A' ' 31' ' ' PRO . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.426 ' O ' HG23 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.569 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.612 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.534 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.423 ' HB3' HD23 ' A' ' 140' ' ' LEU . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.569 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.416 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -92.28 138.1 31.8 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 37.3 tp 76.14 -18.58 0.46 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.12 1.768 . . . . 0.0 112.726 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 182' ' ' GLU . . . . . 0.467 ' HA ' ' OE1' ' A' ' 182' ' ' GLU . 2.8 mm-40 -96.31 141.53 29.53 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 114.411 1.264 . . . . 0.0 114.411 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -134.21 16.11 3.79 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 176.291 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 74.48 -42.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 126.539 1.936 . . . . 0.0 110.082 -173.429 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 43.7 t60 -88.39 110.54 20.89 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 170.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 22.4 t60 -101.08 101.86 12.71 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 120.936 0.398 . . . . 0.0 110.341 -176.218 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -81.4 109.47 15.92 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 80.1 t60 . . . . . 0 C--N 1.298 -1.67 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.712 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.494 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.55 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.457 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.588 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.473 ' HB2' HG22 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.469 ' CG1' HG21 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp -95.29 112.57 24.26 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -111.11 160.33 10.45 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.073 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.91 126.76 31.16 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -73.97 -37.71 48.1 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.644 0.735 . . . . 0.0 109.155 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 107.97 122.71 4.8 Favored Glycine 0 N--CA 1.43 -1.726 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.862 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.66 137.62 9.78 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -176.586 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.19 174.52 16.91 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' ASP . . . . . 0.607 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 1.8 m-20 -76.15 0.01 20.45 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 114.055 1.131 . . . . 0.0 114.055 -174.65 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.8 mt -78.81 -22.88 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 172.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -107.5 -64.93 1.15 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ILE . . . . . 0.607 ' O ' ' HA ' ' A' ' 47' ' ' ASP . 41.8 mm -94.78 107.22 19.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -178.55 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.63 72.22 2.81 Favored Glycine 0 C--N 1.307 -1.076 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.0 t -82.35 -35.42 27.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 -178.153 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.67 127.69 9.33 Favored Glycine 0 N--CA 1.42 -2.395 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -136.38 98.09 3.74 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.209 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.99 164.06 38.68 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.14 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -73.76 117.85 16.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 176.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.35 62.22 0.67 Allowed Glycine 0 N--CA 1.42 -2.43 0 N-CA-C 108.571 -1.812 . . . . 0.0 108.571 -173.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -77.83 -29.3 55.03 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 64.86 82.69 0.18 Allowed 'General case' 0 C--O 1.249 1.035 0 C-N-CA 125.094 1.358 . . . . 0.0 111.746 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -89.18 89.02 1.54 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -69.68 150.13 47.32 Favored 'General case' 0 C--O 1.245 0.834 0 CA-C-O 120.939 0.4 . . . . 0.0 110.132 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -78.44 -38.94 40.1 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.012 -177.163 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.93 139.66 47.24 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-O 121.134 0.492 . . . . 0.0 111.087 -176.665 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 173.13 85.58 0.06 OUTLIER Glycine 0 N--CA 1.422 -2.288 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -178.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.55 -22.89 56.65 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.505 0.669 . . . . 0.0 109.74 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.9 100.34 11.54 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.304 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -85.17 68.9 10.68 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-O 121.705 0.764 . . . . 0.0 110.683 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -158.94 73.42 0.61 Allowed 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 114.577 -1.192 . . . . 0.0 107.815 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 10.9 m -74.92 -24.75 58.56 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.345 -176.918 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -78.63 124.23 27.95 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.674 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -126.86 121.2 31.18 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 173.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -136.87 159.12 42.81 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -173.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.564 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.469 HG21 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.564 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.415 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.457 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.428 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.428 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.43 ' O ' HG23 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.493 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.409 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.404 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.588 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.56 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' MET . . . . . 0.537 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 3.2 m-20 -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.493 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.434 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.55 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.501 ' HA ' HD23 ' A' ' 33' ' ' LEU . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -93.37 102.67 14.92 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -84.67 -28.14 26.61 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.638 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.59 -179.39 6.41 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 175.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.7 t-160 -68.5 -72.92 0.16 Allowed 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 118.421 0.555 . . . . 0.0 110.935 -173.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -157.22 131.54 8.46 Favored 'General case' 0 CA--C 1.493 -1.215 0 C-N-CA 124.091 0.956 . . . . 0.0 109.689 178.019 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 33.1 m80 -78.18 120.15 22.57 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -77.56 146.49 36.24 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 175.607 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 -75.39 90.8 2.69 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.989 -174.372 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 33.3 m170 . . . . . 0 CA--C 1.501 -0.921 0 C-N-CA 125.679 1.592 . . . . 0.0 111.441 -179.306 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD2' HG21 ' A' ' 178' ' ' VAL . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 13' ' ' VAL . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.566 HG22 ' HB2' ' A' ' 35' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLU . . . . . 0.566 ' HB2' HG22 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.418 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 60.3 mtt -79.81 129.01 34.12 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.3 m -118.46 144.85 25.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 175.901 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -78.98 124.07 27.9 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -74.57 96.61 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.345 -175.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -110.66 15.33 29.35 Favored Glycine 0 C--N 1.309 -0.933 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 169.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.6 -21.2 11.36 Favored Glycine 0 C--N 1.341 0.826 0 CA-C-N 113.88 -1.16 . . . . 0.0 113.376 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 101.49 5.33 52.0 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -172.744 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.15 76.61 6.08 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.0 mm 73.68 138.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 124.637 1.175 . . . . 0.0 109.879 -175.16 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.21 121.16 29.28 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.4 mp -84.4 79.65 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.791 0 CA-C-O 122.572 1.177 . . . . 0.0 110.106 -177.954 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -155.91 112.63 0.53 Allowed Glycine 0 N--CA 1.417 -2.606 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 58.4 m -93.46 11.37 28.74 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.998 0.428 . . . . 0.0 110.611 -178.087 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.46 -41.74 0.17 Allowed Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.799 -179.58 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -153.59 162.42 41.28 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -53.97 -40.15 66.62 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 123.702 0.801 . . . . 0.0 111.187 176.763 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -88.67 98.86 11.91 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.958 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.64 171.61 13.92 Favored Glycine 0 C--N 1.311 -0.852 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 106.09 123.19 5.1 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.128 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -98.24 -21.75 16.52 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.326 0.584 . . . . 0.0 110.411 -176.403 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 96.37 37.12 4.92 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -178.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -95.82 -75.01 0.54 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.891 0.377 . . . . 0.0 111.081 -177.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -108.78 -35.39 6.41 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.462 -178.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' GLU . . . . . 0.412 ' H ' ' CD ' ' A' ' 63' ' ' GLU . 1.3 mp0 -34.06 89.58 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 128.107 2.563 . . . . 0.0 114.142 -174.347 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -101.33 -22.02 10.98 Favored Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 178.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 69.95 6.71 Favored 'General case' 0 N--CA 1.427 -1.577 0 CA-C-O 121.51 0.672 . . . . 0.0 110.127 178.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -103.54 93.35 4.89 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 106.244 -1.761 . . . . 0.0 106.244 173.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -112.89 154.96 25.52 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.211 -170.929 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -68.29 93.35 0.46 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.457 0.646 . . . . 0.0 110.661 179.583 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 m -69.24 145.29 53.27 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.821 -178.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.65 135.0 38.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.418 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 0.4 OUTLIER -120.58 130.74 54.32 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.571 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -128.37 160.1 33.29 Favored 'General case' 0 C--N 1.284 -2.254 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 175.727 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLU . . . . . 0.416 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLU . . . . . 0.481 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' ASP . . . . . 0.579 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.579 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.666 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.666 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.427 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.49 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.501 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.403 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' VAL . . . . . 0.417 HG21 ' HD2' ' A' ' 5' ' ' LYS . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -103.17 105.42 15.71 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.1 37.92 1.77 Allowed 'General case' 0 C--N 1.295 -1.79 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.11 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -149.47 121.79 8.42 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-N 114.084 -1.417 . . . . 0.0 107.702 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.1 m-70 -82.63 118.88 23.63 Favored 'General case' 0 CA--C 1.49 -1.344 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 173.922 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -81.0 110.6 16.69 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.736 -177.448 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 57.5 t60 -161.65 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.998 -174.358 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -99.46 123.29 43.61 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -96.3 144.43 26.48 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -178.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 79.7 t60 . . . . . 0 C--N 1.295 -1.778 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 174.234 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.435 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' LYS . . . . . 0.49 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.643 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' GLU . . . . . 0.643 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.474 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' MET . . . . . 0.471 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 89.2 mtp -89.58 123.97 34.13 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 24.3 m -110.18 155.46 11.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.627 178.681 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.492 ' HA ' ' HG2' ' A' ' 71' ' ' LYS . . . -90.46 116.73 28.61 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -172.474 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.99 100.94 11.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 172.557 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -100.29 142.71 16.0 Favored Glycine 0 CA--C 1.494 -1.249 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.294 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 92.5 -50.37 2.66 Favored Glycine 0 N--CA 1.436 -1.361 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.23 91.78 0.74 Allowed Glycine 0 CA--C 1.493 -1.339 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 -178.812 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 34.5 m-20 -101.14 103.02 14.07 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -175.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 45.0 mm -99.97 90.44 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 175.393 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 66.78 34.81 5.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 124.034 0.834 . . . . 0.0 110.538 -174.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 2.1 mp 73.6 107.13 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.587 1.155 . . . . 0.0 110.203 -177.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 169.87 42.77 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.803 -176.888 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 26.1 p -162.98 -45.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 123.461 0.705 . . . . 0.0 109.167 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.18 41.9 0.79 Allowed Glycine 0 N--CA 1.435 -1.41 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -83.69 96.32 8.66 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.08 89.25 3.08 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 63.87 23.63 13.44 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.652 1.181 . . . . 0.0 111.623 -179.587 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 155.41 170.38 20.86 Favored Glycine 0 N--CA 1.432 -1.576 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -178.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.78 -87.52 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.241 -0.981 . . . . 0.0 112.874 -179.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -90.93 157.4 17.33 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.23 0.538 . . . . 0.0 112.054 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.14 149.68 21.7 Favored Glycine 0 N--CA 1.434 -1.435 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 177.912 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -95.58 15.74 19.04 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 117.44 0.62 . . . . 0.0 110.652 -175.273 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -94.94 15.79 17.79 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.427 0.691 . . . . 0.0 110.532 -179.439 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -139.16 147.67 42.17 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.48 82.82 1.1 Allowed Glycine 0 N--CA 1.422 -2.264 0 C-N-CA 120.395 -0.907 . . . . 0.0 113.322 175.73 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.49 -44.59 70.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 174.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -88.19 -57.29 2.98 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 174.456 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 179.18 161.29 0.75 Allowed 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 125.769 1.628 . . . . 0.0 106.834 177.103 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -118.6 26.77 9.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 121.594 0.711 . . . . 0.0 109.755 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.9 p -119.46 177.02 5.08 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.125 -173.853 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -100.62 117.92 35.72 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 170.653 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LYS . . . . . 0.492 ' HG2' ' HA ' ' A' ' 42' ' ' ALA . 60.4 mtpt -111.93 121.84 46.14 Favored 'General case' 0 C--N 1.292 -1.926 0 C-N-CA 119.717 -0.793 . . . . 0.0 112.43 -174.856 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 -130.36 171.08 13.34 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.793 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.8 p-10 -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.582 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.454 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.581 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.553 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.556 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.556 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.451 ' O ' HG23 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.474 ' CE3' HD13 ' A' ' 33' ' ' LEU . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' TYR . . . . . 0.487 ' HA ' HD12 ' A' ' 140' ' ' LEU . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.582 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.425 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' SER . . . . . 0.432 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.403 ' HB3' HD23 ' A' ' 140' ' ' LEU . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.478 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' THR . . . . . 0.419 HG23 ' HA ' ' A' ' 37' ' ' ASP . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.438 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.474 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.435 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 174' ' ' GLY . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.439 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -95.42 114.41 26.18 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -86.65 178.32 7.08 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.02 121.49 15.25 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 2.4 p80 -129.38 98.05 4.75 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 121.997 0.903 . . . . 0.0 113.359 -175.388 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 20.2 m80 -114.96 113.54 24.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 170.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 28.2 t-80 -82.13 96.79 7.91 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -176.712 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -131.58 -47.62 0.97 Allowed 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.9 -177.117 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -109.29 100.83 9.89 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.475 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--N 1.295 -1.773 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 174.622 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.473 ' HB3' ' HB1' ' A' ' 152' ' ' ALA . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.432 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' LEU . . . . . 0.427 ' HB3' HG22 ' A' ' 75' ' ' VAL . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt -85.52 136.74 33.29 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.3 m -123.22 169.31 14.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 175.458 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.19 114.03 24.41 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.247 0.546 . . . . 0.0 109.786 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.4 t -103.47 144.72 13.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -179.07 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 156.6 -53.05 0.41 Allowed Glycine 0 N--CA 1.432 -1.619 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.58 -89.21 1.4 Allowed Glycine 0 CA--C 1.495 -1.157 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -157.51 155.73 26.66 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.48 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.27 -25.19 29.54 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 116.784 0.292 . . . . 0.0 110.492 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.2 mt 61.08 51.28 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 122.983 1.373 . . . . 0.0 107.934 -178.934 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 23.6 t70 70.65 -85.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 113.394 -1.73 . . . . 0.0 111.474 -175.651 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.9 mt 38.41 58.31 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.483 0 C-N-CA 125.344 1.458 . . . . 0.0 111.178 -172.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.15 72.53 2.73 Favored Glycine 0 CA--C 1.496 -1.13 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.499 178.772 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 80.0 m -110.29 113.62 26.43 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.719 0.295 . . . . 0.0 110.544 -177.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.96 93.51 1.51 Allowed Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 175.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 33.1 p30 -62.74 152.09 36.68 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.95 126.84 45.0 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.456 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 60.2 m-85 63.94 -74.77 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.934 1.693 . . . . 0.0 113.836 178.162 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -173.83 167.31 39.8 Favored Glycine 0 N--CA 1.435 -1.371 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.148 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 156.64 -140.11 6.97 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.662 179.09 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -99.61 106.15 18.08 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.148 0.499 . . . . 0.0 110.437 -178.625 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.92 25.99 3.86 Favored Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 67.64 145.1 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 125.279 1.432 . . . . 0.0 114.379 -179.329 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -84.54 -25.41 28.77 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.034 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -81.13 99.77 8.7 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -149.84 162.99 29.3 Favored Glycine 0 N--CA 1.422 -2.243 0 C-N-CA 119.745 -1.217 . . . . 0.0 112.098 -177.606 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.02 24.93 1.68 Allowed 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 123.373 0.669 . . . . 0.0 110.23 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -57.3 -35.63 70.07 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.84 1.256 . . . . 0.0 111.084 -178.322 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -70.51 -64.53 0.88 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 177.58 -51.93 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 105.199 -2.148 . . . . 0.0 105.199 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 8.5 m -153.64 157.11 39.12 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 103.971 -2.603 . . . . 0.0 103.971 174.826 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 62.9 mt-30 -87.62 119.06 27.54 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 119.221 0.919 . . . . 0.0 109.421 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -110.36 121.15 44.61 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.491 173.75 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.14 162.21 40.89 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 23.9 p-10 -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 ' HB3' ' A' ' 18' ' ' LEU . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' SER . . . . . 0.477 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' PHE . . . . . 0.477 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' PHE . . . . . 0.468 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' TYR . . . . . 0.43 ' O ' HG23 ' A' ' 105' ' ' VAL . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 101' ' ' TYR . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' LEU . . . . . 0.437 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.433 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' VAL . . . . . 0.465 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 120' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' PHE . . . . . 0.437 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' PHE . . . . . 0.527 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 132' ' ' TRP . . . . . 0.52 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 134' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.577 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.473 ' HB1' ' HB3' ' A' ' 9' ' ' SER . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' TYR . . . . . 0.4 ' HB3' HD23 ' A' ' 140' ' ' LEU . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' PHE . . . . . 0.464 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 169' ' ' VAL . . . . . 0.52 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.432 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 174' ' ' GLY . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.529 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.75 161.47 18.68 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 181' ' ' LEU . 3.9 pp -110.5 114.17 27.37 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 174.454 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.45 119.26 30.58 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -177.708 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -127.63 11.59 6.77 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.588 -174.664 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -88.34 104.65 16.96 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.865 -0.522 . . . . 0.0 110.144 -178.652 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 61.5 m-70 59.22 77.52 0.3 Allowed 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.392 1.077 . . . . 0.0 112.867 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -148.71 117.06 6.49 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -77.08 94.59 4.06 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.422 -1.858 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.642 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.423 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.423 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.478 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.443 HG23 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.423 HG22 ' HB2' ' A' ' 35' ' ' GLU . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.423 ' HB2' HG22 ' A' ' 23' ' ' VAL . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.497 ' HB3' ' ND2' ' A' ' 74' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . 0.49 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? . . . . . 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.432 -1.359 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.439 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 39' ' ' ALA . 8.0 p30 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.521 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.429 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.521 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.441 ' O ' HG23 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.639 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.402 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.478 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.501 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.478 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.501 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.546 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.508 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.442 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.639 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.515 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.462 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.462 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . 0.49 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.439 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.453 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.526 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 . . . . . 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.53 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.459 HD11 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.467 ' HA ' ' HB2' ' A' ' 35' ' ' GLU . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.507 HG12 HD12 ' A' ' 33' ' ' LEU . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 171' ' ' VAL . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.519 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.539 HG13 HG21 ' A' ' 75' ' ' VAL . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm . . . . . 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.425 -1.7 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.539 HG21 HG13 ' A' ' 36' ' ' VAL . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.588 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.459 ' CE1' HD11 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.588 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . 0.539 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.415 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.539 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.451 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.613 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.613 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.621 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.621 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.708 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.425 ' HB3' HD23 ' A' ' 140' ' ' LEU . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.519 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.571 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.45 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 . . . . . 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.437 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.627 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.471 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' GLU . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.498 HD13 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.471 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' A' ' 23' ' ' VAL . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? . . . . . 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.439 -1.02 0 N-CA-C 111.102 0.038 . . . . 0.0 111.102 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.598 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.627 HG22 ' HB3' ' A' ' 18' ' ' LEU . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.426 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.527 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . 0.557 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.406 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.416 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.427 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.443 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . 0.557 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.604 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.604 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.479 ' SD ' HD11 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.527 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.479 HD11 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.562 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.426 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.445 ' HA ' HD23 ' A' ' 33' ' ' LEU . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.413 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.437 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.466 ' HB2' ' HG3' ' A' ' 176' ' ' LYS . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.4 HG23 HD12 ' A' ' 18' ' ' LEU . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.4 HD12 HG23 ' A' ' 14' ' ' VAL . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.467 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.509 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 171' ' ' VAL . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.459 ' CD2' HG23 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.553 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.441 -0.917 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.51 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.479 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.436 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.53 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.466 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.532 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.509 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.625 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.546 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.57 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.57 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.53 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.625 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.502 ' HA ' HD23 ' A' ' 33' ' ' LEU . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.406 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.437 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG3' ' HB2' ' A' ' 5' ' ' LYS . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 . . . . . 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.468 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.526 HD11 ' HA ' ' A' ' 101' ' ' TYR . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.43 ' HB2' ' HE2' ' A' ' 148' ' ' MET . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.411 HG23 HG12 ' A' ' 14' ' ' VAL . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.411 HG12 HG23 ' A' ' 13' ' ' VAL . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' HG22 ' A' ' 75' ' ' VAL . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.453 HG12 HD12 ' A' ' 33' ' ' LEU . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 HG12 ' A' ' 30' ' ' VAL . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 170' ' ' TYR . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt . . . . . 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.43 -1.426 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.626 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 18' ' ' LEU . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.495 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.498 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 94' ' ' PHE . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.461 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.526 ' HA ' HD11 ' A' ' 8' ' ' ILE . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.406 HG12 ' HB2' ' A' ' 118' ' ' ASP . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.405 HG12 ' O ' ' A' ' 115' ' ' ALA . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.447 ' HB3' ' HZ3' ' A' ' 121' ' ' LYS . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.596 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . 0.443 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.596 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 128' ' ' THR . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.64 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.403 ' HA ' HD12 ' A' ' 140' ' ' LEU . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.43 ' HE2' ' HB2' ' A' ' 11' ' ' ASP . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.498 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.64 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.417 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.468 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 . . . . . 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CE1' HG22 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HA ' ' A' ' 101' ' ' TYR . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.427 ' HA ' ' HB1' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.635 ' HB3' ' HE3' ' A' ' 148' ' ' MET . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HB3' HG22 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.523 HD13 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.444 ' CD2' HG23 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.522 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.401 ' CG1' HG21 ' A' ' 75' ' ' VAL . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt . . . . . 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 . . . . . 0 N--CA 1.421 -1.913 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.502 HG22 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.47 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.513 ' O ' HG23 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.413 ' HA ' HD11 ' A' ' 8' ' ' ILE . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.478 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.464 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.464 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.426 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.474 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.523 ' CE3' HD13 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.615 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.615 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.47 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.635 ' HE3' ' HB3' ' A' ' 11' ' ' ASP . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.575 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.575 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HB1' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.489 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.507 HG12 ' H ' ' A' ' 174' ' ' GLY . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.507 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.417 HG22 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.468 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . 0.433 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.46 HD13 HG13 ' A' ' 75' ' ' VAL . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.424 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.428 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.555 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . 0.447 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.4 mtp . . . . . 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.431 -1.381 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.599 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.599 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HB2' ' A' ' 82' ' ' ALA . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 78' ' ' PRO . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.423 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.454 ' HG ' ' CZ ' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 118' ' ' ASP . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.457 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.457 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.489 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.454 ' CZ ' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.433 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.631 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.696 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.696 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' ALA . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.422 ' HB3' ' HE2' ' A' ' 144' ' ' MET . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.443 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.506 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.447 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.631 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.428 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 174' ' ' GLY . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.496 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . 0.433 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . 0.444 ' CZ ' HG11 ' A' ' 3' ' ' VAL . 13.9 m-85 . . . . . 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.412 ' CG2' ' HA ' ' A' ' 152' ' ' ALA . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HB3' HG22 ' A' ' 75' ' ' VAL . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.488 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.44 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.409 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.515 HD23 ' HA ' ' A' ' 171' ' ' VAL . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.441 ' HB2' HG22 ' A' ' 23' ' ' VAL . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.536 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.449 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . 0.603 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp . . . . . 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.42 -1.961 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.491 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.467 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.498 ' HB3' ' CZ ' ' A' ' 168' ' ' PHE . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.447 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.447 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.45 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.479 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.635 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.485 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.513 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.432 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.513 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.417 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.645 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.645 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.62 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.629 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.433 ' HA ' HD12 ' A' ' 140' ' ' LEU . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.629 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.4 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CG2' ' A' ' 8' ' ' ILE . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.635 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.4 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.519 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.603 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.536 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.62 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.471 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.515 ' HA ' HD23 ' A' ' 33' ' ' LEU . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.424 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.456 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 3' ' ' VAL . 18.1 m-85 . . . . . 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.516 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.436 HD11 ' HA ' ' A' ' 101' ' ' TYR . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.454 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.476 HG12 HD12 ' A' ' 33' ' ' LEU . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . 0.406 ' HA2' ' OG ' ' A' ' 173' ' ' SER . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 171' ' ' VAL . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.562 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 . . . . . 0 N--CA 1.428 -1.561 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.43 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.434 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.409 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . 0.424 ' HA ' ' HB3' ' A' ' 103' ' ' ARG . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.436 ' HA ' HD11 ' A' ' 8' ' ' ILE . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 101' ' ' TYR . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . 0.442 HG12 ' HB2' ' A' ' 118' ' ' ASP . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.431 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.442 ' HB2' HG12 ' A' ' 114' ' ' VAL . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.604 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.441 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.538 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.538 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.489 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.48 ' HB2' ' HB3' ' A' ' 152' ' ' ALA . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 149' ' ' ASN . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.409 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.5 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.404 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.404 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.545 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 174' ' ' GLY . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.4 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.441 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.516 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 . . . . . 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.45 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.489 HD11 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HB2' HD21 ' A' ' 74' ' ' ASN . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.448 HG23 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.51 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.448 ' CD2' HG23 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm . . . . . 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 . . . . . 0 N--CA 1.436 -1.128 0 CA-C-O 119.422 -0.323 . . . . 0.0 110.21 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.424 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.431 HD21 ' HB2' ' A' ' 19' ' ' LYS . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.405 HG22 ' HB3' ' A' ' 18' ' ' LEU . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.489 ' CE1' HD11 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.515 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.436 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.49 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.615 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.44 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.615 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.515 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.515 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.424 ' HB3' HD13 ' A' ' 140' ' ' LEU . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.51 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.484 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 . . . . . 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.481 HG22 ' HA ' ' A' ' 152' ' ' ALA . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.43 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.467 HG23 HD12 ' A' ' 18' ' ' LEU . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.467 HD12 HG23 ' A' ' 14' ' ' VAL . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . 0.419 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . 0.457 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 171' ' ' VAL . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt . . . . . 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.437 -1.099 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.462 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.462 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.443 ' CE1' HD11 ' A' ' 18' ' ' LEU . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.514 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.46 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.46 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.415 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.415 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.583 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.583 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.653 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.435 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.556 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.405 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.556 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.481 ' HA ' HG22 ' A' ' 8' ' ' ILE . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.514 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.539 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.541 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.653 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.43 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 174' ' ' GLY . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.482 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 . . . . . 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.497 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.405 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.427 ' O ' HG13 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 33' ' ' LEU . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.549 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 72.3 mtm . . . . . 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.427 -1.582 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.544 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.544 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.437 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.414 ' O ' HD13 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.416 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.433 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.416 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.451 ' HA ' HD11 ' A' ' 33' ' ' LEU . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.672 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.627 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.627 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 155' ' ' ILE . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE2' ' HA ' ' A' ' 150' ' ' PRO . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . 0.441 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.519 ' HA ' ' HE2' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.405 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' PHE . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.468 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.549 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.672 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.611 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 174' ' ' GLY . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.435 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.497 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 . . . . . 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.502 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 101' ' ' TYR . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.424 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.514 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 75' ' ' VAL . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.435 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.511 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.501 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.411 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 25.1 mmt . . . . . 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.424 -1.73 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . 0.532 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . 0.412 ' HB2' ' CE1' ' A' ' 143' ' ' PHE . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.572 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.572 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.464 ' O ' HG23 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.556 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.437 ' HA ' HD11 ' A' ' 8' ' ' ILE . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.447 HG13 ' HA3' ' A' ' 174' ' ' GLY . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.435 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.647 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.492 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.475 ' HB3' HD11 ' A' ' 154' ' ' LEU . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.532 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.494 ' HE3' ' HA ' ' A' ' 150' ' ' PRO . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.584 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.584 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.424 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.556 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CD2' HD13 ' A' ' 140' ' ' LEU . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.531 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.501 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.647 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.514 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.511 ' HA ' HD23 ' A' ' 33' ' ' LEU . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.538 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.471 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.502 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 . . . . . 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.466 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.493 HD13 HG13 ' A' ' 75' ' ' VAL . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . 0.42 ' CG1' HD12 ' A' ' 33' ' ' LEU . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.577 HD23 ' HA ' ' A' ' 171' ' ' VAL . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.49 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 75' ' ' VAL . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . 0.474 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 58.6 mtt . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.423 -1.79 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.437 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 36' ' ' VAL . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.462 ' HA ' ' CD1' ' A' ' 83' ' ' TYR . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.551 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.463 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.555 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.463 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.452 ' O ' HG23 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 105' ' ' VAL . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.407 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.687 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.53 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.437 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . 0.636 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . 0.636 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.437 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.555 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.579 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.474 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.687 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.577 ' HA ' HD23 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.441 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.419 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 . . . . . 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.414 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.506 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 36' ' ' VAL . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 171' ' ' VAL . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.472 ' HD2' ' HB2' ' A' ' 172' ' ' LYS . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp . . . . . 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.43 -1.436 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.431 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.424 ' CZ ' HD11 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.446 ' O ' HG23 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.523 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . 0.461 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.446 HG13 ' HA2' ' A' ' 174' ' ' GLY . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.623 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.503 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.623 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.503 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.518 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.518 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 134' ' ' VAL . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.633 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 130' ' ' VAL . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.599 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . 0.459 ' HB3' HD11 ' A' ' 154' ' ' LEU . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . 0.417 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.523 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.502 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HD2' HG21 ' A' ' 167' ' ' THR . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 160' ' ' LYS . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.633 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.498 ' HA ' HD23 ' A' ' 33' ' ' LEU . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 34' ' ' PHE . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.607 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 105' ' ' VAL . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 . . . . . 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.411 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . 0.401 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 101' ' ' TYR . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . 0.411 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.464 HG12 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 20' ' ' ILE . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . 0.441 HD12 ' HA ' ' A' ' 16' ' ' ASP . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.475 HD13 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.434 HG11 HG21 ' A' ' 75' ' ' VAL . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm . . . . . 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 . . . . . 0 C--O 1.242 0.701 0 N-CA-C 110.46 -0.2 . . . . 0.0 110.46 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.482 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . 0.419 HD22 ' N ' ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 36' ' ' VAL . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.534 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.459 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HD3' ' HA ' ' A' ' 95' ' ' LYS . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . 0.413 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.417 ' HA ' HD11 ' A' ' 8' ' ' ILE . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.445 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.635 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.635 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.43 ' OE2' ' HB2' ' A' ' 31' ' ' PRO . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.426 ' O ' HG23 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.569 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.612 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.534 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.423 ' HB3' HD23 ' A' ' 140' ' ' LEU . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.569 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.416 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 . . . . . 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . 0.494 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.55 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . 0.494 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.457 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.588 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.473 ' HB2' HG22 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.469 ' CG1' HG21 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp . . . . . 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 . . . . . 0 N--CA 1.435 -1.216 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.564 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.469 HG21 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.564 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.415 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.457 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.428 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.428 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.43 ' O ' HG23 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.493 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.409 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.404 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.588 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.56 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . 0.537 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.493 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.434 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.55 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.501 ' HA ' HD23 ' A' ' 33' ' ' LEU . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 . . . . . 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD2' HG21 ' A' ' 178' ' ' VAL . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 13' ' ' VAL . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.566 HG22 ' HB2' ' A' ' 35' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . 0.566 ' HB2' HG22 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 60.3 mtt . . . . . 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 . . . . . 0 N--CA 1.43 -1.45 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . 0.416 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . 0.481 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . 0.579 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.579 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.666 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.666 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.427 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.49 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.501 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.403 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . 0.417 HG21 ' HD2' ' A' ' 5' ' ' LYS . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 . . . . . 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.435 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . 0.49 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.643 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . 0.643 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.474 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.2 mtp . . . . . 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 . . . . . 0 CA--C 1.504 -0.79 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.582 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.454 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.581 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.553 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.556 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.556 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.451 ' O ' HG23 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.474 ' CE3' HD13 ' A' ' 33' ' ' LEU . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . 0.487 ' HA ' HD12 ' A' ' 140' ' ' LEU . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.582 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.425 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . 0.432 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.403 ' HB3' HD23 ' A' ' 140' ' ' LEU . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.478 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . 0.419 HG23 ' HA ' ' A' ' 37' ' ' ASP . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.438 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.474 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.435 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 174' ' ' GLY . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.439 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 . . . . . 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.473 ' HB3' ' HB1' ' A' ' 152' ' ' ALA . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.432 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' LEU . . . . . 0.427 ' HB3' HG22 ' A' ' 75' ' ' VAL . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt . . . . . 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.433 -1.307 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 ' HB3' ' A' ' 18' ' ' LEU . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' SER . . . . . 0.477 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' PHE . . . . . 0.477 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' PHE . . . . . 0.468 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' TYR . . . . . 0.43 ' O ' HG23 ' A' ' 105' ' ' VAL . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 101' ' ' TYR . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' LEU . . . . . 0.437 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' ALA . . . . . 0.433 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' VAL . . . . . 0.465 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' PHE . . . . . 0.437 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' PHE . . . . . 0.527 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' TRP . . . . . 0.52 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.577 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.473 ' HB1' ' HB3' ' A' ' 9' ' ' SER . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' TYR . . . . . 0.4 ' HB3' HD23 ' A' ' 140' ' ' LEU . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' PHE . . . . . 0.464 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' VAL . . . . . 0.52 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.432 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 174' ' ' GLY . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.529 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 . . . . . 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.423 ' HA ' ' OD2' ' A' ' 16' ' ' ASP . 49.8 ttm . . . . . 0 C--O 1.218 -0.567 0 CA-C-O 120.901 0.381 . . . . 0.0 110.452 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.3 mt -92.65 126.84 45.08 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 N-CA-C 106.835 -1.542 . . . . 0.0 106.835 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.9 p -129.05 145.61 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.131 0 C-N-CA 120.106 -0.638 . . . . 0.0 110.194 -178.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 63.1 m-85 -103.34 113.64 27.28 Favored 'General case' 0 C--N 1.294 -1.835 0 CA-C-N 115.462 -0.79 . . . . 0.0 109.098 177.667 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 61.5 mttm -101.76 129.12 47.88 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.328 177.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -63.88 145.2 56.26 Favored 'General case' 0 C--N 1.313 -0.986 0 O-C-N 124.041 0.838 . . . . 0.0 110.113 176.996 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.4 t -76.62 -25.33 16.04 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.241 0 CA-C-O 120.94 0.4 . . . . 0.0 110.709 -175.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 18.7 mm -83.54 -51.13 14.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 C-N-CA 120.609 -0.436 . . . . 0.0 110.228 -175.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.4 p -86.94 -42.59 13.05 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.553 0.575 . . . . 0.0 112.553 -178.642 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.7 3.51 71.09 Favored Glycine 0 N--CA 1.443 -0.853 0 N-CA-C 110.292 -1.123 . . . . 0.0 110.292 -172.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.1 m-20 -90.43 160.41 16.06 Favored 'General case' 0 CA--C 1.506 -0.729 0 CA-C-O 121.245 0.545 . . . . 0.0 111.694 -177.286 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 41.8 mt-10 -76.02 119.75 20.4 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.494 -177.256 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.493 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 32.6 m -91.97 -26.32 4.98 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 120.915 0.388 . . . . 0.0 110.674 178.589 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.1 p -175.62 156.15 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.248 0.991 0 N-CA-C 108.074 -1.084 . . . . 0.0 108.074 -179.419 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.3 p -127.95 170.47 12.82 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.618 -0.882 . . . . 0.0 108.618 177.893 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.423 ' OD2' ' HA ' ' A' ' 1' ' ' MET . 7.0 p-10 -71.89 -4.82 30.36 Favored 'General case' 0 N--CA 1.481 1.125 0 C-N-CA 123.179 0.591 . . . . 0.0 112.035 -178.75 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.92 -13.73 52.75 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.354 0.597 . . . . 0.0 109.737 177.053 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 87.4 mt -104.69 -178.14 3.57 Favored 'General case' 0 N--CA 1.44 -0.931 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.478 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -80.88 120.38 24.64 Favored 'General case' 0 C--O 1.213 -0.843 0 CA-C-O 120.613 0.244 . . . . 0.0 111.171 -179.264 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.443 HG23 ' CD1' ' A' ' 34' ' ' PHE . 67.8 mt -132.16 112.39 19.71 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.028 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 178.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 18.9 p -127.16 136.1 28.38 Favored Pre-proline 0 C--N 1.296 -1.732 0 C-N-CA 120.871 -0.332 . . . . 0.0 110.168 176.847 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 18.8 Cg_endo -61.6 142.51 94.87 Favored 'Trans proline' 0 C--O 1.24 0.592 0 C-N-CA 121.675 1.583 . . . . 0.0 109.245 174.242 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.423 HG22 ' HB2' ' A' ' 35' ' ' GLU . 88.6 t -59.67 112.54 0.66 Allowed 'Isoleucine or valine' 0 CA--C 1.513 -0.452 0 O-C-N 123.367 0.417 . . . . 0.0 111.917 -175.729 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.7 mtt -122.27 108.83 13.72 Favored 'General case' 0 N--CA 1.425 -1.675 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 173.383 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 7.0 mm-40 -93.84 -174.25 3.38 Favored 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 -179.209 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -58.49 92.65 0.04 OUTLIER Glycine 0 CA--C 1.529 0.961 0 O-C-N 123.657 0.598 . . . . 0.0 114.467 -179.322 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.26 -3.5 84.13 Favored Glycine 0 N--CA 1.442 -0.924 0 N-CA-C 114.92 0.728 . . . . 0.0 114.92 175.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.9 pt-20 -149.19 156.4 42.1 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 118.577 1.189 . . . . 0.0 111.802 -175.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -100.35 154.23 18.67 Favored 'General case' 0 C--N 1.311 -1.088 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 177.132 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 43.6 t -115.89 114.42 41.68 Favored Pre-proline 0 C--N 1.29 -1.999 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 174.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -74.22 146.51 36.26 Favored 'Trans proline' 0 C--O 1.242 0.724 0 C-N-CA 122.887 2.392 . . . . 0.0 113.746 -177.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.99 -4.86 85.49 Favored Glycine 0 CA--C 1.498 -1.008 0 CA-C-N 114.924 -1.035 . . . . 0.0 114.015 174.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 32.2 mt -131.09 152.18 50.65 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 -174.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.443 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.6 p90 -137.2 148.86 46.82 Favored 'General case' 0 N--CA 1.434 -1.271 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 175.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.423 ' HB2' HG22 ' A' ' 23' ' ' VAL . 39.5 tt0 -117.9 146.04 44.22 Favored 'General case' 0 C--N 1.279 -2.472 0 N-CA-C 107.176 -1.416 . . . . 0.0 107.176 -176.362 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.478 HG13 ' O ' ' A' ' 19' ' ' LYS . 98.5 t -111.17 122.46 65.66 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.186 0 CA-C-O 120.725 0.297 . . . . 0.0 111.237 -174.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 51.3 m-20 -65.61 155.91 34.38 Favored 'General case' 0 CA--C 1.504 -0.803 0 O-C-N 124.452 1.095 . . . . 0.0 111.458 179.455 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 32.9 m -100.09 134.93 42.29 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 107.487 -1.301 . . . . 0.0 107.487 171.995 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.497 ' HB3' ' ND2' ' A' ' 74' ' ' ASN . . . -143.01 123.99 14.38 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 175.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.49 ' SD ' ' HB2' ' A' ' 164' ' ' HIS . 3.2 mpp? -93.94 109.52 21.24 Favored 'General case' 0 C--N 1.296 -1.744 0 O-C-N 124.392 1.057 . . . . 0.0 110.699 -171.223 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 35.6 m -113.62 153.84 15.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.403 -179.384 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -65.88 115.41 5.95 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-O 121.252 0.549 . . . . 0.0 111.186 175.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 76.5 t -100.72 138.92 23.38 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.895 0 C-N-CA 124.495 1.118 . . . . 0.0 108.921 178.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -83.0 80.65 1.8 Allowed Glycine 0 N--CA 1.441 -0.972 0 N-CA-C 109.543 -1.423 . . . . 0.0 109.543 175.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -91.58 -31.88 9.12 Favored Glycine 0 N--CA 1.434 -1.461 0 C-N-CA 121.514 -0.374 . . . . 0.0 113.01 -176.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.09 -51.1 4.51 Favored Glycine 0 C--O 1.243 0.69 0 C-N-CA 121.479 -0.391 . . . . 0.0 112.741 179.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 63.69 36.54 10.68 Favored 'General case' 0 N--CA 1.488 1.434 0 C-N-CA 124.236 1.014 . . . . 0.0 110.273 -178.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mm -79.09 -52.88 14.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 114.385 -1.279 . . . . 0.0 109.686 -177.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -98.27 -39.91 8.6 Favored 'General case' 0 C--N 1.313 -1.014 0 CA-C-N 115.421 -0.809 . . . . 0.0 110.645 -179.027 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 67.7 mt -121.79 118.41 55.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.047 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.112 -178.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -83.67 108.55 3.06 Favored Glycine 0 N--CA 1.435 -1.428 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 172.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 75.7 m -78.78 107.63 11.63 Favored 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 121.345 0.593 . . . . 0.0 112.091 -175.15 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.12 -68.72 1.65 Allowed Glycine 0 N--CA 1.433 -1.517 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.681 -179.925 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 35.7 t30 64.24 84.94 0.14 Allowed 'General case' 0 C--O 1.242 0.675 0 C-N-CA 124.379 1.072 . . . . 0.0 111.084 -177.611 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -136.19 144.15 44.79 Favored 'General case' 0 C--N 1.31 -1.124 0 CA-C-N 115.174 -0.921 . . . . 0.0 110.667 -178.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -89.93 121.42 32.02 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 115.777 -0.647 . . . . 0.0 109.295 177.36 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -87.68 111.94 3.78 Favored Glycine 0 N--CA 1.436 -1.323 0 C-N-CA 120.83 -0.7 . . . . 0.0 111.506 179.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -100.13 -36.52 4.14 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 177.878 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -81.57 136.13 35.57 Favored 'General case' 0 N--CA 1.435 -1.184 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 128.98 -71.86 0.49 Allowed Glycine 0 N--CA 1.432 -1.628 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -179.378 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 9.8 t70 -156.57 179.64 9.07 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 106.928 -1.508 . . . . 0.0 106.928 179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -109.78 -66.11 1.09 Allowed 'General case' 0 C--N 1.296 -1.741 0 CA-C-N 118.177 0.444 . . . . 0.0 112.145 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 51.3 mt-10 -103.48 6.79 37.74 Favored 'General case' 0 C--N 1.306 -1.297 0 N-CA-C 112.922 0.712 . . . . 0.0 112.922 -174.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -121.87 68.46 0.44 Allowed Glycine 0 C--N 1.302 -1.314 0 N-CA-C 108.043 -2.023 . . . . 0.0 108.043 171.959 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -138.8 23.74 2.63 Favored 'General case' 0 C--N 1.315 -0.911 0 N-CA-C 112.681 0.623 . . . . 0.0 112.681 -172.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.0 t70 -77.95 111.08 13.44 Favored 'General case' 0 C--N 1.323 -0.573 0 C-N-CA 119.707 -0.797 . . . . 0.0 109.158 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -135.62 123.49 22.6 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.889 -173.8 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -116.49 18.74 15.0 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-O 121.626 0.727 . . . . 0.0 109.302 176.177 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.1 p -104.85 92.59 4.32 Favored 'General case' 0 N--CA 1.422 -1.826 0 CA-C-N 115.854 -0.612 . . . . 0.0 111.752 -176.001 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mm-40 -66.69 119.77 12.35 Favored 'General case' 0 CA--C 1.501 -0.929 0 CA-C-N 115.582 -0.736 . . . . 0.0 109.673 176.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.43 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 32.4 mmtp -97.01 120.77 37.99 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 107.734 -1.21 . . . . 0.0 107.734 179.823 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -140.06 165.72 26.6 Favored 'General case' 0 C--N 1.294 -1.837 0 N-CA-C 105.467 -2.049 . . . . 0.0 105.467 -176.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.439 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 53.1 t30 -69.65 134.28 48.52 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 121.358 0.599 . . . . 0.0 110.815 -177.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.497 ' ND2' ' HB3' ' A' ' 39' ' ' ALA . 8.0 p30 -61.87 -24.64 67.04 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 114.936 -1.029 . . . . 0.0 112.194 -178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.435 HG21 ' CG1' ' A' ' 36' ' ' VAL . 42.9 t -81.11 -34.8 13.83 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.67 -177.056 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.521 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 2.8 p -82.57 -55.72 4.3 Favored 'General case' 0 N--CA 1.422 -1.847 0 CA-C-N 116.364 -0.38 . . . . 0.0 111.481 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.78 88.15 0.01 OUTLIER Glycine 0 CA--C 1.535 1.335 0 O-C-N 124.144 0.903 . . . . 0.0 114.912 175.486 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -55.13 -30.86 72.84 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 123.592 2.861 . . . . 0.0 114.093 -178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 20.1 m -92.35 -1.93 56.72 Favored 'General case' 0 CA--C 1.55 0.96 0 CA-C-O 120.695 0.283 . . . . 0.0 111.733 -178.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.0 m -122.67 -74.05 0.63 Allowed 'General case' 0 CA--C 1.543 0.707 0 O-C-N 122.066 -0.396 . . . . 0.0 111.962 -177.745 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.429 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.8 m-85 -87.9 -46.43 9.41 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 110.333 -0.247 . . . . 0.0 110.333 -176.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.18 98.22 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 124.843 1.257 . . . . 0.0 112.668 177.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.521 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 44.2 m-85 -94.12 121.41 35.59 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-O 121.641 0.734 . . . . 0.0 111.928 -179.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.2 m -92.62 133.94 35.49 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 107.105 -1.442 . . . . 0.0 107.105 179.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -91.46 153.11 20.05 Favored 'General case' 0 C--N 1.306 -1.309 0 CA-C-O 121.274 0.559 . . . . 0.0 112.479 -174.62 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 19.6 mmt -131.79 129.25 21.91 Favored Pre-proline 0 C--N 1.303 -1.43 0 C-N-CA 124.95 1.3 . . . . 0.0 109.202 176.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 86.5 Cg_endo -81.92 166.89 16.71 Favored 'Trans proline' 0 C--O 1.243 0.77 0 C-N-CA 123.558 2.839 . . . . 0.0 112.844 178.5 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 75.2 m-85 -60.9 115.12 3.46 Favored 'General case' 0 CA--C 1.51 -0.596 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 173.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.6 p -95.26 -44.23 7.7 Favored 'General case' 0 C--N 1.284 -2.28 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 175.702 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 42.0 m 58.03 24.35 11.04 Favored 'General case' 0 C--N 1.364 1.208 0 C-N-CA 124.51 1.124 . . . . 0.0 109.991 -178.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 76.3 tttt -92.58 165.51 12.96 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-N 114.63 -1.168 . . . . 0.0 108.521 -173.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -56.17 -40.99 85.31 Favored Glycine 0 N--CA 1.461 0.317 0 O-C-N 123.549 0.531 . . . . 0.0 114.076 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.3 -43.19 92.63 Favored 'General case' 0 C--N 1.328 -0.342 0 C-N-CA 123.418 0.687 . . . . 0.0 110.656 178.613 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.441 ' O ' HG23 ' A' ' 98' ' ' VAL . 81.9 t80 -66.64 -40.69 88.81 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.688 179.776 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.2 mmtp -70.05 -35.99 74.68 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 116.265 -0.425 . . . . 0.0 111.041 -179.771 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 26.5 m -66.85 -34.46 77.86 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 175.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.639 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.4 t90 -62.67 -48.21 80.29 Favored 'General case' 0 C--O 1.211 -0.957 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.198 176.852 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 94' ' ' PHE . 65.4 t -54.53 -42.36 59.19 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.796 0 O-C-N 123.579 0.549 . . . . 0.0 110.545 179.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -61.73 -53.01 61.88 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.346 178.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 6.8 m-20 -69.66 -27.75 65.3 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 -177.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -62.45 -57.77 10.02 Favored 'General case' 0 C--N 1.317 -0.817 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 177.55 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 48.5 t -64.64 -34.0 66.96 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.626 0 CA-C-O 121.006 0.431 . . . . 0.0 109.965 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.402 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 70.8 ttt180 -57.94 -57.39 13.02 Favored 'General case' 0 C--N 1.33 -0.243 0 C-N-CA 124.061 0.945 . . . . 0.0 110.48 177.742 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -71.61 -29.06 64.25 Favored 'General case' 0 CA--C 1.502 -0.894 0 CA-C-N 115.901 -0.59 . . . . 0.0 112.39 -176.506 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 58.7 t -63.33 -46.91 94.27 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.374 0 N-CA-C 108.701 -0.852 . . . . 0.0 108.701 172.52 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.3 mtt180 -64.65 -22.79 67.06 Favored 'General case' 0 C--O 1.236 0.38 0 N-CA-C 112.231 0.456 . . . . 0.0 112.231 176.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.402 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.9 mm-40 -80.76 -34.54 34.17 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 109.773 -0.454 . . . . 0.0 109.773 177.141 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.41 -39.12 91.77 Favored 'General case' 0 N--CA 1.467 0.407 0 N-CA-C 109.557 -0.535 . . . . 0.0 109.557 176.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.478 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -59.12 -36.59 75.47 Favored 'General case' 0 C--O 1.221 -0.399 0 CA-C-N 115.332 -0.849 . . . . 0.0 111.374 174.617 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 50.1 mttp -74.29 -46.1 43.35 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.162 0.506 . . . . 0.0 111.066 177.4 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -72.62 -1.21 52.54 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 115.373 -0.831 . . . . 0.0 114.833 -176.042 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.9 p -72.67 -23.13 60.85 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 117.286 0.543 . . . . 0.0 110.871 -179.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.65 28.31 73.69 Favored Glycine 0 CA--C 1.528 0.901 0 CA-C-N 116.011 -0.54 . . . . 0.0 113.62 179.058 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.9 t -79.6 154.42 4.66 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.368 0 C-N-CA 122.621 0.369 . . . . 0.0 110.402 -178.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -54.21 151.02 7.68 Favored 'General case' 0 CA--C 1.544 0.719 0 C-N-CA 124.552 1.141 . . . . 0.0 111.904 177.84 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 21.4 t -55.36 -49.45 72.73 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 N-CA-C 114.059 1.133 . . . . 0.0 114.059 -169.835 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 -68.17 -30.13 69.17 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.999 0.428 . . . . 0.0 111.177 -177.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 19.6 m-20 -78.74 -31.87 46.48 Favored 'General case' 0 C--N 1.316 -0.889 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.148 178.166 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.501 ' O ' ' HG2' ' A' ' 123' ' ' MET . 19.9 mm -60.13 -40.96 84.95 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.454 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 171.432 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 35.0 mmtp -57.03 -45.97 82.72 Favored 'General case' 0 C--O 1.221 -0.433 0 O-C-N 123.087 0.242 . . . . 0.0 110.765 177.686 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.465 ' HD3' ' HA ' ' A' ' 121' ' ' LYS . 70.9 mmtt -70.03 -33.02 71.45 Favored 'General case' 0 C--N 1.319 -0.753 0 N-CA-C 112.09 0.404 . . . . 0.0 112.09 179.749 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.478 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -66.5 -38.41 87.17 Favored 'General case' 0 C--N 1.31 -1.117 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 179.101 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.501 ' HG2' ' O ' ' A' ' 119' ' ' ILE . 26.2 mmt -80.38 -12.02 59.63 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.808 -1.087 . . . . 0.0 111.596 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 50.2 mt-10 -83.39 -27.33 29.68 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 109.068 -0.716 . . . . 0.0 109.068 173.035 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 34.6 mt-10 -71.57 -31.43 66.97 Favored 'General case' 0 C--N 1.313 -0.983 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.047 172.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.546 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.04 -55.54 29.94 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.207 1.558 . . . . 0.0 115.207 -178.779 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_endo -70.7 -22.02 28.34 Favored 'Trans proline' 0 C--N 1.381 2.268 0 CA-C-N 121.027 1.402 . . . . 0.0 111.564 177.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 31.5 m -70.12 -33.8 72.28 Favored 'General case' 0 N--CA 1.437 -1.079 0 CA-C-N 115.528 -0.76 . . . . 0.0 109.595 178.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.546 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 16.5 m-85 -59.68 -56.29 23.69 Favored 'General case' 0 C--N 1.361 1.079 0 N-CA-C 108.239 -1.022 . . . . 0.0 108.239 174.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 44.1 t -55.13 -54.53 23.43 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.432 -176.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 28.6 tptp -56.46 -48.92 76.06 Favored 'General case' 0 C--O 1.22 -0.479 0 O-C-N 123.81 0.694 . . . . 0.0 112.169 -177.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 43.3 t90 -69.94 -33.03 71.6 Favored 'General case' 0 CA--C 1.552 1.032 0 CA-C-O 120.731 0.3 . . . . 0.0 111.516 -176.038 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.503 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.8 mt -67.52 -40.26 85.1 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 176.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 87.9 t -65.79 -33.44 63.63 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.663 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.347 177.649 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -64.81 -29.7 70.68 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 113.77 1.026 . . . . 0.0 113.77 179.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.508 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.4 OUTLIER -107.32 -0.97 22.11 Favored 'General case' 0 C--N 1.322 -0.62 0 C-N-CA 119.756 -0.777 . . . . 0.0 112.474 176.943 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.442 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 87.8 t80 -49.35 -41.79 39.89 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 -173.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 27.3 m-20 -76.84 -11.74 59.87 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 112.453 0.538 . . . . 0.0 112.453 -174.339 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 60.9 m-20 -114.36 11.07 17.21 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-O 120.816 0.341 . . . . 0.0 110.791 -177.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.508 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.5 mt -83.42 136.37 34.34 Favored 'General case' 0 N--CA 1.43 -1.428 0 CA-C-O 122.783 1.277 . . . . 0.0 114.31 -174.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 4.7 tp10 -105.58 132.78 51.32 Favored 'General case' 0 N--CA 1.4 -2.969 0 N-CA-C 103.012 -2.958 . . . . 0.0 103.012 167.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -97.73 139.43 33.62 Favored 'General case' 0 C--N 1.269 -2.927 0 C-N-CA 119.741 -0.784 . . . . 0.0 109.038 -175.416 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 80.9 m-85 -131.0 162.62 29.36 Favored 'General case' 0 C--N 1.289 -2.026 0 CA-C-O 121.329 0.585 . . . . 0.0 110.693 179.572 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 26.8 mtm -144.52 150.42 37.52 Favored 'General case' 0 C--N 1.274 -2.679 0 N-CA-C 103.249 -2.871 . . . . 0.0 103.249 174.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 29.4 p -77.88 165.68 23.82 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 105.565 -2.013 . . . . 0.0 105.565 168.188 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . 0.486 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 11.6 tmtt? -61.35 -28.43 69.22 Favored 'General case' 0 CA--C 1.561 1.392 0 CA-C-N 119.209 0.913 . . . . 0.0 110.814 -175.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.4 p -78.69 -7.85 58.11 Favored 'General case' 0 CA--C 1.563 1.473 0 N-CA-C 112.965 0.728 . . . . 0.0 112.965 176.658 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 47.9 mtt -98.3 170.84 8.59 Favored 'General case' 0 C--N 1.321 -0.649 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.7 m-80 -129.27 159.11 70.75 Favored Pre-proline 0 C--N 1.308 -1.221 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 -175.222 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 28.8 Cg_endo -65.5 -22.83 58.4 Favored 'Trans proline' 0 C--N 1.357 0.979 0 C-N-CA 121.929 1.753 . . . . 0.0 112.148 179.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -97.1 -9.9 27.09 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.809 -179.812 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -148.96 102.92 3.31 Favored 'General case' 0 C--N 1.312 -1.039 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -174.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.49 41.3 5.15 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.259 -0.972 . . . . 0.0 111.86 -176.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.639 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 36.5 tp -92.2 112.24 24.1 Favored 'General case' 0 N--CA 1.433 -1.309 0 N-CA-C 107.205 -1.405 . . . . 0.0 107.205 176.464 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 93.2 mt -95.43 139.65 18.47 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.436 0 CA-C-N 114.391 -1.277 . . . . 0.0 110.947 -173.005 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.515 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 46.8 m-85 -95.77 137.09 35.33 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 107.875 -1.157 . . . . 0.0 107.875 178.217 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 39.5 m -147.83 155.8 42.03 Favored 'General case' 0 C--N 1.307 -1.266 0 O-C-N 121.879 -0.513 . . . . 0.0 109.837 176.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.462 ' OH ' ' HE3' ' A' ' 160' ' ' LYS . 20.3 p90 -154.47 179.22 9.22 Favored 'General case' 0 C--N 1.306 -1.305 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 176.856 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 8.5 m-85 -118.14 103.51 9.93 Favored 'General case' 0 C--N 1.299 -1.59 0 CA-C-N 118.778 0.717 . . . . 0.0 110.32 -178.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.462 ' HE3' ' OH ' ' A' ' 158' ' ' TYR . 14.9 ptpt -92.82 176.58 6.38 Favored 'General case' 0 C--O 1.24 0.595 0 C-N-CA 119.381 -0.927 . . . . 0.0 110.853 175.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -65.43 127.2 30.84 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.288 -178.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.79 -20.95 42.12 Favored Glycine 0 N--CA 1.443 -0.885 0 CA-C-N 115.289 -0.869 . . . . 0.0 111.302 -179.6 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.28 125.14 34.98 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 121.11 0.481 . . . . 0.0 110.255 -178.707 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . 0.49 ' HB2' ' SD ' ' A' ' 40' ' ' MET . 34.2 m-70 -103.29 11.1 37.17 Favored 'General case' 0 C--N 1.319 -0.752 0 CA-C-O 121.498 0.666 . . . . 0.0 109.789 178.842 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.439 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 58.2 m -147.46 171.83 5.89 Favored Pre-proline 0 C--N 1.302 -1.495 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 -179.416 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 35.0 Cg_exo -61.77 127.76 22.49 Favored 'Trans proline' 0 C--O 1.243 0.75 0 C-N-CA 122.011 1.807 . . . . 0.0 112.103 175.637 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 7.4 m -83.36 115.97 22.26 Favored 'General case' 0 N--CA 1.421 -1.875 0 N-CA-C 105.814 -1.921 . . . . 0.0 105.814 175.499 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.453 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.5 m-85 -81.89 131.94 35.26 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-O 121.376 0.608 . . . . 0.0 111.046 -175.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 93.5 t -103.95 116.87 48.53 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 114.377 -1.283 . . . . 0.0 108.674 -176.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.493 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -132.77 154.73 49.97 Favored 'General case' 0 N--CA 1.444 -0.739 0 CA-C-O 121.892 0.853 . . . . 0.0 112.724 -177.436 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.526 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.4 t -97.75 107.49 20.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.162 0 CA-C-N 114.962 -1.017 . . . . 0.0 109.323 179.019 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.417 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 35.9 ttpt -64.47 -56.88 11.23 Favored 'General case' 0 N--CA 1.474 0.763 0 CA-C-O 121.103 0.478 . . . . 0.0 111.836 -173.142 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.1 m -85.06 -0.14 53.49 Favored 'General case' 0 C--N 1.303 -1.454 0 CA-C-N 115.615 -0.721 . . . . 0.0 111.693 -173.839 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.51 -14.03 33.66 Favored Glycine 0 CA--C 1.491 -1.439 0 C-N-CA 119.495 -1.336 . . . . 0.0 113.04 -173.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 22.5 m-85 -98.15 171.7 8.06 Favored 'General case' 0 C--N 1.312 -1.033 0 CA-C-O 121.177 0.513 . . . . 0.0 110.946 -178.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -85.65 105.88 16.53 Favored 'General case' 0 N--CA 1.431 -1.393 0 N-CA-C 108.07 -1.085 . . . . 0.0 108.07 177.196 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 24.3 t -84.55 103.32 11.63 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 CA-C-N 115.141 -0.936 . . . . 0.0 108.714 -178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 40.7 t -103.51 122.39 56.06 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.732 0 N-CA-C 107.854 -1.165 . . . . 0.0 107.854 -179.181 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.9 mtpm? -106.14 107.31 18.24 Favored 'General case' 0 C--N 1.29 -1.98 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 -178.161 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 55.9 m-85 -87.94 119.98 28.83 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.627 -178.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 6.9 tt -170.36 -61.74 0.02 OUTLIER 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 177.466 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -90.79 89.02 7.3 Favored 'General case' 0 C--N 1.309 -1.185 0 CA-C-N 115.696 -0.684 . . . . 0.0 109.433 -179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 71.4 t60 -85.36 -58.43 2.68 Favored 'General case' 0 C--N 1.306 -1.283 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 178.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 76.5 t60 -100.48 101.16 12.04 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.492 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -155.7 164.04 39.11 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 -178.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -145.43 90.89 2.06 Favored 'General case' 0 C--N 1.293 -1.886 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 175.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 18.6 t60 -87.88 107.6 18.77 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.753 -175.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 41.4 t-80 . . . . . 0 C--N 1.298 -1.651 0 N-CA-C 107.667 -1.234 . . . . 0.0 107.667 177.934 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 43.0 tpp . . . . . 0 CA--C 1.505 -0.76 0 N-CA-C 110.076 -0.342 . . . . 0.0 110.076 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.53 ' HB ' ' HB2' ' A' ' 16' ' ' ASP . 48.5 mm -95.59 138.52 21.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 177.662 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 8.2 p -135.09 137.66 50.09 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.014 0 CA-C-O 121.074 0.464 . . . . 0.0 109.785 179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 45.7 m-85 -97.35 117.73 32.23 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 179.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.45 ' HG3' ' CG2' ' A' ' 178' ' ' VAL . 26.6 mmmt -100.76 130.46 46.79 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-N 115.006 -0.997 . . . . 0.0 109.688 -176.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -71.6 140.34 49.73 Favored 'General case' 0 C--N 1.304 -1.37 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 173.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 51.5 t -84.68 -21.46 8.1 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.72 0 CA-C-O 121.074 0.464 . . . . 0.0 109.843 -176.375 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 23.9 mm -78.38 -55.84 8.98 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.869 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 -177.603 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 61.8 p -90.94 -33.86 15.42 Favored 'General case' 0 C--O 1.246 0.872 0 N-CA-C 112.784 0.661 . . . . 0.0 112.784 -178.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.68 9.25 64.65 Favored Glycine 0 N--CA 1.445 -0.757 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -174.774 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 6.6 t70 -88.36 -175.98 5.19 Favored 'General case' 0 CA--C 1.544 0.735 0 N-CA-C 110.489 -0.189 . . . . 0.0 110.489 -175.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 36.8 mt-10 -108.36 115.77 30.72 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.859 -0.793 . . . . 0.0 108.859 -174.366 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.546 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 31.9 m -88.64 -25.24 5.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -176.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -173.98 161.12 0.33 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.058 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 -179.259 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 51.2 p -133.32 175.34 9.49 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.558 -0.534 . . . . 0.0 109.558 177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.53 ' HB2' ' HB ' ' A' ' 2' ' ' ILE . 38.9 t70 -82.91 7.83 14.29 Favored 'General case' 0 C--O 1.206 -1.202 0 CA-C-O 122.599 1.19 . . . . 0.0 110.344 -179.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.96 -10.73 43.97 Favored 'General case' 0 C--N 1.306 -1.292 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 172.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.459 HD11 ' CE1' ' A' ' 81' ' ' PHE . 52.8 mt -110.81 174.05 6.04 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.882 -174.525 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 43.7 tttm -95.27 128.87 42.45 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-N 116.064 -0.516 . . . . 0.0 109.874 -176.608 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 91.4 mt -132.26 128.28 58.48 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.005 0 CA-C-N 115.011 -0.995 . . . . 0.0 108.802 -177.484 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.1 p -118.77 156.69 51.48 Favored Pre-proline 0 C--N 1.304 -1.378 0 CA-C-O 120.691 0.281 . . . . 0.0 111.385 175.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 62.8 Cg_endo -76.27 139.3 20.98 Favored 'Trans proline' 0 CA--C 1.532 0.424 0 C-N-CA 121.933 1.755 . . . . 0.0 109.513 172.671 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.467 ' HA ' ' HB2' ' A' ' 35' ' ' GLU . 81.4 t -64.01 116.56 3.67 Favored 'Isoleucine or valine' 0 CA--C 1.507 -0.676 0 N-CA-C 111.857 0.317 . . . . 0.0 111.857 -177.039 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.8 mtt -122.61 107.91 12.5 Favored 'General case' 0 C--N 1.304 -1.379 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 170.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 6.2 mm-40 -143.58 129.78 19.77 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-N 114.453 -1.249 . . . . 0.0 109.093 -175.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 84.89 7.17 84.33 Favored Glycine 0 C--N 1.313 -0.744 0 C-N-CA 120.818 -0.706 . . . . 0.0 111.933 -179.254 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 90.92 4.75 68.98 Favored Glycine 0 N--CA 1.44 -1.094 0 N-CA-C 112.106 -0.398 . . . . 0.0 112.106 179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -130.41 161.65 30.89 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 110.446 -0.205 . . . . 0.0 110.446 -177.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -84.75 143.61 29.03 Favored 'General case' 0 C--N 1.315 -0.926 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 176.04 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.507 HG12 HD12 ' A' ' 33' ' ' LEU . 22.5 t -113.49 112.77 48.56 Favored Pre-proline 0 C--N 1.285 -2.221 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 97.3 Cg_endo -76.21 148.02 30.26 Favored 'Trans proline' 0 CA--C 1.542 0.89 0 C-N-CA 122.93 2.42 . . . . 0.0 114.081 -176.386 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 83.69 3.58 89.47 Favored Glycine 0 CA--C 1.499 -0.914 0 CA-C-N 115.362 -0.835 . . . . 0.0 113.781 175.279 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.571 HD23 ' HA ' ' A' ' 171' ' ' VAL . 35.3 mt -136.51 145.09 44.69 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 108.283 -1.006 . . . . 0.0 108.283 -174.797 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 44.5 p90 -125.16 149.36 47.98 Favored 'General case' 0 N--CA 1.432 -1.367 0 C-N-CA 118.786 -1.166 . . . . 0.0 111.455 178.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.519 ' OE2' ' HE3' ' A' ' 160' ' ' LYS . 23.5 tt0 -105.91 150.77 25.34 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 113.098 -1.865 . . . . 0.0 107.554 -172.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.539 HG13 HG21 ' A' ' 75' ' ' VAL . 41.5 t -115.89 113.72 44.1 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.559 0 C-N-CA 119.36 -0.936 . . . . 0.0 110.545 174.806 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 23.6 t70 -79.5 142.13 36.08 Favored 'General case' 0 C--N 1.301 -1.525 0 CA-C-N 114.42 -1.264 . . . . 0.0 108.847 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 19.7 m -98.84 135.52 40.16 Favored 'General case' 0 N--CA 1.42 -1.952 0 CA-C-O 121.636 0.731 . . . . 0.0 111.019 -173.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -136.79 126.62 25.69 Favored 'General case' 0 C--N 1.301 -1.506 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.0 mmm -85.25 108.89 17.98 Favored 'General case' 0 C--N 1.307 -1.255 0 O-C-N 124.041 0.838 . . . . 0.0 108.908 -176.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.415 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 35.7 m -117.12 152.44 18.93 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -76.75 117.99 18.93 Favored 'General case' 0 C--N 1.305 -1.369 0 CA-C-O 121.192 0.52 . . . . 0.0 110.177 178.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.0 t -109.41 112.55 40.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.966 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 178.529 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -72.16 161.3 54.29 Favored Glycine 0 N--CA 1.433 -1.512 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 176.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -72.92 86.36 0.56 Allowed Glycine 0 C--N 1.316 -0.578 0 N-CA-C 111.958 -0.457 . . . . 0.0 111.958 -179.104 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -84.65 -19.45 59.94 Favored Glycine 0 N--CA 1.446 -0.643 0 N-CA-C 111.787 -0.525 . . . . 0.0 111.787 -179.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 12.6 m-20 -77.77 101.21 6.59 Favored 'General case' 0 CA--C 1.495 -1.143 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 176.541 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.3 mt -67.87 111.59 2.5 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.212 0 CA-C-N 115.115 -0.948 . . . . 0.0 109.372 -179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -94.02 148.51 22.09 Favored 'General case' 0 C--N 1.299 -1.622 0 N-CA-C 106.897 -1.52 . . . . 0.0 106.897 176.201 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.4 mm -66.03 -31.46 53.78 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.854 0 CA-C-O 121.39 0.614 . . . . 0.0 110.377 -178.432 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 128.14 -46.59 1.07 Allowed Glycine 0 CA--C 1.48 -2.119 0 N-CA-C 108.173 -1.971 . . . . 0.0 108.173 -176.932 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 49.0 t 179.34 -36.65 0.01 OUTLIER 'General case' 0 C--O 1.21 -1.015 0 C-N-CA 124.917 1.287 . . . . 0.0 107.615 176.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 112.02 0.87 26.99 Favored Glycine 0 N--CA 1.442 -0.921 0 N-CA-C 109.796 -1.321 . . . . 0.0 109.796 -176.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -163.87 150.9 12.01 Favored 'General case' 0 C--O 1.246 0.884 0 C-N-CA 124.191 0.996 . . . . 0.0 108.566 -178.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -96.36 152.44 18.59 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 178.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -104.8 -37.07 7.18 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-O 121.202 0.525 . . . . 0.0 111.038 -178.018 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 151.75 144.59 3.95 Favored Glycine 0 N--CA 1.432 -1.572 0 N-CA-C 110.023 -1.231 . . . . 0.0 110.023 -179.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 68.47 -121.23 12.59 Favored Glycine 0 N--CA 1.445 -0.761 0 N-CA-C 110.232 -1.147 . . . . 0.0 110.232 -176.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -170.35 140.55 1.87 Allowed 'General case' 0 C--N 1.313 -0.981 0 C-N-CA 124.03 0.932 . . . . 0.0 108.973 177.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -91.12 -27.83 17.26 Favored Glycine 0 C--N 1.311 -0.85 0 N-CA-C 109.065 -1.614 . . . . 0.0 109.065 173.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.9 t70 -169.93 165.41 9.59 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 104.606 -2.368 . . . . 0.0 104.606 177.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -68.54 -64.97 0.76 Allowed 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 119.062 0.846 . . . . 0.0 111.553 -177.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.7 pt-20 -102.81 -16.9 15.8 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 119.395 -0.922 . . . . 0.0 112.312 -179.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 74.38 55.97 5.35 Favored Glycine 0 CA--C 1.498 -1.015 0 N-CA-C 107.357 -2.297 . . . . 0.0 107.357 -173.367 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -59.05 -66.95 0.42 Allowed 'General case' 0 C--O 1.239 0.525 0 CA-C-N 114.497 -0.852 . . . . 0.0 112.699 -172.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -148.49 157.02 43.2 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 179.909 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -164.29 166.13 21.17 Favored 'General case' 0 C--N 1.297 -1.696 0 N-CA-C 104.886 -2.264 . . . . 0.0 104.886 177.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 58.51 74.79 0.42 Allowed 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 124.825 1.25 . . . . 0.0 113.926 179.41 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 59.2 m -87.63 95.13 9.94 Favored 'General case' 0 N--CA 1.429 -1.519 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 173.746 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.9 mt-30 -87.07 147.88 25.5 Favored 'General case' 0 C--N 1.293 -1.85 0 CA-C-N 114.459 -1.246 . . . . 0.0 110.068 -173.648 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 63.4 mttp -96.68 120.48 37.09 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 167.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -138.59 171.39 14.43 Favored 'General case' 0 C--N 1.277 -2.553 0 N-CA-C 107.308 -1.367 . . . . 0.0 107.308 -170.466 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 57.2 t30 -74.44 137.44 42.62 Favored 'General case' 0 C--N 1.308 -1.204 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.888 179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 6.9 p30 -56.78 -28.86 62.0 Favored 'General case' 0 N--CA 1.474 0.744 0 C-N-CA 124.504 1.122 . . . . 0.0 112.515 -177.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.539 HG21 HG13 ' A' ' 36' ' ' VAL . 47.0 t -84.61 -31.42 7.37 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.813 0 N-CA-C 112.039 0.385 . . . . 0.0 112.039 -175.101 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.588 ' HA ' ' CE1' ' A' ' 83' ' ' TYR . 2.9 p -79.11 -61.08 2.13 Favored 'General case' 0 N--CA 1.421 -1.903 0 C-N-CA 120.076 -0.65 . . . . 0.0 111.881 -177.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 48.8 91.81 0.01 OUTLIER Glycine 0 CA--C 1.537 1.408 0 O-C-N 124.106 0.879 . . . . 0.0 113.829 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 61.6 Cg_exo -54.45 -32.38 72.97 Favored 'Trans proline' 0 N--CA 1.492 1.433 0 C-N-CA 123.025 2.483 . . . . 0.0 113.197 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.7 m -91.8 6.3 46.58 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.103 -0.499 . . . . 0.0 111.455 179.789 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -120.93 -75.76 0.59 Allowed 'General case' 0 CA--C 1.546 0.81 0 O-C-N 121.891 -0.506 . . . . 0.0 111.366 -179.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.459 ' CE1' HD11 ' A' ' 18' ' ' LEU . 91.1 m-85 -92.95 -36.52 12.72 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 121.088 -0.245 . . . . 0.0 111.343 179.064 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 59.85 95.37 0.03 OUTLIER 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.862 1.265 . . . . 0.0 112.784 -179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.588 ' CE1' ' HA ' ' A' ' 76' ' ' SER . 20.7 m-85 -90.4 123.93 34.53 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.746 -178.504 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.8 m -105.32 126.31 51.96 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 107.681 -1.229 . . . . 0.0 107.681 178.347 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -80.99 141.31 34.55 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 120.902 0.382 . . . . 0.0 111.623 -176.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.4 mmt -135.91 135.35 21.45 Favored Pre-proline 0 C--N 1.308 -1.219 0 C-N-CA 124.238 1.015 . . . . 0.0 109.608 -179.652 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 95.7 Cg_endo -82.34 166.58 16.01 Favored 'Trans proline' 0 C--O 1.247 0.942 0 C-N-CA 122.578 2.186 . . . . 0.0 110.752 174.481 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 24.3 m-85 -62.79 128.71 37.17 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 175.58 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.539 ' OG ' ' HB2' ' A' ' 94' ' ' PHE . 3.0 p -73.37 -27.72 61.64 Favored 'General case' 0 N--CA 1.436 -1.163 0 O-C-N 123.375 0.422 . . . . 0.0 109.999 176.185 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.4 m 67.7 -38.46 0.36 Allowed 'General case' 0 N--CA 1.5 2.048 0 C-N-CA 126.934 2.093 . . . . 0.0 114.528 173.417 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.415 ' HE2' ' OE1' ' A' ' 93' ' ' GLU . 36.0 mtmm -72.51 174.29 7.67 Favored 'General case' 0 C--N 1.299 -1.613 0 C-N-CA 125.902 1.681 . . . . 0.0 110.226 179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -42.06 -28.55 0.5 Allowed Glycine 0 N--CA 1.476 1.346 0 N-CA-C 116.355 1.302 . . . . 0.0 116.355 -176.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.415 ' OE1' ' HE2' ' A' ' 91' ' ' LYS . 2.7 mp0 -52.11 -55.59 19.87 Favored 'General case' 0 C--N 1.342 0.249 0 C-N-CA 123.831 0.853 . . . . 0.0 110.494 176.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.539 ' HB2' ' OG ' ' A' ' 89' ' ' SER . 43.2 t80 -71.42 -33.17 69.19 Favored 'General case' 0 C--N 1.316 -0.859 0 CA-C-N 115.487 -0.779 . . . . 0.0 111.335 -176.793 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.9 mmtp -73.41 -41.01 63.83 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.819 -176.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 18.6 t -73.61 -25.42 60.32 Favored 'General case' 0 N--CA 1.437 -1.112 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.575 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.483 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 77.4 t90 -67.52 -52.47 38.67 Favored 'General case' 0 C--O 1.209 -1.055 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 176.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 71.8 t -56.11 -40.63 65.44 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.216 0 CA-C-O 121.265 0.555 . . . . 0.0 110.173 177.141 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 17.8 tttm -54.97 -57.0 13.43 Favored 'General case' 0 C--N 1.315 -0.922 0 C-N-CA 124.569 1.148 . . . . 0.0 112.263 176.1 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -80.04 -24.73 40.53 Favored 'General case' 0 C--N 1.315 -0.9 0 N-CA-C 113.03 0.752 . . . . 0.0 113.03 -176.788 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 87.8 t80 -60.29 -57.44 12.76 Favored 'General case' 0 C--O 1.224 -0.266 0 C-N-CA 123.046 0.538 . . . . 0.0 110.114 177.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.9 t -62.71 -34.41 65.35 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.616 0 O-C-N 123.396 0.435 . . . . 0.0 110.73 -177.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 47.6 mtp180 -60.17 -58.45 8.47 Favored 'General case' 0 CA--C 1.519 -0.217 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.018 175.358 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 90.0 m-20 -62.12 -33.04 73.71 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.84 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 54.7 t -62.54 -40.83 89.71 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.624 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.373 175.628 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -67.94 -30.81 70.21 Favored 'General case' 0 C--O 1.241 0.655 0 N-CA-C 112.6 0.593 . . . . 0.0 112.6 177.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -65.76 -36.6 84.0 Favored 'General case' 0 N--CA 1.471 0.583 0 CA-C-O 121.265 0.555 . . . . 0.0 109.685 172.081 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.12 -31.81 69.53 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.835 -0.62 . . . . 0.0 111.33 178.472 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.5 mp -66.39 -52.45 46.6 Favored 'General case' 0 C--O 1.219 -0.502 0 N-CA-C 112.604 0.594 . . . . 0.0 112.604 175.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 18.5 ptpt -72.43 -29.98 64.19 Favored 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 120.56 -0.456 . . . . 0.0 111.756 -177.462 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -83.33 -0.36 90.06 Favored Glycine 0 N--CA 1.439 -1.131 0 CA-C-N 115.923 -0.581 . . . . 0.0 114.041 -177.353 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.1 p -71.11 -23.58 62.13 Favored 'General case' 0 CA--C 1.546 0.795 0 N-CA-C 113.514 0.931 . . . . 0.0 113.514 -172.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 71.59 21.92 78.72 Favored Glycine 0 CA--C 1.529 0.962 0 C-N-CA 120.895 -0.669 . . . . 0.0 112.751 -179.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 57.8 t -80.99 153.79 4.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.71 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -53.21 143.72 17.57 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.731 0.812 . . . . 0.0 111.76 179.154 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 71.0 t -53.97 -45.77 64.44 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 C-N-CA 124.372 1.069 . . . . 0.0 113.002 -174.766 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 -59.64 -40.47 87.79 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-O 121.54 0.686 . . . . 0.0 110.677 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.455 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.3 m-20 -70.18 -36.34 74.58 Favored 'General case' 0 C--O 1.211 -0.972 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.421 177.375 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 38.3 mm -60.33 -33.52 54.21 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.888 0 C-N-CA 123.424 0.69 . . . . 0.0 110.518 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.451 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 10.6 mmpt? -58.69 -50.22 74.68 Favored 'General case' 0 N--CA 1.466 0.332 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 177.075 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.613 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 57.1 mttm -68.92 -40.21 79.2 Favored 'General case' 0 C--O 1.205 -1.254 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.571 179.35 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.483 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 6.0 t80 -58.84 -40.29 83.79 Favored 'General case' 0 C--N 1.315 -0.925 0 C-N-CA 126.189 1.795 . . . . 0.0 109.78 -177.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.6 mtp -80.38 -17.33 52.19 Favored 'General case' 0 C--O 1.215 -0.746 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.443 178.491 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.451 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 44.3 mt-10 -76.98 -28.11 54.98 Favored 'General case' 0 CA--C 1.516 -0.358 0 N-CA-C 109.043 -0.725 . . . . 0.0 109.043 173.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.613 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 56.6 mt-10 -72.81 -28.83 62.8 Favored 'General case' 0 C--O 1.211 -0.93 0 CA-C-N 115.148 -0.933 . . . . 0.0 109.959 178.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.621 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.94 -55.59 29.2 Favored Pre-proline 0 CA--C 1.569 1.71 0 N-CA-C 114.712 1.375 . . . . 0.0 114.712 179.923 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.5 Cg_endo -66.09 -24.98 51.5 Favored 'Trans proline' 0 C--N 1.378 2.112 0 C-N-CA 121.347 1.364 . . . . 0.0 111.48 175.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 52.1 m -72.21 -30.73 65.21 Favored 'General case' 0 N--CA 1.437 -1.103 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.67 179.122 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.621 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 17.5 m-85 -58.54 -51.44 69.89 Favored 'General case' 0 C--N 1.36 1.054 0 N-CA-C 107.539 -1.282 . . . . 0.0 107.539 174.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.51 ' O ' HG23 ' A' ' 134' ' ' VAL . 67.9 t -59.18 -50.75 78.67 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.696 0 CA-C-N 114.476 -1.238 . . . . 0.0 110.666 179.733 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 13.0 tmtt? -54.56 -48.84 71.56 Favored 'General case' 0 CA--C 1.55 0.965 0 C-N-CA 124.336 1.054 . . . . 0.0 111.52 -177.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 18.9 t90 -71.27 -34.03 70.32 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-O 120.562 0.22 . . . . 0.0 111.081 -177.384 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.415 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -69.18 -31.32 69.86 Favored 'General case' 0 C--O 1.22 -0.492 0 CA-C-N 116.615 -0.266 . . . . 0.0 110.91 177.109 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.51 HG23 ' O ' ' A' ' 130' ' ' VAL . 95.8 t -72.0 -41.68 68.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.343 0 N-CA-C 109.967 -0.383 . . . . 0.0 109.967 176.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 50.5 m-20 -62.9 -45.55 92.0 Favored 'General case' 0 CA--C 1.495 -1.141 0 N-CA-C 112.352 0.501 . . . . 0.0 112.352 178.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.708 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.1 mptp? -87.27 -3.2 59.03 Favored 'General case' 0 C--O 1.201 -1.454 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 -176.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 47.4 t80 -50.24 -44.98 53.71 Favored 'General case' 0 N--CA 1.489 1.502 0 C-N-CA 124.098 0.959 . . . . 0.0 111.221 -179.039 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 5.8 m-20 -62.56 -34.09 76.25 Favored 'General case' 0 C--N 1.324 -0.536 0 CA-C-N 115.295 -0.866 . . . . 0.0 111.596 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -91.55 -8.3 47.85 Favored 'General case' 0 C--N 1.317 -0.842 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.812 -175.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.708 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.9 mt -82.85 154.98 24.38 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-O 122.256 1.027 . . . . 0.0 113.388 -172.802 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.7 tt0 -144.9 159.73 42.44 Favored 'General case' 0 N--CA 1.408 -2.547 0 N-CA-C 102.645 -3.094 . . . . 0.0 102.645 170.221 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -107.12 151.8 24.9 Favored 'General case' 0 C--N 1.294 -1.826 0 CA-C-N 119.049 0.84 . . . . 0.0 112.73 -174.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.3 m-85 -135.0 168.14 19.65 Favored 'General case' 0 C--N 1.295 -1.775 0 CA-C-N 114.984 -1.007 . . . . 0.0 109.334 175.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 47.4 mtp -149.98 144.57 25.92 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 106.369 -1.715 . . . . 0.0 106.369 178.339 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 99.7 p -83.28 174.92 10.3 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 107.634 -1.247 . . . . 0.0 107.634 173.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 63.7 tttp -51.94 -43.07 63.32 Favored 'General case' 0 C--N 1.313 -0.995 0 C-N-CA 124.115 0.966 . . . . 0.0 111.791 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.4 p -89.31 -3.4 58.51 Favored 'General case' 0 CA--C 1.57 1.733 0 N-CA-C 114.889 1.44 . . . . 0.0 114.889 -177.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 63.4 mtt -87.08 176.78 7.45 Favored 'General case' 0 N--CA 1.483 1.183 0 N-CA-C 114.095 1.146 . . . . 0.0 114.095 -176.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 79.9 m-20 -133.45 152.79 79.84 Favored Pre-proline 0 C--O 1.215 -0.719 0 C-N-CA 124.535 1.134 . . . . 0.0 109.572 -177.003 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -68.39 -23.14 38.39 Favored 'Trans proline' 0 CA--C 1.543 0.929 0 C-N-CA 121.999 1.8 . . . . 0.0 111.799 176.31 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -88.76 -16.34 32.41 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.943 178.743 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -156.73 111.08 2.74 Favored 'General case' 0 C--N 1.314 -0.97 0 N-CA-C 109.762 -0.458 . . . . 0.0 109.762 -174.775 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 42.53 3.88 Favored Glycine 0 C--N 1.306 -1.105 0 C-N-CA 120.11 -1.043 . . . . 0.0 110.918 -175.245 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.483 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 37.7 tp -96.18 111.84 23.76 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 106.296 -1.742 . . . . 0.0 106.296 176.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 82.5 mt -86.73 131.71 34.14 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.886 0 CA-C-N 115.254 -0.885 . . . . 0.0 111.423 -172.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 43.7 m-85 -87.09 133.44 33.61 Favored 'General case' 0 C--N 1.311 -1.071 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 175.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.403 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 20.4 m -147.89 149.84 32.99 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.363 -0.835 . . . . 0.0 110.466 177.292 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.425 ' HB3' HD23 ' A' ' 140' ' ' LEU . 10.2 p90 -145.08 169.93 17.19 Favored 'General case' 0 C--O 1.198 -1.632 0 N-CA-C 107.126 -1.435 . . . . 0.0 107.126 175.691 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 25.1 m-85 -100.36 106.92 18.58 Favored 'General case' 0 C--N 1.277 -2.567 0 N-CA-C 107.285 -1.376 . . . . 0.0 107.285 176.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.519 ' HE3' ' OE2' ' A' ' 35' ' ' GLU . 53.3 tttm -71.73 144.02 49.42 Favored 'General case' 0 C--N 1.316 -0.848 0 N-CA-C 108.206 -1.035 . . . . 0.0 108.206 -179.083 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 38.9 tt0 -57.15 120.44 8.06 Favored 'General case' 0 C--N 1.313 -1.016 0 O-C-N 124.107 0.879 . . . . 0.0 110.179 179.841 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.16 -18.53 36.17 Favored Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.705 -0.68 . . . . 0.0 111.911 -178.14 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.93 144.7 27.81 Favored 'General case' 0 C--N 1.312 -1.032 0 O-C-N 122.434 -0.45 . . . . 0.0 110.086 179.456 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.0 m170 -110.12 14.87 22.76 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.473 0.654 . . . . 0.0 110.233 178.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.5 m -138.99 154.26 72.44 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 179.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -55.79 119.64 6.92 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.536 2.157 . . . . 0.0 112.74 178.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.473 HG23 ' O ' ' A' ' 36' ' ' VAL . 32.1 m -82.16 113.96 20.35 Favored 'General case' 0 N--CA 1.405 -2.68 0 N-CA-C 105.638 -1.986 . . . . 0.0 105.638 175.054 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 65.6 m-85 -81.92 130.59 35.12 Favored 'General case' 0 N--CA 1.422 -1.852 0 CA-C-N 115.693 -0.685 . . . . 0.0 110.373 -174.392 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.8 t -99.76 108.4 22.61 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.819 0 CA-C-N 114.275 -1.33 . . . . 0.0 108.847 -175.231 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.546 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 40.4 m-85 -127.29 142.6 51.42 Favored 'General case' 0 N--CA 1.433 -1.293 0 CA-C-O 121.636 0.731 . . . . 0.0 111.623 -178.792 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.571 ' HA ' HD23 ' A' ' 33' ' ' LEU . 45.0 t -88.9 99.32 9.03 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.616 179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.6 ttpt -57.62 -50.81 71.93 Favored 'General case' 0 N--CA 1.474 0.773 0 C-N-CA 123.909 0.884 . . . . 0.0 111.689 -174.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.483 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 69.9 m -79.78 -7.35 58.6 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.096 -177.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -95.61 -24.55 15.55 Favored Glycine 0 CA--C 1.491 -1.449 0 C-N-CA 120.35 -0.929 . . . . 0.0 111.68 -175.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.6 m-85 -96.9 172.22 8.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 -177.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.416 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 22.8 mmtm -110.57 127.99 55.46 Favored 'General case' 0 C--N 1.295 -1.803 0 CA-C-O 121.572 0.701 . . . . 0.0 112.683 -177.446 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 85.2 t -83.73 106.89 14.64 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 CA-C-N 114.372 -1.286 . . . . 0.0 109.989 -178.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.45 ' CG2' ' HG3' ' A' ' 5' ' ' LYS . 53.4 t -99.36 125.42 52.92 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.806 0 N-CA-C 107.365 -1.346 . . . . 0.0 107.365 175.629 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 61.6 pttt -107.49 113.47 26.82 Favored 'General case' 0 N--CA 1.409 -2.505 0 C-N-CA 119.929 -0.709 . . . . 0.0 111.769 -177.284 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 71.4 m-85 -84.93 122.54 29.34 Favored 'General case' 0 N--CA 1.424 -1.752 0 N-CA-C 106.22 -1.77 . . . . 0.0 106.22 169.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 63.5 tp 75.86 -83.23 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.806 0 C-N-CA 125.299 1.44 . . . . 0.0 110.292 -174.619 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 179.35 162.52 0.86 Allowed 'General case' 0 C--O 1.245 0.846 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 10.0 p80 -80.7 77.73 7.51 Favored 'General case' 0 C--O 1.216 -0.68 0 CA-C-O 122.224 1.011 . . . . 0.0 111.067 176.479 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 28.1 m80 -146.09 -171.49 3.72 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-N 114.435 -1.257 . . . . 0.0 107.761 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . 0.254 79.5 m-70 83.36 171.06 0.09 Allowed 'General case' 0 C--O 1.242 0.674 0 C-N-CA 125.589 1.556 . . . . 0.0 110.476 -177.549 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 39.9 m80 -88.22 90.49 8.41 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 113.713 1.005 . . . . 0.0 113.713 -171.396 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 79.7 t60 -108.8 133.77 52.4 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 170.344 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 21.3 p80 . . . . . 0 C--N 1.29 -1.984 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 -177.285 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.8 ttt . . . . . 0 CA--C 1.515 -0.382 0 CA-C-O 120.982 0.42 . . . . 0.0 110.521 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 42.2 mt -98.73 115.9 40.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.918 0 N-CA-C 106.549 -1.648 . . . . 0.0 106.549 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 10.4 p -129.63 142.58 43.53 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 CA-C-O 121.239 0.542 . . . . 0.0 111.567 -173.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.437 ' CE1' HG22 ' A' ' 177' ' ' VAL . 64.6 m-85 -88.06 114.21 24.44 Favored 'General case' 0 N--CA 1.434 -1.227 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 175.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 28.2 mtpp -107.47 137.22 45.9 Favored 'General case' 0 C--N 1.294 -1.822 0 CA-C-N 115.48 -0.782 . . . . 0.0 109.664 -178.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.413 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.8 t70 -71.73 142.84 49.77 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.553 -0.749 . . . . 0.0 111.938 -176.664 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.5 t -79.93 -27.25 12.26 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.287 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.923 -178.578 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.9 mm -81.81 -49.26 17.82 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-N 116.32 -0.4 . . . . 0.0 111.153 -174.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.6 p -93.8 -42.93 8.85 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.071 0.462 . . . . 0.0 111.915 179.504 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.5 1.19 60.63 Favored Glycine 0 N--CA 1.437 -1.236 0 N-CA-C 110.139 -1.184 . . . . 0.0 110.139 -172.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.0 t70 -83.61 -178.89 7.18 Favored 'General case' 0 CA--C 1.541 0.626 0 N-CA-C 107.847 -1.168 . . . . 0.0 107.847 -178.714 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.9 mt-10 -115.19 125.77 53.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.429 -0.794 . . . . 0.0 111.24 -169.591 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 26.6 m -92.99 -34.15 5.77 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.569 0 N-CA-C 114.049 1.129 . . . . 0.0 114.049 -174.022 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.9 p -169.7 146.98 0.86 Allowed 'Isoleucine or valine' 0 C--O 1.242 0.673 0 N-CA-C 109.271 -0.64 . . . . 0.0 109.271 -178.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 61.9 p -120.12 170.33 9.4 Favored 'General case' 0 N--CA 1.441 -0.897 0 C-N-CA 122.048 0.139 . . . . 0.0 110.857 -179.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.4 p-10 -71.39 -5.98 36.77 Favored 'General case' 0 N--CA 1.483 1.206 0 C-N-CA 123.942 0.897 . . . . 0.0 112.601 -176.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.98 -9.2 56.18 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 121.276 0.56 . . . . 0.0 110.428 176.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.627 ' HB3' HG22 ' A' ' 75' ' ' VAL . 56.9 mt -106.13 -171.84 1.98 Allowed 'General case' 0 C--N 1.315 -0.923 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 -179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -95.33 124.31 39.3 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 119.572 -0.851 . . . . 0.0 111.425 -178.845 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.471 HG23 ' CD2' ' A' ' 34' ' ' PHE . 71.5 mt -133.43 107.76 11.38 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.202 0 CA-C-N 114.802 -1.09 . . . . 0.0 109.464 -177.48 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 9.5 p -125.26 149.6 64.6 Favored Pre-proline 0 C--O 1.204 -1.305 0 O-C-N 122.119 -0.363 . . . . 0.0 110.521 176.587 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -68.04 155.07 71.0 Favored 'Trans proline' 0 N--CA 1.478 0.606 0 C-N-CA 121.842 1.695 . . . . 0.0 111.499 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.44 HG22 ' HB2' ' A' ' 35' ' ' GLU . 65.7 t -71.3 115.39 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.814 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 178.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 88.1 mtp -122.97 113.61 19.31 Favored 'General case' 0 C--N 1.294 -1.814 0 N-CA-C 109.202 -0.666 . . . . 0.0 109.202 176.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 20.9 mt-10 -134.64 122.98 23.04 Favored 'General case' 0 N--CA 1.435 -1.202 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 177.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.63 28.01 52.73 Favored Glycine 0 C--N 1.307 -1.06 0 C-N-CA 121.299 -0.477 . . . . 0.0 113.026 177.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 93.02 -33.27 5.15 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 121.894 -0.193 . . . . 0.0 113.195 175.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -99.71 155.03 17.84 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-O 120.791 0.329 . . . . 0.0 110.146 -176.904 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.2 pt-20 -86.37 148.49 25.56 Favored 'General case' 0 N--CA 1.42 -1.967 0 N-CA-C 107.532 -1.285 . . . . 0.0 107.532 173.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -91.33 114.13 60.68 Favored Pre-proline 0 C--N 1.278 -2.504 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 174.556 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -65.21 127.55 18.57 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.673 2.248 . . . . 0.0 114.374 -171.846 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.99 6.26 63.5 Favored Glycine 0 N--CA 1.428 -1.839 0 CA-C-N 114.602 -1.181 . . . . 0.0 114.092 175.708 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.498 HD13 ' CE3' ' A' ' 132' ' ' TRP . 71.4 mt -131.64 146.46 52.2 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 116.807 0.304 . . . . 0.0 110.878 -176.138 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.471 ' CD2' HG23 ' A' ' 20' ' ' ILE . 27.2 p90 -133.45 150.4 51.75 Favored 'General case' 0 N--CA 1.431 -1.394 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.638 176.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.44 ' HB2' HG22 ' A' ' 23' ' ' VAL . 30.1 tt0 -116.59 150.69 37.62 Favored 'General case' 0 C--N 1.276 -2.605 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -174.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 89.2 t -110.01 113.38 44.06 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.607 0 C-N-CA 118.509 -1.276 . . . . 0.0 108.434 175.25 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -86.85 154.61 20.74 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 113.366 -1.743 . . . . 0.0 106.777 179.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 33.2 p -97.84 134.89 40.37 Favored 'General case' 0 N--CA 1.425 -1.723 0 C-N-CA 118.546 -1.261 . . . . 0.0 112.505 -172.791 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -129.13 123.43 32.13 Favored 'General case' 0 CA--C 1.486 -1.508 0 N-CA-C 106.088 -1.819 . . . . 0.0 106.088 175.456 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 3.2 mpp? -95.85 121.17 37.3 Favored 'General case' 0 C--N 1.29 -2.019 0 O-C-N 123.893 0.746 . . . . 0.0 112.172 -170.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 26.2 m -113.52 153.77 15.02 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.964 0 CA-C-N 114.765 -1.107 . . . . 0.0 108.894 177.691 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -82.34 114.87 21.1 Favored 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.019 179.015 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 62.1 t -85.62 113.8 24.45 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 N-CA-C 107.413 -1.328 . . . . 0.0 107.413 177.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 104.27 74.39 0.98 Allowed Glycine 0 N--CA 1.433 -1.527 0 N-CA-C 109.979 -1.248 . . . . 0.0 109.979 -176.514 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 127.88 119.26 2.21 Favored Glycine 0 N--CA 1.433 -1.505 0 N-CA-C 111.317 -0.713 . . . . 0.0 111.317 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -93.35 77.64 1.1 Allowed Glycine 0 N--CA 1.437 -1.255 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.985 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -77.0 150.4 35.85 Favored 'General case' 0 C--N 1.307 -1.275 0 C-N-CA 123.249 0.62 . . . . 0.0 111.773 -178.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 78.7 mt -91.42 128.05 43.4 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 CA-C-N 115.662 -0.699 . . . . 0.0 110.492 -177.254 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 12.3 t70 72.02 8.83 6.02 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 125.593 1.557 . . . . 0.0 112.397 173.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 49.8 mm -89.18 -19.86 7.35 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.013 0 N-CA-C 108.536 -0.913 . . . . 0.0 108.536 176.899 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -69.06 171.94 38.23 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.042 -0.981 . . . . 0.0 111.625 176.869 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 63.8 m 76.27 -46.16 0.53 Allowed 'General case' 0 N--CA 1.483 1.194 0 C-N-CA 125.473 1.509 . . . . 0.0 111.443 -176.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 146.66 96.81 0.19 Allowed Glycine 0 N--CA 1.432 -1.607 0 N-CA-C 110.26 -1.136 . . . . 0.0 110.26 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.9 t-20 -129.17 97.93 4.75 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -177.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -153.01 -56.31 0.12 Allowed 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 176.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 75.7 m-85 69.79 -55.54 0.59 Allowed 'General case' 0 N--CA 1.48 1.045 0 C-N-CA 126.343 1.857 . . . . 0.0 113.885 176.056 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 156.61 -138.06 5.76 Favored Glycine 0 N--CA 1.42 -2.368 0 C-N-CA 120.653 -0.785 . . . . 0.0 112.842 178.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 97.04 -70.0 0.79 Allowed Glycine 0 N--CA 1.439 -1.159 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 -177.864 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -143.6 112.06 6.39 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.732 -1.21 . . . . 0.0 107.732 177.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -129.7 119.19 2.8 Favored Glycine 0 N--CA 1.433 -1.537 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 -178.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -155.21 176.61 12.33 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 107.914 -1.143 . . . . 0.0 107.914 -179.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -68.17 -36.76 80.13 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 177.292 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 45.6 mt-10 -123.8 121.57 35.77 Favored 'General case' 0 N--CA 1.441 -0.901 0 CA-C-N 115.797 -0.638 . . . . 0.0 109.67 176.295 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -133.94 -158.84 8.73 Favored Glycine 0 N--CA 1.437 -1.255 0 C-N-CA 120.709 -0.757 . . . . 0.0 111.515 -179.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -87.3 -18.87 29.17 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 122.555 0.342 . . . . 0.0 110.506 -179.78 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 32.9 t70 -64.84 132.8 50.44 Favored 'General case' 0 C--O 1.239 0.508 0 CA-C-N 115.744 -0.662 . . . . 0.0 109.479 177.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -69.46 129.46 39.78 Favored 'General case' 0 C--O 1.249 1.062 0 CA-C-N 116.569 -0.287 . . . . 0.0 110.449 -179.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -55.68 102.32 0.07 Allowed 'General case' 0 N--CA 1.44 -0.973 0 O-C-N 124.902 1.376 . . . . 0.0 113.006 -176.007 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 2.7 p -124.61 147.37 48.53 Favored 'General case' 0 N--CA 1.412 -2.335 0 N-CA-C 107.035 -1.469 . . . . 0.0 107.035 176.471 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 49.6 mt-30 -70.76 106.23 3.49 Favored 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 121.189 0.519 . . . . 0.0 110.709 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.9 mttp -113.98 120.56 41.07 Favored 'General case' 0 C--N 1.288 -2.078 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 176.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -154.57 171.54 19.27 Favored 'General case' 0 C--N 1.293 -1.852 0 O-C-N 123.255 0.347 . . . . 0.0 111.102 178.4 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.598 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 49.8 t30 -59.94 128.41 36.75 Favored 'General case' 0 C--N 1.31 -1.128 0 O-C-N 124.085 0.866 . . . . 0.0 113.028 -174.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -52.21 -26.86 12.69 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-N 114.886 -1.052 . . . . 0.0 113.273 178.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.627 HG22 ' HB3' ' A' ' 18' ' ' LEU . 48.7 t -79.88 -45.4 22.88 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 C-N-CA 122.663 0.385 . . . . 0.0 110.824 -179.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.426 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -66.15 -58.16 6.04 Favored 'General case' 0 N--CA 1.439 -1.014 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 -174.19 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 39.92 90.44 0.01 OUTLIER Glycine 0 N--CA 1.475 1.267 0 N-CA-C 115.781 1.072 . . . . 0.0 115.781 173.326 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -62.24 -22.19 73.76 Favored 'Trans proline' 0 C--N 1.355 0.919 0 C-N-CA 122.929 2.419 . . . . 0.0 111.627 -179.356 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 15.0 m -81.0 -28.3 35.55 Favored 'General case' 0 N--CA 1.434 -1.227 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.934 178.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 17.9 m -98.63 -74.32 0.59 Allowed 'General case' 0 CA--C 1.546 0.816 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -174.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -90.33 -47.55 7.69 Favored 'General case' 0 CA--C 1.502 -0.866 0 C-N-CA 120.93 -0.308 . . . . 0.0 111.165 -177.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 66.02 88.41 0.11 Allowed 'General case' 0 C--O 1.235 0.326 0 O-C-N 124.64 1.212 . . . . 0.0 111.345 -176.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -86.67 119.28 26.73 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 115.236 -0.893 . . . . 0.0 108.822 178.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 12.9 m -99.9 132.17 45.42 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 108.429 -0.952 . . . . 0.0 108.429 -179.656 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -78.07 136.85 37.98 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 121.463 0.649 . . . . 0.0 111.636 -178.137 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 90.3 mmm -127.81 120.97 21.83 Favored Pre-proline 0 C--N 1.299 -1.596 0 C-N-CA 125.088 1.355 . . . . 0.0 108.605 179.405 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 68.0 Cg_endo -84.61 125.04 3.24 Favored 'Trans proline' 0 N--CA 1.448 -1.19 0 C-N-CA 121.658 1.572 . . . . 0.0 112.739 178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.8 m-85 -143.61 115.8 8.44 Favored 'General case' 0 C--N 1.309 -1.184 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.536 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 5.6 p -111.44 -58.25 2.14 Favored 'General case' 0 C--N 1.29 -2.012 0 N-CA-C 111.846 0.313 . . . . 0.0 111.846 178.519 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 20.3 p -135.15 20.19 3.43 Favored 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 112.009 0.374 . . . . 0.0 112.009 -176.369 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 78.5 tttt -60.13 131.38 50.63 Favored 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.369 -176.898 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -63.12 -36.62 93.69 Favored Glycine 0 N--CA 1.467 0.702 0 CA-C-N 116.255 -0.429 . . . . 0.0 112.34 -178.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -59.98 -41.51 92.17 Favored 'General case' 0 C--N 1.321 -0.645 0 C-N-CA 123.18 0.592 . . . . 0.0 109.792 175.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 54.5 t80 -66.2 -38.76 88.76 Favored 'General case' 0 C--O 1.214 -0.773 0 CA-C-N 115.722 -0.672 . . . . 0.0 110.668 178.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.1 mmtp -62.8 -38.53 91.02 Favored 'General case' 0 C--O 1.243 0.732 0 CA-C-O 120.853 0.359 . . . . 0.0 111.128 177.473 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.8 m -67.23 -39.22 86.18 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 115.71 -0.677 . . . . 0.0 109.805 177.29 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.527 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.0 t90 -62.98 -39.77 95.73 Favored 'General case' 0 CA--C 1.542 0.638 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.551 177.275 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.5 t -58.21 -40.08 76.05 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.695 0.398 . . . . 0.0 110.446 177.193 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.1 mtpt -62.83 -47.67 82.41 Favored 'General case' 0 C--O 1.224 -0.279 0 CA-C-N 116.075 -0.511 . . . . 0.0 110.655 177.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -63.59 -39.65 94.92 Favored 'General case' 0 N--CA 1.476 0.851 0 O-C-N 123.195 0.309 . . . . 0.0 111.138 178.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.9 t80 -60.52 -60.75 3.32 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.73 -0.668 . . . . 0.0 111.113 -179.032 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 66.9 t -61.27 -37.5 77.71 Favored 'Isoleucine or valine' 0 C--O 1.244 0.803 0 CA-C-O 120.713 0.292 . . . . 0.0 111.171 -177.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.2 ttt180 -60.39 -56.63 19.07 Favored 'General case' 0 CA--C 1.535 0.399 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.419 178.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 48.2 m-80 -70.15 -26.32 63.87 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.723 0.638 . . . . 0.0 112.723 -176.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 56.1 t -63.92 -38.73 83.13 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.561 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 174.057 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 45.1 mtt180 -64.3 -34.11 77.38 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 112.036 0.384 . . . . 0.0 112.036 175.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -66.85 -36.97 83.56 Favored 'General case' 0 N--CA 1.467 0.397 0 CA-C-N 116.713 -0.221 . . . . 0.0 111.183 174.18 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.43 -39.76 81.42 Favored 'General case' 0 C--O 1.242 0.666 0 O-C-N 123.119 0.262 . . . . 0.0 110.588 178.279 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -64.88 -52.18 57.94 Favored 'General case' 0 C--O 1.222 -0.361 0 N-CA-C 112.937 0.717 . . . . 0.0 112.937 177.887 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.557 ' HE2' ' SD ' ' A' ' 123' ' ' MET . 98.8 mttt -76.98 -32.46 57.26 Favored 'General case' 0 C--N 1.315 -0.931 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -176.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.7 -0.24 83.92 Favored Glycine 0 C--N 1.314 -0.642 0 CA-C-N 116.16 -0.473 . . . . 0.0 114.057 -176.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 59.3 p -70.25 -21.9 62.94 Favored 'General case' 0 CA--C 1.541 0.618 0 C-N-CA 122.814 0.446 . . . . 0.0 111.825 -174.543 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 86.2 6.58 81.34 Favored Glycine 0 C--O 1.239 0.44 0 C-N-CA 120.767 -0.73 . . . . 0.0 113.194 177.044 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 84.6 t -67.97 152.07 9.85 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.758 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 177.866 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -58.44 144.44 42.09 Favored 'General case' 0 C--O 1.238 0.464 0 C-N-CA 122.572 0.349 . . . . 0.0 111.07 178.986 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.406 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 88.7 t -50.62 -41.49 20.71 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.009 0 C-N-CA 124.663 1.185 . . . . 0.0 114.04 -173.628 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.416 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 45.3 mt-10 -56.7 -47.75 79.2 Favored 'General case' 0 N--CA 1.478 0.945 0 CA-C-O 121.456 0.646 . . . . 0.0 110.871 178.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.427 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 17.0 m-20 -76.98 -22.81 52.61 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 115.429 -0.805 . . . . 0.0 111.809 -177.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 29.8 mm -65.53 -38.88 83.49 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.655 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 173.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.443 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -58.01 -48.16 80.88 Favored 'General case' 0 N--CA 1.478 0.925 0 CA-C-O 121.056 0.455 . . . . 0.0 110.113 178.521 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.416 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 76.6 mttt -63.96 -40.36 96.24 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 114.596 -1.184 . . . . 0.0 109.843 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.45 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 2.0 t80 -67.26 -37.57 83.71 Favored 'General case' 0 CA--C 1.548 0.866 0 C-N-CA 124.997 1.319 . . . . 0.0 108.85 -176.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . 0.557 ' SD ' ' HE2' ' A' ' 110' ' ' LYS . 64.4 mtm -76.03 -12.91 60.21 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-N 115.98 -0.555 . . . . 0.0 111.906 178.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.443 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 34.3 mt-10 -81.42 -24.71 36.73 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-O 121.726 0.774 . . . . 0.0 109.263 174.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -70.58 -30.36 67.03 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 115.175 -0.92 . . . . 0.0 109.336 173.278 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.571 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.07 -55.58 26.98 Favored Pre-proline 0 CA--C 1.572 1.817 0 N-CA-C 115.155 1.539 . . . . 0.0 115.155 178.596 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -69.21 -20.72 37.03 Favored 'Trans proline' 0 C--N 1.384 2.418 0 CA-C-N 121.191 1.461 . . . . 0.0 111.451 177.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 40.3 m -71.61 -35.92 70.63 Favored 'General case' 0 N--CA 1.432 -1.333 0 CA-C-N 115.823 -0.626 . . . . 0.0 109.936 178.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.571 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-85 -59.26 -55.19 38.04 Favored 'General case' 0 C--N 1.359 1.02 0 N-CA-C 107.983 -1.117 . . . . 0.0 107.983 176.065 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 18.1 t -58.07 -42.31 82.65 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.489 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.637 -178.375 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -56.39 -54.61 43.58 Favored 'General case' 0 C--O 1.222 -0.349 0 O-C-N 123.513 0.508 . . . . 0.0 111.526 179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.669 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 32.8 t90 -68.79 -30.4 68.97 Favored 'General case' 0 CA--C 1.537 0.474 0 O-C-N 123.11 0.256 . . . . 0.0 111.279 -176.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.413 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.5 mt -67.57 -40.35 84.88 Favored 'General case' 0 C--O 1.216 -0.693 0 N-CA-C 110.349 -0.241 . . . . 0.0 110.349 175.872 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 71.3 t -69.19 -36.24 72.0 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.503 0 CA-C-O 120.827 0.346 . . . . 0.0 110.148 176.493 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 69.0 m-20 -68.64 -33.38 73.9 Favored 'General case' 0 CA--C 1.505 -0.762 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.604 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 10.5 tppt? -105.39 4.36 30.71 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.843 -0.343 . . . . 0.0 110.929 -175.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 68.7 t80 -46.01 -51.08 14.16 Favored 'General case' 0 N--CA 1.49 1.574 0 C-N-CA 125.587 1.555 . . . . 0.0 114.501 -174.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.7 m-20 -75.23 -13.44 60.44 Favored 'General case' 0 N--CA 1.472 0.642 0 N-CA-C 112.075 0.398 . . . . 0.0 112.075 -176.813 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 2.5 m-20 -95.3 -6.13 41.98 Favored 'General case' 0 C--N 1.311 -1.092 0 C-N-CA 122.969 0.508 . . . . 0.0 112.049 178.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.604 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.0 mt -83.96 121.19 27.05 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 113.338 0.866 . . . . 0.0 113.338 -174.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -105.49 139.9 39.41 Favored 'General case' 0 N--CA 1.418 -2.033 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 169.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -104.32 151.17 23.76 Favored 'General case' 0 C--N 1.269 -2.899 0 C-N-CA 120.074 -0.65 . . . . 0.0 110.82 -172.016 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 72.6 m-85 -134.1 160.85 36.54 Favored 'General case' 0 C--N 1.285 -2.225 0 CA-C-O 121.407 0.622 . . . . 0.0 110.846 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 52.8 mtp -137.85 141.67 40.75 Favored 'General case' 0 C--N 1.276 -2.604 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 174.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 88.6 p -84.77 169.32 14.34 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.747 -1.575 . . . . 0.0 106.747 172.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 7.0 ttpm? -55.08 -34.58 63.74 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.459 0.704 . . . . 0.0 112.43 -177.911 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.2 p -88.13 -6.8 57.69 Favored 'General case' 0 CA--C 1.556 1.197 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 -178.002 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.479 ' SD ' HD11 ' A' ' 155' ' ' ILE . 53.7 mtt -97.08 179.61 4.87 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 114.029 1.122 . . . . 0.0 114.029 -173.606 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 53.5 m-80 -131.79 161.02 64.97 Favored Pre-proline 0 C--N 1.323 -0.573 0 N-CA-C 108.046 -1.094 . . . . 0.0 108.046 -178.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 59.0 Cg_endo -76.25 -18.95 15.76 Favored 'Trans proline' 0 CA--C 1.533 0.469 0 C-N-CA 121.211 1.274 . . . . 0.0 111.403 177.777 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 43.2 m-20 -87.18 -19.81 27.88 Favored 'General case' 0 CA--C 1.504 -0.809 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.008 -179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -155.73 115.12 3.59 Favored 'General case' 0 N--CA 1.429 -1.48 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 -176.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.08 43.13 3.59 Favored Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.117 -1.039 . . . . 0.0 111.517 -175.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.527 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.0 tp -99.87 115.94 30.77 Favored 'General case' 0 N--CA 1.432 -1.374 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.198 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.479 HD11 ' SD ' ' A' ' 148' ' ' MET . 4.2 mp -88.68 133.68 30.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.515 -176.755 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.562 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 40.2 m-85 -89.46 141.6 28.42 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.339 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.476 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 16.1 t -150.17 157.25 42.9 Favored 'General case' 0 C--N 1.302 -1.495 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.426 ' CE1' ' HB3' ' A' ' 160' ' ' LYS . 21.9 p90 -142.35 173.98 11.04 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 80.9 m-85 -121.46 102.19 8.1 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-O 121.269 0.557 . . . . 0.0 110.289 -179.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.426 ' HB3' ' CE1' ' A' ' 158' ' ' TYR . 64.1 pttt -89.73 173.46 8.26 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.12 -0.946 . . . . 0.0 109.246 178.279 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 43.5 mt-10 -78.67 135.9 37.31 Favored 'General case' 0 C--N 1.312 -1.044 0 N-CA-C 108.08 -1.082 . . . . 0.0 108.08 174.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 93.46 4.82 63.85 Favored Glycine 0 C--N 1.309 -0.94 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 -177.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.43 131.6 44.57 Favored 'General case' 0 N--CA 1.435 -1.22 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 178.459 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 69.7 m80 -110.66 2.93 18.86 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.5 0.667 . . . . 0.0 110.049 -177.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 87.7 m -155.49 165.08 19.14 Favored Pre-proline 0 C--N 1.303 -1.438 0 N-CA-C 105.749 -1.945 . . . . 0.0 105.749 -179.735 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.77 126.82 20.92 Favored 'Trans proline' 0 C--N 1.356 0.926 0 C-N-CA 122.835 2.356 . . . . 0.0 112.185 175.826 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 23.4 m -86.95 109.1 19.13 Favored 'General case' 0 N--CA 1.423 -1.823 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.286 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 81.4 m-85 -81.1 140.67 34.93 Favored 'General case' 0 C--N 1.306 -1.314 0 CA-C-O 121.789 0.804 . . . . 0.0 111.745 -170.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.669 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 52.1 t -109.18 112.43 40.45 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.01 0 CA-C-N 113.769 -1.559 . . . . 0.0 108.422 -176.015 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.5 m-85 -133.15 153.99 51.02 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.757 0.789 . . . . 0.0 110.965 179.986 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.445 ' HA ' HD23 ' A' ' 33' ' ' LEU . 56.9 t -97.23 109.48 23.34 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 CA-C-N 115.425 -0.807 . . . . 0.0 109.865 179.804 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 25.3 ttpp -60.53 -50.67 72.62 Favored 'General case' 0 N--CA 1.473 0.715 0 C-N-CA 123.904 0.882 . . . . 0.0 111.452 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.45 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 37.4 m -89.3 1.38 55.83 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-N 115.201 -0.909 . . . . 0.0 112.243 -175.484 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.411 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -111.19 -15.83 10.24 Favored Glycine 0 C--O 1.215 -1.036 0 C-N-CA 120.23 -0.986 . . . . 0.0 113.736 -174.676 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.413 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 20.2 m-85 -98.02 161.51 13.69 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 109.177 -0.675 . . . . 0.0 109.177 178.008 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 93.1 mttt -85.31 104.06 14.8 Favored 'General case' 0 N--CA 1.426 -1.649 0 CA-C-O 121.171 0.51 . . . . 0.0 110.261 -178.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.437 HG22 ' CE1' ' A' ' 4' ' ' TYR . 13.2 t -78.09 103.39 5.11 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 N-CA-C 106.258 -1.756 . . . . 0.0 106.258 176.44 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 88.0 t -114.27 123.99 70.48 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 CA-C-N 116.163 -0.471 . . . . 0.0 109.957 -176.53 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -97.57 108.04 20.67 Favored 'General case' 0 N--CA 1.425 -1.676 0 CA-C-O 121.715 0.769 . . . . 0.0 110.94 177.145 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -92.01 144.6 25.28 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.12 -1.437 . . . . 0.0 107.12 173.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 59.4 tp 73.59 161.22 0.24 Allowed 'General case' 0 CA--C 1.547 0.848 0 O-C-N 124.589 1.18 . . . . 0.0 110.919 -179.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 183' ' ' HIS . 0.9 OUTLIER -77.4 173.87 11.46 Favored 'General case' 0 CA--C 1.559 1.322 0 N-CA-C 105.771 -1.937 . . . . 0.0 105.771 176.12 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.411 ' H ' ' CD ' ' A' ' 182' ' ' GLU . 12.5 p-80 -75.89 8.29 3.24 Favored 'General case' 0 CA--C 1.549 0.941 0 O-C-N 121.181 -0.95 . . . . 0.0 112.124 -177.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 -79.59 68.51 5.65 Favored 'General case' 0 N--CA 1.451 -0.422 0 CA-C-O 122.272 1.034 . . . . 0.0 109.684 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.0 t-80 -138.03 -4.41 1.73 Allowed 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 113.807 -1.542 . . . . 0.0 107.583 175.126 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 9.9 p-80 56.86 166.73 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.727 0 C-N-CA 126.873 2.069 . . . . 0.0 113.232 -175.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -103.85 94.86 5.65 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 119.186 -1.006 . . . . 0.0 111.642 178.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 23.4 t-80 . . . . . 0 C--N 1.299 -1.59 0 N-CA-C 105.688 -1.968 . . . . 0.0 105.688 174.432 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.9 ttp . . . . . 0 CA--C 1.51 -0.592 0 CA-C-O 121.005 0.431 . . . . 0.0 110.351 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.7 mt -93.99 118.15 39.23 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.007 0 N-CA-C 105.658 -1.978 . . . . 0.0 105.658 173.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 7.1 p -126.01 141.49 45.5 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 CA-C-O 121.465 0.65 . . . . 0.0 110.962 -174.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 54.5 m-85 -95.83 119.55 34.52 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.457 -0.942 . . . . 0.0 108.457 177.306 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.466 ' HB2' ' HG3' ' A' ' 176' ' ' LYS . 66.5 mttm -102.86 138.35 39.86 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.149 -1.056 . . . . 0.0 108.149 176.767 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 19.6 t70 -70.86 144.84 50.58 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.223 -0.658 . . . . 0.0 109.223 178.34 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 63.5 t -79.87 -29.33 12.83 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 N-CA-C 112.096 0.406 . . . . 0.0 112.096 -175.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -81.17 -48.36 19.17 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.914 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 -174.035 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 29.9 p -78.79 -41.51 30.21 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 121.432 0.634 . . . . 0.0 110.16 178.563 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 96.52 1.77 60.38 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.588 -0.733 . . . . 0.0 112.494 178.763 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -119.86 176.66 5.3 Favored 'General case' 0 CA--C 1.549 0.929 0 C-N-CA 119.72 -0.792 . . . . 0.0 112.139 -175.612 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 55.9 mt-10 -76.79 130.44 37.67 Favored 'General case' 0 C--N 1.314 -0.958 0 C-N-CA 125.564 1.546 . . . . 0.0 112.623 -168.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 15.7 m -111.08 -34.64 2.42 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.79 0 N-CA-C 113.09 0.774 . . . . 0.0 113.09 179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.4 HG23 HD12 ' A' ' 18' ' ' LEU . 12.4 p -154.31 145.22 13.94 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.789 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 -177.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.1 p -119.29 170.05 9.45 Favored 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 122.378 0.271 . . . . 0.0 110.972 -178.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.7 p-10 -69.32 -12.7 61.89 Favored 'General case' 0 N--CA 1.485 1.291 0 C-N-CA 123.607 0.763 . . . . 0.0 112.658 -178.59 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.13 -11.96 59.71 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 121.52 0.676 . . . . 0.0 110.286 179.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.4 HD12 HG23 ' A' ' 14' ' ' VAL . 64.6 mt -98.26 175.6 6.01 Favored 'General case' 0 N--CA 1.43 -1.437 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 179.502 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.467 ' HB3' ' HB3' ' A' ' 37' ' ' ASP . 13.6 mmmm -81.9 106.04 13.5 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 118.042 0.383 . . . . 0.0 111.544 -175.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.459 HG23 ' CD2' ' A' ' 34' ' ' PHE . 61.9 mt -112.85 107.94 24.25 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.534 -0.913 . . . . 0.0 108.534 -179.397 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 20.0 p -120.75 140.24 30.31 Favored Pre-proline 0 C--N 1.294 -1.814 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.357 -179.272 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_endo -63.65 143.03 86.04 Favored 'Trans proline' 0 C--O 1.244 0.808 0 C-N-CA 121.529 1.486 . . . . 0.0 109.588 175.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 71.8 t -64.69 113.61 1.95 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.728 0 N-CA-C 110.309 -0.256 . . . . 0.0 110.309 -178.972 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 90.2 mtp -122.68 108.41 13.04 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 109.031 -0.729 . . . . 0.0 109.031 177.304 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 24.3 mm-40 -105.91 104.54 14.27 Favored 'General case' 0 C--N 1.302 -1.475 0 CA-C-N 115.182 -0.917 . . . . 0.0 109.17 -177.595 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 70.95 28.57 70.35 Favored Glycine 0 C--N 1.308 -1.025 0 CA-C-N 115.853 -0.612 . . . . 0.0 113.573 176.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 107.91 -33.94 5.96 Favored Glycine 0 N--CA 1.441 -0.978 0 C-N-CA 120.723 -0.751 . . . . 0.0 113.521 177.261 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -102.27 151.7 21.92 Favored 'General case' 0 C--N 1.306 -1.303 0 O-C-N 122.145 -0.621 . . . . 0.0 110.8 -177.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.5 pt-20 -83.15 154.2 24.42 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-O 121.243 0.544 . . . . 0.0 111.073 -178.545 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 62.0 t -112.4 103.48 55.45 Favored Pre-proline 0 C--N 1.291 -1.957 0 N-CA-C 107.082 -1.451 . . . . 0.0 107.082 174.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 13.6 Cg_endo -60.0 132.99 47.64 Favored 'Trans proline' 0 C--N 1.349 0.56 0 C-N-CA 123.169 2.579 . . . . 0.0 114.663 -174.45 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.509 ' HA3' ' HB3' ' A' ' 125' ' ' GLU . . . 103.24 -8.01 52.42 Favored Glycine 0 CA--C 1.487 -1.698 0 CA-C-N 115.325 -0.852 . . . . 0.0 114.627 174.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.502 HD23 ' HA ' ' A' ' 171' ' ' VAL . 18.0 mt -130.98 153.39 49.27 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 116.888 0.344 . . . . 0.0 111.146 -172.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.459 ' CD2' HG23 ' A' ' 20' ' ' ILE . 26.9 p90 -136.42 144.81 44.68 Favored 'General case' 0 N--CA 1.43 -1.461 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 176.369 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.0 tt0 -106.77 145.1 32.49 Favored 'General case' 0 C--N 1.27 -2.852 0 N-CA-C 106.771 -1.566 . . . . 0.0 106.771 -179.072 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.443 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 58.5 t -109.16 113.84 45.26 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.436 0 N-CA-C 106.582 -1.636 . . . . 0.0 106.582 178.877 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.467 ' HB3' ' HB3' ' A' ' 19' ' ' LYS . 32.6 t70 -79.13 149.15 32.11 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 113.12 -1.855 . . . . 0.0 111.75 -169.492 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.1 m -98.71 134.78 41.13 Favored 'General case' 0 N--CA 1.423 -1.784 0 N-CA-C 109.76 -0.459 . . . . 0.0 109.76 -175.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.553 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.06 123.85 11.24 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 178.407 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 90.6 mtp -87.4 115.17 24.63 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.812 0.695 . . . . 0.0 110.297 -178.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.486 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 32.9 m -110.62 162.63 8.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 -179.899 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.412 ' HA ' ' O ' ' A' ' 70' ' ' GLN . . . -82.5 114.57 21.01 Favored 'General case' 0 C--N 1.308 -1.222 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 179.008 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 21.9 t -98.75 -89.28 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.31 -1.113 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.663 -177.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 70' ' ' GLN . . . 93.98 163.12 36.0 Favored Glycine 0 N--CA 1.443 -0.884 0 N-CA-C 111.127 -0.789 . . . . 0.0 111.127 178.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 141.85 -21.42 2.5 Favored Glycine 0 C--N 1.31 -0.886 0 N-CA-C 111.804 -0.518 . . . . 0.0 111.804 -178.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 176.8 166.26 33.57 Favored Glycine 0 N--CA 1.438 -1.228 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.383 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 58.63 98.72 0.02 OUTLIER 'General case' 0 N--CA 1.487 1.416 0 C-N-CA 125.495 1.518 . . . . 0.0 112.933 -179.189 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 41.9 mm -81.65 114.94 23.36 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 179.36 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 45.3 m-20 -105.37 61.8 0.68 Allowed 'General case' 0 C--N 1.306 -1.321 0 CA-C-O 121.044 0.45 . . . . 0.0 110.404 -178.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 73.1 mt 69.42 109.22 0.04 OUTLIER 'Isoleucine or valine' 0 C--O 1.238 0.485 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.837 -177.206 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -67.88 -23.16 74.21 Favored Glycine 0 CA--C 1.519 0.288 0 CA-C-N 115.972 -0.558 . . . . 0.0 112.334 -178.21 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 25.7 m -83.55 1.33 42.55 Favored 'General case' 0 C--N 1.315 -0.928 0 C-N-CA 122.946 0.498 . . . . 0.0 110.817 178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.44 -5.19 88.83 Favored Glycine 0 C--N 1.336 0.542 0 CA-C-N 116.483 -0.326 . . . . 0.0 112.492 -178.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.5 t-20 -101.02 97.51 8.06 Favored 'General case' 0 C--N 1.312 -1.06 0 N-CA-C 109.527 -0.546 . . . . 0.0 109.527 176.885 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.58 -56.41 2.18 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 177.517 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -131.24 113.88 14.37 Favored 'General case' 0 C--N 1.311 -1.093 0 N-CA-C 107.99 -1.115 . . . . 0.0 107.99 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 149.36 153.73 6.13 Favored Glycine 0 N--CA 1.426 -1.997 0 C-N-CA 120.608 -0.806 . . . . 0.0 111.703 -178.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 123.33 -60.44 0.59 Allowed Glycine 0 N--CA 1.429 -1.774 0 N-CA-C 110.376 -1.09 . . . . 0.0 110.376 -178.636 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 71.76 -58.05 0.59 Allowed 'General case' 0 N--CA 1.479 1.003 0 C-N-CA 126.326 1.85 . . . . 0.0 112.456 179.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 139.29 138.88 3.71 Favored Glycine 0 N--CA 1.427 -1.953 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.43 178.414 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.5 t70 -146.11 152.08 38.71 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 106.873 -1.529 . . . . 0.0 106.873 177.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 23.1 t70 -89.47 -28.12 19.89 Favored 'General case' 0 C--N 1.308 -1.209 0 N-CA-C 112.394 0.516 . . . . 0.0 112.394 -174.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -126.87 -38.57 2.03 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 120.267 -0.573 . . . . 0.0 112.389 -171.895 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -81.57 -31.19 34.02 Favored Glycine 0 N--CA 1.441 -1.012 0 CA-C-N 116.379 -0.373 . . . . 0.0 112.984 -174.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -73.33 97.3 2.46 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.576 0.703 . . . . 0.0 111.994 -177.28 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 20.4 t70 -78.02 -49.3 14.29 Favored 'General case' 0 C--N 1.309 -1.189 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 176.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -163.83 166.61 21.74 Favored 'General case' 0 C--N 1.302 -1.465 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 178.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -79.36 23.03 0.41 Allowed 'General case' 0 C--N 1.308 -1.209 0 C-N-CA 123.089 0.555 . . . . 0.0 111.854 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.1 m -62.69 -64.49 0.91 Allowed 'General case' 0 N--CA 1.447 -0.581 0 C-N-CA 124.618 1.167 . . . . 0.0 110.756 -178.08 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.496 ' HB2' ' H ' ' A' ' 44' ' ' GLY . 97.9 mt-30 -100.62 141.98 32.73 Favored 'General case' 0 CA--C 1.488 -1.426 0 CA-C-N 115.529 -0.76 . . . . 0.0 110.381 -176.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.486 ' HA ' ' O ' ' A' ' 41' ' ' VAL . 9.3 mtmp? -125.71 119.9 29.22 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.474 -1.676 . . . . 0.0 106.474 168.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 161.16 40.92 Favored 'General case' 0 C--N 1.29 -2.01 0 N-CA-C 107.259 -1.385 . . . . 0.0 107.259 -175.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.553 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 35.9 t30 -67.06 126.77 30.2 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-O 121.292 0.568 . . . . 0.0 110.807 -179.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -56.1 -24.41 40.28 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 114.6 -1.182 . . . . 0.0 113.003 179.004 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 39.5 t -81.53 -51.52 15.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.891 -178.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.51 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -63.16 -50.93 68.47 Favored 'General case' 0 N--CA 1.445 -0.676 0 O-C-N 123.387 0.429 . . . . 0.0 111.932 -176.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.16 89.62 0.01 OUTLIER Glycine 0 C--N 1.341 0.86 0 O-C-N 124.917 1.386 . . . . 0.0 115.662 173.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_exo -59.36 -27.55 85.28 Favored 'Trans proline' 0 CA--C 1.541 0.838 0 C-N-CA 122.839 2.359 . . . . 0.0 112.628 -179.155 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 13.1 m -92.58 -14.03 28.82 Favored 'General case' 0 C--N 1.313 -0.993 0 CA-C-O 120.912 0.387 . . . . 0.0 111.976 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 2.7 p -107.4 -79.05 0.58 Allowed 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 113.011 0.745 . . . . 0.0 113.011 -175.283 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.7 m-85 -88.99 -47.29 8.23 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 120.466 0.174 . . . . 0.0 110.742 -176.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 62.39 102.62 0.03 OUTLIER 'General case' 0 C--O 1.244 0.771 0 O-C-N 124.71 1.256 . . . . 0.0 112.838 -179.142 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.479 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 55.7 m-85 -108.06 119.24 38.9 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.096 179.408 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 24.3 m -90.72 135.78 33.49 Favored 'General case' 0 C--N 1.299 -1.611 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.16 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.51 151.33 24.66 Favored 'General case' 0 C--O 1.242 0.689 0 CA-C-O 121.537 0.684 . . . . 0.0 112.438 -177.5 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 20.9 mmt -131.51 144.91 55.35 Favored Pre-proline 0 C--N 1.304 -1.384 0 C-N-CA 125.02 1.328 . . . . 0.0 109.135 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 83.4 Cg_endo -79.9 166.81 20.88 Favored 'Trans proline' 0 C--O 1.25 1.114 0 C-N-CA 123.264 2.643 . . . . 0.0 111.512 176.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 81.7 m-85 -58.94 115.68 3.29 Favored 'General case' 0 CA--C 1.511 -0.551 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 175.42 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.6 p -74.19 -59.87 2.52 Favored 'General case' 0 N--CA 1.421 -1.916 0 N-CA-C 109.608 -0.516 . . . . 0.0 109.608 179.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 15.0 m 62.48 20.83 12.2 Favored 'General case' 0 N--CA 1.476 0.835 0 C-N-CA 124.741 1.216 . . . . 0.0 110.543 178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -93.25 171.34 8.99 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.267 -0.879 . . . . 0.0 109.654 -176.481 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.04 -29.57 75.26 Favored Glycine 0 C--O 1.238 0.4 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 176.765 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -51.42 -47.94 62.83 Favored 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 124.979 1.311 . . . . 0.0 109.885 172.783 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.436 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.6 t80 -69.9 -41.91 74.09 Favored 'General case' 0 N--CA 1.446 -0.658 0 CA-C-N 115.516 -0.765 . . . . 0.0 111.122 -177.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.1 mmtp -64.92 -41.76 95.29 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-N 116.526 -0.307 . . . . 0.0 111.74 -177.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 19.2 m -68.63 -33.18 73.57 Favored 'General case' 0 N--CA 1.441 -0.9 0 CA-C-N 115.943 -0.571 . . . . 0.0 109.969 178.078 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.53 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 88.7 t90 -64.17 -45.7 87.25 Favored 'General case' 0 C--O 1.213 -0.844 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.14 176.498 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.436 HG23 ' O ' ' A' ' 94' ' ' PHE . 88.1 t -58.02 -42.97 84.05 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.999 0 C-N-CA 122.702 0.401 . . . . 0.0 111.031 179.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 60.0 mtpt -59.42 -48.18 82.61 Favored 'General case' 0 C--O 1.238 0.491 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.106 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 26.2 m-20 -75.48 -26.01 57.84 Favored 'General case' 0 CA--C 1.514 -0.411 0 N-CA-C 112.739 0.644 . . . . 0.0 112.739 -179.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 67.3 t80 -62.91 -54.28 41.05 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 176.581 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 59.5 t -63.41 -36.04 74.7 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.706 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.047 179.228 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 70.1 ttt180 -60.04 -59.31 5.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-N 115.252 -0.886 . . . . 0.0 111.023 178.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 -64.89 -28.41 69.52 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.783 -176.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.0 t -65.29 -39.52 85.64 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.735 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.252 173.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 91.9 mtt180 -62.65 -37.94 88.34 Favored 'General case' 0 N--CA 1.473 0.713 0 O-C-N 122.324 -0.235 . . . . 0.0 111.027 177.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -69.41 -33.99 73.83 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.622 -0.263 . . . . 0.0 111.081 176.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.92 -39.94 90.98 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.755 0.312 . . . . 0.0 110.269 177.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.8 mp -61.99 -39.07 90.96 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-N 116.044 -0.525 . . . . 0.0 112.31 176.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -83.39 -50.92 7.85 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -177.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -73.63 -4.68 66.34 Favored Glycine 0 CA--C 1.517 0.182 0 N-CA-C 115.162 0.825 . . . . 0.0 115.162 -173.036 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.8 p -78.54 -21.54 48.62 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 117.561 0.681 . . . . 0.0 111.629 177.809 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.06 38.65 25.84 Favored Glycine 0 C--N 1.34 0.805 0 C-N-CA 120.958 -0.639 . . . . 0.0 113.464 176.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 65.8 t -72.6 149.81 8.61 Favored 'Isoleucine or valine' 0 CA--C 1.568 1.651 0 C-N-CA 122.364 0.266 . . . . 0.0 110.508 -179.699 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.18 157.55 15.86 Favored 'General case' 0 N--CA 1.494 1.743 0 C-N-CA 123.432 0.693 . . . . 0.0 111.499 178.863 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 47.4 t -57.51 -49.85 79.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 C-N-CA 123.722 0.809 . . . . 0.0 112.997 -173.586 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.411 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 20.6 mp0 -63.41 -44.41 94.69 Favored 'General case' 0 CA--C 1.507 -0.71 0 CA-C-O 121.912 0.863 . . . . 0.0 109.327 -177.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.532 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 6.6 m-20 -64.54 -40.2 95.17 Favored 'General case' 0 N--CA 1.428 -1.525 0 CA-C-N 113.832 -1.531 . . . . 0.0 110.375 179.15 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 16.0 mm -57.09 -42.22 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 C-N-CA 124.118 0.967 . . . . 0.0 111.033 175.234 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.43 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.1 mmtp -61.42 -44.96 96.22 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 116.76 -0.2 . . . . 0.0 110.875 -179.494 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.466 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 30.4 mmtm -68.0 -37.52 81.56 Favored 'General case' 0 N--CA 1.476 0.855 0 C-N-CA 123.332 0.653 . . . . 0.0 110.582 177.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.532 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 1.7 t80 -65.02 -35.54 81.52 Favored 'General case' 0 C--N 1.307 -1.248 0 C-N-CA 125.779 1.631 . . . . 0.0 108.543 -177.234 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 89.4 mtp -84.98 -14.11 48.55 Favored 'General case' 0 C--O 1.222 -0.383 0 CA-C-N 115.612 -0.722 . . . . 0.0 112.265 178.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.43 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 54.4 mt-10 -73.69 -32.69 64.06 Favored 'General case' 0 C--O 1.24 0.558 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 172.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.509 ' HB3' ' HA3' ' A' ' 32' ' ' GLY . 50.7 mt-10 -72.35 -33.08 67.01 Favored 'General case' 0 N--CA 1.426 -1.653 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.988 179.514 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.524 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -47.4 -57.47 9.54 Favored Pre-proline 0 CA--C 1.579 2.091 0 N-CA-C 116.066 1.876 . . . . 0.0 116.066 -178.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -67.98 -22.62 41.68 Favored 'Trans proline' 0 C--N 1.375 1.971 0 CA-C-N 120.958 1.378 . . . . 0.0 111.371 -179.499 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 6.2 m -76.48 -28.57 56.53 Favored 'General case' 0 N--CA 1.419 -2.017 0 CA-C-N 114.865 -1.062 . . . . 0.0 110.066 -178.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.524 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -59.04 -52.76 64.37 Favored 'General case' 0 C--N 1.372 1.57 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 174.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 23.7 t -55.34 -50.14 67.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 113.467 -1.697 . . . . 0.0 111.291 -178.221 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.7 tttp -54.02 -50.38 66.78 Favored 'General case' 0 CA--C 1.538 0.495 0 N-CA-C 113.814 1.042 . . . . 0.0 113.814 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.625 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.2 t90 -70.56 -32.21 69.53 Favored 'General case' 0 C--N 1.319 -0.729 0 C-N-CA 121.089 -0.244 . . . . 0.0 110.932 -175.452 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 98.6 mt -68.0 -36.32 79.8 Favored 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 120.909 0.385 . . . . 0.0 110.041 176.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -71.62 -41.37 71.56 Favored 'Isoleucine or valine' 0 C--O 1.241 0.624 0 CA-C-N 116.334 -0.393 . . . . 0.0 110.528 177.402 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.2 m-20 -67.84 -35.18 78.12 Favored 'General case' 0 N--CA 1.473 0.681 0 N-CA-C 113.24 0.83 . . . . 0.0 113.24 179.618 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.546 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.8 mmtt -89.28 -10.81 45.44 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 112.526 0.565 . . . . 0.0 112.526 -179.72 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 71.5 t80 -43.17 -48.13 6.39 Favored 'General case' 0 N--CA 1.487 1.38 0 N-CA-C 115.459 1.652 . . . . 0.0 115.459 -173.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -80.01 -8.12 59.19 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 112.273 0.472 . . . . 0.0 112.273 -173.544 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 43.8 m-20 -109.05 2.24 21.06 Favored 'General case' 0 N--CA 1.469 0.498 0 C-N-CA 122.328 0.251 . . . . 0.0 111.07 -179.249 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.546 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 94.6 mt -83.56 139.07 33.09 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-O 121.943 0.878 . . . . 0.0 113.26 -174.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -115.72 135.89 53.6 Favored 'General case' 0 N--CA 1.413 -2.322 0 N-CA-C 104.916 -2.253 . . . . 0.0 104.916 170.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 97.9 m-85 -93.03 140.34 29.58 Favored 'General case' 0 C--N 1.276 -2.615 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.654 -172.892 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.3 m-85 -131.18 156.52 45.18 Favored 'General case' 0 C--N 1.291 -1.978 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.325 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 66.5 mtp -136.94 126.71 25.55 Favored 'General case' 0 C--N 1.276 -2.616 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 175.323 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 8.1 p -74.03 140.02 45.13 Favored 'General case' 0 N--CA 1.416 -2.143 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 171.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 37.8 ttmt -41.42 -39.55 1.51 Allowed 'General case' 0 N--CA 1.483 1.215 0 N-CA-C 116.775 2.139 . . . . 0.0 116.775 -168.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 42.4 p -81.15 -12.57 59.18 Favored 'General case' 0 C--N 1.31 -1.129 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -177.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -82.31 177.21 8.89 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 113.949 1.092 . . . . 0.0 113.949 -174.121 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.57 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 66.4 t30 -118.51 149.59 46.42 Favored Pre-proline 0 C--N 1.313 -1.001 0 N-CA-C 105.885 -1.894 . . . . 0.0 105.885 -177.451 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.57 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 20.8 Cg_endo -62.15 -19.84 67.91 Favored 'Trans proline' 0 N--CA 1.487 1.1 0 C-N-CA 121.885 1.723 . . . . 0.0 111.78 176.301 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.4 m-20 -99.21 -5.44 29.94 Favored 'General case' 0 N--CA 1.447 -0.611 0 CA-C-N 115.535 -0.757 . . . . 0.0 111.683 178.644 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.02 104.38 3.43 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 -177.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.39 39.62 5.0 Favored Glycine 0 N--CA 1.438 -1.229 0 C-N-CA 120.333 -0.937 . . . . 0.0 111.37 -176.197 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.53 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 47.6 tp -85.88 112.9 21.57 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 177.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 90.3 mt -91.93 131.58 38.65 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.323 0 CA-C-N 114.91 -1.041 . . . . 0.0 111.455 -171.448 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 54.6 m-85 -91.16 140.28 29.95 Favored 'General case' 0 C--N 1.307 -1.273 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 175.144 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 18.0 t -150.13 159.08 44.69 Favored 'General case' 0 C--N 1.292 -1.906 0 N-CA-C 107.783 -1.191 . . . . 0.0 107.783 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 43.2 p90 -146.08 167.57 23.06 Favored 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 174.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 17.8 m-85 -110.66 102.24 10.82 Favored 'General case' 0 C--N 1.287 -2.124 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 179.883 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -74.68 155.26 37.92 Favored 'General case' 0 N--CA 1.44 -0.955 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.542 178.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 12.3 mp0 -61.97 117.18 5.6 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.354 -176.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.9 -6.22 37.3 Favored Glycine 0 N--CA 1.436 -1.344 0 CA-C-N 115.06 -0.973 . . . . 0.0 112.445 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -98.79 141.02 32.12 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-O 121.007 0.432 . . . . 0.0 110.761 179.843 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 25.2 m-70 -92.74 -33.75 14.19 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 121.981 0.896 . . . . 0.0 108.956 178.363 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.1 m -108.39 158.96 32.46 Favored Pre-proline 0 N--CA 1.425 -1.703 0 CA-C-N 114.024 -1.444 . . . . 0.0 110.019 -174.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -61.29 137.42 70.52 Favored 'Trans proline' 0 C--O 1.252 1.195 0 C-N-CA 122.998 2.465 . . . . 0.0 113.656 -178.77 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 31.5 m -102.14 114.05 27.86 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.443 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 92.5 m-85 -82.96 145.05 29.58 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 113.146 0.795 . . . . 0.0 113.146 -170.13 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.625 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.9 t -113.75 120.23 63.06 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 C-N-CA 125.026 1.33 . . . . 0.0 109.294 -175.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.5 m-85 -139.22 159.44 42.16 Favored 'General case' 0 C--O 1.241 0.647 0 CA-C-O 121.367 0.603 . . . . 0.0 110.337 178.329 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.502 ' HA ' HD23 ' A' ' 33' ' ' LEU . 40.3 t -96.2 117.53 40.65 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 N-CA-C 109.025 -0.731 . . . . 0.0 109.025 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.406 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 27.2 ttpp -63.0 -56.51 16.41 Favored 'General case' 0 N--CA 1.476 0.857 0 C-N-CA 123.477 0.711 . . . . 0.0 111.524 -175.629 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.437 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 19.9 m -87.57 -3.96 58.97 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 115.355 -0.839 . . . . 0.0 111.698 -174.799 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.426 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -98.5 -17.64 28.2 Favored Glycine 0 C--O 1.215 -1.073 0 C-N-CA 120.468 -0.872 . . . . 0.0 112.355 -177.323 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.2 m-85 -98.32 158.07 15.8 Favored 'General case' 0 CA--C 1.497 -1.082 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG3' ' HB2' ' A' ' 5' ' ' LYS . 59.9 pttt -92.3 109.82 21.21 Favored 'General case' 0 N--CA 1.424 -1.754 0 CA-C-O 122.016 0.912 . . . . 0.0 110.619 -178.112 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 22.3 t -83.07 110.14 17.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.584 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.054 -178.401 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 35.0 t -111.44 123.05 66.92 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 N-CA-C 108.18 -1.045 . . . . 0.0 108.18 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 7.4 mtpm? -102.65 107.29 18.15 Favored 'General case' 0 C--N 1.291 -1.976 0 CA-C-N 115.531 -0.759 . . . . 0.0 109.718 -176.039 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.4 m-85 -99.73 116.82 32.72 Favored 'General case' 0 C--N 1.312 -1.06 0 CA-C-N 116.456 -0.338 . . . . 0.0 111.101 179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 7.2 mp -90.11 87.6 6.94 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 106.956 -1.498 . . . . 0.0 106.956 170.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -70.85 147.42 48.86 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.181 -176.432 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 7.3 t60 70.34 103.52 0.06 Allowed 'General case' 0 CA--C 1.515 -0.393 0 C-N-CA 125.343 1.457 . . . . 0.0 108.107 -174.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 34.5 p-80 -41.57 116.55 0.79 Allowed 'General case' 0 N--CA 1.475 0.81 0 O-C-N 124.691 1.245 . . . . 0.0 113.25 -176.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 47.4 t-80 -86.6 94.99 9.61 Favored 'General case' 0 C--N 1.306 -1.32 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.91 97.6 6.33 Favored 'General case' 0 C--N 1.296 -1.758 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 -178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 58.2 t-80 -101.03 137.53 39.27 Favored 'General case' 0 C--N 1.291 -1.962 0 N-CA-C 107.238 -1.393 . . . . 0.0 107.238 176.288 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 66.1 t-80 . . . . . 0 N--CA 1.422 -1.843 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 178.985 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 53.1 ttm . . . . . 0 CA--C 1.495 -1.14 0 CA-C-O 120.811 0.338 . . . . 0.0 110.663 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 38.0 mt -95.61 109.91 23.37 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.427 0 N-CA-C 106.25 -1.759 . . . . 0.0 106.25 173.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 11.2 p -106.02 141.53 21.1 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.18 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 -179.5 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -104.91 117.99 35.41 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 109.153 -0.684 . . . . 0.0 109.153 179.847 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 54.5 mttm -100.39 137.16 39.19 Favored 'General case' 0 C--N 1.299 -1.604 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.994 176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.468 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 13.4 t70 -71.91 140.12 49.08 Favored 'General case' 0 C--N 1.301 -1.537 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.511 176.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 25.1 t -77.06 -23.31 14.79 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 CA-C-O 121.155 0.502 . . . . 0.0 110.745 -176.972 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.526 HD11 ' HA ' ' A' ' 101' ' ' TYR . 11.9 mm -82.07 -54.48 9.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.888 0 CA-C-O 121.031 0.443 . . . . 0.0 109.827 -175.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 36.8 p -86.27 -40.98 14.98 Favored 'General case' 0 C--N 1.314 -0.976 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.87 0.47 62.13 Favored Glycine 0 N--CA 1.441 -1.03 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -176.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.43 ' HB2' ' HE2' ' A' ' 148' ' ' MET . 14.9 m-20 -93.36 171.78 8.7 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.171 0.51 . . . . 0.0 112.149 -177.776 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.9 mp0 -83.34 127.74 33.92 Favored 'General case' 0 C--N 1.301 -1.519 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.579 -174.138 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.411 HG23 HG12 ' A' ' 14' ' ' VAL . 21.8 m -96.93 -34.17 4.82 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.919 0 C-N-CA 120.957 -0.297 . . . . 0.0 111.43 177.042 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.411 HG12 HG23 ' A' ' 13' ' ' VAL . 8.1 p -175.2 165.28 0.16 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.844 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 -177.007 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 63.4 p -134.18 166.37 22.93 Favored 'General case' 0 N--CA 1.421 -1.905 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 176.633 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 9.5 p-10 -74.93 1.16 13.48 Favored 'General case' 0 N--CA 1.477 0.897 0 C-N-CA 122.689 0.396 . . . . 0.0 111.423 -179.605 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -80.78 -22.83 39.76 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 108.86 -0.792 . . . . 0.0 108.86 175.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.457 ' HB3' HG22 ' A' ' 75' ' ' VAL . 68.8 mt -96.8 172.42 7.9 Favored 'General case' 0 N--CA 1.43 -1.429 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.392 -177.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 21.4 tptm -68.23 108.46 3.18 Favored 'General case' 0 C--N 1.318 -0.773 0 C-N-CA 122.767 0.427 . . . . 0.0 111.154 -177.049 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 55.1 mt -127.99 119.69 51.84 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 177.506 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 7.8 p -113.59 140.59 24.75 Favored Pre-proline 0 C--N 1.292 -1.901 0 C-N-CA 123.011 0.524 . . . . 0.0 110.177 176.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -68.15 141.55 52.87 Favored 'Trans proline' 0 CA--C 1.541 0.855 0 C-N-CA 121.377 1.385 . . . . 0.0 110.004 174.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.93 112.35 3.65 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.573 0 N-CA-C 110.271 -0.27 . . . . 0.0 110.271 -177.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 67.2 mtt -122.56 116.97 24.8 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-O 120.724 0.297 . . . . 0.0 110.26 176.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.6 mt-10 -124.92 118.12 25.59 Favored 'General case' 0 C--N 1.314 -0.937 0 N-CA-C 109.172 -0.677 . . . . 0.0 109.172 178.17 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.73 21.86 70.82 Favored Glycine 0 C--N 1.315 -0.62 0 C-N-CA 120.983 -0.627 . . . . 0.0 111.825 179.218 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 94.28 -24.04 28.99 Favored Glycine 0 N--CA 1.444 -0.788 0 C-N-CA 121.719 -0.276 . . . . 0.0 113.085 178.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -99.61 151.79 20.78 Favored 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 110.172 -0.307 . . . . 0.0 110.172 -177.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -86.44 153.29 22.0 Favored 'General case' 0 N--CA 1.438 -1.072 0 N-CA-C 109.814 -0.439 . . . . 0.0 109.814 178.513 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.453 HG12 HD12 ' A' ' 33' ' ' LEU . 7.5 t -100.59 116.17 64.55 Favored Pre-proline 0 C--N 1.294 -1.805 0 N-CA-C 105.53 -2.026 . . . . 0.0 105.53 174.219 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -60.83 131.56 38.04 Favored 'Trans proline' 0 CA--C 1.536 0.596 0 C-N-CA 123.758 2.972 . . . . 0.0 116.338 -169.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.27 21.85 79.32 Favored Glycine 0 C--O 1.247 0.91 0 CA-C-N 114.411 -1.268 . . . . 0.0 114.168 174.179 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.453 HD12 HG12 ' A' ' 30' ' ' VAL . 65.2 mt -130.97 146.69 52.45 Favored 'General case' 0 C--N 1.305 -1.338 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 -177.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.413 ' CZ ' ' HB2' ' A' ' 170' ' ' TYR . 33.0 p90 -132.1 153.33 50.58 Favored 'General case' 0 N--CA 1.429 -1.51 0 CA-C-O 121.558 0.694 . . . . 0.0 109.9 177.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 34.1 tt0 -112.45 148.34 34.59 Favored 'General case' 0 C--N 1.266 -3.05 0 CA-C-N 114.177 -1.374 . . . . 0.0 107.41 -177.798 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.496 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.7 t -111.14 114.31 46.75 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.759 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 173.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -86.42 159.85 19.22 Favored 'General case' 0 C--N 1.292 -1.897 0 N-CA-C 107.3 -1.37 . . . . 0.0 107.3 178.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 60.8 p -97.77 135.3 39.74 Favored 'General case' 0 C--N 1.293 -1.882 0 C-N-CA 119.275 -0.97 . . . . 0.0 110.486 -174.588 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.626 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.14 122.9 21.14 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 177.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 41.9 mtt -88.24 112.54 22.9 Favored 'General case' 0 CA--C 1.483 -1.604 0 CA-C-O 121.455 0.645 . . . . 0.0 111.194 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 31.5 m -118.21 162.79 15.98 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.06 178.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -93.26 121.97 35.18 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 176.301 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.419 ' HB ' ' O ' ' A' ' 68' ' ' ALA . 61.7 t -70.78 -33.94 54.46 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.094 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 177.687 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -150.66 153.17 24.86 Favored Glycine 0 N--CA 1.424 -2.104 0 N-CA-C 107.818 -2.113 . . . . 0.0 107.818 175.612 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -119.08 -39.87 0.67 Allowed Glycine 0 C--N 1.314 -0.653 0 C-N-CA 120.7 -0.762 . . . . 0.0 112.788 -179.659 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -104.96 96.46 1.23 Allowed Glycine 0 N--CA 1.44 -1.099 0 N-CA-C 110.966 -0.853 . . . . 0.0 110.966 179.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 7.6 m-20 -45.89 104.81 0.05 Allowed 'General case' 0 N--CA 1.492 1.626 0 C-N-CA 125.725 1.61 . . . . 0.0 112.717 -177.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.3 mt 67.45 -51.76 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 C-N-CA 125.566 1.546 . . . . 0.0 115.092 173.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.0 t70 -50.0 -45.61 51.95 Favored 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.151 1.38 . . . . 0.0 112.34 -177.169 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 50.6 mt -79.31 98.89 3.13 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 N-CA-C 107.136 -1.431 . . . . 0.0 107.136 176.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -85.57 57.06 4.91 Favored Glycine 0 N--CA 1.438 -1.221 0 N-CA-C 111.717 -0.553 . . . . 0.0 111.717 -176.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 44.1 t -123.88 96.44 4.95 Favored 'General case' 0 N--CA 1.415 -2.221 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -115.67 -9.86 12.09 Favored Glycine 0 N--CA 1.435 -1.396 0 N-CA-C 109.851 -1.3 . . . . 0.0 109.851 174.033 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 39.2 m-80 -94.29 112.2 23.98 Favored 'General case' 0 CA--C 1.501 -0.912 0 N-CA-C 109.526 -0.546 . . . . 0.0 109.526 179.247 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -130.76 157.94 41.48 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.957 -176.193 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 83.7 m-85 -92.57 88.7 6.42 Favored 'General case' 0 C--N 1.311 -1.069 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 176.556 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 82.17 -53.55 4.78 Favored Glycine 0 CA--C 1.523 0.557 0 CA-C-N 116.059 -0.519 . . . . 0.0 112.365 -179.511 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -175.53 118.98 0.69 Allowed Glycine 0 N--CA 1.428 -1.885 0 N-CA-C 109.028 -1.629 . . . . 0.0 109.028 178.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -156.88 178.03 10.83 Favored 'General case' 0 C--O 1.245 0.828 0 N-CA-C 109.479 -0.564 . . . . 0.0 109.479 -178.516 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 127.57 163.29 11.36 Favored Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 108.851 -1.699 . . . . 0.0 108.851 -178.715 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -72.44 -49.85 30.48 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 118.1 0.95 . . . . 0.0 108.867 -177.466 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 -109.25 20.37 18.38 Favored 'General case' 0 N--CA 1.479 1.01 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 172.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 73.71 144.5 0.07 Allowed 'General case' 0 C--O 1.24 0.592 0 C-N-CA 125.549 1.54 . . . . 0.0 110.839 -169.8 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -151.24 63.04 0.39 Allowed Glycine 0 N--CA 1.434 -1.498 0 C-N-CA 120.704 -0.76 . . . . 0.0 111.932 -179.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.1 -38.72 63.76 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 121.105 0.479 . . . . 0.0 110.166 178.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.2 m-20 -135.53 150.45 49.75 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 106.689 -1.597 . . . . 0.0 106.689 178.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 36.5 t70 -90.9 81.16 5.72 Favored 'General case' 0 CA--C 1.499 -1.003 0 C-N-CA 118.9 -1.12 . . . . 0.0 110.912 179.422 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.419 ' O ' ' HB ' ' A' ' 43' ' ' VAL . . . -148.13 109.81 4.45 Favored 'General case' 0 C--N 1.283 -2.292 0 N-CA-C 105.819 -1.919 . . . . 0.0 105.819 176.115 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 1.7 m -78.43 48.15 0.75 Allowed 'General case' 0 C--N 1.289 -2.065 0 CA-C-O 121.937 0.875 . . . . 0.0 111.014 -175.794 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.8 mt-30 -99.94 130.2 46.09 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 178.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -101.56 119.72 39.2 Favored 'General case' 0 CA--C 1.483 -1.624 0 N-CA-C 106.91 -1.515 . . . . 0.0 106.91 171.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -157.67 171.66 19.91 Favored 'General case' 0 C--N 1.285 -2.207 0 N-CA-C 106.889 -1.523 . . . . 0.0 106.889 -174.728 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.626 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 32.0 t30 -60.65 122.95 16.0 Favored 'General case' 0 N--CA 1.438 -1.064 0 O-C-N 123.655 0.597 . . . . 0.0 110.019 177.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -49.72 -25.8 3.27 Favored 'General case' 0 N--CA 1.479 0.989 0 C-N-CA 125.391 1.477 . . . . 0.0 114.856 -179.557 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.457 HG22 ' HB3' ' A' ' 18' ' ' LEU . 57.8 t -88.25 -41.32 14.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 C-N-CA 121.103 -0.239 . . . . 0.0 111.619 -178.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.495 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -75.52 -44.9 41.26 Favored 'General case' 0 N--CA 1.436 -1.157 0 CA-C-O 119.357 -0.354 . . . . 0.0 110.803 179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 29.22 85.27 0.01 OUTLIER Glycine 0 C--N 1.359 1.821 0 O-C-N 125.439 1.712 . . . . 0.0 115.686 174.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 50.2 Cg_exo -57.72 -24.41 63.06 Favored 'Trans proline' 0 N--CA 1.494 1.511 0 C-N-CA 123.67 2.913 . . . . 0.0 112.885 -177.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 1.4 m -78.88 -21.24 47.77 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.339 -179.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 7.4 m -128.18 -67.12 0.82 Allowed 'General case' 0 N--CA 1.443 -0.794 0 N-CA-C 112.355 0.502 . . . . 0.0 112.355 -171.189 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -88.11 -32.75 18.53 Favored 'General case' 0 C--O 1.221 -0.41 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.871 -174.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.435 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 53.56 87.56 0.04 OUTLIER 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.684 1.594 . . . . 0.0 115.169 175.536 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.476 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.6 m-85 -92.73 113.25 25.48 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.158 178.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 23.1 m -101.88 139.02 38.07 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 108.273 -1.01 . . . . 0.0 108.273 178.115 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -84.14 146.29 27.95 Favored 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -174.426 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 91.9 mmm -127.53 126.94 24.15 Favored Pre-proline 0 C--N 1.309 -1.155 0 C-N-CA 125.773 1.629 . . . . 0.0 108.545 178.171 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 85.6 Cg_endo -80.91 166.21 19.18 Favored 'Trans proline' 0 C--O 1.244 0.81 0 C-N-CA 122.422 2.081 . . . . 0.0 110.641 175.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 90.0 m-85 -64.56 115.22 4.97 Favored 'General case' 0 CA--C 1.512 -0.506 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 176.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 8.1 p -86.58 -40.55 15.08 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 108.644 -0.872 . . . . 0.0 108.644 174.645 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 77.5 p 54.9 22.8 4.51 Favored 'General case' 0 N--CA 1.477 0.893 0 C-N-CA 125.946 1.698 . . . . 0.0 113.39 177.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.8 ttmt -91.59 172.76 8.28 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -48.95 -45.53 32.38 Favored Glycine 0 C--O 1.219 -0.811 0 N-CA-C 115.59 0.996 . . . . 0.0 115.59 -177.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.3 mp0 -58.67 -46.08 87.99 Favored 'General case' 0 N--CA 1.471 0.595 0 CA-C-N 118.369 1.085 . . . . 0.0 110.576 179.54 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.409 ' O ' HG23 ' A' ' 98' ' ' VAL . 88.8 t80 -61.41 -42.16 98.29 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.857 179.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.5 mmmm -73.0 -31.09 64.27 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.522 -0.308 . . . . 0.0 111.085 -179.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 37.4 m -70.39 -32.7 70.46 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 116.277 -0.42 . . . . 0.0 109.885 175.948 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.498 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 92.2 t90 -63.1 -45.24 92.99 Favored 'General case' 0 C--O 1.215 -0.739 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 174.984 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.409 HG23 ' O ' ' A' ' 94' ' ' PHE . 93.8 t -57.38 -41.46 78.55 Favored 'Isoleucine or valine' 0 C--O 1.239 0.521 0 O-C-N 123.519 0.512 . . . . 0.0 110.008 177.218 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.461 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 68.3 mttm -61.34 -56.72 17.26 Favored 'General case' 0 N--CA 1.452 -0.372 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.655 176.781 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 54.3 m-20 -63.43 -31.11 72.18 Favored 'General case' 0 CA--C 1.501 -0.932 0 N-CA-C 112.956 0.725 . . . . 0.0 112.956 -177.236 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.526 ' HA ' HD11 ' A' ' 8' ' ' ILE . 88.0 t80 -60.97 -54.44 44.98 Favored 'General case' 0 C--N 1.315 -0.931 0 O-C-N 123.323 0.39 . . . . 0.0 109.964 177.382 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 40.2 t -66.74 -33.54 64.08 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.055 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.595 -178.267 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 92.0 mtt180 -62.16 -57.18 12.49 Favored 'General case' 0 N--CA 1.471 0.599 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 175.885 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -59.35 -34.31 72.22 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 113.102 0.779 . . . . 0.0 113.102 -177.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.422 HG23 ' O ' ' A' ' 101' ' ' TYR . 73.1 t -62.07 -38.89 81.96 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.854 0 O-C-N 123.506 0.504 . . . . 0.0 110.587 175.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 2.6 mpt_? -64.06 -38.93 92.86 Favored 'General case' 0 N--CA 1.472 0.666 0 O-C-N 121.985 -0.447 . . . . 0.0 112.06 177.355 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -71.1 -33.44 70.16 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.873 -0.331 . . . . 0.0 110.56 177.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.78 -43.91 87.37 Favored 'General case' 0 C--O 1.222 -0.367 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.362 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.418 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 9.2 mp -59.62 -37.14 77.81 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 112.915 0.709 . . . . 0.0 112.915 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -83.54 -42.55 16.69 Favored 'General case' 0 C--N 1.308 -1.229 0 N-CA-C 112.542 0.571 . . . . 0.0 112.542 -178.063 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -85.68 -1.95 87.11 Favored Glycine 0 C--N 1.318 -0.448 0 N-CA-C 114.997 0.759 . . . . 0.0 114.997 -173.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.5 p -75.92 -21.84 56.66 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 113.384 0.883 . . . . 0.0 113.384 -177.854 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 73.83 38.37 49.57 Favored Glycine 0 CA--C 1.523 0.553 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.288 177.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.406 HG12 ' HB2' ' A' ' 118' ' ' ASP . 14.6 t -82.46 153.75 3.96 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.954 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 178.024 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.405 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -60.54 148.55 37.57 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 118.068 0.394 . . . . 0.0 111.61 -178.507 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 73.6 t -55.99 -38.99 55.23 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 C-N-CA 123.527 0.731 . . . . 0.0 112.853 -176.001 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.442 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.5 mp0 -61.06 -46.77 89.3 Favored 'General case' 0 C--O 1.248 1.013 0 CA-C-O 121.897 0.856 . . . . 0.0 108.804 179.705 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.501 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 11.2 m-20 -65.96 -41.63 90.98 Favored 'General case' 0 C--O 1.2 -1.55 0 CA-C-N 114.485 -1.234 . . . . 0.0 109.579 178.145 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.405 HG12 ' O ' ' A' ' 115' ' ' ALA . 31.8 mm -54.65 -37.68 40.28 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.23 0 C-N-CA 124.31 1.044 . . . . 0.0 111.093 177.849 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -59.24 -52.07 67.24 Favored 'General case' 0 CA--C 1.516 -0.354 0 N-CA-C 110.483 -0.192 . . . . 0.0 110.483 177.619 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.447 ' HB3' ' HZ3' ' A' ' 121' ' ' LYS . 2.2 mmmp? -61.88 -48.8 78.88 Favored 'General case' 0 C--O 1.208 -1.089 0 O-C-N 123.897 0.748 . . . . 0.0 110.68 176.132 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.501 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 2.5 t80 -54.06 -40.65 67.33 Favored 'General case' 0 CA--C 1.557 1.241 0 C-N-CA 127.267 2.227 . . . . 0.0 110.239 -175.733 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.9 mtp -81.31 -26.71 35.44 Favored 'General case' 0 CA--C 1.532 0.287 0 CA-C-N 116.312 -0.404 . . . . 0.0 111.98 179.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -75.88 -38.02 58.28 Favored 'General case' 0 N--CA 1.473 0.714 0 CA-C-O 121.395 0.617 . . . . 0.0 110.707 178.548 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 37.9 mt-10 -81.96 -17.75 45.89 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.63 -178.429 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.596 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.98 -52.01 65.68 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 114.517 1.303 . . . . 0.0 114.517 178.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 14.1 Cg_endo -59.43 -31.77 95.35 Favored 'Trans proline' 0 C--N 1.379 2.177 0 C-N-CA 122.061 1.841 . . . . 0.0 112.032 176.174 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . 0.443 ' HA ' ' HB2' ' A' ' 131' ' ' LYS . 11.2 m -70.16 -27.12 64.29 Favored 'General case' 0 CA--C 1.551 0.982 0 C-N-CA 123.601 0.76 . . . . 0.0 111.014 -178.384 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.596 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 13.0 m-30 -66.76 -47.76 71.21 Favored 'General case' 0 CA--C 1.51 -0.573 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.611 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.0 t -63.73 -42.25 95.34 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.275 0 CA-C-N 114.702 -1.135 . . . . 0.0 109.546 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.443 ' HB2' ' HA ' ' A' ' 128' ' ' THR . 14.6 mmmt -52.68 -55.62 21.34 Favored 'General case' 0 CA--C 1.512 -0.493 0 C-N-CA 123.921 0.888 . . . . 0.0 112.284 176.212 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.64 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 31.3 t90 -65.06 -35.27 80.62 Favored 'General case' 0 C--O 1.213 -0.844 0 O-C-N 123.36 0.412 . . . . 0.0 111.487 -176.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.417 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 96.7 mt -66.0 -40.08 90.83 Favored 'General case' 0 CA--C 1.537 0.473 0 CA-C-O 120.822 0.344 . . . . 0.0 111.316 178.023 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 94.9 t -74.61 -40.52 48.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.612 0 CA-C-N 116.581 -0.281 . . . . 0.0 110.845 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 8.6 m-20 -76.1 -16.39 59.91 Favored 'General case' 0 N--CA 1.472 0.633 0 N-CA-C 113.059 0.763 . . . . 0.0 113.059 -179.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.3 tppt? -104.63 -6.99 19.96 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.554 -0.458 . . . . 0.0 110.19 177.995 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.403 ' HA ' HD12 ' A' ' 140' ' ' LEU . 80.2 t80 -52.77 -36.17 57.61 Favored 'General case' 0 N--CA 1.479 1.018 0 C-N-CA 124.475 1.11 . . . . 0.0 113.929 -176.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 10.7 m-20 -78.54 -2.95 41.27 Favored 'General case' 0 N--CA 1.479 0.993 0 N-CA-C 113.097 0.777 . . . . 0.0 113.097 179.822 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -109.45 -6.52 15.41 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 109.596 -0.52 . . . . 0.0 109.596 174.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.532 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 80.4 mt -84.25 156.47 21.97 Favored 'General case' 0 N--CA 1.435 -1.225 0 CA-C-O 121.889 0.852 . . . . 0.0 112.878 -174.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -142.09 158.34 43.86 Favored 'General case' 0 C--N 1.288 -2.083 0 C-N-CA 127.711 2.405 . . . . 0.0 104.623 170.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -111.1 151.56 27.96 Favored 'General case' 0 C--N 1.287 -2.109 0 C-N-CA 119.675 -0.81 . . . . 0.0 112.472 -171.629 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 69.6 m-85 -136.57 169.16 18.17 Favored 'General case' 0 C--N 1.302 -1.496 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.025 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.476 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 46.0 mtm -142.22 141.15 32.5 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.144 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 72.6 p -88.62 169.9 11.3 Favored 'General case' 0 C--N 1.298 -1.636 0 N-CA-C 108.161 -1.052 . . . . 0.0 108.161 173.999 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . 0.435 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 81.9 tttt -52.35 -38.93 59.99 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 124.817 1.247 . . . . 0.0 110.716 177.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.2 p -82.69 -4.0 57.18 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 114.912 -1.04 . . . . 0.0 113.164 -177.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.43 ' HE2' ' HB2' ' A' ' 11' ' ' ASP . 57.3 mtt -119.83 174.34 6.5 Favored 'General case' 0 C--N 1.32 -0.71 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 -171.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 37.0 m-80 -133.11 166.73 27.17 Favored Pre-proline 0 C--N 1.315 -0.905 0 N-CA-C 107.565 -1.272 . . . . 0.0 107.565 -173.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 43.9 Cg_endo -72.26 -22.44 22.09 Favored 'Trans proline' 0 CA--C 1.541 0.864 0 C-N-CA 121.218 1.279 . . . . 0.0 111.259 175.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.0 m-20 -87.23 -19.25 28.61 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.204 -0.907 . . . . 0.0 111.364 -179.956 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -152.83 108.53 3.31 Favored 'General case' 0 C--N 1.315 -0.933 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 -175.297 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.92 42.39 4.12 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.554 -0.831 . . . . 0.0 112.006 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.498 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 44.6 tp -87.03 112.84 22.25 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 107.587 -1.264 . . . . 0.0 107.587 177.666 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 91.6 mt -87.78 135.74 24.76 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.021 0 CA-C-N 114.836 -1.075 . . . . 0.0 111.578 -172.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.529 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 59.3 m-85 -93.95 138.62 31.86 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 108.05 -1.093 . . . . 0.0 108.05 177.651 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.406 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 13.5 t -150.22 148.62 29.12 Favored 'General case' 0 C--O 1.205 -1.239 0 CA-C-N 118.633 0.651 . . . . 0.0 110.231 175.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 28.5 p90 -131.99 178.78 6.52 Favored 'General case' 0 C--N 1.315 -0.925 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 173.486 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 86.5 m-85 -121.84 108.28 13.28 Favored 'General case' 0 C--N 1.3 -1.555 0 CA-C-N 118.823 0.738 . . . . 0.0 110.789 179.769 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -80.83 152.34 28.26 Favored 'General case' 0 C--O 1.248 0.994 0 N-CA-C 107.982 -1.118 . . . . 0.0 107.982 174.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.7 mm-40 -74.9 132.41 41.44 Favored 'General case' 0 C--N 1.306 -1.302 0 C-N-CA 119.623 -0.831 . . . . 0.0 110.522 174.74 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.64 -12.4 42.53 Favored Glycine 0 N--CA 1.44 -1.098 0 CA-C-N 115.534 -0.757 . . . . 0.0 111.722 -177.177 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.36 134.44 34.07 Favored 'General case' 0 N--CA 1.444 -0.763 0 N-CA-C 109.678 -0.49 . . . . 0.0 109.678 178.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 9.8 m170 -78.73 -28.49 44.98 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 121.131 0.491 . . . . 0.0 110.426 177.147 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.461 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 27.2 m -128.01 164.23 38.45 Favored Pre-proline 0 C--N 1.3 -1.553 0 N-CA-C 108.598 -0.889 . . . . 0.0 108.598 -175.117 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_endo -51.07 139.62 42.06 Favored 'Trans proline' 0 C--N 1.361 1.23 0 C-N-CA 123.235 2.624 . . . . 0.0 113.83 177.497 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 21.6 m -93.89 109.63 21.33 Favored 'General case' 0 N--CA 1.431 -1.387 0 CA-C-N 114.79 -1.095 . . . . 0.0 108.175 -178.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 69.6 m-85 -82.31 145.25 30.07 Favored 'General case' 0 C--N 1.307 -1.241 0 CA-C-O 121.538 0.685 . . . . 0.0 112.206 -172.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.64 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 49.3 t -115.85 116.73 53.3 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 C-N-CA 125.021 1.328 . . . . 0.0 109.733 -173.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.413 ' HB2' ' CZ ' ' A' ' 34' ' ' PHE . 72.0 m-85 -139.38 152.16 46.9 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.284 0.564 . . . . 0.0 109.927 178.092 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.417 ' HA ' HD23 ' A' ' 33' ' ' LEU . 47.8 t -90.51 118.36 35.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.493 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 178.193 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 23.3 ttpp -65.95 -49.74 66.85 Favored 'General case' 0 N--CA 1.47 0.56 0 CA-C-O 121.373 0.606 . . . . 0.0 110.672 -175.372 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 129' ' ' PHE . 20.1 m -89.62 4.73 48.49 Favored 'General case' 0 C--N 1.297 -1.684 0 CA-C-N 115.3 -0.864 . . . . 0.0 112.43 -177.205 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -106.91 -17.4 11.85 Favored Glycine 0 CA--C 1.5 -0.863 0 C-N-CA 119.983 -1.103 . . . . 0.0 112.321 -177.384 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.468 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 10.4 m-85 -98.12 167.68 10.73 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 179.688 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.482 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 96.7 mttt -85.24 103.38 14.14 Favored 'General case' 0 C--N 1.304 -1.37 0 CA-C-O 121.342 0.592 . . . . 0.0 110.338 -177.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.7 t -79.08 109.6 13.94 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 CA-C-N 114.525 -1.216 . . . . 0.0 109.648 179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.1 t -120.91 136.52 57.6 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.9 126.84 52.66 Favored 'General case' 0 N--CA 1.446 -0.652 0 C-N-CA 120.117 -0.633 . . . . 0.0 111.616 178.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 61.6 m-85 -121.28 161.45 21.98 Favored 'General case' 0 C--N 1.299 -1.613 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.53 175.681 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.651 ' H ' HD23 ' A' ' 181' ' ' LEU . 1.3 pt? -97.07 112.89 24.46 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 106.919 -1.512 . . . . 0.0 106.919 174.082 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -108.51 -3.84 17.76 Favored 'General case' 0 C--N 1.307 -1.252 0 N-CA-C 114.136 1.161 . . . . 0.0 114.136 -166.336 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.465 ' CE1' ' HB2' ' A' ' 186' ' ' HIS . 4.7 t-160 -80.89 -40.53 24.54 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 118.616 -1.234 . . . . 0.0 112.533 -169.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 53.7 59.8 4.08 Favored 'General case' 0 CA--C 1.549 0.926 0 O-C-N 124.05 0.844 . . . . 0.0 111.034 177.302 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 51.6 m-70 75.77 177.06 0.2 Allowed 'General case' 0 N--CA 1.48 1.059 0 C-N-CA 125.543 1.537 . . . . 0.0 113.028 -178.106 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . 0.465 ' HB2' ' CE1' ' A' ' 183' ' ' HIS . 10.1 t-80 -165.78 101.79 0.68 Allowed 'General case' 0 N--CA 1.437 -1.084 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 176.135 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.5 t-80 -79.33 93.26 5.27 Favored 'General case' 0 C--N 1.307 -1.278 0 CA-C-O 121.334 0.587 . . . . 0.0 110.637 -177.807 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 57.0 t-80 . . . . . 0 C--N 1.293 -1.876 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 177.668 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.447 -0.597 0 N-CA-C 108.153 -1.055 . . . . 0.0 108.153 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.5 mt -103.01 135.43 40.49 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.672 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.4 p -133.38 141.8 43.51 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 109.763 -0.458 . . . . 0.0 109.763 -179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.417 ' CE1' HG22 ' A' ' 177' ' ' VAL . 59.7 m-85 -96.46 112.61 24.29 Favored 'General case' 0 C--N 1.305 -1.353 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.7 mtpp -105.4 130.69 53.44 Favored 'General case' 0 C--N 1.287 -2.136 0 CA-C-N 114.891 -1.05 . . . . 0.0 109.002 -178.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -72.97 144.71 47.15 Favored 'General case' 0 C--N 1.302 -1.467 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.335 -177.373 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 42.5 t -84.54 -24.74 7.26 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 115.925 -0.579 . . . . 0.0 110.19 -177.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.413 HD11 ' HA ' ' A' ' 101' ' ' TYR . 20.5 mm -78.28 -55.12 10.88 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 N-CA-C 109.951 -0.388 . . . . 0.0 109.951 -176.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.427 ' HA ' ' HB1' ' A' ' 152' ' ' ALA . 46.7 p -82.86 -42.3 17.95 Favored 'General case' 0 C--N 1.313 -0.987 0 CA-C-O 121.204 0.525 . . . . 0.0 111.629 -179.838 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.5 22.32 44.28 Favored Glycine 0 N--CA 1.433 -1.501 0 N-CA-C 109.947 -1.261 . . . . 0.0 109.947 -173.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.635 ' HB3' ' HE3' ' A' ' 148' ' ' MET . 8.7 t70 -117.49 -179.65 3.79 Favored 'General case' 0 CA--C 1.545 0.774 0 N-CA-C 108.286 -1.005 . . . . 0.0 108.286 -179.131 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -98.11 134.14 41.6 Favored 'General case' 0 C--N 1.304 -1.4 0 C-N-CA 123.314 0.646 . . . . 0.0 111.799 -170.868 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 24.9 m -106.33 -34.64 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.836 0 N-CA-C 113.207 0.818 . . . . 0.0 113.207 178.708 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 10.4 p -164.35 156.11 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 -176.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 35.8 p -124.9 166.86 15.52 Favored 'General case' 0 N--CA 1.429 -1.493 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 178.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 7.5 p-10 -69.97 -14.59 62.78 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 113.235 0.828 . . . . 0.0 113.235 -175.475 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -78.96 -12.78 60.04 Favored 'General case' 0 C--O 1.243 0.75 0 CA-C-O 121.216 0.531 . . . . 0.0 110.694 178.007 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.502 ' HB3' HG22 ' A' ' 75' ' ' VAL . 96.9 mt -92.83 174.07 7.44 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 179.831 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 22.2 tptm -83.03 106.58 14.96 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.235 0.54 . . . . 0.0 110.417 -175.594 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.444 HG23 ' CD2' ' A' ' 34' ' ' PHE . 77.6 mt -116.49 117.63 56.1 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.587 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 19.0 p -119.32 146.31 40.6 Favored Pre-proline 0 C--N 1.294 -1.83 0 N-CA-C 109.863 -0.421 . . . . 0.0 109.863 177.798 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -72.08 145.18 43.95 Favored 'Trans proline' 0 C--N 1.328 -0.547 0 C-N-CA 121.334 1.356 . . . . 0.0 110.582 175.389 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.2 t -69.65 110.33 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.472 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 178.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 59.3 mtt -115.59 112.25 21.88 Favored 'General case' 0 C--N 1.294 -1.83 0 CA-C-O 120.877 0.37 . . . . 0.0 110.218 175.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 15.4 mt-10 -135.94 122.85 21.29 Favored 'General case' 0 N--CA 1.44 -0.971 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 177.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.05 17.38 43.81 Favored Glycine 0 C--N 1.308 -0.984 0 C-N-CA 121.095 -0.574 . . . . 0.0 112.26 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 79.6 21.99 65.42 Favored Glycine 0 N--CA 1.453 -0.199 0 C-N-CA 121.274 -0.489 . . . . 0.0 112.827 178.384 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -156.47 165.28 36.78 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 108.701 -0.851 . . . . 0.0 108.701 179.25 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -86.81 153.11 21.92 Favored 'General case' 0 N--CA 1.437 -1.097 0 CA-C-O 121.276 0.56 . . . . 0.0 110.597 -179.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 26.1 t -100.77 115.63 65.1 Favored Pre-proline 0 C--N 1.288 -2.108 0 N-CA-C 105.264 -2.124 . . . . 0.0 105.264 172.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -68.68 130.99 21.77 Favored 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.722 2.282 . . . . 0.0 114.735 -172.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 92.76 3.5 66.17 Favored Glycine 0 N--CA 1.439 -1.1 0 CA-C-N 114.974 -1.012 . . . . 0.0 114.44 174.609 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.523 HD13 ' CE3' ' A' ' 132' ' ' TRP . 47.6 mt -130.39 145.98 51.89 Favored 'General case' 0 C--N 1.302 -1.458 0 CA-C-N 117.127 0.464 . . . . 0.0 110.946 -175.69 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.444 ' CD2' HG23 ' A' ' 20' ' ' ILE . 32.3 p90 -130.93 154.24 48.33 Favored 'General case' 0 N--CA 1.442 -0.857 0 CA-C-O 121.298 0.571 . . . . 0.0 110.011 176.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.522 ' HB2' HG22 ' A' ' 23' ' ' VAL . 43.0 tt0 -122.02 151.9 40.34 Favored 'General case' 0 C--N 1.275 -2.633 0 N-CA-C 107.196 -1.409 . . . . 0.0 107.196 -175.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.401 ' CG1' HG21 ' A' ' 75' ' ' VAL . 81.8 t -111.55 115.28 49.43 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.444 0 C-N-CA 120.037 -0.665 . . . . 0.0 111.363 -179.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -78.51 153.23 31.5 Favored 'General case' 0 C--N 1.313 -1.001 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.514 176.08 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 22.0 p -99.38 135.53 40.66 Favored 'General case' 0 N--CA 1.427 -1.597 0 N-CA-C 113.342 0.867 . . . . 0.0 113.342 -173.598 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -131.69 124.65 30.25 Favored 'General case' 0 N--CA 1.439 -1.012 0 N-CA-C 107.083 -1.451 . . . . 0.0 107.083 174.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 33.0 mtt -85.2 135.44 33.95 Favored 'General case' 0 CA--C 1.498 -1.048 0 N-CA-C 114.832 1.419 . . . . 0.0 114.832 -174.271 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 16.6 m -122.4 141.08 44.2 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.312 0 CA-C-N 114.088 -1.414 . . . . 0.0 108.474 171.899 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -80.31 118.43 21.96 Favored 'General case' 0 C--N 1.311 -1.076 0 C-N-CA 123.195 0.598 . . . . 0.0 109.741 -179.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 46.7 t -113.47 129.91 68.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.417 0 N-CA-C 108.51 -0.922 . . . . 0.0 108.51 -179.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -84.24 93.46 1.77 Allowed Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 110.344 -1.102 . . . . 0.0 110.344 178.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -84.61 69.12 3.38 Favored Glycine 0 N--CA 1.439 -1.147 0 C-N-CA 121.73 -0.271 . . . . 0.0 113.03 -177.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.27 99.69 2.23 Favored Glycine 0 N--CA 1.424 -2.155 0 N-CA-C 108.826 -1.71 . . . . 0.0 108.826 174.177 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 19.2 m-20 70.96 161.75 0.24 Allowed 'General case' 0 N--CA 1.489 1.5 0 C-N-CA 125.993 1.717 . . . . 0.0 110.359 -175.123 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.7 mt -77.3 -40.8 29.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 N-CA-C 106.136 -1.801 . . . . 0.0 106.136 170.147 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.1 t70 -155.79 -59.7 0.1 Allowed 'General case' 0 C--N 1.308 -1.234 0 N-CA-C 105.393 -2.077 . . . . 0.0 105.393 170.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 55.7 mt -139.6 94.35 0.79 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.869 0 N-CA-C 105.756 -1.942 . . . . 0.0 105.756 173.015 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 68.79 -132.03 26.36 Favored Glycine 0 C--N 1.309 -0.927 0 N-CA-C 109.474 -1.45 . . . . 0.0 109.474 -172.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.8 t -104.55 -45.84 4.52 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 109.071 -0.714 . . . . 0.0 109.071 176.465 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 153.37 -76.51 0.22 Allowed Glycine 0 N--CA 1.437 -1.27 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -178.695 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 27.6 t-20 -78.99 152.65 30.86 Favored 'General case' 0 C--N 1.311 -1.066 0 C-N-CA 123.074 0.55 . . . . 0.0 110.018 -179.81 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -62.2 -35.68 79.62 Favored 'General case' 0 N--CA 1.475 0.794 0 C-N-CA 123.261 0.625 . . . . 0.0 112.543 -178.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.8 m-85 -104.83 6.99 34.32 Favored 'General case' 0 C--N 1.314 -0.978 0 CA-C-O 121.414 0.626 . . . . 0.0 109.957 179.301 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -94.07 138.58 14.12 Favored Glycine 0 N--CA 1.421 -2.327 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.072 -178.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 151.7 -66.44 0.34 Allowed Glycine 0 N--CA 1.428 -1.838 0 N-CA-C 110.188 -1.165 . . . . 0.0 110.188 -179.46 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 57.93 -87.94 0.02 OUTLIER 'General case' 0 N--CA 1.469 0.51 0 C-N-CA 125.02 1.328 . . . . 0.0 113.11 178.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -109.86 1.41 30.26 Favored Glycine 0 C--O 1.224 -0.48 0 N-CA-C 112.086 -0.406 . . . . 0.0 112.086 -179.306 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.0 m-20 -117.92 16.23 14.28 Favored 'General case' 0 N--CA 1.474 0.76 0 N-CA-C 108.482 -0.933 . . . . 0.0 108.482 177.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 10.6 t70 -78.08 -54.61 6.07 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.783 -0.644 . . . . 0.0 112.076 -173.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 12.2 tp10 -83.77 101.79 11.85 Favored 'General case' 0 N--CA 1.432 -1.369 0 CA-C-O 121.535 0.683 . . . . 0.0 111.141 -174.027 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -172.6 57.99 0.16 Allowed Glycine 0 N--CA 1.418 -2.557 0 CA-C-N 115.178 -0.919 . . . . 0.0 110.874 179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -64.39 -53.29 50.88 Favored 'General case' 0 C--O 1.217 -0.637 0 O-C-N 124.112 0.537 . . . . 0.0 111.336 -177.346 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -158.9 95.89 1.32 Allowed 'General case' 0 CA--C 1.507 -0.675 0 CA-C-O 121.092 0.472 . . . . 0.0 111.578 176.222 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 3.9 p30 -144.77 -177.95 5.77 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 177.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -136.3 44.43 2.42 Favored 'General case' 0 C--N 1.308 -1.201 0 CA-C-O 121.577 0.703 . . . . 0.0 109.686 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 6.0 m -78.9 -3.59 45.5 Favored 'General case' 0 CA--C 1.558 1.283 0 CA-C-O 122.112 0.958 . . . . 0.0 109.189 179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 17.7 mp0 -97.98 111.64 23.88 Favored 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.625 -173.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 60.8 mtpt -127.01 119.97 27.91 Favored 'General case' 0 C--N 1.281 -2.379 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 169.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.8 tp10 -129.0 165.83 20.37 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -170.215 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.46 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 45.0 t30 -73.45 139.35 45.75 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.581 -0.525 . . . . 0.0 109.581 179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -60.57 -16.04 33.79 Favored 'General case' 0 N--CA 1.478 0.96 0 N-CA-C 113.018 0.748 . . . . 0.0 113.018 179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.502 HG22 ' HB3' ' A' ' 18' ' ' LEU . 39.7 t -83.76 -33.14 9.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.589 0 CA-C-O 120.96 0.41 . . . . 0.0 110.409 -179.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.7 p -83.38 -53.93 5.36 Favored 'General case' 0 N--CA 1.424 -1.73 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.045 176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 43.38 94.02 0.01 OUTLIER Glycine 0 C--N 1.35 1.314 0 C-N-CA 124.679 1.133 . . . . 0.0 115.394 173.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -54.51 -34.21 81.19 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 123.486 2.791 . . . . 0.0 113.568 -178.371 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.9 p -86.88 -11.53 50.48 Favored 'General case' 0 C--N 1.307 -1.258 0 C-N-CA 123.155 0.582 . . . . 0.0 112.226 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 22.9 t -109.58 -78.52 0.59 Allowed 'General case' 0 N--CA 1.436 -1.149 0 CA-C-N 116.446 -0.343 . . . . 0.0 110.427 -175.582 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 91.0 m-85 -92.16 -36.09 13.49 Favored 'General case' 0 C--O 1.24 0.603 0 O-C-N 122.068 -0.395 . . . . 0.0 111.426 -177.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.54 90.11 0.09 Allowed 'General case' 0 N--CA 1.467 0.409 0 C-N-CA 125.358 1.463 . . . . 0.0 112.785 179.52 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.47 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 3.7 m-30 -91.75 111.28 22.74 Favored 'General case' 0 C--N 1.303 -1.414 0 CA-C-N 115.085 -0.961 . . . . 0.0 110.051 179.297 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 15.1 m -91.1 129.17 37.12 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 178.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.43 141.4 32.77 Favored 'General case' 0 C--N 1.308 -1.231 0 N-CA-C 112.642 0.608 . . . . 0.0 112.642 -174.488 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -124.92 141.31 37.95 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.327 -0.99 . . . . 0.0 108.327 175.725 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_exo -72.34 165.77 31.69 Favored 'Trans proline' 0 C--O 1.257 1.447 0 C-N-CA 122.207 1.938 . . . . 0.0 111.427 175.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 93.3 m-85 -47.45 116.27 1.38 Allowed 'General case' 0 N--CA 1.483 1.183 0 O-C-N 123.946 0.778 . . . . 0.0 110.084 175.579 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 17.7 p -81.37 -73.09 0.4 Allowed 'General case' 0 N--CA 1.431 -1.418 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.874 -178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 69.1 m 59.51 17.28 5.93 Favored 'General case' 0 CA--C 1.542 0.66 0 N-CA-C 114.058 1.133 . . . . 0.0 114.058 178.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 55.5 mtpt -77.63 171.21 15.27 Favored 'General case' 0 C--N 1.322 -0.599 0 C-N-CA 122.875 0.47 . . . . 0.0 112.2 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -65.77 -40.84 95.88 Favored Glycine 0 C--O 1.234 0.117 0 CA-C-N 115.889 -0.596 . . . . 0.0 112.611 -179.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 2.1 mp0 -66.41 -30.84 71.29 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 178.433 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.513 ' O ' HG23 ' A' ' 98' ' ' VAL . 63.8 t80 -71.47 -36.08 71.07 Favored 'General case' 0 N--CA 1.438 -1.073 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.385 177.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -65.1 -42.97 93.52 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.044 0.449 . . . . 0.0 109.876 175.95 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 30.3 m -66.99 -29.27 69.06 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.768 176.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.7 t90 -66.08 -45.64 80.51 Favored 'General case' 0 C--O 1.206 -1.196 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.513 HG23 ' O ' ' A' ' 94' ' ' PHE . 64.6 t -60.57 -39.54 81.7 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.586 0 C-N-CA 122.777 0.431 . . . . 0.0 110.003 177.871 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.47 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 99.2 mttt -59.68 -53.26 60.12 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.631 175.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 16.4 m-20 -66.15 -27.92 68.39 Favored 'General case' 0 CA--C 1.504 -0.821 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 179.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.413 ' HA ' HD11 ' A' ' 8' ' ' ILE . 56.1 t80 -62.87 -51.85 65.37 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 176.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 90.6 t -63.28 -40.05 87.58 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.64 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.288 178.163 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.47 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 98.7 mtt180 -59.47 -57.43 13.01 Favored 'General case' 0 N--CA 1.469 0.525 0 C-N-CA 122.738 0.415 . . . . 0.0 110.798 177.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 93.8 m-20 -63.95 -35.38 80.5 Favored 'General case' 0 CA--C 1.502 -0.897 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -175.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.9 t -64.8 -44.73 96.37 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.729 0 N-CA-C 110.093 -0.336 . . . . 0.0 110.093 175.285 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 23.7 mtp180 -64.73 -32.54 74.26 Favored 'General case' 0 N--CA 1.472 0.629 0 N-CA-C 112.107 0.41 . . . . 0.0 112.107 177.671 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.4 mp0 -69.42 -35.34 75.63 Favored 'General case' 0 C--N 1.324 -0.518 0 C-N-CA 121.087 -0.245 . . . . 0.0 111.17 173.661 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.2 -40.25 93.92 Favored 'General case' 0 N--CA 1.467 0.4 0 C-N-CA 122.896 0.478 . . . . 0.0 110.074 176.558 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.7 mp -56.55 -43.92 80.4 Favored 'General case' 0 N--CA 1.473 0.716 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.564 175.416 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 65.2 mttm -74.16 -45.24 49.88 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.79 -179.404 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.92 -0.92 70.95 Favored Glycine 0 C--N 1.319 -0.388 0 CA-C-N 115.408 -0.814 . . . . 0.0 114.438 -174.427 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 78.8 p -71.17 -23.2 62.01 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.957 0.378 . . . . 0.0 111.452 -176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.84 25.95 73.11 Favored Glycine 0 C--N 1.338 0.652 0 C-N-CA 121.646 -0.311 . . . . 0.0 113.278 179.079 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 t -88.92 154.57 3.17 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.254 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.478 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -51.14 154.02 1.75 Allowed 'General case' 0 N--CA 1.477 0.923 0 C-N-CA 124.559 1.144 . . . . 0.0 113.352 -178.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.03 -40.19 86.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.664 0 C-N-CA 123.753 0.821 . . . . 0.0 112.816 -174.304 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -61.6 -42.24 98.58 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 122.045 0.926 . . . . 0.0 108.83 -179.845 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -68.48 -39.95 81.17 Favored 'General case' 0 N--CA 1.438 -1.027 0 CA-C-N 113.989 -1.46 . . . . 0.0 110.34 178.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.478 HG12 ' O ' ' A' ' 115' ' ' ALA . 41.2 mm -60.41 -36.55 70.05 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.709 0 O-C-N 123.446 0.466 . . . . 0.0 110.81 177.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.464 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.3 mmtt -58.32 -51.28 70.46 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.39 -0.226 . . . . 0.0 110.39 177.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 32.5 mmtm -64.63 -34.92 79.42 Favored 'General case' 0 N--CA 1.472 0.656 0 CA-C-N 115.847 -0.615 . . . . 0.0 111.67 177.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -68.35 -34.62 76.42 Favored 'General case' 0 C--N 1.31 -1.133 0 N-CA-C 108.233 -1.025 . . . . 0.0 108.233 -177.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 68.9 mtm -79.37 -18.6 52.04 Favored 'General case' 0 C--O 1.214 -0.764 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.102 177.311 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.464 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 43.5 mt-10 -78.68 -31.6 46.7 Favored 'General case' 0 C--N 1.323 -0.559 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 174.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.426 ' O ' ' HB ' ' A' ' 128' ' ' THR . 42.6 mt-10 -70.46 -26.47 63.66 Favored 'General case' 0 CA--C 1.543 0.706 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.69 174.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.474 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -56.04 -57.11 24.09 Favored Pre-proline 0 CA--C 1.561 1.374 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -179.067 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 41.3 Cg_endo -69.14 -20.36 37.87 Favored 'Trans proline' 0 C--N 1.383 2.38 0 C-N-CA 121.543 1.495 . . . . 0.0 111.161 177.332 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . 0.426 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 85.0 m -67.72 -39.04 84.36 Favored 'General case' 0 N--CA 1.441 -0.898 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.87 178.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.474 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.8 m-85 -61.39 -53.2 59.61 Favored 'General case' 0 C--N 1.351 0.639 0 N-CA-C 108.296 -1.002 . . . . 0.0 108.296 177.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 47.0 t -60.28 -48.21 89.15 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.356 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.384 -177.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -55.9 -54.4 45.19 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 123.622 0.769 . . . . 0.0 111.347 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.523 ' CE3' HD13 ' A' ' 33' ' ' LEU . 49.7 t90 -66.81 -36.41 82.31 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.728 -0.669 . . . . 0.0 111.24 -176.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.6 mt -67.1 -37.25 83.6 Favored 'General case' 0 C--O 1.222 -0.356 0 CA-C-O 120.443 0.164 . . . . 0.0 111.264 177.662 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 75.8 t -68.45 -39.72 81.15 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.509 0 CA-C-O 120.882 0.372 . . . . 0.0 110.297 177.189 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 13.5 m-20 -76.15 -21.15 56.9 Favored 'General case' 0 C--N 1.317 -0.818 0 N-CA-C 113.35 0.87 . . . . 0.0 113.35 -179.673 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.615 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 11.9 tppt? -101.84 -3.93 27.14 Favored 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 120.942 -0.303 . . . . 0.0 110.287 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 57.4 t80 -46.04 -48.07 16.87 Favored 'General case' 0 N--CA 1.49 1.536 0 C-N-CA 125.564 1.546 . . . . 0.0 114.652 -173.908 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 -81.5 -4.11 55.0 Favored 'General case' 0 N--CA 1.474 0.763 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.623 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 15.0 m-20 -100.34 -14.59 18.32 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 176.923 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.615 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.7 mt -84.75 120.83 26.87 Favored 'General case' 0 N--CA 1.434 -1.239 0 N-CA-C 114.464 1.283 . . . . 0.0 114.464 -174.142 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 44.2 mt-10 -103.6 170.46 7.92 Favored 'General case' 0 C--N 1.305 -1.355 0 N-CA-C 105.76 -1.941 . . . . 0.0 105.76 170.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 79.8 m-85 -121.75 147.83 45.42 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 119.069 -1.053 . . . . 0.0 112.354 -170.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.47 ' CD1' ' HB3' ' A' ' 83' ' ' TYR . 40.0 m-85 -130.19 159.68 36.13 Favored 'General case' 0 C--N 1.297 -1.717 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.791 176.983 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.458 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 0.6 OUTLIER -126.52 138.11 53.45 Favored 'General case' 0 C--N 1.292 -1.914 0 N-CA-C 107.328 -1.36 . . . . 0.0 107.328 176.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.0 p -88.14 166.53 14.33 Favored 'General case' 0 C--N 1.284 -2.257 0 N-CA-C 105.633 -1.988 . . . . 0.0 105.633 169.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 24.4 tptp -60.8 -31.03 70.43 Favored 'General case' 0 C--N 1.314 -0.972 0 CA-C-N 118.118 0.417 . . . . 0.0 111.559 -175.844 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.2 p -88.98 -8.18 54.6 Favored 'General case' 0 CA--C 1.561 1.375 0 N-CA-C 114.502 1.297 . . . . 0.0 114.502 -176.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.635 ' HE3' ' HB3' ' A' ' 11' ' ' ASP . 58.9 mtt -103.5 177.61 4.79 Favored 'General case' 0 N--CA 1.477 0.883 0 N-CA-C 115.509 1.67 . . . . 0.0 115.509 -171.535 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.575 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 58.8 t30 -133.21 150.32 75.03 Favored Pre-proline 0 C--O 1.214 -0.816 0 N-CA-C 106.673 -1.603 . . . . 0.0 106.673 -175.399 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.575 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 19.1 Cg_endo -62.41 -17.77 59.5 Favored 'Trans proline' 0 N--CA 1.488 1.19 0 C-N-CA 122.476 2.118 . . . . 0.0 112.913 -179.43 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 10.3 m-20 -92.96 -10.61 35.78 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.218 179.122 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.427 ' HB1' ' HA ' ' A' ' 9' ' ' SER . . . -154.51 105.67 2.66 Favored 'General case' 0 N--CA 1.432 -1.37 0 CA-C-N 116.946 -0.116 . . . . 0.0 110.691 -175.745 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.59 43.54 3.63 Favored Glycine 0 C--O 1.216 -0.994 0 C-N-CA 119.85 -1.167 . . . . 0.0 112.648 -179.125 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 42.0 tp -88.83 117.75 28.05 Favored 'General case' 0 C--N 1.307 -1.279 0 N-CA-C 109.257 -0.646 . . . . 0.0 109.257 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.3 mp -81.98 128.93 38.28 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.624 0 C-N-CA 123.351 0.66 . . . . 0.0 111.14 -175.347 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.432 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 79.9 m-85 -88.52 142.38 27.75 Favored 'General case' 0 CA--C 1.547 0.853 0 N-CA-C 109.055 -0.72 . . . . 0.0 109.055 174.518 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.565 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 59.1 p -150.44 155.88 40.39 Favored 'General case' 0 C--O 1.205 -1.259 0 O-C-N 121.934 -0.479 . . . . 0.0 111.26 178.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 25.4 p90 -149.66 176.61 10.51 Favored 'General case' 0 C--N 1.319 -0.748 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.089 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -108.58 110.1 21.48 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.643 0.656 . . . . 0.0 111.141 177.275 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 23.8 ttmm -78.54 143.25 36.71 Favored 'General case' 0 C--N 1.313 -1.002 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 174.504 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -67.75 116.32 8.31 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 109.556 -0.535 . . . . 0.0 109.556 177.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.63 -13.36 42.6 Favored Glycine 0 N--CA 1.435 -1.402 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.381 -178.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -82.0 133.27 35.28 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 107.903 -1.147 . . . . 0.0 107.903 177.74 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -91.66 -7.99 48.39 Favored 'General case' 0 C--N 1.299 -1.615 0 CA-C-O 121.022 0.439 . . . . 0.0 111.755 -175.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 64.7 m -139.93 168.85 13.52 Favored Pre-proline 0 C--N 1.303 -1.416 0 N-CA-C 107.222 -1.399 . . . . 0.0 107.222 178.151 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -57.46 133.25 55.7 Favored 'Trans proline' 0 C--N 1.364 1.388 0 C-N-CA 122.1 1.867 . . . . 0.0 112.705 178.365 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 25.5 m -86.46 111.15 20.28 Favored 'General case' 0 N--CA 1.423 -1.808 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 69.3 m-85 -83.01 145.55 29.26 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 121.272 0.558 . . . . 0.0 111.498 -174.884 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.489 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.3 t -119.21 120.83 65.01 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.733 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.166 -174.495 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 79.0 m-85 -139.59 153.95 47.49 Favored 'General case' 0 C--O 1.24 0.562 0 CA-C-O 121.451 0.643 . . . . 0.0 111.191 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.507 HG12 ' H ' ' A' ' 174' ' ' GLY . 95.8 t -89.76 122.16 40.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 N-CA-C 108.247 -1.02 . . . . 0.0 108.247 175.96 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 38.1 ttpt -75.29 -57.87 3.63 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 112.508 0.559 . . . . 0.0 112.508 -173.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.3 m -81.88 -15.0 55.43 Favored 'General case' 0 C--N 1.316 -0.869 0 CA-C-O 121.295 0.569 . . . . 0.0 111.629 -173.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.507 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.63 -14.11 63.96 Favored Glycine 0 C--O 1.22 -0.753 0 CA-C-N 115.636 -0.711 . . . . 0.0 112.641 -176.477 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -98.5 169.3 9.62 Favored 'General case' 0 C--N 1.312 -1.055 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 178.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 63.1 mttm -85.63 100.35 11.9 Favored 'General case' 0 N--CA 1.422 -1.866 0 CA-C-O 121.336 0.589 . . . . 0.0 109.898 179.956 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.417 HG22 ' CE1' ' A' ' 4' ' ' TYR . 21.5 t -81.41 102.32 7.17 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 105.86 -1.904 . . . . 0.0 105.86 176.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.5 110.81 33.57 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.092 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 -177.256 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 21.0 pttm -90.39 106.61 18.61 Favored 'General case' 0 N--CA 1.413 -2.289 0 CA-C-N 114.93 -1.032 . . . . 0.0 108.981 177.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -86.96 102.45 14.39 Favored 'General case' 0 N--CA 1.414 -2.274 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 175.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 80.6 mt -83.82 113.85 21.22 Favored 'General case' 0 N--CA 1.412 -2.361 0 N-CA-C 107.963 -1.125 . . . . 0.0 107.963 177.701 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -59.27 -41.67 89.43 Favored 'General case' 0 C--N 1.316 -0.875 0 O-C-N 124.476 1.11 . . . . 0.0 108.41 178.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 91.4 m-70 -118.32 102.08 8.68 Favored 'General case' 0 N--CA 1.428 -1.545 0 CA-C-N 114.999 -1.0 . . . . 0.0 108.956 178.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -81.49 79.9 7.98 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 174.309 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 5.0 t60 -106.0 117.38 33.89 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 -177.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.8 p80 -80.99 103.99 11.19 Favored 'General case' 0 C--N 1.308 -1.207 0 C-N-CA 119.632 -0.827 . . . . 0.0 110.538 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 7.5 t60 -90.7 88.52 7.13 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 104.262 -2.495 . . . . 0.0 104.262 169.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 53.5 t-80 . . . . . 0 C--N 1.31 -1.119 0 N-CA-C 106.277 -1.749 . . . . 0.0 106.277 -171.162 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.468 ' SD ' ' HB3' ' A' ' 16' ' ' ASP . 53.1 tpp . . . . . 0 C--O 1.235 0.309 0 CA-C-O 121.316 0.579 . . . . 0.0 110.584 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.5 mm -85.42 139.86 16.81 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 106.56 -1.645 . . . . 0.0 106.56 175.262 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.444 HG11 ' CZ ' ' A' ' 180' ' ' PHE . 10.0 p -140.04 150.68 21.67 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.971 0 N-CA-C 108.933 -0.766 . . . . 0.0 108.933 -178.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . 0.433 ' CE1' HG22 ' A' ' 177' ' ' VAL . 34.1 m-85 -110.74 118.73 36.96 Favored 'General case' 0 C--N 1.294 -1.826 0 N-CA-C 109.824 -0.435 . . . . 0.0 109.824 177.815 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -100.67 133.32 45.3 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.774 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.96 148.85 49.54 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.461 174.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 65.8 t -80.67 -26.84 11.25 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.231 0 CA-C-O 120.988 0.423 . . . . 0.0 110.311 -178.679 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 16.6 mm -78.45 -52.08 16.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.838 0 N-CA-C 109.655 -0.498 . . . . 0.0 109.655 -176.187 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.8 p -91.38 -42.97 10.03 Favored 'General case' 0 C--N 1.309 -1.158 0 N-CA-C 112.473 0.546 . . . . 0.0 112.473 -178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 91.08 7.84 65.38 Favored Glycine 0 N--CA 1.439 -1.144 0 N-CA-C 110.779 -0.928 . . . . 0.0 110.779 -173.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 21.8 m-20 -91.61 167.7 12.02 Favored 'General case' 0 C--O 1.24 0.572 0 CA-C-O 121.172 0.51 . . . . 0.0 111.99 -177.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.9 mp0 -80.77 116.08 20.59 Favored 'General case' 0 C--N 1.314 -0.962 0 C-N-CA 124.612 1.165 . . . . 0.0 110.45 -177.333 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.428 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.8 m -98.53 -17.63 6.63 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 179.829 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 11.8 p -172.89 152.53 0.55 Allowed 'Isoleucine or valine' 0 C--O 1.243 0.739 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 52.7 p -133.95 170.85 15.0 Favored 'General case' 0 N--CA 1.443 -0.815 0 C-N-CA 122.354 0.262 . . . . 0.0 110.587 -178.322 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.468 ' HB3' ' SD ' ' A' ' 1' ' ' MET . 12.5 t70 -55.21 -29.59 58.25 Favored 'General case' 0 N--CA 1.49 1.541 0 C-N-CA 125.635 1.574 . . . . 0.0 113.075 179.634 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.09 -6.93 50.52 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.928 -178.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.46 HD13 HG13 ' A' ' 75' ' ' VAL . 86.0 mt -111.35 177.28 4.71 Favored 'General case' 0 N--CA 1.441 -0.9 0 N-CA-C 109.708 -0.479 . . . . 0.0 109.708 -178.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 36' ' ' VAL . 14.6 mmmm -84.46 106.2 15.87 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-O 120.88 0.371 . . . . 0.0 110.885 -178.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 69.9 mt -107.18 108.22 24.68 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.424 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 10.3 p -124.72 149.05 61.19 Favored Pre-proline 0 C--N 1.299 -1.607 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.644 -178.163 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -72.33 158.28 51.85 Favored 'Trans proline' 0 N--CA 1.457 -0.621 0 C-N-CA 121.221 1.281 . . . . 0.0 109.596 173.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.555 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 48.5 t -74.7 107.84 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.074 0 N-CA-C 107.689 -1.226 . . . . 0.0 107.689 177.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 79.8 mtp -101.04 108.13 19.75 Favored 'General case' 0 C--N 1.285 -2.198 0 C-N-CA 120.065 -0.654 . . . . 0.0 110.131 -179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.428 ' OE1' ' HE2' ' A' ' 136' ' ' LYS . 25.8 mt-10 -134.48 104.62 6.18 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.256 -1.016 . . . . 0.0 108.256 176.306 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 105.55 -2.27 39.54 Favored Glycine 0 C--N 1.309 -0.942 0 C-N-CA 121.137 -0.554 . . . . 0.0 111.91 -178.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 117.46 -42.93 1.73 Allowed Glycine 0 N--CA 1.445 -0.716 0 C-N-CA 121.106 -0.569 . . . . 0.0 112.008 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -103.32 177.82 4.73 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 110.05 -0.352 . . . . 0.0 110.05 179.086 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.555 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 9.3 pt-20 -80.81 148.73 29.87 Favored 'General case' 0 N--CA 1.436 -1.125 0 C-N-CA 120.713 -0.395 . . . . 0.0 110.182 178.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 46.8 t -78.37 110.02 12.36 Favored Pre-proline 0 N--CA 1.425 -1.704 0 N-CA-C 103.139 -2.911 . . . . 0.0 103.139 167.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 12.1 Cg_endo -52.77 124.88 16.42 Favored 'Trans proline' 0 C--N 1.357 0.978 0 C-N-CA 123.424 2.749 . . . . 0.0 116.424 -166.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 87.68 5.8 77.72 Favored Glycine 0 C--O 1.246 0.9 0 CA-C-N 113.98 -1.464 . . . . 0.0 114.511 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . . . . . . . . . 38.4 mt -125.13 152.68 44.11 Favored 'General case' 0 C--N 1.302 -1.483 0 CA-C-O 120.9 0.381 . . . . 0.0 111.179 -176.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.424 ' HB2' ' O ' ' A' ' 21' ' ' THR . 8.3 p90 -144.47 148.87 35.09 Favored 'General case' 0 N--CA 1.431 -1.384 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 177.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -120.23 156.42 31.21 Favored 'General case' 0 C--N 1.28 -2.417 0 N-CA-C 106.646 -1.613 . . . . 0.0 106.646 179.764 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.524 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 95.4 t -109.6 113.55 44.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.894 0 N-CA-C 106.237 -1.764 . . . . 0.0 106.237 179.008 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -74.77 150.4 39.38 Favored 'General case' 0 C--N 1.3 -1.574 0 CA-C-N 114.021 -1.445 . . . . 0.0 111.771 -171.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 5.9 m -99.35 135.14 41.19 Favored 'General case' 0 N--CA 1.412 -2.349 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.743 -174.356 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.427 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -147.31 124.6 11.54 Favored 'General case' 0 C--N 1.313 -1.014 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 174.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.47 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 80.4 mtp -88.52 109.31 19.95 Favored 'General case' 0 C--N 1.305 -1.342 0 CA-C-O 121.294 0.569 . . . . 0.0 110.018 -176.336 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.439 ' O ' ' HA ' ' A' ' 71' ' ' LYS . 33.7 m -110.59 157.39 11.37 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 CA-C-N 115.342 -0.845 . . . . 0.0 108.888 -177.31 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.407 ' HA ' ' O ' ' A' ' 70' ' ' GLN . . . -71.07 114.24 8.93 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-O 121.156 0.503 . . . . 0.0 110.319 176.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 58.2 t -70.29 -42.37 78.78 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 CA-C-N 114.497 -1.229 . . . . 0.0 110.322 -179.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -85.02 -78.19 1.16 Allowed Glycine 0 N--CA 1.441 -0.989 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 177.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -160.96 144.2 9.66 Favored Glycine 0 N--CA 1.422 -2.271 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 157.87 -28.45 0.47 Allowed Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.287 -0.959 . . . . 0.0 112.436 -179.655 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -81.74 60.53 4.71 Favored 'General case' 0 N--CA 1.47 0.57 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -179.141 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 68.1 mt -146.2 101.4 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 174.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.1 t70 67.06 117.36 0.03 OUTLIER 'General case' 0 N--CA 1.499 2.021 0 C-N-CA 124.605 1.162 . . . . 0.0 113.423 179.696 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt 72.0 -38.66 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.497 1.91 0 C-N-CA 125.026 1.33 . . . . 0.0 112.899 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -70.18 -9.57 64.02 Favored Glycine 0 CA--C 1.527 0.785 0 CA-C-N 116.421 -0.354 . . . . 0.0 113.839 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.2 m -92.39 -5.38 52.19 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 117.537 0.669 . . . . 0.0 110.89 178.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -83.82 96.0 1.93 Allowed Glycine 0 N--CA 1.433 -1.518 0 N-CA-C 110.29 -1.124 . . . . 0.0 110.29 177.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -81.69 80.09 8.1 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.538 0.685 . . . . 0.0 109.4 -179.871 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.28 23.99 7.49 Favored 'General case' 0 C--N 1.303 -1.436 0 CA-C-N 115.234 -0.894 . . . . 0.0 110.204 -178.065 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 65.4 m-85 -101.89 -62.25 1.28 Allowed 'General case' 0 C--N 1.312 -1.035 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 177.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 131.04 -71.96 0.49 Allowed Glycine 0 N--CA 1.428 -1.898 0 N-CA-C 110.056 -1.217 . . . . 0.0 110.056 -179.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 164.79 96.39 0.11 Allowed Glycine 0 N--CA 1.431 -1.687 0 N-CA-C 109.177 -1.569 . . . . 0.0 109.177 -179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -78.35 94.41 4.85 Favored 'General case' 0 C--N 1.308 -1.226 0 C-N-CA 122.492 0.317 . . . . 0.0 111.59 -175.65 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 140.74 -123.33 2.33 Favored Glycine 0 N--CA 1.435 -1.389 0 C-N-CA 121.045 -0.598 . . . . 0.0 111.854 179.176 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -160.78 -65.34 0.06 Allowed 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 -178.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -86.38 -48.25 8.62 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-O 122.227 1.013 . . . . 0.0 108.304 178.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -102.34 140.18 36.96 Favored 'General case' 0 C--N 1.286 -2.153 0 N-CA-C 103.412 -2.81 . . . . 0.0 103.412 177.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -130.68 28.16 3.79 Favored Glycine 0 C--O 1.247 0.932 0 C-N-CA 119.636 -1.269 . . . . 0.0 114.936 -169.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -155.18 -152.26 0.39 Allowed 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 178.339 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 6.2 p-10 -127.58 171.74 11.37 Favored 'General case' 0 C--O 1.257 1.493 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 175.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -83.2 82.52 8.22 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-O 122.296 1.046 . . . . 0.0 109.916 -179.067 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -156.78 -47.48 0.07 Allowed 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 176.366 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 t -143.79 103.73 4.09 Favored 'General case' 0 N--CA 1.405 -2.719 0 CA-C-N 114.078 -1.419 . . . . 0.0 109.202 176.033 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . 0.407 ' O ' ' HA ' ' A' ' 42' ' ' ALA . 23.1 mm-40 -84.98 112.16 20.34 Favored 'General case' 0 CA--C 1.49 -1.328 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.609 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.47 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 55.6 mttm -97.38 122.31 40.28 Favored 'General case' 0 C--N 1.292 -1.926 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.806 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.64 162.24 36.43 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 177.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.599 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 46.9 t30 -65.42 134.38 53.36 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-O 121.233 0.54 . . . . 0.0 110.746 -177.821 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.1 p30 -53.95 -23.97 14.88 Favored 'General case' 0 N--CA 1.486 1.338 0 C-N-CA 125.348 1.459 . . . . 0.0 112.921 -176.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.47 HG21 ' CG1' ' A' ' 36' ' ' VAL . 43.2 t -92.33 -45.87 14.2 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.091 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.242 -178.709 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.599 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 9.5 p -72.29 -18.99 61.75 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 113.246 0.832 . . . . 0.0 113.246 -174.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -31.6 114.91 0.07 OUTLIER Glycine 0 C--O 1.26 1.779 0 C-N-CA 125.894 1.711 . . . . 0.0 115.475 -179.193 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.441 ' HA ' ' HB2' ' A' ' 82' ' ' ALA . 31.3 Cg_exo -64.5 -8.63 17.69 Favored 'Trans proline' 0 C--N 1.362 1.254 0 C-N-CA 124.083 3.189 . . . . 0.0 114.228 -179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -77.75 -21.28 52.04 Favored 'General case' 0 N--CA 1.437 -1.094 0 C-N-CA 121.165 -0.214 . . . . 0.0 111.04 178.86 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.5 m -122.45 -70.03 0.8 Allowed 'General case' 0 N--CA 1.442 -0.832 0 C-N-CA 120.063 -0.655 . . . . 0.0 112.254 -177.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 94.5 m-85 -91.58 -45.0 8.73 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 112.003 0.372 . . . . 0.0 112.003 -174.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.441 ' HB2' ' HA ' ' A' ' 78' ' ' PRO . . . 60.35 88.39 0.08 Allowed 'General case' 0 N--CA 1.471 0.59 0 O-C-N 124.226 0.954 . . . . 0.0 112.469 179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 85.8 m-85 -95.08 114.78 26.63 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.697 -178.994 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 27.5 m -89.23 126.41 35.48 Favored 'General case' 0 C--N 1.302 -1.475 0 C-N-CA 123.652 0.781 . . . . 0.0 109.572 179.31 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.28 124.74 30.88 Favored 'General case' 0 C--O 1.238 0.497 0 CA-C-O 121.04 0.447 . . . . 0.0 112.183 -178.219 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.3 mmt -111.41 128.1 25.88 Favored Pre-proline 0 C--N 1.296 -1.746 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 175.417 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.9 Cg_endo -73.16 166.19 30.65 Favored 'Trans proline' 0 C--O 1.251 1.151 0 C-N-CA 123.14 2.56 . . . . 0.0 112.107 178.145 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 68.3 m-85 -53.66 124.24 14.53 Favored 'General case' 0 CA--C 1.515 -0.402 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.623 176.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.7 p -93.55 -34.21 13.44 Favored 'General case' 0 C--N 1.298 -1.666 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 171.825 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 9.5 m 60.76 15.22 5.69 Favored 'General case' 0 C--N 1.361 1.108 0 C-N-CA 125.708 1.603 . . . . 0.0 111.611 177.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 1.6 tpmt? -80.9 152.49 28.07 Favored 'General case' 0 N--CA 1.437 -1.113 0 CA-C-N 115.153 -0.931 . . . . 0.0 109.291 -174.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.06 -28.53 63.98 Favored Glycine 0 C--O 1.214 -1.129 0 O-C-N 123.445 0.466 . . . . 0.0 113.366 -179.18 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -66.24 -30.77 71.28 Favored 'General case' 0 C--N 1.32 -0.675 0 C-N-CA 123.713 0.805 . . . . 0.0 111.806 177.606 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 62.7 t80 -72.3 -35.86 68.77 Favored 'General case' 0 C--N 1.305 -1.342 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 175.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.2 mmmm -73.0 -29.11 62.78 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.103 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 21.3 m -60.69 -44.79 96.1 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 171.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 93.0 t90 -61.25 -47.18 87.24 Favored 'General case' 0 C--O 1.218 -0.58 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.564 178.512 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 89.6 t -54.87 -46.43 75.57 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.042 0 O-C-N 123.485 0.491 . . . . 0.0 110.622 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.423 ' O ' ' HG2' ' A' ' 103' ' ' ARG . 25.4 ttpp -57.33 -55.58 32.88 Favored 'General case' 0 N--CA 1.447 -0.623 0 CA-C-N 115.567 -0.742 . . . . 0.0 111.175 177.76 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -67.94 -29.57 68.67 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 112.48 0.548 . . . . 0.0 112.48 -176.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 81.3 t80 -61.01 -52.67 64.01 Favored 'General case' 0 C--N 1.321 -0.652 0 N-CA-C 109.299 -0.63 . . . . 0.0 109.299 174.684 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 84.7 t -62.68 -39.41 84.63 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.499 0 CA-C-N 116.013 -0.539 . . . . 0.0 110.402 178.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.423 ' HG2' ' O ' ' A' ' 99' ' ' LYS . 19.4 mmt180 -60.46 -54.16 48.84 Favored 'General case' 0 N--CA 1.468 0.436 0 C-N-CA 122.7 0.4 . . . . 0.0 111.514 178.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.5 m-80 -57.08 -42.98 81.69 Favored 'General case' 0 N--CA 1.479 1.001 0 O-C-N 123.17 0.294 . . . . 0.0 111.768 -179.681 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 94.6 t -63.85 -50.22 78.51 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 O-C-N 123.459 0.475 . . . . 0.0 110.076 177.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.2 ttt180 -56.06 -45.67 79.18 Favored 'General case' 0 C--O 1.252 1.186 0 C-N-CA 124.078 0.951 . . . . 0.0 111.732 -179.737 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.76 -36.91 81.38 Favored 'General case' 0 CA--C 1.516 -0.342 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.771 177.486 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -62.84 -41.79 99.48 Favored 'General case' 0 C--O 1.218 -0.6 0 O-C-N 123.293 0.371 . . . . 0.0 110.62 177.661 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.454 ' HG ' ' CZ ' ' A' ' 122' ' ' PHE . 9.4 mp -50.22 -50.39 49.79 Favored 'General case' 0 N--CA 1.479 1.022 0 CA-C-O 121.189 0.519 . . . . 0.0 112.215 175.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 12.3 ptmm? -84.37 -32.43 24.21 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 113.873 1.064 . . . . 0.0 113.873 -176.254 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -88.18 -6.05 75.48 Favored Glycine 0 CA--C 1.537 1.459 0 N-CA-C 116.337 1.295 . . . . 0.0 116.337 -176.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -77.26 -20.64 54.87 Favored 'General case' 0 C--O 1.244 0.805 0 N-CA-C 114.592 1.33 . . . . 0.0 114.592 -175.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.25 38.2 6.83 Favored Glycine 0 N--CA 1.448 -0.549 0 C-N-CA 121.258 -0.496 . . . . 0.0 112.939 178.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.414 HG12 ' HB2' ' A' ' 118' ' ' ASP . 21.9 t -83.15 151.91 3.96 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.988 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 179.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.457 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -63.63 154.46 32.79 Favored 'General case' 0 C--N 1.327 -0.385 0 C-N-CA 122.73 0.412 . . . . 0.0 112.088 -178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.1 t -58.12 -45.89 88.42 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.024 0 C-N-CA 124.035 0.934 . . . . 0.0 113.024 -172.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 40.5 mt-10 -62.34 -42.47 99.41 Favored 'General case' 0 N--CA 1.475 0.819 0 CA-C-O 121.451 0.643 . . . . 0.0 110.322 179.457 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.432 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 13.9 m-20 -65.19 -37.49 87.49 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.822 -1.081 . . . . 0.0 110.273 179.038 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.457 HG12 ' O ' ' A' ' 115' ' ' ALA . 32.2 mm -58.81 -39.65 77.69 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.462 0 C-N-CA 123.434 0.694 . . . . 0.0 110.879 176.396 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.489 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 75.2 mmtt -58.62 -51.35 70.27 Favored 'General case' 0 CA--C 1.513 -0.444 0 CA-C-O 120.642 0.258 . . . . 0.0 110.55 178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.3 mmmt -65.22 -37.73 88.19 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.509 -0.769 . . . . 0.0 110.842 178.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.454 ' CZ ' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -67.84 -34.35 76.54 Favored 'General case' 0 C--N 1.318 -0.776 0 C-N-CA 124.053 0.941 . . . . 0.0 108.893 -175.608 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 87.8 mtp -78.65 -18.06 55.02 Favored 'General case' 0 C--O 1.222 -0.39 0 CA-C-N 115.692 -0.686 . . . . 0.0 111.593 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.489 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 8.7 mm-40 -76.94 -33.08 57.73 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 174.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.0 mt-10 -75.12 -31.21 61.05 Favored 'General case' 0 C--N 1.312 -1.044 0 CA-C-N 114.375 -1.284 . . . . 0.0 111.033 178.138 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.433 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -50.21 -57.22 13.48 Favored Pre-proline 0 CA--C 1.566 1.584 0 N-CA-C 114.856 1.428 . . . . 0.0 114.856 -178.293 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -68.4 -23.29 38.14 Favored 'Trans proline' 0 C--N 1.384 2.406 0 CA-C-N 120.663 1.272 . . . . 0.0 111.458 179.108 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 26.5 m -70.69 -36.01 73.08 Favored 'General case' 0 N--CA 1.437 -1.085 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.337 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.455 ' O ' ' HG ' ' A' ' 133' ' ' LEU . 18.2 m-85 -59.06 -54.97 41.07 Favored 'General case' 0 C--N 1.354 0.792 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 176.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 29.8 t -57.63 -49.68 79.81 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.724 -179.238 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -56.34 -49.93 72.95 Favored 'General case' 0 CA--C 1.537 0.444 0 C-N-CA 123.708 0.803 . . . . 0.0 112.221 -177.723 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.631 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 72.1 t90 -68.35 -33.37 74.16 Favored 'General case' 0 CA--C 1.546 0.822 0 N-CA-C 111.987 0.366 . . . . 0.0 111.987 -177.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.455 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.4 mt -65.83 -38.85 90.0 Favored 'General case' 0 N--CA 1.47 0.572 0 CA-C-O 121.263 0.554 . . . . 0.0 109.536 176.496 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.9 t -69.47 -38.13 76.35 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.319 177.239 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 48.7 m-20 -62.87 -36.06 82.03 Favored 'General case' 0 N--CA 1.474 0.738 0 CA-C-O 120.798 0.333 . . . . 0.0 111.752 178.481 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.696 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.8 mptp? -96.41 3.07 53.09 Favored 'General case' 0 C--O 1.197 -1.662 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 179.005 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 63.2 t80 -52.13 -26.11 10.5 Favored 'General case' 0 N--CA 1.502 2.157 0 C-N-CA 124.214 1.006 . . . . 0.0 113.443 -177.929 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 15.1 m-20 -83.26 -29.2 28.6 Favored 'General case' 0 N--CA 1.473 0.722 0 CA-C-O 121.829 0.823 . . . . 0.0 110.476 178.427 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -93.4 -7.34 44.9 Favored 'General case' 0 C--N 1.302 -1.476 0 CA-C-N 115.573 -0.739 . . . . 0.0 111.115 -173.456 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.696 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.0 mt -83.65 134.22 34.79 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.54 0.941 . . . . 0.0 113.54 -174.05 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.5 mt-10 -123.08 153.62 39.67 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 105.464 -2.05 . . . . 0.0 105.464 166.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 27.1 m-85 -106.63 120.87 43.11 Favored 'General case' 0 C--N 1.294 -1.807 0 C-N-CA 120.026 -0.67 . . . . 0.0 110.931 -168.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 37.5 m-85 -110.23 146.31 35.83 Favored 'General case' 0 C--N 1.286 -2.192 0 CA-C-O 121.461 0.648 . . . . 0.0 111.182 -176.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.422 ' HE2' ' HB3' ' A' ' 150' ' ' PRO . 56.6 mtt -130.41 126.71 37.68 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 106.555 -1.646 . . . . 0.0 106.555 177.252 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . 0.412 ' HA ' ' O ' ' A' ' 82' ' ' ALA . 9.7 p -79.98 152.94 29.21 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 174.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 12.3 tptt -54.91 -35.77 64.51 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -172.136 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 40.8 p -88.76 -3.61 58.72 Favored 'General case' 0 C--N 1.294 -1.817 0 N-CA-C 113.44 0.904 . . . . 0.0 113.44 -177.052 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 90.2 mtp -107.75 174.19 5.99 Favored 'General case' 0 C--O 1.246 0.909 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -174.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 63.3 t30 -110.29 140.73 22.73 Favored Pre-proline 0 C--N 1.319 -0.719 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.22 -172.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.422 ' HB3' ' HE2' ' A' ' 144' ' ' MET . 11.5 Cg_endo -57.48 -18.57 32.44 Favored 'Trans proline' 0 CA--C 1.548 1.184 0 C-N-CA 123.592 2.862 . . . . 0.0 113.49 173.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 14.5 m-20 -99.56 -25.26 14.48 Favored 'General case' 0 CA--C 1.485 -1.523 0 CA-C-O 121.346 0.593 . . . . 0.0 110.221 -178.488 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -128.28 100.2 5.73 Favored 'General case' 0 N--CA 1.412 -2.358 0 CA-C-N 115.628 -0.714 . . . . 0.0 109.429 -173.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 92.58 44.0 4.09 Favored Glycine 0 N--CA 1.416 -2.7 0 C-N-CA 119.069 -1.539 . . . . 0.0 112.376 -177.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 63.3 tp -83.01 113.01 20.29 Favored 'General case' 0 N--CA 1.439 -0.993 0 N-CA-C 107.057 -1.46 . . . . 0.0 107.057 175.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.7 mp -81.06 127.52 39.48 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.849 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.633 -172.855 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.47 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 69.3 m-85 -87.4 140.87 29.1 Favored 'General case' 0 C--N 1.306 -1.295 0 N-CA-C 107.333 -1.358 . . . . 0.0 107.333 171.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.443 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 25.5 m -145.44 152.13 39.32 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.591 -0.693 . . . . 0.0 109.387 175.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.506 ' CE2' ' HB3' ' A' ' 160' ' ' LYS . 3.9 p90 -138.87 164.54 29.39 Favored 'General case' 0 C--N 1.307 -1.257 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.263 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 44.4 m-85 -113.78 102.22 10.03 Favored 'General case' 0 C--N 1.298 -1.664 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.54 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.506 ' HB3' ' CE2' ' A' ' 158' ' ' TYR . 23.8 pttm -92.66 179.01 5.62 Favored 'General case' 0 C--N 1.309 -1.19 0 C-N-CA 120.445 -0.502 . . . . 0.0 110.908 178.741 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.96 121.93 14.77 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-O 121.637 0.732 . . . . 0.0 112.19 177.661 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 102.36 -20.63 44.1 Favored Glycine 0 N--CA 1.442 -0.916 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.641 -178.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.01 123.96 37.71 Favored 'General case' 0 N--CA 1.431 -1.413 0 O-C-N 122.435 -0.45 . . . . 0.0 110.231 -177.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 35.3 m-70 -101.15 -11.49 19.53 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.93 0.871 . . . . 0.0 108.827 177.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.447 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 71.6 m -121.43 160.74 44.69 Favored Pre-proline 0 N--CA 1.429 -1.506 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 -179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -58.72 130.4 36.81 Favored 'Trans proline' 0 C--O 1.249 1.048 0 C-N-CA 122.702 2.268 . . . . 0.0 113.875 -179.612 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 99.0 m -93.78 121.83 35.62 Favored 'General case' 0 N--CA 1.422 -1.839 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 170.222 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.524 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 83.6 m-85 -82.49 139.27 34.02 Favored 'General case' 0 C--N 1.296 -1.723 0 CA-C-O 121.371 0.605 . . . . 0.0 112.098 -171.486 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.631 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 60.3 t -108.19 112.39 40.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.629 0 C-N-CA 124.93 1.292 . . . . 0.0 109.514 -175.202 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.428 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 55.0 m-85 -135.97 161.6 35.21 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.476 0.655 . . . . 0.0 109.732 178.632 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.496 HG12 ' H ' ' A' ' 174' ' ' GLY . 29.2 t -99.96 118.15 46.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 N-CA-C 108.063 -1.088 . . . . 0.0 108.063 179.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.2 ttpt -66.58 -56.25 11.65 Favored 'General case' 0 N--CA 1.474 0.754 0 N-CA-C 112.189 0.44 . . . . 0.0 112.189 -173.414 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.8 m -83.03 -14.45 53.9 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.23 0.538 . . . . 0.0 111.08 -177.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.496 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -87.05 -19.97 54.39 Favored Glycine 0 C--O 1.21 -1.37 0 CA-C-N 115.661 -0.699 . . . . 0.0 112.315 -176.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 4.8 m-30 -98.02 170.91 8.6 Favored 'General case' 0 C--N 1.313 -0.997 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.0 mtmt -97.28 110.28 22.87 Favored 'General case' 0 N--CA 1.424 -1.742 0 CA-C-O 121.229 0.537 . . . . 0.0 110.423 -176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . 0.433 HG22 ' CE1' ' A' ' 4' ' ' TYR . 25.0 t -82.9 105.64 12.91 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.95 0 CA-C-N 114.969 -1.014 . . . . 0.0 108.56 -178.342 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 42.6 t -113.99 147.47 17.49 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.817 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -175.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.2 pttm -112.89 118.83 35.98 Favored 'General case' 0 C--N 1.289 -2.027 0 N-CA-C 108.941 -0.762 . . . . 0.0 108.941 175.784 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . 0.444 ' CZ ' HG11 ' A' ' 3' ' ' VAL . 13.9 m-85 -73.36 103.07 3.91 Favored 'General case' 0 CA--C 1.511 -0.548 0 CA-C-O 121.061 0.458 . . . . 0.0 110.329 -179.387 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 1.9 tm? -122.13 -47.23 2.16 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.008 -1.478 . . . . 0.0 107.008 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -80.46 -40.25 26.62 Favored 'General case' 0 C--N 1.296 -1.732 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.187 176.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 35.3 m80 -80.17 118.48 21.9 Favored 'General case' 0 CA--C 1.505 -0.781 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.146 176.765 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 90.3 m-70 -115.48 130.49 56.9 Favored 'General case' 0 CA--C 1.493 -1.212 0 CA-C-N 115.905 -0.589 . . . . 0.0 109.898 179.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 19.3 m-70 -97.41 158.43 15.48 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.56 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 64.2 t60 -74.58 112.55 10.88 Favored 'General case' 0 C--N 1.309 -1.183 0 CA-C-O 121.24 0.543 . . . . 0.0 110.259 -179.123 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 9.3 t-160 -88.48 120.94 30.33 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 -178.942 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 m-70 . . . . . 0 N--CA 1.485 1.323 0 C-N-CA 124.718 1.207 . . . . 0.0 110.246 -175.459 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.5 ttt . . . . . 0 N--CA 1.449 -0.476 0 N-CA-C 109.434 -0.58 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 30.9 mm -87.54 141.48 14.27 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.885 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.493 HG11 ' CE2' ' A' ' 180' ' ' PHE . 10.1 p -140.45 145.11 26.34 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-O 121.098 0.475 . . . . 0.0 109.914 178.669 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.4 m-85 -102.91 113.97 27.85 Favored 'General case' 0 N--CA 1.43 -1.47 0 N-CA-C 109.46 -0.57 . . . . 0.0 109.46 178.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 25.9 mmmt -103.56 120.7 41.4 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-N 114.914 -1.039 . . . . 0.0 108.411 -178.633 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.7 t0 -63.14 148.59 47.53 Favored 'General case' 0 C--N 1.311 -1.082 0 O-C-N 123.327 0.392 . . . . 0.0 110.955 179.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 21.6 t -85.76 -31.22 6.55 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 N-CA-C 109.625 -0.509 . . . . 0.0 109.625 -178.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.412 ' CG2' ' HA ' ' A' ' 152' ' ' ALA . 13.4 mm -78.08 -52.28 16.23 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.633 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.709 -173.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 63.8 p -87.46 -42.24 12.94 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-O 121.209 0.528 . . . . 0.0 110.604 178.106 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 102.95 0.45 48.5 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.992 -0.623 . . . . 0.0 113.486 179.188 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -110.89 176.57 4.97 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 113.397 0.888 . . . . 0.0 113.397 -177.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mp0 -63.44 130.65 45.29 Favored 'General case' 0 C--N 1.315 -0.892 0 C-N-CA 125.527 1.531 . . . . 0.0 112.482 -177.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 34.4 m -103.98 -20.0 5.99 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.094 174.04 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.3 p -175.94 159.48 0.25 Allowed 'Isoleucine or valine' 0 C--O 1.246 0.905 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 -179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 13.2 p -135.58 161.89 34.23 Favored 'General case' 0 N--CA 1.431 -1.38 0 CA-C-N 117.751 0.25 . . . . 0.0 111.254 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -44.43 -46.5 9.6 Favored 'General case' 0 N--CA 1.496 1.833 0 C-N-CA 127.449 2.3 . . . . 0.0 113.747 -176.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -71.25 -5.98 36.21 Favored 'General case' 0 N--CA 1.471 0.576 0 N-CA-C 113.307 0.854 . . . . 0.0 113.307 -176.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.441 ' HB3' HG22 ' A' ' 75' ' ' VAL . 91.2 mt -99.35 -177.84 3.72 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 23.1 tptm -82.43 105.38 13.44 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-O 121.058 0.456 . . . . 0.0 110.1 -177.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.1 mt -113.69 113.34 43.63 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.153 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 176.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.5 p -127.16 159.77 63.3 Favored Pre-proline 0 C--N 1.307 -1.258 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.699 -177.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 78.9 Cg_endo -79.57 165.5 22.75 Favored 'Trans proline' 0 C--O 1.246 0.876 0 C-N-CA 121.94 1.76 . . . . 0.0 111.085 174.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.441 HG22 ' HB2' ' A' ' 35' ' ' GLU . 63.3 t -90.04 120.92 39.65 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.132 0 N-CA-C 108.342 -0.985 . . . . 0.0 108.342 175.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.488 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 64.9 mtt -122.13 109.06 14.06 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-O 121.252 0.549 . . . . 0.0 111.01 174.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -106.23 104.59 14.33 Favored 'General case' 0 C--N 1.311 -1.091 0 N-CA-C 107.922 -1.14 . . . . 0.0 107.922 178.165 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.55 -4.86 80.5 Favored Glycine 0 C--N 1.311 -0.832 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.982 179.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.31 -12.52 11.25 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.733 -0.746 . . . . 0.0 113.233 179.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 24' ' ' MET . 12.7 pt-20 -99.8 161.54 13.55 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 177.172 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.44 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 13.6 pt-20 -87.27 153.9 21.12 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 177.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 97.3 t -101.51 106.91 48.78 Favored Pre-proline 0 C--N 1.294 -1.838 0 N-CA-C 107.253 -1.388 . . . . 0.0 107.253 173.566 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -60.48 125.59 17.78 Favored 'Trans proline' 0 N--CA 1.456 -0.713 0 C-N-CA 122.684 2.256 . . . . 0.0 114.462 -173.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.409 ' HA2' ' OE1' ' A' ' 125' ' ' GLU . . . 103.29 -13.73 54.99 Favored Glycine 0 N--CA 1.431 -1.649 0 CA-C-N 114.62 -1.173 . . . . 0.0 114.179 175.892 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.515 HD23 ' HA ' ' A' ' 171' ' ' VAL . 74.9 mt -121.95 158.13 29.75 Favored 'General case' 0 C--N 1.296 -1.727 0 O-C-N 122.553 -0.38 . . . . 0.0 111.112 -173.867 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 13.1 p90 -140.26 151.69 45.33 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 107.377 -1.342 . . . . 0.0 107.377 175.428 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.441 ' HB2' HG22 ' A' ' 23' ' ' VAL . 37.7 tt0 -113.01 149.65 33.04 Favored 'General case' 0 C--N 1.273 -2.753 0 N-CA-C 107.656 -1.238 . . . . 0.0 107.656 -176.725 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.536 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 40.0 t -109.44 113.21 43.54 Favored 'Isoleucine or valine' 0 N--CA 1.39 -3.433 0 N-CA-C 106.043 -1.836 . . . . 0.0 106.043 174.5 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -73.47 140.16 46.26 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.606 -1.634 . . . . 0.0 108.782 -178.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.449 ' HA ' ' OD1' ' A' ' 73' ' ' ASN . 2.9 p -98.0 133.82 41.95 Favored 'General case' 0 N--CA 1.395 -3.175 0 CA-C-O 121.412 0.625 . . . . 0.0 110.805 -174.338 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -130.73 125.13 33.08 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 106.952 -1.499 . . . . 0.0 106.952 179.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.603 ' HG2' ' SG ' ' A' ' 165' ' ' CYS . 80.2 mtp -85.64 109.4 18.54 Favored 'General case' 0 C--N 1.299 -1.593 0 O-C-N 123.786 0.679 . . . . 0.0 111.466 -175.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.2 m -110.64 145.12 17.42 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.77 125.48 34.9 Favored 'General case' 0 C--N 1.303 -1.435 0 CA-C-O 121.594 0.711 . . . . 0.0 111.627 -177.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.5 t -96.96 98.41 7.49 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.683 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 177.578 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -73.77 130.03 12.59 Favored Glycine 0 N--CA 1.438 -1.214 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 178.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 71.04 -146.05 40.65 Favored Glycine 0 N--CA 1.442 -0.933 0 N-CA-C 110.744 -0.942 . . . . 0.0 110.744 -176.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.63 -53.53 4.83 Favored Glycine 0 C--N 1.316 -0.557 0 CA-C-N 117.065 0.432 . . . . 0.0 113.196 176.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 15.2 m-20 58.14 71.41 0.58 Allowed 'General case' 0 CA--C 1.497 -1.075 0 C-N-CA 124.395 1.078 . . . . 0.0 111.953 -176.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -108.61 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.232 -178.525 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 29.4 t70 63.13 133.71 0.01 OUTLIER 'General case' 0 C--O 1.251 1.154 0 C-N-CA 124.834 1.254 . . . . 0.0 111.671 -174.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 38.7 mm -80.57 75.24 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.313 -0.999 0 CA-C-O 122.155 0.979 . . . . 0.0 109.898 -179.358 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -158.55 20.12 0.32 Allowed Glycine 0 C--N 1.3 -1.437 0 N-CA-C 109.39 -1.484 . . . . 0.0 109.39 175.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 81.3 m -87.11 112.66 22.14 Favored 'General case' 0 N--CA 1.439 -0.998 0 CA-C-N 114.936 -0.632 . . . . 0.0 109.59 -178.967 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 130.13 -63.74 0.62 Allowed Glycine 0 N--CA 1.433 -1.532 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 178.624 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 43.4 m-80 -92.76 89.25 6.55 Favored 'General case' 0 C--N 1.305 -1.347 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -90.85 109.86 21.08 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 178.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -74.74 -45.91 40.93 Favored 'General case' 0 C--N 1.303 -1.423 0 CA-C-N 115.704 -0.68 . . . . 0.0 109.606 -178.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.52 88.76 1.34 Allowed Glycine 0 N--CA 1.432 -1.576 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.812 179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -83.13 154.25 31.6 Favored Glycine 0 N--CA 1.436 -1.364 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 178.235 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -76.19 127.76 33.56 Favored 'General case' 0 C--N 1.311 -1.089 0 N-CA-C 109.932 -0.396 . . . . 0.0 109.932 -179.289 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.98 -71.74 2.35 Favored Glycine 0 C--N 1.305 -1.183 0 N-CA-C 111.763 -0.535 . . . . 0.0 111.763 -179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 27.9 t70 -149.47 137.59 20.57 Favored 'General case' 0 C--N 1.312 -1.062 0 C-N-CA 122.707 0.403 . . . . 0.0 110.173 -177.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.6 m-20 -81.68 77.73 8.49 Favored 'General case' 0 CA--C 1.502 -0.887 0 C-N-CA 123.174 0.59 . . . . 0.0 109.618 175.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -33.27 107.17 0.04 OUTLIER 'General case' 0 C--O 1.25 1.127 0 C-N-CA 125.32 1.448 . . . . 0.0 114.091 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -120.54 -98.22 1.65 Allowed Glycine 0 N--CA 1.432 -1.629 0 CA-C-N 114.56 -1.2 . . . . 0.0 110.678 179.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -163.48 177.91 8.47 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.164 0.507 . . . . 0.0 111.319 179.942 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -139.75 156.03 47.0 Favored 'General case' 0 C--N 1.311 -1.095 0 N-CA-C 105.408 -2.071 . . . . 0.0 105.408 177.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 28.9 t70 76.45 -26.37 0.19 Allowed 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 124.667 1.187 . . . . 0.0 112.829 178.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 64.47 85.49 0.14 Allowed 'General case' 0 CA--C 1.515 -0.37 0 C-N-CA 124.938 1.295 . . . . 0.0 110.668 179.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . 0.452 ' O ' ' HG3' ' A' ' 71' ' ' LYS . 14.2 t -120.3 23.81 10.72 Favored 'General case' 0 C--N 1.297 -1.706 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.681 -175.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 37.5 mt-30 -45.4 117.29 1.37 Allowed 'General case' 0 N--CA 1.481 1.1 0 C-N-CA 126.432 1.893 . . . . 0.0 111.519 -178.086 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.452 ' HG3' ' O ' ' A' ' 69' ' ' THR . 62.7 mttp -112.52 120.99 43.52 Favored 'General case' 0 C--N 1.294 -1.839 0 C-N-CA 119.652 -0.819 . . . . 0.0 109.901 177.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.4 165.72 24.52 Favored 'General case' 0 C--N 1.288 -2.099 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 -175.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.491 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 32.9 t30 -66.44 133.84 51.25 Favored 'General case' 0 C--N 1.293 -1.88 0 C-N-CA 122.813 0.445 . . . . 0.0 109.817 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -47.98 -24.5 1.07 Allowed 'General case' 0 N--CA 1.496 1.858 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 -179.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.467 HG21 ' CG1' ' A' ' 36' ' ' VAL . 84.9 t -90.57 -51.06 12.38 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.902 0 CA-C-O 120.775 0.321 . . . . 0.0 111.397 -177.704 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.498 ' HB3' ' CZ ' ' A' ' 168' ' ' PHE . 3.3 p -77.34 -19.34 56.45 Favored 'General case' 0 C--O 1.252 1.232 0 N-CA-C 112.816 0.673 . . . . 0.0 112.816 -177.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.447 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -34.72 118.71 0.28 Allowed Glycine 0 C--O 1.252 1.257 0 O-C-N 125.813 1.946 . . . . 0.0 113.323 178.301 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.447 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 76.4 Cg_exo -56.54 -14.92 14.12 Favored 'Trans proline' 0 C--N 1.352 0.718 0 C-N-CA 124.335 3.357 . . . . 0.0 114.131 -177.763 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.1 m -59.99 -35.47 75.1 Favored 'General case' 0 N--CA 1.432 -1.353 0 C-N-CA 123.685 0.794 . . . . 0.0 110.352 175.135 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 39.3 m -118.88 -65.55 1.16 Allowed 'General case' 0 N--CA 1.437 -1.105 0 N-CA-C 112.618 0.599 . . . . 0.0 112.618 -176.797 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 25.0 m-85 -91.87 -53.11 4.41 Favored 'General case' 0 C--N 1.327 -0.403 0 N-CA-C 114.672 1.36 . . . . 0.0 114.672 -173.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.21 103.79 0.05 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 121.946 0.879 . . . . 0.0 111.97 -178.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.45 ' CE2' ' HA ' ' A' ' 76' ' ' SER . 37.1 m-85 -106.08 147.57 28.78 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.608 0.718 . . . . 0.0 112.566 -178.691 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 89.4 m -94.59 128.72 41.4 Favored 'General case' 0 C--N 1.298 -1.641 0 CA-C-N 114.361 -1.291 . . . . 0.0 107.702 176.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -94.48 131.42 40.21 Favored 'General case' 0 C--N 1.314 -0.947 0 O-C-N 123.452 0.47 . . . . 0.0 110.95 -178.08 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.2 mmt -127.03 122.18 23.1 Favored Pre-proline 0 C--N 1.303 -1.417 0 C-N-CA 124.103 0.961 . . . . 0.0 108.514 175.378 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -64.25 165.9 18.44 Favored 'Trans proline' 0 C--O 1.251 1.14 0 C-N-CA 122.684 2.256 . . . . 0.0 112.403 177.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 76.6 m-85 -45.82 115.97 1.09 Allowed 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 125.049 1.339 . . . . 0.0 110.397 177.75 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.8 p -78.98 -49.49 12.66 Favored 'General case' 0 N--CA 1.435 -1.194 0 O-C-N 123.191 0.307 . . . . 0.0 110.624 -178.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.9 m 61.56 18.22 9.28 Favored 'General case' 0 CA--C 1.551 0.998 0 C-N-CA 124.954 1.302 . . . . 0.0 112.926 175.435 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 83.7 tttt -94.52 152.06 18.86 Favored 'General case' 0 CA--C 1.545 0.788 0 C-N-CA 123.147 0.579 . . . . 0.0 109.522 -176.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -62.52 -27.93 70.44 Favored Glycine 0 N--CA 1.478 1.472 0 N-CA-C 111.858 -0.497 . . . . 0.0 111.858 179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 33.0 tt0 -53.05 -35.3 59.36 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 126.138 1.775 . . . . 0.0 111.096 174.783 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.479 ' O ' HG23 ' A' ' 98' ' ' VAL . 94.1 t80 -69.69 -36.59 76.1 Favored 'General case' 0 N--CA 1.438 -1.029 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.329 -179.839 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 35.3 mmtp -68.46 -38.14 80.8 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.726 -0.472 . . . . 0.0 109.726 179.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 15.0 m -63.04 -40.37 97.52 Favored 'General case' 0 N--CA 1.442 -0.859 0 CA-C-N 115.377 -0.828 . . . . 0.0 109.606 176.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.635 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 79.3 t90 -62.61 -42.83 99.81 Favored 'General case' 0 C--O 1.221 -0.409 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.599 176.487 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.479 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.0 t -57.28 -39.06 65.36 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.632 0 C-N-CA 122.686 0.395 . . . . 0.0 110.868 179.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 53.2 mtpt -66.62 -37.76 85.52 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.642 -0.254 . . . . 0.0 111.408 179.981 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -72.25 -39.09 68.68 Favored 'General case' 0 N--CA 1.476 0.825 0 CA-C-O 120.808 0.337 . . . . 0.0 110.669 175.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 64.5 t80 -59.1 -55.41 35.34 Favored 'General case' 0 C--N 1.317 -0.827 0 C-N-CA 123.732 0.813 . . . . 0.0 109.844 179.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.485 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 98.4 t -61.34 -37.31 77.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.496 0 CA-C-N 115.728 -0.669 . . . . 0.0 110.843 179.482 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.4 ttm180 -55.03 -57.69 10.69 Favored 'General case' 0 N--CA 1.469 0.521 0 C-N-CA 122.802 0.441 . . . . 0.0 110.817 176.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.2 m-80 -62.7 -35.29 79.25 Favored 'General case' 0 N--CA 1.474 0.768 0 O-C-N 123.396 0.435 . . . . 0.0 111.627 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 48.1 t -61.04 -44.71 98.81 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.773 0 O-C-N 123.784 0.678 . . . . 0.0 110.33 175.046 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . 0.485 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 71.7 mtp180 -68.86 -26.38 65.11 Favored 'General case' 0 CA--C 1.54 0.581 0 O-C-N 122.084 -0.385 . . . . 0.0 111.796 -179.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -68.78 -35.44 77.06 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 120.26 -0.576 . . . . 0.0 110.417 171.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.86 -38.85 89.91 Favored 'General case' 0 C--N 1.331 -0.236 0 N-CA-C 110.008 -0.367 . . . . 0.0 110.008 176.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.513 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.7 mp -55.06 -57.66 10.82 Favored 'General case' 0 N--CA 1.474 0.774 0 C-N-CA 123.647 0.779 . . . . 0.0 112.147 176.099 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -76.55 -25.25 53.87 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 113.096 0.776 . . . . 0.0 113.096 -177.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.42 -0.8 84.3 Favored Glycine 0 C--N 1.31 -0.912 0 N-CA-C 114.431 0.532 . . . . 0.0 114.431 -178.716 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 65.9 p -70.71 -22.69 62.42 Favored 'General case' 0 C--N 1.316 -0.855 0 N-CA-C 113.596 0.962 . . . . 0.0 113.596 -172.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.71 20.01 78.55 Favored Glycine 0 CA--C 1.525 0.67 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.986 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 43.6 t -86.09 155.01 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.192 0 C-N-CA 123.271 0.628 . . . . 0.0 109.352 -179.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.75 150.93 2.62 Favored 'General case' 0 N--CA 1.477 0.883 0 C-N-CA 124.833 1.253 . . . . 0.0 112.948 -179.298 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 42.9 t -55.9 -47.48 79.79 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.363 0 C-N-CA 124.253 1.021 . . . . 0.0 111.817 -174.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 24.2 mp0 -62.37 -37.89 87.47 Favored 'General case' 0 C--N 1.311 -1.077 0 C-N-CA 124.094 0.958 . . . . 0.0 110.648 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.471 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 3.9 m-20 -71.28 -38.17 71.83 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.932 177.236 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 115' ' ' ALA . 48.2 mm -61.31 -34.61 61.62 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.823 0 O-C-N 123.773 0.671 . . . . 0.0 110.165 177.345 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.417 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 75.0 mmtt -61.71 -49.63 75.7 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 120.87 0.367 . . . . 0.0 110.527 177.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.432 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 35.1 mmtm -68.61 -29.76 68.35 Favored 'General case' 0 C--O 1.217 -0.633 0 CA-C-N 115.819 -0.628 . . . . 0.0 111.444 178.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.513 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -68.75 -37.5 79.43 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 124.784 1.234 . . . . 0.0 108.492 -179.324 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 63.5 mtt -77.87 -12.81 60.01 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.11 -0.496 . . . . 0.0 111.272 177.409 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.417 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 49.7 mt-10 -85.45 -23.72 27.73 Favored 'General case' 0 C--O 1.241 0.614 0 CA-C-O 121.655 0.74 . . . . 0.0 109.499 173.363 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.432 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 41.1 mt-10 -74.01 -31.38 62.91 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.101 174.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.645 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -50.92 -56.28 20.86 Favored Pre-proline 0 CA--C 1.567 1.611 0 N-CA-C 115.394 1.627 . . . . 0.0 115.394 -178.696 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 29.1 Cg_endo -63.23 -25.7 72.23 Favored 'Trans proline' 0 C--N 1.382 2.335 0 C-N-CA 121.727 1.618 . . . . 0.0 112.091 179.471 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 4.9 m -79.34 -28.24 42.05 Favored 'General case' 0 N--CA 1.424 -1.734 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.841 -177.133 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.645 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -59.16 -54.09 50.94 Favored 'General case' 0 C--N 1.361 1.099 0 N-CA-C 107.867 -1.16 . . . . 0.0 107.867 175.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 39.1 t -58.38 -45.33 89.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 CA-C-N 113.702 -1.59 . . . . 0.0 110.143 -178.209 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.9 tttp -50.48 -59.6 3.85 Favored 'General case' 0 CA--C 1.536 0.42 0 N-CA-C 113.585 0.957 . . . . 0.0 113.585 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.62 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 19.9 t90 -69.66 -28.74 66.13 Favored 'General case' 0 C--O 1.243 0.758 0 N-CA-C 112.306 0.484 . . . . 0.0 112.306 -171.025 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.534 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 76.0 mt -66.0 -42.6 89.52 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 176.692 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 97.3 t -69.85 -33.37 55.56 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.94 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.567 178.665 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 -70.08 -27.44 64.62 Favored 'General case' 0 N--CA 1.47 0.55 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -179.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.629 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.54 4.22 30.21 Favored 'General case' 0 C--O 1.213 -0.847 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 175.959 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.433 ' HA ' HD12 ' A' ' 140' ' ' LEU . 79.2 t80 -46.57 -41.94 15.19 Favored 'General case' 0 N--CA 1.487 1.389 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -176.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 44.4 m-20 -80.0 -0.12 34.01 Favored 'General case' 0 N--CA 1.476 0.847 0 N-CA-C 112.477 0.547 . . . . 0.0 112.477 -177.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -114.63 -6.61 12.77 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 109.609 -0.515 . . . . 0.0 109.609 179.254 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.629 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 88.8 mt -84.37 123.33 30.09 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 114.658 1.355 . . . . 0.0 114.658 -172.47 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 27.3 mt-10 -104.46 161.63 13.93 Favored 'General case' 0 N--CA 1.428 -1.527 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 168.075 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 56.6 m-85 -115.01 132.54 56.57 Favored 'General case' 0 C--N 1.286 -2.166 0 C-N-CA 119.945 -0.702 . . . . 0.0 111.452 -169.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.4 ' O ' ' HB ' ' A' ' 155' ' ' ILE . 93.5 m-85 -129.12 151.78 49.43 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.915 -177.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.5 mpp? -138.59 147.59 43.17 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 104.64 -2.356 . . . . 0.0 104.64 171.908 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 52.6 p -74.7 163.17 28.0 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 118.19 -1.404 . . . . 0.0 107.914 174.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 53.4 tptt -59.21 -26.72 65.08 Favored 'General case' 0 CA--C 1.557 1.217 0 N-CA-C 112.668 0.618 . . . . 0.0 112.668 -175.187 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 9.2 p -81.49 -20.2 40.66 Favored 'General case' 0 CA--C 1.559 1.305 0 N-CA-C 112.336 0.495 . . . . 0.0 112.336 179.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.8 mtt -87.21 -177.65 6.03 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 112.755 0.65 . . . . 0.0 112.755 -174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -125.79 161.56 50.36 Favored Pre-proline 0 C--N 1.319 -0.751 0 C-N-CA 123.946 0.898 . . . . 0.0 108.905 -178.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -65.61 -17.35 56.74 Favored 'Trans proline' 0 CA--C 1.549 1.232 0 C-N-CA 122.345 2.03 . . . . 0.0 112.708 175.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 25.6 m-20 -102.81 -39.52 6.95 Favored 'General case' 0 CA--C 1.515 -0.391 0 C-N-CA 120.427 -0.509 . . . . 0.0 109.704 175.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HA ' ' CG2' ' A' ' 8' ' ' ILE . . . -102.88 100.23 10.2 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.768 -179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.13 42.22 3.81 Favored Glycine 0 N--CA 1.436 -1.3 0 CA-C-N 115.514 -0.766 . . . . 0.0 112.24 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.635 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 38.9 tp -88.09 112.77 23.04 Favored 'General case' 0 N--CA 1.442 -0.849 0 N-CA-C 107.086 -1.45 . . . . 0.0 107.086 174.998 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.4 ' HB ' ' O ' ' A' ' 143' ' ' PHE . 93.9 mt -99.9 138.75 23.27 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.551 0 CA-C-N 114.936 -1.029 . . . . 0.0 111.742 -172.564 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.519 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 22.1 m-85 -89.89 136.1 33.24 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 107.474 -1.306 . . . . 0.0 107.474 178.252 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.404 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 38.7 m -148.09 148.12 30.29 Favored 'General case' 0 C--N 1.305 -1.344 0 O-C-N 121.53 -0.731 . . . . 0.0 110.384 174.939 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 40.7 p90 -134.7 179.4 6.32 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 107.34 -1.356 . . . . 0.0 107.34 177.063 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 33.9 m-85 -115.91 111.32 20.25 Favored 'General case' 0 C--N 1.287 -2.113 0 N-CA-C 108.208 -1.034 . . . . 0.0 108.208 178.879 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 21.0 ptmt -77.68 177.43 8.12 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-N 116.539 -0.3 . . . . 0.0 110.362 179.87 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.2 mm-40 -67.1 123.51 20.47 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-O 120.897 0.38 . . . . 0.0 111.383 179.356 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.76 -5.78 69.75 Favored Glycine 0 N--CA 1.448 -0.539 0 CA-C-N 115.435 -0.802 . . . . 0.0 111.838 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -93.24 127.47 38.83 Favored 'General case' 0 N--CA 1.434 -1.271 0 CA-C-O 121.532 0.682 . . . . 0.0 111.171 -178.255 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 46.5 m-70 -113.55 9.82 18.02 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 107.383 -1.34 . . . . 0.0 107.383 175.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.603 ' SG ' ' HG2' ' A' ' 40' ' ' MET . 61.4 m -139.03 155.25 72.89 Favored Pre-proline 0 N--CA 1.432 -1.327 0 N-CA-C 106.031 -1.84 . . . . 0.0 106.031 -176.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 21.2 Cg_endo -59.96 130.33 34.2 Favored 'Trans proline' 0 CA--C 1.543 0.952 0 C-N-CA 122.968 2.445 . . . . 0.0 115.262 -175.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 41.5 m -94.59 118.33 31.52 Favored 'General case' 0 N--CA 1.431 -1.423 0 N-CA-C 105.937 -1.875 . . . . 0.0 105.937 173.351 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.536 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 60.0 m-85 -84.89 132.4 34.39 Favored 'General case' 0 C--N 1.299 -1.587 0 N-CA-C 114.414 1.264 . . . . 0.0 114.414 -171.744 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.62 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 65.4 t -100.67 109.64 25.76 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 CA-C-N 113.474 -1.694 . . . . 0.0 107.683 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.471 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 19.0 m-85 -128.61 149.21 50.74 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.259 1.028 . . . . 0.0 113.22 -175.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.515 ' HA ' HD23 ' A' ' 33' ' ' LEU . 23.8 t -94.99 98.5 8.07 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 CA-C-N 114.618 -1.174 . . . . 0.0 109.399 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.424 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 28.1 ttpp -54.8 -56.68 16.71 Favored 'General case' 0 N--CA 1.487 1.389 0 C-N-CA 124.025 0.93 . . . . 0.0 112.328 -174.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.456 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 9.6 m -88.9 4.19 48.76 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 115.4 -0.818 . . . . 0.0 110.898 -175.02 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -100.23 -17.47 24.6 Favored Glycine 0 CA--C 1.485 -1.819 0 C-N-CA 119.837 -1.173 . . . . 0.0 112.314 -176.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 25.8 m-85 -98.03 169.21 9.78 Favored 'General case' 0 C--N 1.309 -1.16 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 177.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.3 mtmt -85.6 108.61 18.05 Favored 'General case' 0 N--CA 1.42 -1.959 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 41.9 t -76.55 108.44 9.29 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 179.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 98.6 t -117.68 144.09 26.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 -177.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 36.8 mttp -112.31 118.39 35.12 Favored 'General case' 0 C--N 1.299 -1.63 0 N-CA-C 107.332 -1.358 . . . . 0.0 107.332 176.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . 0.493 ' CE2' HG11 ' A' ' 3' ' ' VAL . 18.1 m-85 -86.94 126.85 34.97 Favored 'General case' 0 C--N 1.307 -1.278 0 C-N-CA 120.24 -0.584 . . . . 0.0 109.671 176.985 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -87.48 178.28 6.85 Favored 'General case' 0 C--N 1.3 -1.586 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.788 -178.86 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -94.6 146.5 24.09 Favored 'General case' 0 C--N 1.3 -1.563 0 CA-C-N 115.657 -0.702 . . . . 0.0 111.848 -177.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 18.3 p80 -119.56 120.54 37.04 Favored 'General case' 0 C--N 1.3 -1.564 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.586 -179.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -102.57 -39.45 7.08 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 115.936 -0.575 . . . . 0.0 112.314 -175.95 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.7 t-80 -72.43 -32.97 66.76 Favored 'General case' 0 C--O 1.221 -0.4 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 -178.053 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 11.5 t60 -91.73 110.76 22.1 Favored 'General case' 0 N--CA 1.427 -1.587 0 N-CA-C 104.819 -2.289 . . . . 0.0 104.819 171.576 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 74.9 m-70 -88.0 -178.29 5.96 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.196 -173.516 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 46.6 m80 . . . . . 0 C--N 1.306 -1.298 0 N-CA-C 108.346 -0.983 . . . . 0.0 108.346 177.467 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 57.2 ttp . . . . . 0 N--CA 1.446 -0.649 0 CA-C-O 121.215 0.531 . . . . 0.0 109.785 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 56.4 mt -88.17 130.16 38.22 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.956 0 N-CA-C 106.295 -1.743 . . . . 0.0 106.295 178.677 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.5 p -122.42 143.28 35.71 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.344 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.663 -176.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 90.2 m-85 -98.32 118.8 35.79 Favored 'General case' 0 N--CA 1.425 -1.697 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 176.104 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 66.5 mttm -102.97 140.11 37.66 Favored 'General case' 0 C--N 1.296 -1.737 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 177.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.516 ' HA ' ' CE2' ' A' ' 175' ' ' TYR . 17.3 t70 -68.02 143.44 55.55 Favored 'General case' 0 C--N 1.313 -0.999 0 O-C-N 123.974 0.796 . . . . 0.0 110.852 -179.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 14.5 t -78.54 -25.15 13.56 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.902 -176.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.436 HD11 ' HA ' ' A' ' 101' ' ' TYR . 18.4 mm -86.52 -44.05 16.37 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.414 -173.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 35.2 p -87.72 -42.46 12.6 Favored 'General case' 0 C--N 1.312 -1.049 0 CA-C-O 121.204 0.526 . . . . 0.0 110.935 178.507 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 97.46 2.56 58.82 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 121.16 -0.543 . . . . 0.0 112.053 -178.514 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 11.9 t70 -112.49 -175.21 2.63 Favored 'General case' 0 CA--C 1.557 1.227 0 CA-C-N 117.258 0.529 . . . . 0.0 110.093 -177.68 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.454 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.4 mt-10 -88.41 136.94 32.74 Favored 'General case' 0 C--N 1.313 -0.994 0 N-CA-C 113.732 1.012 . . . . 0.0 113.732 -165.276 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 16.9 m -116.28 -35.14 1.92 Allowed 'Isoleucine or valine' 0 C--O 1.204 -1.332 0 CA-C-N 115.818 -0.628 . . . . 0.0 112.615 179.573 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 12.1 p -160.52 149.62 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.673 0 N-CA-C 108.999 -0.741 . . . . 0.0 108.999 -176.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 43.3 p -119.6 162.39 19.03 Favored 'General case' 0 C--N 1.313 -1.008 0 CA-C-N 117.629 0.195 . . . . 0.0 110.488 -178.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 -69.32 -9.69 54.47 Favored 'General case' 0 N--CA 1.494 1.739 0 C-N-CA 123.625 0.77 . . . . 0.0 111.478 -178.353 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -75.23 -19.0 60.0 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.737 -0.665 . . . . 0.0 109.92 177.15 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 93.7 mt -94.19 -170.83 2.38 Favored 'General case' 0 N--CA 1.443 -0.781 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.903 179.861 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 36' ' ' VAL . 59.2 tptt -85.54 106.79 17.12 Favored 'General case' 0 C--O 1.212 -0.902 0 CA-C-O 120.87 0.367 . . . . 0.0 111.438 -175.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 2.8 mp -122.75 111.24 29.19 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 175.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.1 p -116.9 137.71 24.04 Favored Pre-proline 0 C--N 1.296 -1.748 0 CA-C-N 116.037 -0.529 . . . . 0.0 112.047 179.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.4 136.95 41.6 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.321 2.014 . . . . 0.0 110.66 177.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 37.4 t -75.8 111.69 12.53 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 109.68 -0.489 . . . . 0.0 109.68 -178.094 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 70.7 mtm -117.36 109.56 16.96 Favored 'General case' 0 C--N 1.301 -1.502 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -135.73 118.62 16.25 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 115.453 -0.794 . . . . 0.0 108.958 -179.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.33 20.08 33.64 Favored Glycine 0 C--N 1.313 -0.697 0 C-N-CA 121.217 -0.516 . . . . 0.0 113.452 176.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 86.04 3.89 84.85 Favored Glycine 0 CA--C 1.509 -0.331 0 CA-C-O 121.317 0.398 . . . . 0.0 112.531 178.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -140.81 164.0 31.41 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 -178.326 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -84.06 154.04 23.45 Favored 'General case' 0 N--CA 1.43 -1.467 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 176.041 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.476 HG12 HD12 ' A' ' 33' ' ' LEU . 22.6 t -96.16 104.09 15.93 Favored Pre-proline 0 C--N 1.287 -2.135 0 N-CA-C 103.639 -2.726 . . . . 0.0 103.639 170.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 70.0 Cg_endo -66.39 136.69 44.28 Favored 'Trans proline' 0 C--O 1.239 0.547 0 C-N-CA 122.72 2.28 . . . . 0.0 115.425 -168.022 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . 0.406 ' HA2' ' OG ' ' A' ' 173' ' ' SER . . . 85.33 13.88 69.95 Favored Glycine 0 N--CA 1.426 -1.992 0 CA-C-N 114.024 -1.444 . . . . 0.0 114.261 174.356 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.491 HD23 ' HA ' ' A' ' 171' ' ' VAL . 36.8 mt -135.41 150.27 49.84 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-N 116.917 0.358 . . . . 0.0 110.663 -176.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -136.2 142.7 44.12 Favored 'General case' 0 N--CA 1.434 -1.254 0 N-CA-C 109.591 -0.522 . . . . 0.0 109.591 175.617 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -106.66 148.43 28.36 Favored 'General case' 0 N--CA 1.412 -2.338 0 N-CA-C 105.999 -1.852 . . . . 0.0 105.999 177.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.562 HG13 ' O ' ' A' ' 19' ' ' LYS . 89.6 t -109.78 113.86 45.36 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.685 0 N-CA-C 106.721 -1.585 . . . . 0.0 106.721 179.85 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -79.74 159.26 26.67 Favored 'General case' 0 C--N 1.304 -1.39 0 CA-C-N 114.946 -1.024 . . . . 0.0 109.843 -177.524 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.541 ' HB3' ' HB2' ' A' ' 165' ' ' CYS . 7.9 m -99.21 135.25 40.89 Favored 'General case' 0 N--CA 1.404 -2.764 0 CA-C-O 121.022 0.439 . . . . 0.0 111.669 -171.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.41 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -146.29 161.68 39.77 Favored 'General case' 0 N--CA 1.441 -0.885 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 175.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 73.3 mtm -114.16 146.95 39.64 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -179.129 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 74' ' ' ASN . 24.7 m -132.63 167.68 25.99 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.623 -0.717 . . . . 0.0 109.336 175.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -75.59 118.35 18.35 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.406 0.622 . . . . 0.0 110.761 -179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 68.3 t -100.6 132.05 47.01 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.768 0 N-CA-C 108.574 -0.898 . . . . 0.0 108.574 179.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -116.57 -133.1 5.07 Favored Glycine 0 N--CA 1.431 -1.635 0 N-CA-C 108.912 -1.675 . . . . 0.0 108.912 177.183 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -95.05 -60.98 1.05 Allowed Glycine 0 N--CA 1.434 -1.476 0 N-CA-C 110.043 -1.223 . . . . 0.0 110.043 175.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 126.36 -35.83 2.84 Favored Glycine 0 N--CA 1.438 -1.192 0 N-CA-C 110.709 -0.956 . . . . 0.0 110.709 179.831 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 21.3 m-20 70.49 19.51 6.25 Favored 'General case' 0 N--CA 1.486 1.372 0 C-N-CA 125.034 1.334 . . . . 0.0 111.241 176.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 62.7 mt -101.88 106.0 18.96 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.064 0 CA-C-N 115.639 -0.709 . . . . 0.0 109.911 -177.191 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 24.6 t70 70.86 -46.65 0.64 Allowed 'General case' 0 N--CA 1.492 1.651 0 C-N-CA 125.744 1.617 . . . . 0.0 115.039 174.396 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 64.0 mt -67.35 121.47 16.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.98 0 C-N-CA 123.044 0.538 . . . . 0.0 110.157 -178.474 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -110.27 -162.36 18.67 Favored Glycine 0 N--CA 1.433 -1.508 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 55.8 m 71.41 -30.73 0.21 Allowed 'General case' 0 N--CA 1.494 1.775 0 C-N-CA 125.999 1.72 . . . . 0.0 113.576 178.024 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -77.3 -14.25 82.74 Favored Glycine 0 N--CA 1.45 -0.399 0 N-CA-C 111.293 -0.723 . . . . 0.0 111.293 176.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -78.87 132.84 36.94 Favored 'General case' 0 CA--C 1.502 -0.894 0 N-CA-C 108.431 -0.952 . . . . 0.0 108.431 178.756 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . 72.07 -44.73 0.6 Allowed 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.436 1.495 . . . . 0.0 113.922 177.098 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -82.91 102.53 11.74 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.824 -0.436 . . . . 0.0 109.824 -179.075 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -125.79 91.21 0.39 Allowed Glycine 0 N--CA 1.441 -1.029 0 N-CA-C 111.425 -0.67 . . . . 0.0 111.425 179.59 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 155.73 66.29 0.01 OUTLIER Glycine 0 N--CA 1.438 -1.211 0 N-CA-C 111.36 -0.696 . . . . 0.0 111.36 -179.66 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -119.11 19.22 12.97 Favored 'General case' 0 C--N 1.308 -1.229 0 CA-C-O 121.831 0.824 . . . . 0.0 109.452 179.884 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 111.38 -70.6 0.21 Allowed Glycine 0 N--CA 1.419 -2.472 0 N-CA-C 106.698 -2.561 . . . . 0.0 106.698 -174.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 58.45 26.57 14.36 Favored 'General case' 0 N--CA 1.473 0.71 0 C-N-CA 124.717 1.207 . . . . 0.0 111.762 172.536 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -71.31 -33.56 69.8 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.04 -176.777 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.421 ' CD ' ' H ' ' A' ' 63' ' ' GLU . 0.0 OUTLIER -96.54 1.71 51.65 Favored 'General case' 0 C--N 1.307 -1.24 0 CA-C-N 115.141 -0.936 . . . . 0.0 109.71 -178.955 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -107.46 -64.09 0.59 Allowed Glycine 0 N--CA 1.428 -1.873 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.865 -178.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -111.08 90.39 3.32 Favored 'General case' 0 C--N 1.309 -1.173 0 CA-C-O 121.06 0.457 . . . . 0.0 111.46 -175.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 -99.22 -14.28 19.36 Favored 'General case' 0 C--N 1.311 -1.076 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 173.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.5 t70 -140.97 128.75 21.65 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 106.459 -1.682 . . . . 0.0 106.459 176.406 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -76.48 110.19 10.82 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 110.099 -0.334 . . . . 0.0 110.099 -178.072 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 35.2 m 72.17 91.62 0.09 Allowed 'General case' 0 C--O 1.24 0.559 0 C-N-CA 124.726 1.21 . . . . 0.0 109.612 -174.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 20.9 mp0 -75.74 150.38 37.83 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.046 -177.505 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.463 ' HD2' ' N ' ' A' ' 71' ' ' LYS . 6.0 mptt -116.57 121.46 41.82 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 178.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 29.5 mt-10 -128.19 172.73 10.74 Favored 'General case' 0 C--N 1.281 -2.413 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.968 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.412 ' OD1' ' HE1' ' A' ' 168' ' ' PHE . 27.4 t-20 -51.35 133.48 29.1 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-O 122.685 1.231 . . . . 0.0 113.088 -177.27 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.466 ' HA ' HG22 ' A' ' 41' ' ' VAL . 24.1 p-10 -61.53 -30.95 70.97 Favored 'General case' 0 C--N 1.297 -1.704 0 C-N-CA 126.557 1.943 . . . . 0.0 114.025 -177.286 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.43 HG21 ' CG1' ' A' ' 36' ' ' VAL . 57.9 t -91.01 -34.17 6.24 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.821 0 CA-C-N 116.555 -0.293 . . . . 0.0 110.598 -176.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 24.9 p -66.78 -46.31 75.71 Favored 'General case' 0 C--O 1.24 0.575 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.269 177.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.26 82.23 0.02 OUTLIER Glycine 0 C--N 1.357 1.73 0 O-C-N 125.061 1.476 . . . . 0.0 115.354 173.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 84.8 Cg_exo -53.78 -33.59 71.31 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 123.693 2.929 . . . . 0.0 113.802 -179.016 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 16.5 m -85.6 2.08 46.52 Favored 'General case' 0 CA--C 1.553 1.076 0 CA-C-N 116.311 -0.404 . . . . 0.0 111.754 -178.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 37.1 m -132.63 -76.19 0.5 Allowed 'General case' 0 CA--C 1.549 0.918 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -176.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 87.2 m-85 -92.06 -34.81 14.25 Favored 'General case' 0 C--O 1.243 0.758 0 CA-C-N 116.663 -0.244 . . . . 0.0 111.651 -175.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.63 81.52 0.14 Allowed 'General case' 0 C--O 1.237 0.436 0 C-N-CA 125.346 1.458 . . . . 0.0 113.491 179.172 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 2.6 m-30 -86.25 111.37 20.36 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.633 177.234 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -93.07 129.78 38.91 Favored 'General case' 0 C--N 1.3 -1.579 0 C-N-CA 123.532 0.733 . . . . 0.0 109.091 178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -88.92 145.85 25.28 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 122.822 0.449 . . . . 0.0 111.88 -176.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.8 mmt -138.09 132.33 16.96 Favored Pre-proline 0 C--O 1.243 0.737 0 C-N-CA 124.794 1.237 . . . . 0.0 109.008 176.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 39.4 Cg_exo -64.04 164.5 22.02 Favored 'Trans proline' 0 CA--C 1.552 1.424 0 C-N-CA 123.191 2.594 . . . . 0.0 113.562 178.092 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 36.2 m-85 -49.02 119.08 2.97 Favored 'General case' 0 N--CA 1.488 1.431 0 C-N-CA 124.23 1.012 . . . . 0.0 111.633 176.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.3 p -92.48 -59.67 2.02 Favored 'General case' 0 N--CA 1.43 -1.45 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 172.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 8.4 t 57.38 28.3 15.14 Favored 'General case' 0 CA--C 1.559 1.325 0 C-N-CA 125.108 1.363 . . . . 0.0 111.762 174.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -80.08 172.06 14.27 Favored 'General case' 0 C--O 1.242 0.694 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.316 -179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.63 -32.82 82.81 Favored Glycine 0 N--CA 1.462 0.422 0 N-CA-C 111.473 -0.651 . . . . 0.0 111.473 178.532 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 7.5 pt-20 -61.72 -32.35 72.56 Favored 'General case' 0 C--O 1.22 -0.465 0 C-N-CA 123.234 0.614 . . . . 0.0 110.88 175.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.434 ' O ' HG23 ' A' ' 98' ' ' VAL . 71.9 t80 -74.34 -31.46 62.43 Favored 'General case' 0 C--O 1.209 -1.027 0 N-CA-C 109.535 -0.542 . . . . 0.0 109.535 179.045 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 74.0 mmtt -71.07 -34.11 70.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 116.385 -0.371 . . . . 0.0 110.076 176.653 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -69.7 -32.74 71.51 Favored 'General case' 0 N--CA 1.447 -0.595 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 174.143 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.409 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.0 t90 -67.15 -47.2 71.75 Favored 'General case' 0 C--O 1.2 -1.508 0 CA-C-N 115.575 -0.739 . . . . 0.0 109.893 176.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.434 HG23 ' O ' ' A' ' 94' ' ' PHE . 98.7 t -58.27 -43.32 85.75 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.972 0 CA-C-O 121.027 0.441 . . . . 0.0 110.286 177.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 11.5 tmtt? -60.36 -46.54 89.59 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-N 115.408 -0.815 . . . . 0.0 111.707 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . 0.424 ' HA ' ' HB3' ' A' ' 103' ' ' ARG . 0.6 OUTLIER -76.44 -21.22 56.21 Favored 'General case' 0 CA--C 1.514 -0.425 0 N-CA-C 112.713 0.634 . . . . 0.0 112.713 178.006 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.436 ' HA ' HD11 ' A' ' 8' ' ' ILE . 50.0 t80 -64.84 -52.57 55.96 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 108.405 -0.961 . . . . 0.0 108.405 175.923 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 60.3 t -63.49 -39.06 83.93 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.695 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.029 178.007 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HB3' ' HA ' ' A' ' 100' ' ' ASP . 9.8 tpt180 -52.79 -59.55 4.36 Favored 'General case' 0 N--CA 1.47 0.551 0 C-N-CA 124.633 1.173 . . . . 0.0 110.849 176.965 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.9 m-80 -67.39 -29.55 69.09 Favored 'General case' 0 CA--C 1.509 -0.599 0 CA-C-N 115.827 -0.624 . . . . 0.0 112.252 -175.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.403 HG23 ' O ' ' A' ' 101' ' ' TYR . 52.9 t -64.17 -40.09 87.82 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.609 0 O-C-N 123.388 0.43 . . . . 0.0 110.025 175.376 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 96.9 mtt180 -57.26 -38.05 73.28 Favored 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 122.456 0.302 . . . . 0.0 111.36 177.211 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -67.46 -37.55 83.11 Favored 'General case' 0 C--O 1.217 -0.636 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.039 176.473 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.75 -35.29 80.31 Favored 'General case' 0 N--CA 1.468 0.455 0 C-N-CA 122.423 0.289 . . . . 0.0 111.212 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.0 mp -57.7 -50.94 71.53 Favored 'General case' 0 N--CA 1.476 0.87 0 CA-C-O 121.399 0.619 . . . . 0.0 111.631 176.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 93.8 mttt -83.58 -49.47 9.18 Favored 'General case' 0 C--N 1.309 -1.179 0 CA-C-N 115.504 -0.771 . . . . 0.0 112.006 -174.845 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -67.17 -13.51 62.34 Favored Glycine 0 C--O 1.221 -0.683 0 N-CA-C 116.027 1.171 . . . . 0.0 116.027 -171.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.4 p -78.57 -11.91 59.99 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-N 118.183 0.992 . . . . 0.0 111.66 179.233 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 89.32 28.37 20.15 Favored Glycine 0 C--N 1.338 0.683 0 CA-C-N 115.908 -0.587 . . . . 0.0 113.37 176.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . 0.442 HG12 ' HB2' ' A' ' 118' ' ' ASP . 22.7 t -72.33 152.28 8.01 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.132 0 N-CA-C 109.661 -0.496 . . . . 0.0 109.661 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -70.0 152.46 44.39 Favored 'General case' 0 N--CA 1.472 0.671 0 C-N-CA 122.506 0.322 . . . . 0.0 111.235 -179.743 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 92.4 t -53.33 -46.49 57.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 C-N-CA 123.974 0.91 . . . . 0.0 112.196 -178.584 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.431 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 1.7 mp0 -55.63 -47.09 77.17 Favored 'General case' 0 C--O 1.243 0.761 0 C-N-CA 124.116 0.966 . . . . 0.0 109.855 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.442 ' HB2' HG12 ' A' ' 114' ' ' VAL . 7.9 m-20 -69.46 -43.49 73.13 Favored 'General case' 0 C--O 1.206 -1.203 0 CA-C-N 114.126 -1.397 . . . . 0.0 111.055 -178.997 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 70.7 mt -59.69 -36.57 66.37 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 O-C-N 123.427 0.455 . . . . 0.0 111.347 -179.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 44.3 mmtm -59.56 -46.59 88.47 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 120.878 0.37 . . . . 0.0 110.654 175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.604 ' HA ' ' HE2' ' A' ' 121' ' ' LYS . 10.1 mmpt? -68.29 -37.2 80.41 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.601 0.715 . . . . 0.0 109.896 178.912 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.441 ' CE2' ' HB3' ' A' ' 173' ' ' SER . 0.8 OUTLIER -67.0 -35.0 78.98 Favored 'General case' 0 C--N 1.304 -1.379 0 C-N-CA 125.661 1.584 . . . . 0.0 109.683 -178.362 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 92.5 mtp -75.81 -19.87 58.62 Favored 'General case' 0 C--O 1.216 -0.684 0 O-C-N 122.013 -0.43 . . . . 0.0 111.178 178.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.5 mt-10 -78.12 -28.68 48.59 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 121.849 0.833 . . . . 0.0 109.076 172.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.425 ' O ' ' HB ' ' A' ' 128' ' ' THR . 48.1 mt-10 -72.12 -28.23 63.14 Favored 'General case' 0 C--O 1.215 -0.715 0 CA-C-N 115.309 -0.859 . . . . 0.0 111.24 173.946 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.538 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -54.56 -54.94 43.15 Favored Pre-proline 0 CA--C 1.572 1.797 0 N-CA-C 114.441 1.274 . . . . 0.0 114.441 -179.185 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.5 -21.59 39.96 Favored 'Trans proline' 0 C--N 1.382 2.32 0 C-N-CA 121.484 1.456 . . . . 0.0 111.502 176.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . 0.425 ' HB ' ' O ' ' A' ' 125' ' ' GLU . 52.5 m -67.4 -37.83 83.72 Favored 'General case' 0 C--O 1.244 0.814 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.835 178.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.538 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -59.89 -50.22 74.64 Favored 'General case' 0 C--N 1.356 0.866 0 N-CA-C 108.313 -0.995 . . . . 0.0 108.313 176.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.6 t -58.97 -50.17 80.6 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.247 0 CA-C-N 114.269 -1.332 . . . . 0.0 110.841 -178.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 52.1 tttp -56.09 -53.25 59.33 Favored 'General case' 0 C--O 1.233 0.223 0 N-CA-C 112.79 0.663 . . . . 0.0 112.79 -179.335 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.545 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.8 t90 -65.78 -34.28 77.8 Favored 'General case' 0 C--N 1.323 -0.584 0 O-C-N 123.298 0.374 . . . . 0.0 111.457 -174.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.1 mt -66.11 -41.44 90.58 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.776 0.322 . . . . 0.0 110.446 175.91 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 91.1 t -68.11 -34.29 65.79 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.706 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.126 178.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 19.1 m-20 -72.95 -19.48 61.23 Favored 'General case' 0 N--CA 1.472 0.656 0 N-CA-C 112.614 0.598 . . . . 0.0 112.614 178.501 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.489 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.3 mmtt -98.31 -12.22 21.74 Favored 'General case' 0 C--N 1.322 -0.601 0 O-C-N 122.043 -0.411 . . . . 0.0 111.273 178.177 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 37.6 t80 -48.21 -32.55 7.27 Favored 'General case' 0 N--CA 1.498 1.93 0 C-N-CA 126.475 1.91 . . . . 0.0 113.456 -172.079 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -60.93 -29.91 69.89 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.701 0.8 . . . . 0.0 112.403 -178.52 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.9 m-20 -116.76 3.11 12.97 Favored 'General case' 0 C--N 1.323 -0.583 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 -177.134 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.489 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 90.1 mt -83.21 118.94 23.96 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -172.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -111.2 170.52 8.06 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 106.645 -1.613 . . . . 0.0 106.645 173.717 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 52.0 m-85 -113.41 139.43 48.9 Favored 'General case' 0 C--N 1.291 -1.939 0 C-N-CA 119.049 -1.06 . . . . 0.0 112.967 -168.109 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -125.24 153.71 42.76 Favored 'General case' 0 C--N 1.293 -1.855 0 CA-C-N 115.083 -0.962 . . . . 0.0 108.802 175.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 59.3 mtt -131.85 127.1 35.86 Favored 'General case' 0 C--N 1.287 -2.112 0 N-CA-C 108.158 -1.053 . . . . 0.0 108.158 176.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 6.7 p -74.97 151.86 38.81 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.615 -1.624 . . . . 0.0 106.615 170.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 13.2 tppt? -62.33 -15.61 49.19 Favored 'General case' 0 CA--C 1.553 1.076 0 N-CA-C 113.589 0.959 . . . . 0.0 113.589 -171.667 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.3 p -88.64 -13.81 38.96 Favored 'General case' 0 CA--C 1.565 1.541 0 N-CA-C 112.987 0.736 . . . . 0.0 112.987 177.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -98.22 169.12 9.81 Favored 'General case' 0 N--CA 1.479 0.985 0 N-CA-C 114.888 1.44 . . . . 0.0 114.888 -172.656 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.48 ' HB2' ' HB3' ' A' ' 152' ' ' ALA . 3.1 m-20 -112.74 158.47 37.49 Favored Pre-proline 0 C--N 1.321 -0.632 0 N-CA-C 107.212 -1.403 . . . . 0.0 107.212 -179.166 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -62.02 -34.09 81.36 Favored 'Trans proline' 0 CA--C 1.54 0.785 0 C-N-CA 121.563 1.509 . . . . 0.0 112.459 175.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.5 m-20 -95.31 2.17 54.66 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.612 -0.267 . . . . 0.0 111.439 -179.414 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 149' ' ' ASN . . . -147.04 98.45 3.04 Favored 'General case' 0 C--N 1.315 -0.933 0 O-C-N 122.355 -0.215 . . . . 0.0 110.773 -178.067 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.51 42.12 4.3 Favored Glycine 0 N--CA 1.444 -0.806 0 C-N-CA 120.811 -0.709 . . . . 0.0 112.372 -177.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.409 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 29.0 tp -84.47 112.74 20.65 Favored 'General case' 0 N--CA 1.434 -1.245 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 178.556 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 72.4 mt -81.92 127.11 39.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.774 -173.458 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.5 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 64.9 m-85 -87.0 134.84 33.45 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 106.727 -1.583 . . . . 0.0 106.727 174.873 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 15.6 m -148.38 149.9 32.58 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 118.648 0.658 . . . . 0.0 111.28 178.24 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.404 ' O ' ' HB ' ' A' ' 167' ' ' THR . 10.0 p90 -147.31 170.97 16.18 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.098 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 13.0 m-85 -112.55 102.39 10.48 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 108.318 -0.993 . . . . 0.0 108.318 177.541 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.3 pttm -80.03 157.49 26.75 Favored 'General case' 0 C--N 1.32 -0.71 0 C-N-CA 120.382 -0.527 . . . . 0.0 110.155 178.825 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -64.2 122.91 17.75 Favored 'General case' 0 C--O 1.242 0.69 0 CA-C-O 121.767 0.794 . . . . 0.0 112.051 179.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 107.44 -22.16 29.31 Favored Glycine 0 N--CA 1.441 -1.028 0 CA-C-N 114.365 -1.289 . . . . 0.0 110.803 -175.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.76 125.11 45.61 Favored 'General case' 0 N--CA 1.443 -0.801 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 175.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -111.76 23.52 13.76 Favored 'General case' 0 C--N 1.309 -1.194 0 CA-C-O 121.964 0.888 . . . . 0.0 111.75 -178.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.541 ' HB2' ' HB3' ' A' ' 38' ' ' SER . 73.1 m -143.4 164.52 30.51 Favored Pre-proline 0 C--N 1.293 -1.882 0 N-CA-C 105.942 -1.873 . . . . 0.0 105.942 178.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 29.7 Cg_exo -61.29 126.56 19.64 Favored 'Trans proline' 0 C--N 1.355 0.904 0 C-N-CA 122.19 1.926 . . . . 0.0 113.574 -176.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.404 ' HB ' ' O ' ' A' ' 158' ' ' TYR . 95.4 m -97.7 115.95 28.96 Favored 'General case' 0 N--CA 1.426 -1.635 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 174.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.412 ' HE1' ' OD1' ' A' ' 73' ' ' ASN . 63.6 m-85 -91.06 148.57 22.3 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.121 0.486 . . . . 0.0 111.106 -172.973 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.545 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 69.0 t -120.46 124.89 73.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.379 -0.828 . . . . 0.0 109.665 -176.14 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -139.21 157.56 45.71 Favored 'General case' 0 C--O 1.241 0.608 0 CA-C-O 121.388 0.613 . . . . 0.0 110.737 178.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.508 HG12 ' H ' ' A' ' 174' ' ' GLY . 44.8 t -92.92 119.48 40.68 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 N-CA-C 108.269 -1.011 . . . . 0.0 108.269 177.787 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.4 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 39.6 ttpt -74.44 -56.43 4.86 Favored 'General case' 0 N--CA 1.47 0.53 0 N-CA-C 112.503 0.557 . . . . 0.0 112.503 -173.047 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.441 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 34.6 m -80.41 -17.21 52.51 Favored 'General case' 0 C--N 1.308 -1.206 0 CA-C-O 121.209 0.528 . . . . 0.0 111.188 -176.788 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.508 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -82.32 -21.87 59.78 Favored Glycine 0 C--N 1.3 -1.46 0 C-N-CA 120.753 -0.736 . . . . 0.0 113.363 -176.291 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.516 ' CE2' ' HA ' ' A' ' 6' ' ' ASP . 3.6 m-85 -96.44 170.92 8.89 Favored 'General case' 0 C--O 1.245 0.82 0 CA-C-O 121.397 0.618 . . . . 0.0 112.404 -175.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.529 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 65.3 mttm -85.21 110.6 19.14 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.994 -1.003 . . . . 0.0 109.6 -176.655 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 33.4 t -92.89 103.52 14.76 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.898 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 178.169 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.4 t -118.44 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.995 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 -177.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 88.9 mttt -89.06 112.32 23.25 Favored 'General case' 0 C--N 1.304 -1.406 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.19 -177.998 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -113.13 102.81 10.73 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-O 121.275 0.56 . . . . 0.0 111.763 176.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.48 ' H ' HD23 ' A' ' 181' ' ' LEU . 1.5 pt? -100.44 -17.26 17.26 Favored 'General case' 0 C--N 1.287 -2.109 0 N-CA-C 107.064 -1.458 . . . . 0.0 107.064 169.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 43.1 mt-10 68.27 -7.81 0.64 Allowed 'General case' 0 C--N 1.351 0.652 0 C-N-CA 127.308 2.243 . . . . 0.0 113.596 176.947 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.2 m-70 61.65 59.03 1.89 Allowed 'General case' 0 CA--C 1.509 -0.598 0 C-N-CA 123.848 0.859 . . . . 0.0 110.213 -177.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 89.9 m-70 -79.99 94.68 5.96 Favored 'General case' 0 CA--C 1.501 -0.928 0 N-CA-C 108.254 -1.017 . . . . 0.0 108.254 177.392 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 16.8 t60 -134.26 84.5 2.12 Favored 'General case' 0 C--N 1.305 -1.349 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 -175.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 80.4 t60 -83.45 110.84 18.51 Favored 'General case' 0 C--N 1.304 -1.403 0 CA-C-N 115.756 -0.657 . . . . 0.0 112.208 -175.571 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . 0.436 ' O ' ' HB2' ' A' ' 188' ' ' HIS . 61.4 t60 -109.39 90.31 3.26 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 176.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . 0.436 ' HB2' ' O ' ' A' ' 187' ' ' HIS . 6.0 t60 . . . . . 0 N--CA 1.484 1.239 0 C-N-CA 126.545 1.938 . . . . 0.0 106.029 174.515 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.509 -0.601 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 19.1 mt -111.35 148.23 14.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.063 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 -177.437 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . 0.54 ' HB ' ' CE2' ' A' ' 180' ' ' PHE . 7.6 p -131.57 147.17 32.66 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.052 0 CA-C-O 121.166 0.507 . . . . 0.0 109.996 -179.148 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 33.1 m-85 -104.86 114.87 29.34 Favored 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -100.49 139.75 35.72 Favored 'General case' 0 C--N 1.306 -1.289 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.172 -178.41 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.45 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 17.3 t70 -74.46 139.38 43.87 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.414 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 43.8 t -74.52 -31.15 26.92 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.463 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.573 -176.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 17.8 mm -83.23 -52.0 13.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.001 0 CA-C-N 116.297 -0.41 . . . . 0.0 111.269 -172.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 51.9 p -84.6 -42.11 15.74 Favored 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.189 0.518 . . . . 0.0 111.626 -179.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 95.39 2.64 61.79 Favored Glycine 0 N--CA 1.434 -1.453 0 N-CA-C 110.617 -0.993 . . . . 0.0 110.617 -175.169 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -89.87 -173.87 4.05 Favored 'General case' 0 CA--C 1.545 0.77 0 N-CA-C 107.646 -1.242 . . . . 0.0 107.646 -179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.9 mt-10 -112.94 129.05 56.61 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.613 -0.679 . . . . 0.0 109.61 -172.323 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . . . . . . . . . 21.9 m -95.71 -33.25 4.66 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 N-CA-C 113.295 0.85 . . . . 0.0 113.295 -176.441 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.0 p -164.95 163.66 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -176.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 28.0 p -131.84 164.63 25.64 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 109.352 -0.61 . . . . 0.0 109.352 179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -73.1 -6.19 44.02 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 122.708 0.403 . . . . 0.0 111.983 -175.709 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -89.4 -6.45 56.57 Favored 'General case' 0 C--N 1.319 -0.734 0 C-N-CA 122.858 0.463 . . . . 0.0 110.559 178.121 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.489 HD11 ' CE1' ' A' ' 81' ' ' PHE . 85.7 mt -98.91 -179.11 4.17 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 109.524 -0.546 . . . . 0.0 109.524 179.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.431 ' HB2' HD21 ' A' ' 74' ' ' ASN . 5.1 tmtp? -82.25 106.59 14.26 Favored 'General case' 0 C--N 1.315 -0.906 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -177.562 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.448 HG23 ' CD2' ' A' ' 34' ' ' PHE . 64.9 mt -121.27 122.47 67.48 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.28 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -121.71 136.73 26.32 Favored Pre-proline 0 C--N 1.3 -1.559 0 N-CA-C 111.886 0.328 . . . . 0.0 111.886 179.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -66.24 138.75 52.49 Favored 'Trans proline' 0 C--O 1.238 0.516 0 C-N-CA 122.329 2.02 . . . . 0.0 110.276 176.843 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 85.2 t -67.39 112.13 2.51 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.72 0 CA-C-O 120.708 0.29 . . . . 0.0 111.052 -178.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 65.5 mtt -123.13 108.04 12.42 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 173.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.8 mm-40 -131.6 115.28 15.88 Favored 'General case' 0 C--N 1.307 -1.264 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 -175.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.35 14.16 59.08 Favored Glycine 0 N--CA 1.447 -0.568 0 N-CA-C 111.433 -0.667 . . . . 0.0 111.433 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.16 -23.97 30.98 Favored Glycine 0 N--CA 1.448 -0.549 0 N-CA-C 111.985 -0.446 . . . . 0.0 111.985 -179.037 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 6.9 pt-20 -99.96 152.8 19.77 Favored 'General case' 0 C--N 1.304 -1.388 0 C-N-CA 123.156 0.582 . . . . 0.0 110.56 -178.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -87.09 153.67 21.34 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-O 121.211 0.529 . . . . 0.0 110.144 178.344 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 55.3 t -113.61 118.21 43.58 Favored Pre-proline 0 C--N 1.288 -2.079 0 N-CA-C 107.194 -1.41 . . . . 0.0 107.194 175.243 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 72.5 Cg_endo -75.91 142.01 24.72 Favored 'Trans proline' 0 CA--C 1.539 0.744 0 C-N-CA 122.749 2.3 . . . . 0.0 113.846 -177.628 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.46 1.72 74.31 Favored Glycine 0 N--CA 1.439 -1.148 0 CA-C-N 115.359 -0.837 . . . . 0.0 114.438 174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.51 HD23 ' HA ' ' A' ' 171' ' ' VAL . 41.0 mt -135.7 152.77 51.5 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 122.548 -0.384 . . . . 0.0 111.436 -173.657 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.448 ' CD2' HG23 ' A' ' 20' ' ' ILE . 42.9 p90 -141.88 139.44 32.61 Favored 'General case' 0 N--CA 1.443 -0.817 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 174.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -112.19 155.93 23.15 Favored 'General case' 0 C--N 1.285 -2.198 0 N-CA-C 105.415 -2.068 . . . . 0.0 105.415 179.18 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . . . . . . . . . 75.9 t -110.58 113.72 45.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-O 121.743 0.782 . . . . 0.0 110.993 -176.084 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 31.6 t70 -82.14 159.04 23.43 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 174.77 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 24.7 m -97.85 138.08 35.74 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-O 121.546 0.688 . . . . 0.0 112.275 -170.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.412 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -136.93 124.61 22.38 Favored 'General case' 0 C--O 1.247 0.944 0 N-CA-C 107.132 -1.433 . . . . 0.0 107.132 176.138 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 51.9 mtm -93.67 128.86 40.07 Favored 'General case' 0 C--N 1.3 -1.577 0 CA-C-O 121.192 0.52 . . . . 0.0 111.909 -173.39 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.9 m -122.54 167.82 15.7 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.712 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 175.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -66.25 113.96 4.97 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 123.903 0.752 . . . . 0.0 110.633 173.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 92.0 t -109.01 97.44 5.73 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.653 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 174.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -104.1 169.35 17.6 Favored Glycine 0 N--CA 1.42 -2.382 0 CA-C-N 115.119 -0.946 . . . . 0.0 113.042 -173.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -78.93 63.78 3.78 Favored Glycine 0 N--CA 1.434 -1.442 0 CA-C-N 115.42 -0.39 . . . . 0.0 112.488 176.924 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -102.05 107.36 3.15 Favored Glycine 0 N--CA 1.421 -2.312 0 N-CA-C 107.94 -2.064 . . . . 0.0 107.94 176.016 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 11.6 m-20 -60.58 126.12 26.25 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -175.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.4 mm -88.81 74.69 1.11 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.642 0 N-CA-C 105.147 -2.168 . . . . 0.0 105.147 170.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -94.0 -40.03 10.32 Favored 'General case' 0 C--N 1.3 -1.561 0 CA-C-N 113.333 -1.758 . . . . 0.0 109.262 -176.047 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 57.3 mt 61.37 82.15 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.836 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.772 -178.176 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -135.63 129.07 4.87 Favored Glycine 0 CA--C 1.488 -1.628 0 N-CA-C 108.965 -1.654 . . . . 0.0 108.965 178.481 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 72.5 m 60.32 21.79 11.28 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 123.933 0.893 . . . . 0.0 111.074 -176.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.89 157.4 25.88 Favored Glycine 0 N--CA 1.428 -1.886 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 -175.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 71.83 6.35 5.61 Favored 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 125.464 1.506 . . . . 0.0 112.994 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.97 -49.95 5.32 Favored 'General case' 0 N--CA 1.435 -1.196 0 N-CA-C 107.329 -1.36 . . . . 0.0 107.329 175.115 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -126.44 -63.46 1.09 Allowed 'General case' 0 C--N 1.309 -1.171 0 CA-C-N 114.946 -1.025 . . . . 0.0 108.236 176.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -90.0 -162.84 38.69 Favored Glycine 0 N--CA 1.443 -0.847 0 CA-C-N 115.847 -0.615 . . . . 0.0 112.522 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -85.42 174.74 49.0 Favored Glycine 0 C--N 1.311 -0.813 0 C-N-CA 121.671 -0.299 . . . . 0.0 113.008 -176.195 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -137.55 -178.76 5.37 Favored 'General case' 0 C--N 1.309 -1.171 0 N-CA-C 109.247 -0.649 . . . . 0.0 109.247 179.613 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 105.23 -110.02 3.39 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 109.189 -1.564 . . . . 0.0 109.189 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -164.47 100.68 0.82 Allowed 'General case' 0 C--N 1.293 -1.872 0 N-CA-C 106.113 -1.81 . . . . 0.0 106.113 176.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -87.21 -31.3 20.39 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.051 -177.404 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -170.57 74.58 0.07 Allowed 'General case' 0 N--CA 1.434 -1.231 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -136.49 -76.36 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.778 0 N-CA-C 109.825 -1.31 . . . . 0.0 109.825 175.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -115.57 93.21 4.18 Favored 'General case' 0 C--N 1.294 -1.84 0 CA-C-O 121.44 0.638 . . . . 0.0 109.403 178.415 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -88.2 115.94 26.04 Favored 'General case' 0 C--N 1.311 -1.073 0 CA-C-N 115.903 -0.589 . . . . 0.0 110.685 -179.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 11.0 t70 -132.88 141.89 48.64 Favored 'General case' 0 C--N 1.297 -1.692 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.239 -179.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -150.37 30.18 0.69 Allowed 'General case' 0 C--N 1.316 -0.859 0 O-C-N 123.562 0.539 . . . . 0.0 109.939 -177.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 31.1 m -69.5 -35.8 75.87 Favored 'General case' 0 CA--C 1.558 1.288 0 N-CA-C 112.819 0.674 . . . . 0.0 112.819 -176.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 24.9 mt-30 -100.32 119.69 38.8 Favored 'General case' 0 C--N 1.307 -1.244 0 O-C-N 122.021 -0.424 . . . . 0.0 110.035 179.67 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 32.7 mmtp -105.54 120.39 41.51 Favored 'General case' 0 C--N 1.303 -1.415 0 N-CA-C 106.964 -1.495 . . . . 0.0 106.964 171.313 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -154.6 171.56 19.26 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.21 -177.148 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.424 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 56.5 t30 -56.79 124.98 20.35 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.811 0.815 . . . . 0.0 113.189 -172.386 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.431 HD21 ' HB2' ' A' ' 19' ' ' LYS . 7.8 p30 -58.14 -30.42 66.34 Favored 'General case' 0 N--CA 1.481 1.077 0 C-N-CA 125.435 1.494 . . . . 0.0 112.886 -177.757 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.405 HG22 ' HB3' ' A' ' 18' ' ' LEU . 25.9 t -73.19 -46.63 49.95 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.061 -177.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.424 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.0 p -76.33 -19.01 58.64 Favored 'General case' 0 N--CA 1.443 -0.782 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -41.61 117.6 1.23 Allowed Glycine 0 C--N 1.35 1.314 0 O-C-N 124.702 1.252 . . . . 0.0 114.218 -179.181 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -67.91 -14.25 40.77 Favored 'Trans proline' 0 C--N 1.361 1.213 0 C-N-CA 123.489 2.792 . . . . 0.0 113.121 -177.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 7.6 m -68.04 -26.35 65.83 Favored 'General case' 0 N--CA 1.441 -0.876 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.239 176.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 31.8 m -116.76 -70.61 0.78 Allowed 'General case' 0 N--CA 1.434 -1.256 0 N-CA-C 111.877 0.325 . . . . 0.0 111.877 -177.593 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.489 ' CE1' HD11 ' A' ' 18' ' ' LEU . 35.3 m-85 -92.19 -51.76 5.02 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 113.983 1.105 . . . . 0.0 113.983 -175.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 67.51 100.04 0.05 Allowed 'General case' 0 N--CA 1.49 1.526 0 C-N-CA 124.216 1.006 . . . . 0.0 113.218 179.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 70.6 m-85 -113.03 138.32 50.08 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-N 116.199 -0.455 . . . . 0.0 109.933 178.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 22.0 m -104.43 135.37 46.01 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.667 -1.235 . . . . 0.0 107.667 175.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -83.0 131.95 35.16 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 120.761 0.315 . . . . 0.0 111.033 -178.824 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.8 mmt -124.72 132.4 24.3 Favored Pre-proline 0 C--N 1.307 -1.246 0 C-N-CA 123.811 0.845 . . . . 0.0 108.8 178.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -65.12 165.22 22.47 Favored 'Trans proline' 0 CA--C 1.55 1.296 0 C-N-CA 123.378 2.718 . . . . 0.0 114.909 -175.679 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 19.8 m-85 -59.08 115.82 3.42 Favored 'General case' 0 N--CA 1.474 0.741 0 C-N-CA 124.128 0.971 . . . . 0.0 110.006 177.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 13.9 p -95.65 -68.04 0.82 Allowed 'General case' 0 C--N 1.299 -1.621 0 N-CA-C 111.831 0.308 . . . . 0.0 111.831 -179.696 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 70.3 m 60.89 22.63 12.74 Favored 'General case' 0 N--CA 1.474 0.732 0 C-N-CA 124.414 1.085 . . . . 0.0 111.548 -176.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 47.7 tttm -74.6 167.23 22.16 Favored 'General case' 0 CA--C 1.543 0.699 0 C-N-CA 124.847 1.259 . . . . 0.0 109.184 -176.223 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.66 -46.08 92.57 Favored Glycine 0 N--CA 1.465 0.624 0 O-C-N 122.966 0.166 . . . . 0.0 113.095 -178.799 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 3.2 mp0 -65.83 -30.28 70.88 Favored 'General case' 0 N--CA 1.449 -0.51 0 C-N-CA 123.525 0.73 . . . . 0.0 110.725 178.588 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 70.9 t80 -70.14 -37.41 75.26 Favored 'General case' 0 N--CA 1.442 -0.852 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.736 176.713 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.8 mmtp -67.22 -36.63 82.1 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 177.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 68.3 m -61.08 -39.36 89.6 Favored 'General case' 0 N--CA 1.442 -0.835 0 O-C-N 123.626 0.579 . . . . 0.0 109.801 173.694 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.515 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.5 t90 -64.16 -47.67 78.97 Favored 'General case' 0 C--O 1.199 -1.586 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.071 177.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 87.9 t -56.78 -50.1 76.04 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.983 0 C-N-CA 123.082 0.553 . . . . 0.0 111.742 -179.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.3 mttt -61.71 -47.55 84.75 Favored 'General case' 0 C--N 1.322 -0.612 0 O-C-N 123.397 0.435 . . . . 0.0 111.182 -178.804 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -70.69 -29.64 66.0 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.169 -0.469 . . . . 0.0 112.082 -179.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.447 ' O ' HG23 ' A' ' 105' ' ' VAL . 80.1 t80 -63.64 -55.94 19.68 Favored 'General case' 0 C--N 1.321 -0.672 0 C-N-CA 123.223 0.609 . . . . 0.0 109.735 175.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 71.7 t -56.25 -44.12 78.53 Favored 'Isoleucine or valine' 0 C--O 1.255 1.385 0 C-N-CA 123.469 0.708 . . . . 0.0 110.366 179.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.436 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.1 OUTLIER -60.28 -55.73 30.19 Favored 'General case' 0 N--CA 1.443 -0.777 0 CA-C-N 114.708 -1.133 . . . . 0.0 110.057 179.7 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.4 m-80 -68.06 -20.72 64.99 Favored 'General case' 0 CA--C 1.505 -0.787 0 N-CA-C 114.007 1.114 . . . . 0.0 114.007 -175.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.447 HG23 ' O ' ' A' ' 101' ' ' TYR . 51.6 t -62.08 -44.0 98.44 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.654 0 N-CA-C 108.673 -0.862 . . . . 0.0 108.673 171.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 42.5 mtt85 -68.89 -24.15 64.28 Favored 'General case' 0 CA--C 1.54 0.578 0 N-CA-C 112.131 0.419 . . . . 0.0 112.131 176.055 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -69.84 -28.58 65.8 Favored 'General case' 0 C--O 1.221 -0.424 0 CA-C-O 120.575 0.226 . . . . 0.0 110.636 172.513 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -75.01 -37.85 61.72 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 175.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 10.9 mp -59.2 -43.6 92.24 Favored 'General case' 0 N--CA 1.473 0.688 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.985 176.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 19.6 ptpt -84.21 -31.13 25.22 Favored 'General case' 0 C--N 1.32 -0.676 0 C-N-CA 120.384 -0.527 . . . . 0.0 112.383 179.142 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -79.21 -3.76 88.58 Favored Glycine 0 CA--C 1.511 -0.166 0 N-CA-C 114.181 0.432 . . . . 0.0 114.181 -175.171 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.1 p -91.21 -15.48 29.21 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-N 116.826 0.313 . . . . 0.0 111.302 177.365 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 65.47 38.7 95.11 Favored Glycine 0 C--N 1.34 0.796 0 C-N-CA 121.513 -0.375 . . . . 0.0 114.035 176.123 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 11.4 t -72.89 154.18 7.32 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.393 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 -178.345 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -64.99 150.01 48.79 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 122.328 0.251 . . . . 0.0 110.782 178.407 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 58.4 t -54.4 -43.49 63.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.33 0 N-CA-C 114.22 1.193 . . . . 0.0 114.22 -172.589 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -62.95 -41.42 99.51 Favored 'General case' 0 C--O 1.243 0.739 0 CA-C-O 120.962 0.41 . . . . 0.0 110.589 -179.427 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 9.3 m-20 -69.92 -36.16 75.13 Favored 'General case' 0 CA--C 1.506 -0.747 0 CA-C-N 115.896 -0.593 . . . . 0.0 109.922 176.236 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.1 mm -57.86 -39.3 70.62 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.771 0 C-N-CA 123.483 0.713 . . . . 0.0 110.897 176.252 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.49 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 68.4 mmtt -57.42 -49.49 76.05 Favored 'General case' 0 C--O 1.22 -0.462 0 O-C-N 123.158 0.286 . . . . 0.0 111.115 175.759 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.2 mmtm -63.38 -39.01 93.36 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.289 177.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.6 OUTLIER -68.61 -34.13 75.23 Favored 'General case' 0 CA--C 1.556 1.204 0 C-N-CA 124.363 1.065 . . . . 0.0 108.713 -175.959 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 59.7 mtt -80.45 -20.34 44.04 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.867 -0.606 . . . . 0.0 111.881 177.352 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.49 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 46.5 mt-10 -71.72 -33.67 68.93 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 108.464 -0.939 . . . . 0.0 108.464 173.593 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.83 -32.47 61.95 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 114.345 -1.298 . . . . 0.0 111.756 179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.615 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.65 -58.68 10.1 Favored Pre-proline 0 CA--C 1.57 1.724 0 N-CA-C 115.617 1.71 . . . . 0.0 115.617 -175.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.44 ' O ' ' HG3' ' A' ' 131' ' ' LYS . 36.9 Cg_endo -66.96 -27.44 42.92 Favored 'Trans proline' 0 C--N 1.375 1.97 0 CA-C-N 120.414 1.184 . . . . 0.0 111.068 178.676 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 46.6 m -66.67 -34.97 79.05 Favored 'General case' 0 N--CA 1.436 -1.153 0 C-N-CA 123.829 0.852 . . . . 0.0 110.495 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.615 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 18.4 m-85 -57.61 -52.59 64.78 Favored 'General case' 0 C--N 1.359 1.016 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 176.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.449 ' O ' HG23 ' A' ' 134' ' ' VAL . 14.9 t -60.53 -49.53 84.02 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.341 0 CA-C-N 114.187 -1.369 . . . . 0.0 111.524 -176.36 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.44 ' HG3' ' O ' ' A' ' 127' ' ' PRO . 94.4 mttt -55.95 -47.8 76.94 Favored 'General case' 0 N--CA 1.476 0.865 0 N-CA-C 112.929 0.714 . . . . 0.0 112.929 -176.511 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.515 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 50.0 t90 -70.68 -29.56 65.9 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-O 120.731 0.301 . . . . 0.0 111.653 -176.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.467 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -67.81 -36.28 80.12 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.727 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.449 HG23 ' O ' ' A' ' 130' ' ' VAL . 96.9 t -66.15 -37.29 79.43 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.538 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.624 176.602 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -62.0 -32.44 72.91 Favored 'General case' 0 N--CA 1.477 0.911 0 N-CA-C 113.672 0.99 . . . . 0.0 113.672 179.032 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.691 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -105.2 2.95 29.64 Favored 'General case' 0 C--O 1.21 -0.99 0 C-N-CA 119.607 -0.837 . . . . 0.0 113.201 178.084 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 60.4 t80 -51.45 -34.43 35.17 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 113.957 1.095 . . . . 0.0 113.957 -175.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 42.9 m-20 -88.99 2.71 53.56 Favored 'General case' 0 C--N 1.319 -0.73 0 O-C-N 121.737 -0.602 . . . . 0.0 112.515 -178.742 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 31.8 m-20 -114.78 -15.68 11.86 Favored 'General case' 0 C--N 1.31 -1.152 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.712 176.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.691 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 95.9 mt -83.16 119.87 25.07 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.916 0.865 . . . . 0.0 112.934 -172.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.4 tt0 -105.33 155.82 18.74 Favored 'General case' 0 N--CA 1.407 -2.591 0 N-CA-C 103.898 -2.63 . . . . 0.0 103.898 171.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 51.5 m-85 -106.63 145.32 32.09 Favored 'General case' 0 C--N 1.283 -2.321 0 C-N-CA 119.608 -0.837 . . . . 0.0 112.494 -165.318 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 32.3 m-85 -126.17 156.94 39.37 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.725 179.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 57.9 mtt -139.65 145.39 38.4 Favored 'General case' 0 C--N 1.29 -1.986 0 N-CA-C 106.15 -1.796 . . . . 0.0 106.15 177.233 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 80.8 p -85.68 175.02 8.97 Favored 'General case' 0 C--N 1.298 -1.649 0 N-CA-C 106.975 -1.491 . . . . 0.0 106.975 170.226 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 50.5 tptt -65.55 -29.33 69.93 Favored 'General case' 0 C--N 1.311 -1.078 0 CA-C-N 118.328 0.513 . . . . 0.0 111.69 -174.23 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 15.5 p -88.53 -4.04 58.68 Favored 'General case' 0 C--N 1.307 -1.24 0 N-CA-C 112.3 0.482 . . . . 0.0 112.3 179.671 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.8 mtt -102.26 157.97 16.52 Favored 'General case' 0 C--O 1.242 0.662 0 N-CA-C 113.759 1.022 . . . . 0.0 113.759 -174.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 83.6 m-20 -117.18 163.76 21.86 Favored Pre-proline 0 C--N 1.31 -1.144 0 CA-C-N 114.328 -1.305 . . . . 0.0 109.127 -174.818 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_endo -66.31 -28.03 47.47 Favored 'Trans proline' 0 C--N 1.352 0.73 0 C-N-CA 121.83 1.686 . . . . 0.0 110.521 173.105 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -86.1 -12.97 48.63 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-N 114.546 -1.207 . . . . 0.0 111.533 -176.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -160.19 113.14 2.1 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 -175.585 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 93.05 43.5 4.08 Favored Glycine 0 N--CA 1.447 -0.629 0 C-N-CA 119.431 -1.366 . . . . 0.0 112.468 -178.442 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.515 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 30.8 tp -99.57 114.46 27.49 Favored 'General case' 0 N--CA 1.431 -1.401 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 178.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 4.0 mp -88.24 140.82 15.19 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 123.809 0.844 . . . . 0.0 110.482 -175.476 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.424 ' HB3' HD13 ' A' ' 140' ' ' LEU . 85.5 m-85 -95.41 131.83 41.12 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 175.857 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 29.4 m -149.41 155.27 40.17 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 118.681 0.673 . . . . 0.0 111.277 176.354 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 33.7 p90 -149.98 179.4 8.09 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 174.501 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 32.2 m-85 -112.64 111.92 23.07 Favored 'General case' 0 C--N 1.291 -1.946 0 N-CA-C 109.33 -0.619 . . . . 0.0 109.33 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 66.0 tttt -91.8 154.48 18.89 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 -179.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 36.8 tt0 -62.59 122.82 16.76 Favored 'General case' 0 C--O 1.243 0.744 0 CA-C-O 121.157 0.503 . . . . 0.0 110.763 -178.582 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.62 -21.69 31.95 Favored Glycine 0 N--CA 1.439 -1.147 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 -178.325 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.47 124.58 44.75 Favored 'General case' 0 N--CA 1.427 -1.583 0 N-CA-C 109.15 -0.685 . . . . 0.0 109.15 176.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 88.4 m-70 -110.98 16.65 21.09 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-O 122.551 1.167 . . . . 0.0 108.189 177.479 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 78.5 m -125.17 158.95 61.75 Favored Pre-proline 0 N--CA 1.416 -2.155 0 N-CA-C 105.826 -1.916 . . . . 0.0 105.826 177.383 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -60.12 120.03 7.57 Favored 'Trans proline' 0 C--O 1.239 0.528 0 C-N-CA 121.734 1.623 . . . . 0.0 111.939 179.242 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.1 m -83.92 107.44 16.3 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 176.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.7 m-85 -82.13 145.51 30.09 Favored 'General case' 0 C--N 1.308 -1.231 0 CA-C-O 121.052 0.453 . . . . 0.0 110.918 -175.167 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.515 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 56.0 t -121.71 117.13 51.53 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.873 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.654 -178.932 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -136.25 163.74 29.71 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-O 121.619 0.724 . . . . 0.0 110.142 -179.798 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.51 ' HA ' HD23 ' A' ' 33' ' ' LEU . 39.6 t -100.17 127.59 52.99 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.775 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 177.555 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 36.8 ttpt -74.58 -56.63 4.61 Favored 'General case' 0 N--CA 1.47 0.529 0 CA-C-O 121.042 0.448 . . . . 0.0 111.172 -173.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 11.1 m -88.9 -3.76 58.65 Favored 'General case' 0 C--N 1.308 -1.228 0 CA-C-N 115.73 -0.668 . . . . 0.0 110.845 -175.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.484 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -88.25 -25.13 32.02 Favored Glycine 0 CA--C 1.497 -1.083 0 C-N-CA 121.008 -0.615 . . . . 0.0 111.806 -178.359 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.45 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 13.9 m-85 -96.86 157.26 15.99 Favored 'General case' 0 CA--C 1.489 -1.368 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 178.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 52.6 mtmt -85.05 109.6 18.34 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-O 121.309 0.576 . . . . 0.0 110.175 -174.336 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 47.5 t -79.53 103.38 6.42 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.022 0 CA-C-N 114.482 -1.236 . . . . 0.0 108.781 -178.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 59.8 t -113.82 135.85 52.16 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.264 -176.206 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.8 135.6 33.98 Favored 'General case' 0 C--N 1.285 -2.233 0 N-CA-C 107.322 -1.362 . . . . 0.0 107.322 178.523 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . 0.54 ' CE2' ' HB ' ' A' ' 3' ' ' VAL . 45.4 m-85 -68.41 117.64 10.45 Favored 'General case' 0 C--O 1.249 1.036 0 CA-C-O 121.014 0.435 . . . . 0.0 110.316 179.364 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 56.1 tp 71.11 -73.63 0.1 Allowed 'General case' 0 N--CA 1.453 -0.301 0 C-N-CA 126.029 1.732 . . . . 0.0 111.127 -177.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 52.09 74.61 0.26 Allowed 'General case' 0 C--O 1.24 0.577 0 CA-C-O 122.56 1.171 . . . . 0.0 110.942 -175.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 57.6 t60 -149.41 101.5 3.11 Favored 'General case' 0 C--N 1.297 -1.715 0 N-CA-C 105.809 -1.923 . . . . 0.0 105.809 179.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 35.8 t60 67.15 19.41 10.39 Favored 'General case' 0 N--CA 1.486 1.344 0 C-N-CA 124.41 1.084 . . . . 0.0 108.553 -176.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.0 t-160 63.83 -78.26 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.614 0 C-N-CA 125.173 1.389 . . . . 0.0 109.887 -172.028 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 1.9 m80 166.16 -79.13 0.0 OUTLIER 'General case' 0 N--CA 1.483 1.211 0 C-N-CA 128.238 2.615 . . . . 0.0 107.718 -179.996 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 38.8 t-80 -107.4 90.94 3.45 Favored 'General case' 0 N--CA 1.435 -1.215 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 17.4 t-80 . . . . . 0 C--O 1.246 0.899 0 C-N-CA 124.743 1.217 . . . . 0.0 110.497 -176.718 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 23.2 ttt . . . . . 0 CA--C 1.51 -0.589 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.455 ' HB ' ' HB3' ' A' ' 16' ' ' ASP . 44.8 mm -107.55 124.01 63.26 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.785 0 N-CA-C 106.276 -1.75 . . . . 0.0 106.276 178.803 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 6.1 p -132.13 147.93 32.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 C-N-CA 119.718 -0.793 . . . . 0.0 110.139 -178.658 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 71.8 m-85 -97.76 123.71 41.81 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.945 -0.571 . . . . 0.0 109.554 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 5.3 tptp -99.92 124.51 45.32 Favored 'General case' 0 C--N 1.299 -1.598 0 N-CA-C 107.07 -1.456 . . . . 0.0 107.07 179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.8 t70 -70.3 143.34 52.08 Favored 'General case' 0 C--N 1.312 -1.052 0 O-C-N 123.577 0.548 . . . . 0.0 110.446 178.481 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 18.8 t -80.85 -24.69 10.86 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 120.959 0.409 . . . . 0.0 110.752 -176.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.481 HG22 ' HA ' ' A' ' 152' ' ' ALA . 11.2 mm -83.1 -53.71 10.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.839 0 C-N-CA 120.13 -0.628 . . . . 0.0 110.334 -175.407 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 53.0 p -86.29 -42.49 13.69 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.38 0.609 . . . . 0.0 111.069 -179.676 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.84 9.12 61.36 Favored Glycine 0 N--CA 1.437 -1.284 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -175.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.8 t70 -99.78 177.14 5.22 Favored 'General case' 0 C--O 1.248 0.983 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 -176.504 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 -88.54 121.57 31.07 Favored 'General case' 0 C--N 1.32 -0.694 0 C-N-CA 122.548 0.339 . . . . 0.0 110.94 -175.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.43 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 9.0 m -93.16 -34.71 6.04 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.958 0 N-CA-C 112.549 0.574 . . . . 0.0 112.549 178.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.467 HG23 HD12 ' A' ' 18' ' ' LEU . 12.2 p -166.99 150.66 1.53 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.818 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -176.435 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 58.8 p -120.84 173.43 7.23 Favored 'General case' 0 C--N 1.302 -1.483 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 179.212 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.455 ' HB3' ' HB ' ' A' ' 2' ' ' ILE . 6.2 p-10 -70.71 -14.1 62.32 Favored 'General case' 0 N--CA 1.476 0.851 0 C-N-CA 123.383 0.673 . . . . 0.0 110.879 178.132 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.2 -25.82 59.91 Favored 'General case' 0 N--CA 1.441 -0.923 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.278 178.921 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.467 HD12 HG23 ' A' ' 14' ' ' VAL . 76.7 mt -89.4 178.72 6.25 Favored 'General case' 0 C--O 1.246 0.874 0 N-CA-C 109.605 -0.517 . . . . 0.0 109.605 -179.922 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.583 ' HE2' ' HA ' ' A' ' 19' ' ' LYS . 5.4 mmpt? -85.15 106.53 16.67 Favored 'General case' 0 C--O 1.212 -0.915 0 N-CA-C 113.593 0.96 . . . . 0.0 113.593 -176.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 75.9 mt -105.31 125.46 60.48 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 CA-C-N 115.404 -0.816 . . . . 0.0 108.863 179.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -121.37 140.5 31.47 Favored Pre-proline 0 C--N 1.3 -1.552 0 C-N-CA 122.665 0.386 . . . . 0.0 110.196 176.937 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.84 141.64 33.96 Favored 'Trans proline' 0 N--CA 1.452 -0.916 0 C-N-CA 121.134 1.223 . . . . 0.0 109.092 173.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 88.9 t -70.23 109.49 2.81 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.082 0 C-N-CA 120.719 -0.392 . . . . 0.0 110.716 -177.318 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . 0.419 ' HA ' ' O ' ' A' ' 28' ' ' GLU . 59.7 mtt -120.52 109.3 15.11 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-O 121.212 0.529 . . . . 0.0 110.227 176.193 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . 0.457 ' O ' ' HG2' ' A' ' 28' ' ' GLU . 71.9 mm-40 -98.65 103.95 15.94 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.02 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.89 19.62 63.47 Favored Glycine 0 CA--C 1.533 1.189 0 N-CA-C 114.355 0.502 . . . . 0.0 114.355 177.887 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 115.99 -21.85 11.92 Favored Glycine 0 N--CA 1.445 -0.723 0 C-N-CA 119.891 -1.147 . . . . 0.0 113.665 178.044 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 25' ' ' GLU . 14.3 pt-20 -99.33 147.1 25.56 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.052 -1.092 . . . . 0.0 108.052 -179.628 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.401 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.3 pt-20 -91.88 149.07 21.76 Favored 'General case' 0 N--CA 1.431 -1.402 0 C-N-CA 118.203 -1.399 . . . . 0.0 109.16 177.163 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 64.8 t -100.05 111.04 61.39 Favored Pre-proline 0 C--N 1.282 -2.352 0 N-CA-C 106.802 -1.555 . . . . 0.0 106.802 175.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -64.89 132.87 33.83 Favored 'Trans proline' 0 N--CA 1.455 -0.755 0 C-N-CA 122.847 2.365 . . . . 0.0 113.931 -174.033 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 90.9 0.14 75.34 Favored Glycine 0 N--CA 1.435 -1.422 0 CA-C-N 115.03 -0.986 . . . . 0.0 114.77 174.727 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.459 HD23 ' HA ' ' A' ' 171' ' ' VAL . 96.0 mt -122.96 158.91 29.42 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 117.437 0.618 . . . . 0.0 111.246 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.9 p90 -144.95 155.14 43.24 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 176.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -113.76 148.17 36.98 Favored 'General case' 0 C--N 1.264 -3.118 0 N-CA-C 106.68 -1.6 . . . . 0.0 106.68 -179.313 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 43.2 t -111.67 114.74 47.92 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.273 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 173.071 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -75.01 156.14 36.55 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.721 -171.341 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.8 m -99.0 134.25 42.11 Favored 'General case' 0 N--CA 1.412 -2.326 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 -177.332 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -154.04 124.73 7.14 Favored 'General case' 0 C--N 1.298 -1.673 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 66.8 mtt -79.14 140.81 37.69 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 123.359 0.412 . . . . 0.0 111.494 -178.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.8 m -136.28 159.81 38.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 172.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.78 140.51 36.87 Favored 'General case' 0 C--N 1.296 -1.74 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 175.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 77.4 t -63.01 -43.72 99.23 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-O 121.135 0.493 . . . . 0.0 109.779 179.029 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 111.84 158.87 14.79 Favored Glycine 0 N--CA 1.426 -1.975 0 C-N-CA 120.456 -0.878 . . . . 0.0 111.377 177.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.9 -170.97 23.27 Favored Glycine 0 N--CA 1.424 -2.148 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -177.86 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 65.07 -155.18 49.21 Favored Glycine 0 N--CA 1.446 -0.655 0 N-CA-C 111.193 -0.763 . . . . 0.0 111.193 179.452 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.509 ' HB2' ' CD1' ' A' ' 50' ' ' ILE . 9.2 m-20 -119.73 -28.55 5.22 Favored 'General case' 0 C--N 1.289 -2.042 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 176.503 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 71.6 mt 73.76 -29.58 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.557 1.214 0 C-N-CA 124.74 1.216 . . . . 0.0 112.742 179.904 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 38.9 m-20 -71.66 -3.46 21.79 Favored 'General case' 0 N--CA 1.475 0.793 0 C-N-CA 123.911 0.884 . . . . 0.0 112.707 -178.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.509 ' CD1' ' HB2' ' A' ' 47' ' ' ASP . 2.6 mp -78.66 115.14 20.34 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 179.15 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 78.57 -129.31 9.21 Favored Glycine 0 N--CA 1.422 -2.288 0 CA-C-N 115.52 -0.764 . . . . 0.0 112.444 177.276 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 60.0 m -126.98 132.54 50.78 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -176.89 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -71.08 -15.06 74.14 Favored Glycine 0 C--O 1.222 -0.619 0 N-CA-C 114.499 0.56 . . . . 0.0 114.499 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 46.0 m-80 -100.5 -0.22 38.31 Favored 'General case' 0 C--N 1.311 -1.099 0 O-C-N 122.012 -0.699 . . . . 0.0 111.132 177.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.51 125.65 42.32 Favored 'General case' 0 N--CA 1.434 -1.269 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 -179.989 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 84.9 m-85 -138.71 178.49 7.11 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 -178.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -86.74 -117.44 1.07 Allowed Glycine 0 N--CA 1.426 -2.01 0 O-C-N 123.888 0.743 . . . . 0.0 112.498 -179.665 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 82.81 22.95 57.07 Favored Glycine 0 C--N 1.31 -0.898 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 -174.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -161.42 40.17 0.14 Allowed 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 107.438 -1.319 . . . . 0.0 107.438 -179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 148.42 -76.19 0.26 Allowed Glycine 0 CA--C 1.491 -1.413 0 N-CA-C 108.575 -1.81 . . . . 0.0 108.575 -176.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 26.7 m-20 -87.76 88.24 7.6 Favored 'General case' 0 CA--C 1.492 -1.272 0 N-CA-C 107.456 -1.312 . . . . 0.0 107.456 170.603 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 30.2 m-20 -86.85 -58.81 2.46 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-N 114.724 -1.125 . . . . 0.0 108.5 -176.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -103.48 35.5 2.57 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.618 -179.306 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -162.5 -171.81 29.14 Favored Glycine 0 N--CA 1.43 -1.761 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -171.8 -172.35 1.0 Allowed 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 -178.869 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 36.9 t70 -100.32 3.82 43.63 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 122.595 1.188 . . . . 0.0 109.92 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -141.06 -161.16 1.17 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 105.863 -1.903 . . . . 0.0 105.863 178.462 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -119.28 33.52 5.61 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-O 122.17 0.986 . . . . 0.0 109.006 -179.636 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 4.6 m -78.0 2.09 18.77 Favored 'General case' 0 CA--C 1.577 1.989 0 CA-C-N 114.251 -1.34 . . . . 0.0 110.21 179.842 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 6.1 mp0 -47.71 125.41 8.55 Favored 'General case' 0 C--O 1.24 0.578 0 C-N-CA 125.719 1.608 . . . . 0.0 111.764 179.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 27.5 mtpp -105.48 128.06 53.35 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 178.36 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -138.07 159.78 41.12 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 107.463 -1.31 . . . . 0.0 107.463 -178.182 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.462 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 41.1 t30 -68.03 137.98 55.48 Favored 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 109.239 -0.652 . . . . 0.0 109.239 178.481 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.0 p30 -51.75 -27.77 13.06 Favored 'General case' 0 N--CA 1.491 1.606 0 C-N-CA 124.974 1.31 . . . . 0.0 113.332 -177.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 5.8 t -85.32 -39.66 14.14 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-O 121.179 0.514 . . . . 0.0 110.893 -176.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.462 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 2.9 p -83.07 -17.97 41.32 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 112.421 0.526 . . . . 0.0 112.421 -177.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -38.06 119.15 0.74 Allowed Glycine 0 C--O 1.254 1.362 0 C-N-CA 125.946 1.736 . . . . 0.0 114.867 -178.67 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 28.3 Cg_exo -66.5 -11.61 32.35 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.872 3.048 . . . . 0.0 113.18 -179.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.3 p -75.07 -8.31 56.17 Favored 'General case' 0 N--CA 1.427 -1.608 0 C-N-CA 123.551 0.74 . . . . 0.0 112.141 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 69.4 m -146.43 -62.78 0.31 Allowed 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 112.437 0.532 . . . . 0.0 112.437 177.643 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.443 ' CE1' HD11 ' A' ' 18' ' ' LEU . 74.4 m-85 -91.85 -44.48 8.92 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 113.117 0.784 . . . . 0.0 113.117 -173.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.421 ' HB3' ' HB2' ' A' ' 146' ' ' LYS . . . 60.14 89.75 0.07 Allowed 'General case' 0 N--CA 1.476 0.864 0 O-C-N 124.543 1.152 . . . . 0.0 112.266 -179.629 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.446 ' HA ' ' O ' ' A' ' 144' ' ' MET . 7.5 m-30 -95.01 126.7 40.54 Favored 'General case' 0 C--N 1.3 -1.566 0 CA-C-N 115.707 -0.678 . . . . 0.0 112.376 -178.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 25.9 m -112.05 137.57 49.9 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 107.558 -1.275 . . . . 0.0 107.558 176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.45 154.22 25.25 Favored 'General case' 0 C--N 1.323 -0.554 0 N-CA-C 113.354 0.872 . . . . 0.0 113.354 -175.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 95.4 mmm -140.19 132.69 14.74 Favored Pre-proline 0 C--N 1.323 -0.564 0 C-N-CA 125.837 1.655 . . . . 0.0 107.815 177.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -87.97 166.31 7.11 Favored 'Trans proline' 0 C--O 1.253 1.23 0 C-N-CA 122.39 2.06 . . . . 0.0 113.486 -178.494 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 47.5 m-85 -62.46 117.8 6.67 Favored 'General case' 0 CA--C 1.51 -0.56 0 CA-C-N 115.7 -0.682 . . . . 0.0 110.293 173.538 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.6 p -83.87 -41.5 17.39 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 171.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.3 m 63.26 16.07 9.14 Favored 'General case' 0 C--N 1.359 1.017 0 C-N-CA 125.545 1.538 . . . . 0.0 111.377 179.087 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.474 ' HA ' ' HE2' ' A' ' 91' ' ' LYS . 11.1 mmpt? -94.0 173.8 7.48 Favored 'General case' 0 N--CA 1.434 -1.246 0 CA-C-N 115.253 -0.885 . . . . 0.0 108.885 -178.757 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -53.16 -28.09 33.01 Favored Glycine 0 CA--C 1.531 1.049 0 O-C-N 123.878 0.736 . . . . 0.0 114.762 -178.234 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.408 ' OE2' ' HB2' ' A' ' 91' ' ' LYS . 0.0 OUTLIER -68.93 -43.14 75.73 Favored 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 118.379 1.09 . . . . 0.0 110.533 -179.392 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 77.8 t80 -67.6 -39.42 84.79 Favored 'General case' 0 N--CA 1.441 -0.903 0 C-N-CA 123.519 0.728 . . . . 0.0 109.912 177.936 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 14.3 mmmm -62.91 -41.84 99.58 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.571 177.854 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 50.4 m -68.13 -35.5 78.2 Favored 'General case' 0 N--CA 1.44 -0.931 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.482 177.828 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.514 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 84.7 t90 -63.39 -44.43 94.73 Favored 'General case' 0 C--O 1.22 -0.45 0 N-CA-C 110.154 -0.313 . . . . 0.0 110.154 177.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 81.6 t -58.95 -44.52 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.685 0 C-N-CA 122.607 0.363 . . . . 0.0 110.501 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 59.4 mtpt -65.22 -42.3 93.58 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.72 178.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -61.79 -42.59 99.2 Favored 'General case' 0 CA--C 1.504 -0.823 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.237 176.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 68.8 t80 -58.53 -49.46 77.32 Favored 'General case' 0 C--N 1.319 -0.742 0 C-N-CA 123.602 0.761 . . . . 0.0 109.929 179.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 92.1 t -61.27 -39.07 81.35 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.801 0 O-C-N 123.375 0.422 . . . . 0.0 110.735 178.527 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 33.6 ttm180 -64.97 -54.12 35.57 Favored 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 122.421 0.288 . . . . 0.0 111.031 177.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -62.17 -37.36 84.94 Favored 'General case' 0 CA--C 1.503 -0.852 0 O-C-N 123.816 0.698 . . . . 0.0 112.433 -175.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 55.7 t -62.97 -43.79 99.25 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.537 0 N-CA-C 109.854 -0.424 . . . . 0.0 109.854 174.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 82.5 mtm180 -66.46 -22.37 66.2 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 112.207 0.447 . . . . 0.0 112.207 179.0 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 22.0 mm-40 -72.3 -36.72 68.99 Favored 'General case' 0 CA--C 1.513 -0.455 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 178.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -65.36 -39.46 92.35 Favored 'General case' 0 C--O 1.225 -0.233 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.053 178.233 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 11.0 mp -58.21 -42.87 87.15 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-O 121.167 0.508 . . . . 0.0 111.793 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 96.1 mttt -83.34 -40.63 19.19 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 112.562 0.579 . . . . 0.0 112.562 -176.47 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.24 -3.0 82.59 Favored Glycine 0 C--N 1.317 -0.491 0 N-CA-C 116.133 1.213 . . . . 0.0 116.133 -172.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.4 p -74.78 -21.6 59.23 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 114.523 1.305 . . . . 0.0 114.523 -176.946 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 81.07 37.58 18.17 Favored Glycine 0 C--N 1.314 -0.652 0 C-N-CA 121.415 -0.422 . . . . 0.0 112.07 177.877 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.5 t -89.21 153.78 3.21 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 108.709 -0.848 . . . . 0.0 108.709 -179.373 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.46 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -68.05 153.99 42.58 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 122.521 0.329 . . . . 0.0 111.83 -178.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 85.6 t -53.59 -48.64 58.88 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.941 0 N-CA-C 115.357 1.614 . . . . 0.0 115.357 -170.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -67.28 -36.5 81.67 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 118.471 0.578 . . . . 0.0 111.164 -178.506 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.421 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.0 OUTLIER -64.94 -37.58 88.12 Favored 'General case' 0 CA--C 1.507 -0.674 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.88 174.125 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.46 HG12 ' O ' ' A' ' 115' ' ' ALA . 38.6 mm -57.37 -43.7 82.93 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.029 0 O-C-N 123.908 0.755 . . . . 0.0 110.669 176.141 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.415 ' O ' ' HG3' ' A' ' 124' ' ' GLU . 34.4 mmtp -62.06 -42.76 99.52 Favored 'General case' 0 C--N 1.321 -0.668 0 N-CA-C 111.869 0.322 . . . . 0.0 111.869 -179.924 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 9.4 mmpt? -69.24 -36.43 77.18 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-O 121.341 0.591 . . . . 0.0 109.994 179.414 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 0.8 OUTLIER -65.03 -35.82 82.39 Favored 'General case' 0 CA--C 1.551 1.001 0 C-N-CA 125.398 1.479 . . . . 0.0 108.818 -179.103 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 93.4 mtp -78.28 -17.11 57.07 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.715 -0.675 . . . . 0.0 112.014 179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.415 ' HG3' ' O ' ' A' ' 120' ' ' LYS . 36.5 mt-10 -75.79 -32.6 59.96 Favored 'General case' 0 CA--C 1.515 -0.398 0 N-CA-C 108.115 -1.068 . . . . 0.0 108.115 174.035 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -68.04 -30.7 69.99 Favored 'General case' 0 C--O 1.209 -1.031 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.142 177.792 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.583 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.21 -59.36 7.88 Favored Pre-proline 0 CA--C 1.578 2.044 0 N-CA-C 115.383 1.623 . . . . 0.0 115.383 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.29 -25.6 42.45 Favored 'Trans proline' 0 C--N 1.383 2.354 0 CA-C-N 120.849 1.339 . . . . 0.0 111.226 178.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 24.6 m -69.97 -33.58 72.27 Favored 'General case' 0 N--CA 1.435 -1.22 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.47 -179.656 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.583 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 20.5 m-85 -58.74 -51.71 68.78 Favored 'General case' 0 C--N 1.36 1.035 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 175.408 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 37.2 t -61.72 -41.0 88.8 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.838 0 CA-C-N 114.139 -1.391 . . . . 0.0 111.776 -177.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 58.6 mtpt -54.41 -50.21 68.11 Favored 'General case' 0 N--CA 1.482 1.168 0 N-CA-C 112.366 0.506 . . . . 0.0 112.366 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.653 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 21.3 t90 -71.83 -31.08 66.16 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.85 -175.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.524 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.7 mt -64.33 -41.62 96.7 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.641 -0.503 . . . . 0.0 109.641 176.377 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 90.8 t -70.75 -34.48 56.67 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.04 0 CA-C-O 121.1 0.476 . . . . 0.0 110.646 177.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -69.77 -27.86 65.28 Favored 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 113.495 0.924 . . . . 0.0 113.495 178.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.532 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.4 mmtt -103.95 -1.23 27.93 Favored 'General case' 0 C--N 1.31 -1.109 0 C-N-CA 120.555 -0.458 . . . . 0.0 111.024 178.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.435 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 69.8 t80 -56.07 -32.96 64.58 Favored 'General case' 0 N--CA 1.473 0.722 0 C-N-CA 124.87 1.268 . . . . 0.0 113.451 -174.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 26.6 m-20 -89.05 -6.14 57.36 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-O 121.305 0.574 . . . . 0.0 111.312 -176.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -108.56 5.74 25.37 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 116.11 -0.496 . . . . 0.0 110.462 177.584 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 157' ' ' SER . 90.0 mt -83.11 154.43 24.34 Favored 'General case' 0 N--CA 1.426 -1.627 0 CA-C-O 122.709 1.243 . . . . 0.0 114.017 -173.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 8.4 tp10 -142.2 149.45 39.71 Favored 'General case' 0 N--CA 1.402 -2.848 0 N-CA-C 103.362 -2.829 . . . . 0.0 103.362 170.228 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 91.9 m-85 -109.52 150.9 27.47 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.943 -1.103 . . . . 0.0 112.152 -175.735 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 62.8 m-85 -136.91 169.88 17.03 Favored 'General case' 0 C--N 1.298 -1.667 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.366 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.556 ' SD ' ' HD3' ' A' ' 150' ' ' PRO . 45.4 mtm -143.55 153.33 42.46 Favored 'General case' 0 C--N 1.291 -1.943 0 N-CA-C 104.754 -2.313 . . . . 0.0 104.754 175.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 91.5 p -87.26 174.73 8.4 Favored 'General case' 0 C--N 1.297 -1.679 0 N-CA-C 106.54 -1.652 . . . . 0.0 106.54 169.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . 0.421 ' HB2' ' HB3' ' A' ' 82' ' ' ALA . 50.4 tttp -65.45 -25.16 67.38 Favored 'General case' 0 C--N 1.308 -1.222 0 CA-C-O 121.607 0.717 . . . . 0.0 110.541 -178.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.3 p -89.54 -4.19 58.0 Favored 'General case' 0 CA--C 1.564 1.498 0 N-CA-C 113.743 1.016 . . . . 0.0 113.743 177.431 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 66.6 mtt -106.83 -178.33 3.62 Favored 'General case' 0 N--CA 1.476 0.849 0 N-CA-C 113.206 0.817 . . . . 0.0 113.206 -176.124 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.405 ' CG ' ' HD2' ' A' ' 150' ' ' PRO . 14.2 t-20 -144.65 157.79 54.68 Favored Pre-proline 0 C--O 1.215 -0.723 0 N-CA-C 106.262 -1.755 . . . . 0.0 106.262 -175.886 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.556 ' HD3' ' SD ' ' A' ' 144' ' ' MET . 38.7 Cg_endo -69.97 -18.03 36.25 Favored 'Trans proline' 0 CA--C 1.535 0.558 0 CA-C-N 121.259 1.485 . . . . 0.0 112.196 177.575 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -84.07 -25.87 29.46 Favored 'General case' 0 CA--C 1.506 -0.737 0 CA-C-O 121.049 0.452 . . . . 0.0 109.946 177.164 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.481 ' HA ' HG22 ' A' ' 8' ' ' ILE . . . -144.31 104.69 4.12 Favored 'General case' 0 N--CA 1.43 -1.459 0 CA-C-N 115.789 -0.641 . . . . 0.0 110.122 -175.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.49 42.87 3.56 Favored Glycine 0 N--CA 1.446 -0.686 0 C-N-CA 119.845 -1.169 . . . . 0.0 112.402 -177.512 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.514 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 43.4 tp -85.96 112.23 21.0 Favored 'General case' 0 N--CA 1.436 -1.155 0 N-CA-C 107.418 -1.326 . . . . 0.0 107.418 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 98.0 mt -85.07 131.57 33.81 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-N 114.846 -1.07 . . . . 0.0 111.684 -173.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.539 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 77.6 m-85 -89.44 137.01 32.7 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.541 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 79.1 p -149.42 149.7 31.23 Favored 'General case' 0 C--N 1.305 -1.34 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 174.519 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 11.7 p90 -136.62 161.92 34.57 Favored 'General case' 0 C--N 1.305 -1.352 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -94.55 107.21 19.2 Favored 'General case' 0 C--N 1.294 -1.815 0 C-N-CA 120.243 -0.583 . . . . 0.0 109.536 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 39.0 ttpt -81.17 156.69 25.58 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.768 -0.827 . . . . 0.0 108.768 178.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 72.4 mm-40 -57.39 126.42 27.21 Favored 'General case' 0 C--O 1.242 0.695 0 CA-C-O 121.306 0.574 . . . . 0.0 111.249 -179.01 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 92.32 -20.74 41.86 Favored Glycine 0 N--CA 1.441 -1.009 0 CA-C-N 115.387 -0.824 . . . . 0.0 112.898 179.085 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -86.53 124.96 33.41 Favored 'General case' 0 N--CA 1.437 -1.094 0 CA-C-O 120.797 0.332 . . . . 0.0 110.548 -177.35 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 30.5 m-70 -95.16 -3.58 47.6 Favored 'General case' 0 CA--C 1.506 -0.722 0 CA-C-O 121.337 0.589 . . . . 0.0 110.976 177.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 73.7 m -119.55 152.9 53.77 Favored Pre-proline 0 C--N 1.294 -1.812 0 N-CA-C 107.478 -1.304 . . . . 0.0 107.478 176.723 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 13.1 Cg_endo -56.93 133.28 56.95 Favored 'Trans proline' 0 C--O 1.249 1.047 0 C-N-CA 122.902 2.402 . . . . 0.0 113.215 179.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.5 m -98.23 123.26 42.21 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.753 -1.943 . . . . 0.0 105.753 176.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.492 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 91.1 m-85 -88.56 140.75 29.14 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 113.872 1.064 . . . . 0.0 113.872 -168.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.653 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 77.9 t -109.24 115.99 50.94 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.223 0 CA-C-N 113.999 -1.455 . . . . 0.0 109.208 -174.681 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.43 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 66.2 m-85 -138.93 158.29 44.48 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 121.592 0.71 . . . . 0.0 110.571 178.38 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.482 HG12 ' H ' ' A' ' 174' ' ' GLY . 57.9 t -92.18 119.68 40.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 CA-C-N 115.483 -0.781 . . . . 0.0 108.994 178.273 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -70.23 -56.0 7.89 Favored 'General case' 0 CA--C 1.505 -0.758 0 N-CA-C 112.134 0.42 . . . . 0.0 112.134 -174.391 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 12.3 m -80.8 -9.06 59.85 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.34 0.591 . . . . 0.0 111.299 -176.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.482 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -93.91 -20.58 30.63 Favored Glycine 0 C--O 1.214 -1.125 0 CA-C-N 115.797 -0.638 . . . . 0.0 112.758 -175.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.4 m-85 -97.25 156.6 16.35 Favored 'General case' 0 CA--C 1.487 -1.443 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 179.292 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 94.7 mttt -86.71 111.28 20.54 Favored 'General case' 0 C--N 1.298 -1.665 0 C-N-CA 120.485 -0.486 . . . . 0.0 111.023 -175.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 59.8 t -75.5 103.71 3.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.474 0 N-CA-C 107.965 -1.124 . . . . 0.0 107.965 175.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 44.8 t -113.68 128.63 70.47 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.814 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 -179.016 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 63.5 pttt -102.32 137.64 40.31 Favored 'General case' 0 N--CA 1.415 -2.203 0 C-N-CA 119.037 -1.065 . . . . 0.0 111.2 179.053 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 75.0 m-85 -117.64 157.48 26.35 Favored 'General case' 0 C--N 1.288 -2.076 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.017 177.011 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -148.89 154.76 39.92 Favored 'General case' 0 C--N 1.285 -2.23 0 N-CA-C 105.184 -2.154 . . . . 0.0 105.184 176.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -77.96 106.98 10.17 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 178.094 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 11.6 t-160 -147.03 -10.47 0.44 Allowed 'General case' 0 C--N 1.3 -1.579 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.186 -176.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 11.4 m170 -143.25 23.09 1.85 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 123.119 0.567 . . . . 0.0 110.895 178.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 11.7 t60 -119.66 57.57 0.91 Allowed 'General case' 0 C--N 1.306 -1.314 0 N-CA-C 107.872 -1.158 . . . . 0.0 107.872 178.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 36.6 m-70 -104.61 147.94 27.08 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-N 115.225 -0.898 . . . . 0.0 109.125 178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 1.4 p-80 -105.43 176.69 5.08 Favored 'General case' 0 C--N 1.303 -1.427 0 CA-C-O 121.286 0.565 . . . . 0.0 112.379 -175.023 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 78.5 t60 . . . . . 0 N--CA 1.429 -1.518 0 N-CA-C 106.511 -1.662 . . . . 0.0 106.511 175.536 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 49.0 ttp . . . . . 0 CA--C 1.519 -0.235 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 50.3 mm -84.96 135.72 24.24 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.148 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.6 p -135.47 142.82 38.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.8 0 N-CA-C 108.215 -1.032 . . . . 0.0 108.215 175.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 60.8 m-85 -106.49 122.56 46.55 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-N 116.458 -0.337 . . . . 0.0 110.368 -179.381 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 57.8 mttm -100.67 136.28 40.79 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.667 174.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.497 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 17.8 t70 -65.37 141.58 58.5 Favored 'General case' 0 C--N 1.314 -0.941 0 O-C-N 124.129 0.893 . . . . 0.0 109.905 176.532 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.5 t -68.32 -32.25 54.88 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.277 0 N-CA-C 112.22 0.452 . . . . 0.0 112.22 -176.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 14.5 mm -88.01 -46.66 15.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.244 0 C-N-CA 120.063 -0.655 . . . . 0.0 110.735 -172.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.405 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 33.0 p -87.34 -42.76 12.64 Favored 'General case' 0 C--N 1.31 -1.134 0 CA-C-O 121.023 0.44 . . . . 0.0 112.057 -178.543 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.22 11.44 64.7 Favored Glycine 0 N--CA 1.43 -1.729 0 N-CA-C 110.172 -1.171 . . . . 0.0 110.172 -172.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -95.05 157.78 15.75 Favored 'General case' 0 C--O 1.24 0.571 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 -179.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -78.35 128.24 33.38 Favored 'General case' 0 C--N 1.309 -1.167 0 CA-C-O 120.971 0.415 . . . . 0.0 111.742 -173.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 28.8 m -101.27 -28.34 3.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.996 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.854 -178.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -169.69 160.3 0.6 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.862 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 -178.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 72.8 p -135.98 171.65 14.15 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-O 120.716 0.293 . . . . 0.0 110.366 -179.31 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 20.5 t70 -64.58 -20.17 66.09 Favored 'General case' 0 N--CA 1.479 0.978 0 C-N-CA 125.516 1.526 . . . . 0.0 111.236 177.355 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -81.26 -7.18 59.52 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.487 179.19 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 84.7 mt -109.81 -168.01 1.27 Allowed 'General case' 0 N--CA 1.436 -1.151 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.537 -179.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.427 ' O ' HG13 ' A' ' 36' ' ' VAL . 27.6 mmmt -82.78 118.81 23.66 Favored 'General case' 0 C--N 1.309 -1.168 0 C-N-CA 123.102 0.561 . . . . 0.0 111.3 -178.628 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 70.5 mt -125.48 107.89 18.71 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.224 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 3.4 p -128.48 142.27 44.22 Favored Pre-proline 0 C--N 1.311 -1.098 0 N-CA-C 111.709 0.262 . . . . 0.0 111.709 -178.572 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -69.19 146.13 62.7 Favored 'Trans proline' 0 CA--C 1.536 0.612 0 C-N-CA 122.034 1.823 . . . . 0.0 111.187 176.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 48.2 t -75.45 118.32 21.28 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.849 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 179.578 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 62.6 mtt -117.12 108.46 15.74 Favored 'General case' 0 C--N 1.292 -1.908 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 175.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 5.1 mm-40 -137.8 112.98 9.21 Favored 'General case' 0 C--N 1.31 -1.149 0 O-C-N 123.749 0.656 . . . . 0.0 109.509 -177.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 102.14 -9.56 56.38 Favored Glycine 0 N--CA 1.437 -1.241 0 CA-C-N 115.5 -0.773 . . . . 0.0 111.629 179.342 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.55 -34.69 4.15 Favored Glycine 0 N--CA 1.432 -1.614 0 N-CA-C 110.839 -0.904 . . . . 0.0 110.839 -178.52 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -99.03 176.49 5.55 Favored 'General case' 0 N--CA 1.433 -1.31 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 177.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -94.51 154.27 17.49 Favored 'General case' 0 N--CA 1.427 -1.615 0 N-CA-C 109.086 -0.709 . . . . 0.0 109.086 178.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.402 ' CG1' HD12 ' A' ' 33' ' ' LEU . 21.7 t -101.64 117.17 62.37 Favored Pre-proline 0 C--N 1.287 -2.112 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 176.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 49.5 Cg_endo -68.05 136.44 37.92 Favored 'Trans proline' 0 C--O 1.239 0.565 0 C-N-CA 123.095 2.53 . . . . 0.0 115.069 -174.431 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 77.63 10.14 86.42 Favored Glycine 0 N--CA 1.448 -0.54 0 CA-C-N 114.452 -1.249 . . . . 0.0 114.514 173.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.451 HD11 ' HA ' ' A' ' 129' ' ' PHE . 88.4 mt -129.63 143.84 51.0 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.559 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 p90 -135.25 142.99 46.07 Favored 'General case' 0 N--CA 1.427 -1.62 0 C-N-CA 119.911 -0.716 . . . . 0.0 109.24 177.371 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.0 tt0 -103.37 146.36 28.6 Favored 'General case' 0 C--N 1.279 -2.468 0 N-CA-C 106.441 -1.688 . . . . 0.0 106.441 -179.182 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.549 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 68.9 t -110.37 112.88 42.49 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 N-CA-C 106.866 -1.531 . . . . 0.0 106.866 177.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -76.33 158.81 31.13 Favored 'General case' 0 C--N 1.301 -1.509 0 CA-C-N 114.168 -1.378 . . . . 0.0 109.83 -175.308 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 13.3 m -98.9 134.16 42.15 Favored 'General case' 0 N--CA 1.416 -2.174 0 CA-C-O 121.527 0.68 . . . . 0.0 109.904 -174.788 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.447 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -145.42 124.48 12.82 Favored 'General case' 0 C--N 1.311 -1.096 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -179.645 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.532 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 72.3 mtm -87.45 128.99 35.21 Favored 'General case' 0 C--N 1.302 -1.462 0 CA-C-O 121.173 0.511 . . . . 0.0 111.744 -178.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.2 m -121.28 165.46 16.84 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.961 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -69.08 114.82 7.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 124.143 0.902 . . . . 0.0 111.482 179.253 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 99.1 t -82.36 -48.31 18.27 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 107.392 -1.336 . . . . 0.0 107.392 175.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 158.43 -156.57 27.54 Favored Glycine 0 N--CA 1.417 -2.609 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -104.21 119.9 6.46 Favored Glycine 0 N--CA 1.429 -1.777 0 N-CA-C 110.809 -0.916 . . . . 0.0 110.809 178.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -103.01 -172.66 26.37 Favored Glycine 0 C--N 1.302 -1.309 0 N-CA-C 110.741 -0.943 . . . . 0.0 110.741 179.768 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 27.9 m-20 -88.55 -54.93 3.93 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 117.481 0.64 . . . . 0.0 111.712 -176.87 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 30.1 mt -92.11 79.35 1.46 Allowed 'Isoleucine or valine' 0 C--N 1.312 -1.029 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.454 -173.048 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 11.7 t70 177.15 114.44 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 105.871 -1.9 . . . . 0.0 105.871 173.306 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 62.4 mt -115.31 92.31 2.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 C-N-CA 120.477 -0.489 . . . . 0.0 111.185 -174.242 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 74.2 -81.1 0.82 Allowed Glycine 0 C--O 1.239 0.418 0 CA-C-N 115.431 -0.804 . . . . 0.0 113.381 176.513 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 39.6 m 66.21 179.33 0.21 Allowed 'General case' 0 C--O 1.254 1.33 0 C-N-CA 125.682 1.593 . . . . 0.0 111.834 178.21 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -86.41 70.7 2.92 Favored Glycine 0 CA--C 1.5 -0.856 0 N-CA-C 107.949 -2.061 . . . . 0.0 107.949 173.512 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 24.9 t30 -121.68 135.17 54.97 Favored 'General case' 0 C--N 1.293 -1.884 0 C-N-CA 123.864 0.865 . . . . 0.0 110.254 -169.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.21 121.68 27.41 Favored 'General case' 0 C--N 1.31 -1.123 0 N-CA-C 109.319 -0.622 . . . . 0.0 109.319 178.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 67.7 m-85 -93.19 6.36 48.29 Favored 'General case' 0 C--N 1.302 -1.469 0 CA-C-O 120.871 0.367 . . . . 0.0 111.498 -176.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -134.27 120.06 2.37 Favored Glycine 0 N--CA 1.439 -1.107 0 N-CA-C 110.392 -1.083 . . . . 0.0 110.392 177.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -116.8 -105.32 2.4 Favored Glycine 0 N--CA 1.436 -1.307 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.262 -177.889 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -127.13 -19.76 4.28 Favored 'General case' 0 C--N 1.309 -1.186 0 CA-C-O 121.083 0.468 . . . . 0.0 110.985 -178.799 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -163.33 43.43 0.33 Allowed Glycine 0 CA--C 1.484 -1.874 0 N-CA-C 108.345 -1.902 . . . . 0.0 108.345 -179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -115.45 14.94 16.78 Favored 'General case' 0 C--N 1.302 -1.485 0 CA-C-N 113.856 -1.172 . . . . 0.0 108.906 -172.018 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -59.8 -54.68 43.4 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 113.753 -1.567 . . . . 0.0 111.168 -174.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -119.54 29.23 7.72 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.516 -174.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -61.42 -45.93 95.4 Favored Glycine 0 C--N 1.337 0.636 0 N-CA-C 110.182 -1.167 . . . . 0.0 110.182 176.496 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -177.67 158.36 1.33 Allowed 'General case' 0 N--CA 1.446 -0.668 0 C-N-CA 125.719 1.607 . . . . 0.0 106.688 175.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 37.9 t70 -96.55 66.45 2.34 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-O 122.002 0.906 . . . . 0.0 110.483 179.273 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.8 t70 156.21 81.97 0.0 OUTLIER 'General case' 0 CA--C 1.497 -1.087 0 C-N-CA 129.048 2.939 . . . . 0.0 104.967 177.758 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . 0.423 ' O ' ' HE3' ' A' ' 71' ' ' LYS . . . -87.24 72.81 9.82 Favored 'General case' 0 C--N 1.295 -1.768 0 CA-C-N 115.851 -0.613 . . . . 0.0 111.012 -177.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -87.04 -43.57 12.22 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.799 -179.287 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -85.1 122.33 29.16 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.5 0.667 . . . . 0.0 112.083 -179.61 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.532 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 2.2 mptm? -120.66 143.26 48.79 Favored 'General case' 0 C--N 1.306 -1.315 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.074 176.881 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -152.65 160.35 43.17 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 105.74 -1.948 . . . . 0.0 105.74 176.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.544 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 36.9 t30 -61.93 129.82 42.72 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 123.723 0.639 . . . . 0.0 109.841 179.506 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -47.84 -29.53 3.31 Favored 'General case' 0 N--CA 1.486 1.343 0 N-CA-C 114.449 1.277 . . . . 0.0 114.449 -178.334 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . . . . . . . . . 21.7 t -84.31 -47.36 17.56 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.99 0 CA-C-O 120.609 0.242 . . . . 0.0 110.632 -177.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.544 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 4.9 p -76.13 -19.14 58.77 Favored 'General case' 0 C--O 1.244 0.816 0 N-CA-C 113.583 0.957 . . . . 0.0 113.583 -175.186 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -34.74 108.82 0.05 OUTLIER Glycine 0 C--N 1.361 1.956 0 O-C-N 125.201 1.563 . . . . 0.0 114.691 -178.662 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -60.92 -29.58 88.33 Favored 'Trans proline' 0 C--N 1.364 1.367 0 C-N-CA 124.231 3.288 . . . . 0.0 114.601 -175.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 32.4 t -72.27 -20.2 61.56 Favored 'General case' 0 C--N 1.314 -0.954 0 CA-C-O 120.858 0.361 . . . . 0.0 111.118 -179.497 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.6 m -113.75 -74.57 0.62 Allowed 'General case' 0 N--CA 1.435 -1.19 0 O-C-N 121.939 -0.476 . . . . 0.0 111.811 -176.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 93.6 m-85 -92.29 -48.15 6.83 Favored 'General case' 0 C--O 1.24 0.555 0 N-CA-C 112.681 0.622 . . . . 0.0 112.681 -177.326 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 64.9 88.54 0.1 Allowed 'General case' 0 N--CA 1.478 0.956 0 C-N-CA 124.613 1.165 . . . . 0.0 113.732 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.441 ' CE1' ' HB3' ' A' ' 145' ' ' SER . 72.2 m-85 -108.18 120.25 41.81 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 109.23 -0.656 . . . . 0.0 109.23 176.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 18.7 m -100.96 133.27 45.7 Favored 'General case' 0 C--N 1.306 -1.293 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.876 -177.119 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -82.01 128.39 34.04 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 120.979 0.418 . . . . 0.0 110.505 179.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 22.7 mmt -114.29 141.89 27.17 Favored Pre-proline 0 C--N 1.291 -1.944 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.26 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -68.03 164.42 32.01 Favored 'Trans proline' 0 CA--C 1.544 0.999 0 C-N-CA 122.835 2.357 . . . . 0.0 114.602 -174.254 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -58.04 136.66 57.18 Favored 'General case' 0 N--CA 1.473 0.706 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.318 175.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 11.7 p -111.21 -63.34 1.42 Allowed 'General case' 0 C--N 1.296 -1.729 0 N-CA-C 109.451 -0.574 . . . . 0.0 109.451 175.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 50.3 m 59.77 21.06 9.85 Favored 'General case' 0 N--CA 1.473 0.697 0 C-N-CA 125.022 1.329 . . . . 0.0 112.856 177.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 57.0 tttm -80.44 164.94 22.66 Favored 'General case' 0 CA--C 1.541 0.599 0 N-CA-C 108.342 -0.984 . . . . 0.0 108.342 -177.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -50.77 -50.55 36.99 Favored Glycine 0 N--CA 1.476 1.332 0 O-C-N 123.303 0.377 . . . . 0.0 113.949 -177.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -58.37 -35.28 71.75 Favored 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.136 0.974 . . . . 0.0 111.361 178.43 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -72.85 -36.0 67.35 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.411 179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.437 ' O ' ' HG3' ' A' ' 99' ' ' LYS . 14.6 mmmm -67.2 -33.81 76.17 Favored 'General case' 0 C--N 1.321 -0.658 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.167 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.2 m -62.08 -38.27 88.19 Favored 'General case' 0 CA--C 1.548 0.867 0 CA-C-N 115.911 -0.586 . . . . 0.0 109.829 173.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.608 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 86.3 t90 -63.49 -44.69 93.62 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.187 177.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 68.0 t -55.55 -42.83 70.2 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.775 0 O-C-N 123.565 0.54 . . . . 0.0 110.119 179.658 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.437 ' HG3' ' O ' ' A' ' 95' ' ' LYS . 93.8 mttt -63.17 -51.48 66.24 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.522 -0.763 . . . . 0.0 110.086 178.204 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 75.5 m-20 -61.49 -38.52 87.59 Favored 'General case' 0 CA--C 1.505 -0.784 0 O-C-N 123.517 0.511 . . . . 0.0 112.169 -179.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 85.8 t80 -58.86 -54.47 46.75 Favored 'General case' 0 C--N 1.318 -0.792 0 C-N-CA 122.891 0.476 . . . . 0.0 110.0 176.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 75.2 t -57.78 -40.86 77.97 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.793 0 O-C-N 123.58 0.55 . . . . 0.0 111.237 179.303 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' O ' ' A' ' 99' ' ' LYS . 9.8 mpt_? -71.29 -44.67 64.74 Favored 'General case' 0 C--O 1.215 -0.73 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -179.805 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 29.3 m-80 -65.22 -32.6 74.35 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 117.904 0.32 . . . . 0.0 111.852 179.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.414 ' O ' HD13 ' A' ' 109' ' ' LEU . 54.5 t -63.29 -40.23 88.25 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.785 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 173.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 36.0 ttm180 -68.05 -28.88 67.76 Favored 'General case' 0 CA--C 1.546 0.814 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.687 179.717 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.2 mp0 -67.43 -35.29 78.95 Favored 'General case' 0 C--O 1.225 -0.197 0 O-C-N 122.259 -0.275 . . . . 0.0 110.595 172.178 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.62 -34.56 77.23 Favored 'General case' 0 N--CA 1.468 0.453 0 CA-C-O 120.739 0.304 . . . . 0.0 110.283 178.064 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.416 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.1 mp -57.03 -39.16 74.26 Favored 'General case' 0 N--CA 1.477 0.895 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.86 174.256 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 94.6 mttt -83.51 -44.14 15.01 Favored 'General case' 0 C--N 1.314 -0.962 0 CA-C-N 115.757 -0.656 . . . . 0.0 111.559 -179.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -66.81 -18.13 68.09 Favored Glycine 0 N--CA 1.466 0.69 0 N-CA-C 114.81 0.684 . . . . 0.0 114.81 -174.904 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.3 p -76.4 -14.86 60.05 Favored 'General case' 0 C--N 1.312 -1.059 0 CA-C-N 117.17 0.485 . . . . 0.0 112.139 179.191 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 67.09 38.94 92.74 Favored Glycine 0 C--N 1.342 0.908 0 C-N-CA 121.088 -0.577 . . . . 0.0 113.412 175.649 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.1 t -71.91 154.45 7.62 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.314 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 -179.394 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -62.74 160.19 14.82 Favored 'General case' 0 CA--C 1.551 0.985 0 N-CA-C 112.575 0.583 . . . . 0.0 112.575 -177.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 68.4 t -53.88 -56.1 10.77 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.794 0 N-CA-C 114.572 1.323 . . . . 0.0 114.572 -172.349 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.433 ' O ' ' HG3' ' A' ' 121' ' ' LYS . 39.4 mt-10 -68.87 -28.99 67.2 Favored 'General case' 0 CA--C 1.51 -0.581 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 -179.062 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -66.55 -40.85 89.25 Favored 'General case' 0 C--O 1.207 -1.169 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.738 174.35 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 26.8 mm -58.71 -39.99 78.15 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.565 0 C-N-CA 123.784 0.834 . . . . 0.0 110.501 175.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -53.22 -54.74 31.68 Favored 'General case' 0 N--CA 1.475 0.797 0 O-C-N 123.742 0.651 . . . . 0.0 109.588 176.172 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.433 ' HG3' ' O ' ' A' ' 117' ' ' GLU . 5.7 mtpm? -63.76 -44.91 92.05 Favored 'General case' 0 C--O 1.207 -1.181 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.848 -179.217 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.416 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -61.0 -39.92 91.53 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.805 1.242 . . . . 0.0 109.97 -173.274 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 67.1 mtt -83.0 -14.17 54.5 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 112.215 0.45 . . . . 0.0 112.215 179.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -87.66 -25.96 23.25 Favored 'General case' 0 C--N 1.321 -0.64 0 CA-C-O 121.469 0.652 . . . . 0.0 110.076 173.878 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 43.0 mt-10 -82.79 -16.67 46.96 Favored 'General case' 0 C--N 1.305 -1.349 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.034 174.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.44 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -57.31 -48.43 97.36 Favored Pre-proline 0 CA--C 1.565 1.53 0 N-CA-C 113.596 0.961 . . . . 0.0 113.596 177.812 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_endo -63.14 -24.65 72.96 Favored 'Trans proline' 0 C--N 1.385 2.471 0 C-N-CA 121.932 1.755 . . . . 0.0 112.759 173.93 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 7.4 m -68.45 -34.5 76.08 Favored 'General case' 0 CA--C 1.541 0.614 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 178.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.451 ' HA ' HD11 ' A' ' 33' ' ' LEU . 12.5 m-30 -62.96 -42.74 99.91 Favored 'General case' 0 CA--C 1.509 -0.612 0 N-CA-C 108.441 -0.948 . . . . 0.0 108.441 176.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 58.2 t -62.65 -50.92 77.86 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.467 0 CA-C-N 114.354 -1.293 . . . . 0.0 110.022 179.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 57.2 mttm -52.05 -50.29 61.79 Favored 'General case' 0 CA--C 1.512 -0.508 0 N-CA-C 114.346 1.239 . . . . 0.0 114.346 -178.406 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.672 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 17.4 t90 -66.02 -37.0 84.78 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 123.425 0.453 . . . . 0.0 111.494 -176.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.2 mt -67.8 -43.35 79.9 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-O 120.957 0.408 . . . . 0.0 110.06 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 88.0 t -66.67 -40.95 87.36 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.774 0 CA-C-N 115.781 -0.645 . . . . 0.0 111.183 179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -64.99 -33.44 76.06 Favored 'General case' 0 N--CA 1.476 0.831 0 N-CA-C 112.277 0.473 . . . . 0.0 112.277 178.368 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.627 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 5.7 mptp? -97.76 2.0 49.04 Favored 'General case' 0 C--O 1.208 -1.115 0 N-CA-C 113.048 0.758 . . . . 0.0 113.048 -179.461 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.8 t80 -47.17 -47.0 23.99 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 113.855 1.057 . . . . 0.0 113.855 -174.275 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -74.83 -3.87 34.41 Favored 'General case' 0 N--CA 1.481 1.093 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 13.4 m-20 -108.64 -21.02 12.89 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.327 0.251 . . . . 0.0 110.826 177.703 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.627 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 85.6 mt -83.64 119.71 25.09 Favored 'General case' 0 N--CA 1.437 -1.089 0 CA-C-O 121.271 0.558 . . . . 0.0 111.923 -172.714 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 40.6 mt-10 -104.91 157.05 17.48 Favored 'General case' 0 N--CA 1.417 -2.111 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 173.026 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.405 ' HA ' ' O ' ' A' ' 155' ' ' ILE . 40.3 m-85 -104.28 110.97 23.4 Favored 'General case' 0 C--N 1.286 -2.168 0 CA-C-O 121.642 0.734 . . . . 0.0 112.046 -164.903 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.482 ' CE2' ' HB2' ' A' ' 157' ' ' SER . 15.8 m-85 -95.03 144.33 25.79 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.783 -177.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.519 ' HE2' ' HA ' ' A' ' 150' ' ' PRO . 50.7 mtt -132.89 137.07 46.54 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 105.228 -2.138 . . . . 0.0 105.228 176.143 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . 0.441 ' HB3' ' CE1' ' A' ' 83' ' ' TYR . 84.3 p -79.59 175.22 10.81 Favored 'General case' 0 C--N 1.303 -1.413 0 C-N-CA 118.922 -1.111 . . . . 0.0 108.708 175.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -61.06 -32.62 72.26 Favored 'General case' 0 C--N 1.297 -1.678 0 CA-C-N 115.546 -0.752 . . . . 0.0 109.988 177.276 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.9 p -90.01 -3.9 57.72 Favored 'General case' 0 CA--C 1.566 1.586 0 N-CA-C 114.234 1.198 . . . . 0.0 114.234 178.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 54.9 mtt -101.26 176.19 5.33 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -175.133 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -134.82 162.82 55.42 Favored Pre-proline 0 C--O 1.22 -0.479 0 C-N-CA 124.617 1.167 . . . . 0.0 109.195 -175.346 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.519 ' HA ' ' HE2' ' A' ' 144' ' ' MET . 19.5 Cg_endo -61.18 -36.59 79.92 Favored 'Trans proline' 0 C--N 1.362 1.267 0 C-N-CA 122.455 2.103 . . . . 0.0 113.856 176.976 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 12.3 m-20 -87.62 -32.46 19.27 Favored 'General case' 0 CA--C 1.495 -1.171 0 C-N-CA 120.226 -0.589 . . . . 0.0 110.44 -179.285 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.405 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -122.22 108.16 12.97 Favored 'General case' 0 N--CA 1.424 -1.736 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.648 -175.142 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.22 43.12 3.56 Favored Glycine 0 N--CA 1.44 -1.08 0 C-N-CA 120.072 -1.061 . . . . 0.0 112.171 -178.475 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.608 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 24.0 tp -99.59 112.09 24.35 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 177.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . 0.405 ' O ' ' HA ' ' A' ' 142' ' ' PHE . 96.5 mt -93.39 135.74 27.17 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 CA-C-N 114.658 -1.156 . . . . 0.0 111.636 -173.922 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 87.5 m-85 -89.92 132.69 35.17 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 172.923 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.482 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 37.4 m -149.3 149.56 31.12 Favored 'General case' 0 C--N 1.311 -1.071 0 O-C-N 121.616 -0.678 . . . . 0.0 110.065 174.758 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.7 p90 -140.42 162.78 34.5 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 120.756 -0.378 . . . . 0.0 110.944 178.829 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 15.0 m-85 -99.79 103.81 15.46 Favored 'General case' 0 C--N 1.288 -2.095 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 175.378 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 60.3 pttt -80.59 171.76 14.63 Favored 'General case' 0 C--N 1.313 -0.995 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.079 177.442 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.9 mp0 -55.19 116.93 3.08 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 123.522 0.729 . . . . 0.0 111.662 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 94.32 -12.68 68.62 Favored Glycine 0 N--CA 1.442 -0.912 0 CA-C-N 115.923 -0.581 . . . . 0.0 113.298 176.821 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -78.18 124.88 28.58 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.155 0.502 . . . . 0.0 110.123 -178.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 64.0 m80 -90.81 -29.76 17.39 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 178.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.468 ' CB ' ' HB2' ' A' ' 73' ' ' ASN . 65.0 m -111.45 160.49 29.16 Favored Pre-proline 0 C--N 1.289 -2.025 0 CA-C-N 114.554 -1.203 . . . . 0.0 107.972 179.709 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.9 139.78 75.91 Favored 'Trans proline' 0 C--O 1.247 0.931 0 C-N-CA 122.317 2.011 . . . . 0.0 113.964 -178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 61.7 m -99.85 116.54 32.16 Favored 'General case' 0 C--N 1.292 -1.931 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 174.835 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.549 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 59.5 m-85 -84.05 145.86 28.25 Favored 'General case' 0 C--N 1.311 -1.071 0 CA-C-O 121.328 0.585 . . . . 0.0 112.289 -171.743 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.672 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 48.4 t -120.7 116.72 50.85 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.831 0 C-N-CA 124.594 1.157 . . . . 0.0 110.153 -174.923 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.611 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 49.4 m-85 -139.15 155.04 48.14 Favored 'General case' 0 C--O 1.241 0.618 0 CA-C-O 121.117 0.484 . . . . 0.0 110.387 179.803 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.435 HG12 ' H ' ' A' ' 174' ' ' GLY . 37.4 t -90.1 121.22 40.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 176.055 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 37.7 ttpt -70.35 -56.63 6.23 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 121.379 0.609 . . . . 0.0 111.046 -174.562 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.4 m -81.36 -10.35 59.56 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.202 -0.908 . . . . 0.0 111.554 -174.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.435 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -95.36 -17.64 36.02 Favored Glycine 0 N--CA 1.44 -1.069 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.856 -176.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.497 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.3 m-85 -97.16 164.53 12.46 Favored 'General case' 0 CA--C 1.502 -0.873 0 CA-C-O 121.074 0.464 . . . . 0.0 111.187 -177.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 53.6 mtmt -86.08 104.68 15.9 Favored 'General case' 0 N--CA 1.429 -1.478 0 CA-C-N 115.567 -0.742 . . . . 0.0 110.935 -176.027 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 43.4 t -82.07 109.96 16.75 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 CA-C-N 114.059 -1.428 . . . . 0.0 108.38 179.317 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 21.8 t -116.73 138.2 48.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 179.584 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -112.64 109.04 18.32 Favored 'General case' 0 C--N 1.294 -1.808 0 CA-C-O 121.466 0.65 . . . . 0.0 112.473 179.766 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 68.6 m-85 -107.45 143.42 35.83 Favored 'General case' 0 C--N 1.306 -1.302 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 176.589 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.8 tm? -95.92 -29.32 14.24 Favored 'General case' 0 C--N 1.296 -1.725 0 N-CA-C 106.291 -1.744 . . . . 0.0 106.291 177.311 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 5.0 pm0 -77.35 156.14 31.46 Favored 'General case' 0 N--CA 1.426 -1.673 0 CA-C-N 114.366 -1.288 . . . . 0.0 108.854 176.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 44.3 m80 -117.88 129.56 55.71 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 106.987 -1.486 . . . . 0.0 106.987 -179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 44.4 m80 -87.66 12.27 13.08 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-O 122.163 0.982 . . . . 0.0 110.699 -178.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 46.7 t-80 -122.99 86.38 2.57 Favored 'General case' 0 C--N 1.301 -1.533 0 N-CA-C 103.335 -2.839 . . . . 0.0 103.335 172.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 8.4 t60 -119.75 -10.89 9.47 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.26 -0.882 . . . . 0.0 111.571 -170.038 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -71.53 129.29 38.4 Favored 'General case' 0 C--N 1.304 -1.389 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 179.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 12.8 p80 . . . . . 0 C--N 1.31 -1.151 0 N-CA-C 108.216 -1.031 . . . . 0.0 108.216 178.858 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 24.8 ttt . . . . . 0 C--O 1.218 -0.602 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.1 mt -103.44 125.68 57.94 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.813 0 N-CA-C 107.073 -1.454 . . . . 0.0 107.073 174.464 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.4 p -131.02 148.12 33.04 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.823 0 CA-C-O 120.931 0.396 . . . . 0.0 110.013 -176.571 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 50.3 m-85 -103.82 122.26 44.75 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 179.373 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 176' ' ' LYS . 65.7 mttm -100.85 139.03 37.1 Favored 'General case' 0 C--N 1.301 -1.516 0 N-CA-C 109.333 -0.618 . . . . 0.0 109.333 175.467 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.502 ' HA ' ' CE1' ' A' ' 175' ' ' TYR . 14.9 t70 -65.83 137.89 57.52 Favored 'General case' 0 C--N 1.313 -0.993 0 O-C-N 123.813 0.696 . . . . 0.0 109.414 174.586 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 33.7 t -65.17 -28.72 45.32 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 112.746 0.647 . . . . 0.0 112.746 -175.078 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.437 HD11 ' HA ' ' A' ' 101' ' ' TYR . 19.0 mm -91.91 -42.28 13.48 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 C-N-CA 119.967 -0.693 . . . . 0.0 110.908 -173.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.424 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 32.2 p -88.81 -42.5 11.86 Favored 'General case' 0 C--N 1.316 -0.854 0 N-CA-C 112.378 0.511 . . . . 0.0 112.378 -178.975 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 86.71 16.42 61.71 Favored Glycine 0 N--CA 1.438 -1.212 0 N-CA-C 110.259 -1.136 . . . . 0.0 110.259 -172.695 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 20.7 t70 -101.41 158.04 16.36 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 -178.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 6.3 mp0 -73.72 129.11 37.25 Favored 'General case' 0 C--N 1.309 -1.186 0 C-N-CA 123.379 0.672 . . . . 0.0 111.895 -174.556 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.514 ' HB ' ' CZ ' ' A' ' 170' ' ' TYR . 30.7 m -102.75 -30.52 2.95 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-O 120.962 0.411 . . . . 0.0 111.741 177.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 8.8 p -172.89 155.66 0.51 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.856 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 34.8 p -123.58 164.08 19.73 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 3.2 p-10 -68.53 -15.25 63.48 Favored 'General case' 0 N--CA 1.485 1.301 0 N-CA-C 112.936 0.717 . . . . 0.0 112.936 -175.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.55 -19.89 57.44 Favored 'General case' 0 C--O 1.239 0.537 0 CA-C-O 121.183 0.516 . . . . 0.0 110.321 177.109 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.442 HD13 ' HA ' ' A' ' 75' ' ' VAL . 93.6 mt -89.67 172.03 9.23 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.264 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.411 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 5.1 tmtm? -77.0 106.7 8.85 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-O 120.809 0.338 . . . . 0.0 110.224 -176.149 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.435 HG23 ' CD2' ' A' ' 34' ' ' PHE . 68.0 mt -118.5 124.27 72.87 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 177.988 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.2 p -127.66 144.44 51.14 Favored Pre-proline 0 C--N 1.305 -1.362 0 C-N-CA 122.306 0.242 . . . . 0.0 110.574 177.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -69.73 152.55 69.49 Favored 'Trans proline' 0 C--O 1.244 0.804 0 C-N-CA 121.584 1.523 . . . . 0.0 109.859 174.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 78.7 t -68.77 116.89 10.21 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 C-N-CA 120.879 -0.328 . . . . 0.0 111.113 -179.279 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 63.6 mtt -120.17 108.95 14.85 Favored 'General case' 0 N--CA 1.425 -1.679 0 N-CA-C 109.321 -0.622 . . . . 0.0 109.321 176.158 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 60.2 mm-40 -90.44 -173.63 3.85 Favored 'General case' 0 C--N 1.308 -1.238 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 177.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -69.36 90.9 0.29 Allowed Glycine 0 C--N 1.308 -0.972 0 C-N-CA 121.532 -0.366 . . . . 0.0 113.418 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 120.42 -54.82 0.65 Allowed Glycine 0 N--CA 1.439 -1.102 0 CA-C-O 119.658 -0.524 . . . . 0.0 113.497 176.627 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.03 172.41 9.99 Favored 'General case' 0 C--N 1.31 -1.112 0 CA-C-N 118.021 0.911 . . . . 0.0 110.884 -178.105 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 11.1 pt-20 -92.04 153.83 19.16 Favored 'General case' 0 N--CA 1.435 -1.219 0 N-CA-C 107.687 -1.227 . . . . 0.0 107.687 173.401 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 48.6 t -100.0 106.87 43.89 Favored Pre-proline 0 C--N 1.289 -2.039 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 175.021 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_endo -66.5 129.46 21.36 Favored 'Trans proline' 0 N--CA 1.449 -1.101 0 C-N-CA 122.702 2.268 . . . . 0.0 114.85 -171.628 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 99.38 -3.11 57.84 Favored Glycine 0 CA--C 1.493 -1.304 0 CA-C-N 114.728 -1.124 . . . . 0.0 114.033 174.157 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.511 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.3 mt -121.03 154.15 36.42 Favored 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 110.078 -0.342 . . . . 0.0 110.078 -178.034 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.435 ' CD2' HG23 ' A' ' 20' ' ' ILE . 29.3 p90 -135.05 145.37 47.93 Favored 'General case' 0 N--CA 1.425 -1.686 0 C-N-CA 120.037 -0.665 . . . . 0.0 109.818 176.492 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -107.98 148.69 29.35 Favored 'General case' 0 C--N 1.282 -2.364 0 N-CA-C 107.155 -1.424 . . . . 0.0 107.155 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.501 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 72.2 t -109.97 114.87 48.2 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.695 0 CA-C-O 121.903 0.858 . . . . 0.0 108.947 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.411 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 22.4 t70 -83.0 157.57 22.88 Favored 'General case' 0 C--N 1.294 -1.833 0 CA-C-N 113.478 -1.692 . . . . 0.0 109.066 -179.14 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 18.9 m -98.94 135.28 40.59 Favored 'General case' 0 N--CA 1.427 -1.619 0 C-N-CA 120.083 -0.647 . . . . 0.0 110.684 -175.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -132.56 124.83 29.16 Favored 'General case' 0 C--N 1.304 -1.386 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 177.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 25.1 mmt -84.23 116.71 23.1 Favored 'General case' 0 C--N 1.311 -1.108 0 O-C-N 123.91 0.756 . . . . 0.0 111.393 -175.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.5 m -120.84 154.2 24.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.111 177.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -79.19 133.12 36.71 Favored 'General case' 0 C--N 1.301 -1.543 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 176.453 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 59.0 t -65.99 97.93 0.27 Allowed 'Isoleucine or valine' 0 C--O 1.245 0.834 0 CA-C-O 121.514 0.673 . . . . 0.0 111.554 -178.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -160.86 84.12 0.12 Allowed Glycine 0 N--CA 1.431 -1.644 0 N-CA-C 108.404 -1.878 . . . . 0.0 108.404 176.837 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -106.03 154.87 16.89 Favored Glycine 0 N--CA 1.44 -1.099 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.955 -175.173 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 151.57 -158.27 27.65 Favored Glycine 0 N--CA 1.431 -1.667 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 17.3 m-20 -75.79 122.45 24.08 Favored 'General case' 0 C--N 1.307 -1.269 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 176.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 3.2 mp 66.23 69.01 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.547 0.829 0 CA-C-O 123.019 1.39 . . . . 0.0 107.841 -171.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -96.32 177.84 5.57 Favored 'General case' 0 C--N 1.299 -1.63 0 CA-C-N 113.498 -1.683 . . . . 0.0 111.551 -176.179 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 51.2 mm -90.61 90.7 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.017 0 N-CA-C 108.285 -1.006 . . . . 0.0 108.285 176.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -168.78 178.75 42.01 Favored Glycine 0 N--CA 1.432 -1.633 0 N-CA-C 109.449 -1.461 . . . . 0.0 109.449 -179.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 85.1 m 68.64 -65.19 0.28 Allowed 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 125.077 1.351 . . . . 0.0 111.083 -177.352 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -101.88 63.67 0.49 Allowed Glycine 0 CA--C 1.493 -1.343 0 N-CA-C 108.048 -2.021 . . . . 0.0 108.048 175.741 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 9.9 m-80 -54.83 -50.58 68.25 Favored 'General case' 0 C--N 1.318 -0.787 0 C-N-CA 125.946 1.699 . . . . 0.0 111.7 -173.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.77 -39.64 2.95 Favored 'General case' 0 C--N 1.303 -1.424 0 CA-C-N 115.755 -0.657 . . . . 0.0 110.325 -178.898 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 59.1 m-85 -126.74 138.9 53.45 Favored 'General case' 0 CA--C 1.501 -0.91 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -178.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 80.01 39.6 16.16 Favored Glycine 0 C--N 1.31 -0.896 0 C-N-CA 120.988 -0.625 . . . . 0.0 112.19 178.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 169.7 -44.57 0.21 Allowed Glycine 0 N--CA 1.44 -1.09 0 C-N-CA 120.356 -0.925 . . . . 0.0 112.449 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -93.72 92.62 7.57 Favored 'General case' 0 C--N 1.314 -0.935 0 O-C-N 122.642 -0.328 . . . . 0.0 111.146 179.378 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -107.41 -146.17 12.64 Favored Glycine 0 N--CA 1.447 -0.579 0 N-CA-C 110.778 -0.929 . . . . 0.0 110.778 178.786 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.3 p-10 -89.65 60.81 5.23 Favored 'General case' 0 N--CA 1.473 0.696 0 CA-C-O 122.724 1.25 . . . . 0.0 110.765 -179.783 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 15.6 m-20 -108.81 -48.92 3.22 Favored 'General case' 0 C--N 1.304 -1.401 0 CA-C-N 115.135 -0.939 . . . . 0.0 111.105 -177.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER 63.39 70.55 0.53 Allowed 'General case' 0 C--O 1.241 0.621 0 O-C-N 124.267 0.98 . . . . 0.0 111.37 -172.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -111.72 128.19 8.5 Favored Glycine 0 N--CA 1.435 -1.422 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 176.103 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 72.6 -43.06 0.55 Allowed 'General case' 0 N--CA 1.485 1.287 0 C-N-CA 125.235 1.414 . . . . 0.0 112.796 -177.604 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 65.7 t0 -76.84 102.25 6.24 Favored 'General case' 0 C--N 1.32 -0.691 0 N-CA-C 109.521 -0.548 . . . . 0.0 109.521 178.962 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 20.0 t70 -150.91 -63.27 0.19 Allowed 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 177.248 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -152.19 82.63 1.26 Allowed 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 107.977 -1.119 . . . . 0.0 107.977 171.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 15.2 t -143.9 170.97 14.9 Favored 'General case' 0 N--CA 1.434 -1.263 0 N-CA-C 108.796 -0.816 . . . . 0.0 108.796 -176.427 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -77.54 149.35 34.92 Favored 'General case' 0 N--CA 1.427 -1.617 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 176.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -118.64 121.2 39.6 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 174.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.48 171.55 14.32 Favored 'General case' 0 C--N 1.285 -2.214 0 CA-C-N 115.174 -0.921 . . . . 0.0 108.693 -170.902 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 43.0 t30 -70.83 131.19 43.42 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 176.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -51.76 -29.71 19.91 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 114.032 1.123 . . . . 0.0 114.032 179.421 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 40.6 t -83.61 -33.06 9.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 120.732 0.301 . . . . 0.0 111.692 -174.588 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 2.9 p -77.11 -41.99 39.81 Favored 'General case' 0 N--CA 1.415 -2.189 0 C-N-CA 120.591 -0.443 . . . . 0.0 111.079 -179.402 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 37.32 88.85 0.01 OUTLIER Glycine 0 C--N 1.358 1.757 0 O-C-N 125.034 1.459 . . . . 0.0 115.186 173.349 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -56.91 -27.95 75.23 Favored 'Trans proline' 0 N--CA 1.492 1.426 0 C-N-CA 123.34 2.693 . . . . 0.0 114.333 -177.04 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 14.8 m -92.34 0.26 57.43 Favored 'General case' 0 C--N 1.313 -0.983 0 N-CA-C 111.772 0.286 . . . . 0.0 111.772 -179.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 19.5 m -127.24 -70.25 0.72 Allowed 'General case' 0 N--CA 1.441 -0.884 0 CA-C-O 120.897 0.38 . . . . 0.0 111.673 -174.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.4 m-85 -91.47 -51.53 5.23 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.449 -175.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.13 89.35 0.05 Allowed 'General case' 0 N--CA 1.475 0.78 0 C-N-CA 125.002 1.321 . . . . 0.0 112.808 178.057 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 98.7 m-85 -94.35 135.45 35.75 Favored 'General case' 0 C--N 1.31 -1.118 0 CA-C-O 121.396 0.617 . . . . 0.0 111.39 -178.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . 0.532 ' O ' ' HA ' ' A' ' 143' ' ' PHE . 20.8 m -104.74 126.95 52.33 Favored 'General case' 0 C--N 1.297 -1.683 0 CA-C-N 115.446 -0.797 . . . . 0.0 109.014 179.162 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . 0.412 ' HB2' ' CE1' ' A' ' 143' ' ' PHE . . . -91.88 124.75 36.23 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 123.355 0.662 . . . . 0.0 111.183 -177.355 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 24.1 mmt -111.98 142.52 26.93 Favored Pre-proline 0 C--N 1.297 -1.696 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.206 176.938 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -68.34 167.11 23.18 Favored 'Trans proline' 0 C--O 1.252 1.211 0 C-N-CA 123.839 3.026 . . . . 0.0 112.155 175.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 54.5 m-85 -53.8 115.82 2.2 Favored 'General case' 0 N--CA 1.472 0.629 0 C-N-CA 122.699 0.4 . . . . 0.0 111.803 177.594 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.6 p -84.67 -51.23 6.98 Favored 'General case' 0 N--CA 1.42 -1.945 0 CA-C-N 115.404 -0.817 . . . . 0.0 109.592 177.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.9 m 57.94 29.54 17.8 Favored 'General case' 0 C--N 1.356 0.875 0 C-N-CA 124.491 1.116 . . . . 0.0 111.264 177.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.572 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 31.3 mmmt -78.64 161.27 27.06 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.605 -176.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -69.86 -37.46 75.08 Favored Glycine 0 C--O 1.238 0.369 0 N-CA-C 111.923 -0.471 . . . . 0.0 111.923 179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.572 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 1.9 pm0 -70.36 -27.95 64.74 Favored 'General case' 0 C--O 1.22 -0.461 0 N-CA-C 109.805 -0.443 . . . . 0.0 109.805 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.464 ' O ' HG23 ' A' ' 98' ' ' VAL . 42.6 t80 -68.64 -41.08 79.89 Favored 'General case' 0 C--O 1.215 -0.76 0 CA-C-N 115.505 -0.77 . . . . 0.0 109.948 174.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -68.12 -32.69 73.17 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-O 120.965 0.412 . . . . 0.0 110.769 178.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 33.8 m -69.24 -36.35 77.09 Favored 'General case' 0 N--CA 1.443 -0.819 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.539 175.144 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.556 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 87.6 t90 -61.86 -44.75 96.18 Favored 'General case' 0 C--O 1.204 -1.338 0 CA-C-N 115.883 -0.598 . . . . 0.0 109.448 174.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.464 HG23 ' O ' ' A' ' 94' ' ' PHE . 84.5 t -55.42 -42.39 67.24 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.839 0 C-N-CA 122.962 0.505 . . . . 0.0 110.601 178.685 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 98.8 mttt -63.59 -49.94 71.39 Favored 'General case' 0 N--CA 1.452 -0.342 0 CA-C-N 116.065 -0.516 . . . . 0.0 111.365 177.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 45.2 m-20 -70.25 -27.08 64.16 Favored 'General case' 0 CA--C 1.506 -0.734 0 N-CA-C 112.813 0.671 . . . . 0.0 112.813 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.437 ' HA ' HD11 ' A' ' 8' ' ' ILE . 72.8 t80 -60.79 -60.38 3.88 Favored 'General case' 0 C--N 1.312 -1.03 0 C-N-CA 123.373 0.669 . . . . 0.0 109.72 175.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 35.0 t -63.33 -33.38 60.87 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.787 0 CA-C-O 121.038 0.447 . . . . 0.0 110.334 -178.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 69.8 ttt180 -59.73 -58.09 10.09 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.746 0.818 . . . . 0.0 110.427 177.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 43.0 m-80 -67.29 -28.68 68.22 Favored 'General case' 0 CA--C 1.513 -0.468 0 N-CA-C 111.932 0.345 . . . . 0.0 111.932 -178.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.447 HG13 ' HA3' ' A' ' 174' ' ' GLY . 38.9 t -64.15 -43.62 97.43 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.565 0 CA-C-N 116.207 -0.451 . . . . 0.0 109.944 172.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 24.5 ttm-85 -64.91 -32.92 74.87 Favored 'General case' 0 CA--C 1.548 0.887 0 CA-C-O 121.47 0.652 . . . . 0.0 110.35 178.511 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -72.54 -28.3 62.76 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.647 174.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.67 -31.01 67.76 Favored 'General case' 0 C--N 1.327 -0.382 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 176.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.0 mp -63.17 -33.36 75.31 Favored 'General case' 0 C--O 1.223 -0.291 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.91 173.692 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 67.4 mttm -83.61 -43.71 15.36 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.759 178.162 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -74.55 -15.69 80.4 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 115.234 0.854 . . . . 0.0 115.234 -175.047 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.7 p -71.99 -21.54 61.56 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 117.817 0.808 . . . . 0.0 112.718 -178.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 70.21 38.62 72.16 Favored Glycine 0 C--N 1.335 0.511 0 C-N-CA 120.783 -0.722 . . . . 0.0 113.068 177.221 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 46.7 t -76.73 153.78 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.561 1.387 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 178.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.435 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -55.52 147.72 17.18 Favored 'General case' 0 N--CA 1.482 1.144 0 C-N-CA 123.639 0.775 . . . . 0.0 111.708 -179.379 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 49.3 t -55.79 -46.77 79.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 C-N-CA 124.134 0.974 . . . . 0.0 112.866 -173.29 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 -61.83 -44.14 97.44 Favored 'General case' 0 C--O 1.251 1.147 0 CA-C-O 121.457 0.646 . . . . 0.0 110.464 179.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.529 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 1.2 m-20 -61.93 -41.54 98.07 Favored 'General case' 0 C--O 1.204 -1.331 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.112 176.056 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.435 HG12 ' O ' ' A' ' 115' ' ' ALA . 29.9 mm -55.41 -37.14 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.003 0 C-N-CA 124.509 1.124 . . . . 0.0 111.513 177.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 33.0 mmtp -60.59 -49.17 78.62 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 120.992 0.425 . . . . 0.0 110.133 179.59 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 65.4 mmtt -73.35 -29.36 62.6 Favored 'General case' 0 C--O 1.209 -1.074 0 CA-C-N 115.942 -0.572 . . . . 0.0 112.142 176.882 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.538 ' CE1' ' HB3' ' A' ' 173' ' ' SER . 4.9 t80 -67.06 -33.79 76.27 Favored 'General case' 0 C--N 1.304 -1.402 0 C-N-CA 124.972 1.309 . . . . 0.0 107.899 -177.486 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 71.5 mtm -76.5 -27.81 56.18 Favored 'General case' 0 C--O 1.212 -0.877 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.584 175.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -71.54 -29.78 65.15 Favored 'General case' 0 N--CA 1.471 0.596 0 CA-C-O 121.34 0.591 . . . . 0.0 109.63 174.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 38.2 mt-10 -66.18 -31.77 72.81 Favored 'General case' 0 CA--C 1.547 0.834 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.265 174.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.4 -57.99 13.4 Favored Pre-proline 0 CA--C 1.572 1.811 0 N-CA-C 115.319 1.6 . . . . 0.0 115.319 -179.679 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -67.64 -21.91 44.87 Favored 'Trans proline' 0 C--N 1.383 2.349 0 C-N-CA 121.532 1.488 . . . . 0.0 111.625 178.039 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 29.2 m -72.19 -34.94 68.79 Favored 'General case' 0 N--CA 1.432 -1.372 0 CA-C-N 115.258 -0.883 . . . . 0.0 110.026 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.2 m-85 -58.4 -52.61 64.89 Favored 'General case' 0 C--N 1.358 0.936 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 175.17 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 43.3 t -56.76 -46.55 83.27 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.345 0 CA-C-N 114.132 -1.394 . . . . 0.0 110.932 -178.792 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 59.3 tttm -55.03 -54.62 40.71 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 115.949 -0.569 . . . . 0.0 112.193 -178.382 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.647 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 25.9 t90 -68.37 -34.66 76.46 Favored 'General case' 0 C--N 1.327 -0.4 0 O-C-N 123.513 0.508 . . . . 0.0 111.215 -175.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.501 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 99.2 mt -63.24 -42.4 99.21 Favored 'General case' 0 C--O 1.222 -0.379 0 CA-C-N 116.591 -0.277 . . . . 0.0 110.421 177.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 96.4 t -73.38 -37.84 52.08 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.678 0 CA-C-N 116.458 -0.337 . . . . 0.0 111.261 -179.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 72.0 m-20 -67.43 -35.69 79.74 Favored 'General case' 0 N--CA 1.475 0.814 0 C-N-CA 121.117 -0.233 . . . . 0.0 111.566 -179.682 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 10.1 tppt? -94.81 -4.01 47.95 Favored 'General case' 0 CA--C 1.547 0.847 0 CA-C-N 116.313 -0.403 . . . . 0.0 110.858 -176.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.492 ' HA ' ' CD1' ' A' ' 140' ' ' LEU . 89.3 t80 -51.09 -38.2 50.36 Favored 'General case' 0 N--CA 1.481 1.097 0 N-CA-C 114.817 1.414 . . . . 0.0 114.817 -174.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -73.62 -8.95 58.02 Favored 'General case' 0 C--N 1.305 -1.328 0 N-CA-C 113.315 0.857 . . . . 0.0 113.315 -174.438 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -110.17 1.5 18.79 Favored 'General case' 0 C--N 1.314 -0.959 0 CA-C-N 116.659 -0.246 . . . . 0.0 111.422 178.164 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.492 ' CD1' ' HA ' ' A' ' 137' ' ' TYR . 78.5 mt -84.64 130.95 34.65 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.794 1.035 . . . . 0.0 113.794 -173.865 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 32.2 mt-10 -105.5 156.1 18.54 Favored 'General case' 0 C--N 1.305 -1.369 0 N-CA-C 105.958 -1.868 . . . . 0.0 105.958 165.295 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.475 ' HB3' HD11 ' A' ' 154' ' ' LEU . 80.5 m-85 -105.67 116.48 32.02 Favored 'General case' 0 C--N 1.294 -1.822 0 C-N-CA 120.536 -0.466 . . . . 0.0 110.707 -173.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.532 ' HA ' ' O ' ' A' ' 84' ' ' THR . 34.8 m-85 -109.81 152.7 25.39 Favored 'General case' 0 C--N 1.297 -1.711 0 CA-C-N 115.612 -0.722 . . . . 0.0 111.852 -175.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.494 ' HE3' ' HA ' ' A' ' 150' ' ' PRO . 2.3 mpt? -134.47 150.03 50.78 Favored 'General case' 0 C--N 1.301 -1.537 0 N-CA-C 105.849 -1.908 . . . . 0.0 105.849 171.442 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 84.8 p -78.6 175.22 10.58 Favored 'General case' 0 C--O 1.252 1.211 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 171.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 85.1 tttt -61.25 -34.62 75.45 Favored 'General case' 0 C--N 1.309 -1.176 0 CA-C-O 120.745 0.307 . . . . 0.0 111.042 -179.823 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 6.0 p -88.86 -3.39 58.76 Favored 'General case' 0 CA--C 1.561 1.399 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 57.5 mtt -91.16 175.37 6.97 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 113.021 0.749 . . . . 0.0 113.021 -178.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.584 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 65.6 t30 -133.28 152.13 78.85 Favored Pre-proline 0 C--O 1.212 -0.911 0 N-CA-C 106.408 -1.701 . . . . 0.0 106.408 -176.197 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.584 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 9.4 Cg_endo -56.92 -24.88 59.2 Favored 'Trans proline' 0 N--CA 1.488 1.198 0 C-N-CA 122.667 2.245 . . . . 0.0 112.992 175.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 18.7 m-20 -88.35 -21.66 24.24 Favored 'General case' 0 CA--C 1.506 -0.727 0 CA-C-N 115.859 -0.609 . . . . 0.0 111.228 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.424 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -143.69 110.32 5.55 Favored 'General case' 0 N--CA 1.426 -1.663 0 N-CA-C 109.595 -0.521 . . . . 0.0 109.595 -173.702 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.94 42.81 3.71 Favored Glycine 0 N--CA 1.433 -1.516 0 C-N-CA 119.602 -1.285 . . . . 0.0 111.167 -175.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.556 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 26.6 tp -93.45 111.52 23.2 Favored 'General case' 0 N--CA 1.422 -1.831 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 177.408 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 97.7 mt -97.99 134.67 35.42 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.503 0 CA-C-N 114.941 -1.027 . . . . 0.0 111.701 -173.393 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.414 ' CD2' HD13 ' A' ' 140' ' ' LEU . 68.9 m-85 -88.95 136.4 33.03 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.77 -1.196 . . . . 0.0 107.77 175.142 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.531 ' HB2' ' CE2' ' A' ' 143' ' ' PHE . 31.4 m -149.45 144.82 26.58 Favored 'General case' 0 C--N 1.307 -1.257 0 O-C-N 121.66 -0.65 . . . . 0.0 110.086 174.221 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.9 p90 -127.32 179.03 5.67 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.991 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -122.59 104.2 9.19 Favored 'General case' 0 C--N 1.306 -1.323 0 N-CA-C 109.065 -0.717 . . . . 0.0 109.065 179.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 65.2 pttt -84.11 166.64 17.48 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.921 -178.632 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -73.79 124.64 26.45 Favored 'General case' 0 C--N 1.311 -1.093 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.381 179.214 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.93 -21.12 32.43 Favored Glycine 0 C--N 1.305 -1.143 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.406 -177.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.46 127.5 45.52 Favored 'General case' 0 N--CA 1.443 -0.821 0 N-CA-C 109.541 -0.54 . . . . 0.0 109.541 178.618 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 98.8 m-70 -103.8 9.87 36.78 Favored 'General case' 0 C--N 1.312 -1.065 0 CA-C-O 121.591 0.71 . . . . 0.0 110.619 178.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 85.3 m -131.25 161.39 62.16 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 107.641 -1.244 . . . . 0.0 107.641 179.406 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -53.81 124.47 15.94 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 122.686 2.258 . . . . 0.0 112.65 177.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 19.7 m -90.15 110.84 21.84 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 105.591 -2.003 . . . . 0.0 105.591 176.607 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.501 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 90.2 m-85 -81.27 138.57 35.73 Favored 'General case' 0 C--N 1.306 -1.283 0 CA-C-O 121.652 0.739 . . . . 0.0 111.666 -171.043 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.647 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.7 t -106.8 110.5 31.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 CA-C-N 113.817 -1.538 . . . . 0.0 108.096 -177.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.514 ' CZ ' ' HB ' ' A' ' 13' ' ' VAL . 44.0 m-85 -134.19 157.82 45.26 Favored 'General case' 0 C--O 1.243 0.759 0 CA-C-O 121.81 0.814 . . . . 0.0 111.381 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.511 ' HA ' HD23 ' A' ' 33' ' ' LEU . 38.4 t -99.57 117.68 45.07 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-N 115.027 -0.988 . . . . 0.0 108.351 178.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 32.3 ttpt -72.45 -56.53 5.27 Favored 'General case' 0 N--CA 1.472 0.643 0 CA-C-O 121.627 0.727 . . . . 0.0 110.408 -175.323 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.538 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 48.4 m -77.18 -10.93 59.72 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 114.571 -1.195 . . . . 0.0 112.114 -175.047 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.471 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -106.16 -11.11 28.5 Favored Glycine 0 N--CA 1.434 -1.44 0 C-N-CA 120.673 -0.775 . . . . 0.0 114.36 -173.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.502 ' CE1' ' HA ' ' A' ' 6' ' ' ASP . 3.0 m-85 -97.15 171.27 8.56 Favored 'General case' 0 CA--C 1.492 -1.254 0 CA-C-N 117.307 0.553 . . . . 0.0 110.636 -179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.402 ' HB2' ' HB2' ' A' ' 5' ' ' LYS . 35.1 mmtp -85.38 103.32 14.17 Favored 'General case' 0 N--CA 1.425 -1.709 0 N-CA-C 109.199 -0.667 . . . . 0.0 109.199 -178.311 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 37.5 t -85.46 102.0 10.64 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.91 0 N-CA-C 106.871 -1.529 . . . . 0.0 106.871 179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 11.5 t -97.79 109.04 22.8 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 -177.276 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . 0.489 ' HB2' ' CE1' ' A' ' 183' ' ' HIS . 39.9 pttt -103.54 105.57 15.85 Favored 'General case' 0 C--N 1.269 -2.919 0 CA-C-N 115.306 -0.861 . . . . 0.0 109.893 -176.514 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -87.56 103.1 15.23 Favored 'General case' 0 C--O 1.247 0.942 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.697 -179.259 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.593 ' HB3' ' CE1' ' A' ' 183' ' ' HIS . 45.2 tp 170.4 163.56 0.07 Allowed 'General case' 0 C--N 1.307 -1.246 0 N-CA-C 103.359 -2.83 . . . . 0.0 103.359 177.08 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.5 mt-10 -58.76 -49.87 76.03 Favored 'General case' 0 C--N 1.312 -1.043 0 CA-C-N 118.366 0.53 . . . . 0.0 112.23 -177.371 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . 0.593 ' CE1' ' HB3' ' A' ' 181' ' ' LEU . 73.7 m80 57.92 50.76 9.87 Favored 'General case' 0 N--CA 1.481 1.082 0 N-CA-C 108.458 -0.941 . . . . 0.0 108.458 -177.417 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 8.7 t-80 -72.67 -10.7 60.1 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 113.702 -1.59 . . . . 0.0 112.978 -169.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 9.5 p-80 -55.47 113.03 1.26 Allowed 'General case' 0 N--CA 1.47 0.531 0 CA-C-O 121.611 0.719 . . . . 0.0 111.096 177.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 17.8 p-80 -100.06 -25.51 14.28 Favored 'General case' 0 C--N 1.298 -1.642 0 CA-C-N 115.018 -0.992 . . . . 0.0 111.7 -175.586 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.6 t-80 -109.49 144.52 37.63 Favored 'General case' 0 C--N 1.305 -1.359 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 -179.635 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 30.6 m80 . . . . . 0 C--N 1.295 -1.791 0 CA-C-O 118.458 -0.782 . . . . 0.0 109.542 174.116 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.512 -0.509 0 N-CA-C 110.08 -0.341 . . . . 0.0 110.08 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.9 mm -102.16 139.18 23.89 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.247 0 N-CA-C 107.321 -1.363 . . . . 0.0 107.321 -178.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.7 p -142.47 142.45 27.02 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 CA-C-O 121.12 0.486 . . . . 0.0 110.66 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 85.3 m-85 -96.2 117.61 31.11 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 176.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.466 ' O ' ' HG2' ' A' ' 176' ' ' LYS . 29.0 mtpp -110.08 131.55 54.96 Favored 'General case' 0 C--N 1.298 -1.639 0 CA-C-N 115.866 -0.606 . . . . 0.0 109.919 -179.032 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 9.6 t70 -63.21 148.67 47.45 Favored 'General case' 0 C--N 1.308 -1.215 0 C-N-CA 124.095 0.958 . . . . 0.0 112.504 -176.705 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 46.1 t -75.64 -36.93 35.43 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 C-N-CA 124.011 0.925 . . . . 0.0 109.729 -178.226 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.5 mm -78.5 -58.29 4.29 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.918 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.236 -172.817 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 62.6 p -78.46 -42.23 30.44 Favored 'General case' 0 C--O 1.244 0.776 0 CA-C-O 121.51 0.672 . . . . 0.0 111.371 -178.45 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 89.97 7.63 68.01 Favored Glycine 0 N--CA 1.428 -1.852 0 N-CA-C 110.263 -1.135 . . . . 0.0 110.263 -174.37 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -100.7 -171.23 1.98 Allowed 'General case' 0 N--CA 1.448 -0.543 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 -176.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 33.9 mt-10 -96.81 131.33 43.66 Favored 'General case' 0 C--N 1.298 -1.65 0 C-N-CA 122.588 0.355 . . . . 0.0 111.294 -171.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.465 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 29.3 m -102.57 -27.52 3.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.833 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.15 177.346 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.2 p -175.5 153.91 0.36 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.641 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 32.5 p -116.78 165.77 12.91 Favored 'General case' 0 N--CA 1.433 -1.299 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 177.322 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 29.8 t70 -72.74 -10.64 60.03 Favored 'General case' 0 N--CA 1.487 1.386 0 CA-C-O 122.079 0.942 . . . . 0.0 111.031 179.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -77.77 -7.94 57.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.272 176.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.493 HD13 HG13 ' A' ' 75' ' ' VAL . 87.9 mt -104.28 177.54 4.82 Favored 'General case' 0 N--CA 1.437 -1.09 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 178.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 36' ' ' VAL . 5.2 tmtt? -85.46 106.59 16.91 Favored 'General case' 0 C--O 1.212 -0.875 0 CA-C-O 120.936 0.398 . . . . 0.0 110.731 -173.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.49 HG23 ' CD1' ' A' ' 34' ' ' PHE . 73.8 mt -112.15 116.66 53.17 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.351 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 -178.498 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 34.0 p -109.33 132.77 21.08 Favored Pre-proline 0 C--N 1.305 -1.337 0 CA-C-N 116.56 -0.291 . . . . 0.0 110.354 179.486 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -70.45 134.41 26.47 Favored 'Trans proline' 0 C--O 1.241 0.646 0 C-N-CA 121.399 1.399 . . . . 0.0 108.65 174.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 61.2 t -71.22 107.29 2.29 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.344 0 CA-C-O 121.774 0.797 . . . . 0.0 111.723 -175.126 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 87.2 mtp -125.28 109.17 12.49 Favored 'General case' 0 C--N 1.293 -1.89 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 173.646 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 79.9 mt-10 -121.64 179.74 4.37 Favored 'General case' 0 C--N 1.307 -1.243 0 C-N-CA 120.617 -0.433 . . . . 0.0 110.857 -178.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.57 120.41 20.39 Favored Glycine 0 C--O 1.246 0.846 0 O-C-N 123.344 0.403 . . . . 0.0 113.196 -177.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 108.53 -49.85 0.82 Allowed Glycine 0 N--CA 1.428 -1.862 0 C-N-CA 121.075 -0.583 . . . . 0.0 113.052 177.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.1 pt-20 -143.5 149.3 37.31 Favored 'General case' 0 C--N 1.309 -1.166 0 CA-C-O 120.894 0.378 . . . . 0.0 111.365 -174.36 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -83.58 144.55 29.4 Favored 'General case' 0 C--O 1.252 1.215 0 N-CA-C 104.971 -2.233 . . . . 0.0 104.971 168.857 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . 0.42 ' CG1' HD12 ' A' ' 33' ' ' LEU . 39.5 t -113.07 102.3 54.6 Favored Pre-proline 0 C--N 1.287 -2.111 0 C-N-CA 119.654 -0.819 . . . . 0.0 111.471 -174.071 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -76.38 147.32 28.82 Favored 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.695 2.263 . . . . 0.0 112.893 178.227 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.1 -5.13 81.6 Favored Glycine 0 N--CA 1.436 -1.324 0 CA-C-N 115.616 -0.72 . . . . 0.0 113.575 175.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.577 HD23 ' HA ' ' A' ' 171' ' ' VAL . 80.4 mt -131.84 149.98 52.29 Favored 'General case' 0 C--N 1.303 -1.432 0 CA-C-O 120.852 0.358 . . . . 0.0 111.383 -175.303 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.49 ' CD1' HG23 ' A' ' 20' ' ' ILE . 35.4 p90 -138.09 153.29 49.31 Favored 'General case' 0 N--CA 1.428 -1.571 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 175.487 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.0 tt0 -115.62 156.04 26.55 Favored 'General case' 0 C--N 1.257 -3.419 0 N-CA-C 106.415 -1.698 . . . . 0.0 106.415 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 75' ' ' VAL . 93.0 t -114.79 115.4 49.41 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.176 0 C-N-CA 120.16 -0.616 . . . . 0.0 109.367 176.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -73.91 137.37 43.6 Favored 'General case' 0 C--N 1.308 -1.22 0 CA-C-N 114.55 -1.205 . . . . 0.0 109.197 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . 0.474 ' HB2' ' HB2' ' A' ' 165' ' ' CYS . 5.3 p -99.3 133.84 43.02 Favored 'General case' 0 N--CA 1.397 -3.109 0 CA-C-O 121.282 0.563 . . . . 0.0 110.682 -179.584 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -144.79 131.61 20.17 Favored 'General case' 0 C--O 1.249 1.043 0 N-CA-C 108.45 -0.945 . . . . 0.0 108.45 -178.175 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.441 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 58.6 mtt -81.67 150.28 28.11 Favored 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 114.19 1.182 . . . . 0.0 114.19 -174.353 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 18.5 m -131.96 148.54 32.25 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.194 0 CA-C-N 113.739 -1.573 . . . . 0.0 107.444 172.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.454 ' HA ' ' HG2' ' A' ' 71' ' ' LYS . . . -74.33 114.59 12.88 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-O 121.287 0.565 . . . . 0.0 110.66 178.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 56.8 t -113.93 140.98 31.65 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.358 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 -179.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -79.41 128.76 8.72 Favored Glycine 0 N--CA 1.43 -1.735 0 N-CA-C 109.109 -1.596 . . . . 0.0 109.109 174.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -125.64 43.98 1.31 Allowed Glycine 0 C--N 1.301 -1.389 0 C-N-CA 120.527 -0.844 . . . . 0.0 112.046 -175.676 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 77.78 -128.11 8.66 Favored Glycine 0 N--CA 1.43 -1.735 0 C-N-CA 121.164 -0.541 . . . . 0.0 112.131 178.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -83.25 -37.31 23.71 Favored 'General case' 0 C--N 1.308 -1.211 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 -177.829 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.1 mt 75.05 -48.88 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.479 0.992 0 C-N-CA 125.939 1.695 . . . . 0.0 112.806 176.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 72.09 -65.2 0.36 Allowed 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 125.648 1.579 . . . . 0.0 113.451 179.434 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 46.0 mm 68.76 99.11 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.241 0.656 0 C-N-CA 124.713 1.205 . . . . 0.0 111.459 -176.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -123.2 131.33 8.12 Favored Glycine 0 N--CA 1.423 -2.223 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 177.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 61.8 m -67.53 117.37 9.39 Favored 'General case' 0 C--O 1.25 1.112 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 177.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.6 63.14 4.26 Favored Glycine 0 N--CA 1.44 -1.077 0 CA-C-N 115.602 -0.727 . . . . 0.0 113.649 -174.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -65.54 -36.66 84.47 Favored 'General case' 0 C--N 1.313 -0.98 0 C-N-CA 123.338 0.655 . . . . 0.0 110.091 179.718 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -76.45 -10.3 59.29 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.658 -177.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 92.5 m-85 -94.12 -26.05 16.88 Favored 'General case' 0 C--O 1.238 0.471 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 177.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 90.98 -76.56 1.51 Allowed Glycine 0 N--CA 1.435 -1.413 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -178.505 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -103.35 70.96 0.28 Allowed Glycine 0 N--CA 1.433 -1.515 0 N-CA-C 111.464 -0.654 . . . . 0.0 111.464 -179.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -80.32 120.56 24.54 Favored 'General case' 0 N--CA 1.442 -0.832 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 178.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 100.4 83.6 1.75 Allowed Glycine 0 N--CA 1.422 -2.282 0 N-CA-C 108.081 -2.007 . . . . 0.0 108.081 -174.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -64.81 -47.96 76.13 Favored 'General case' 0 C--N 1.313 -1.006 0 C-N-CA 123.47 0.708 . . . . 0.0 111.046 -174.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -81.89 -18.43 43.76 Favored 'General case' 0 C--N 1.307 -1.272 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.289 177.927 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 62.02 79.87 0.24 Allowed 'General case' 0 C--O 1.239 0.527 0 C-N-CA 125.455 1.502 . . . . 0.0 111.223 -176.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -153.25 -91.39 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.816 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.371 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 58.71 -165.59 0.18 Allowed 'General case' 0 N--CA 1.477 0.912 0 C-N-CA 124.645 1.178 . . . . 0.0 111.947 179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 29.2 t70 -162.8 147.86 11.91 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 107.231 -1.396 . . . . 0.0 107.231 174.936 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 -90.83 -22.15 21.12 Favored 'General case' 0 C--N 1.311 -1.107 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -174.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -101.38 -39.0 7.78 Favored 'General case' 0 C--N 1.312 -1.028 0 C-N-CA 120.238 -0.585 . . . . 0.0 111.21 -175.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 24.8 p -128.91 174.34 9.59 Favored 'General case' 0 C--N 1.291 -1.973 0 CA-C-N 115.767 -0.651 . . . . 0.0 109.382 -178.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 95.9 mt-30 -100.55 112.74 25.15 Favored 'General case' 0 N--CA 1.411 -2.376 0 N-CA-C 106.383 -1.71 . . . . 0.0 106.383 171.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.454 ' HG2' ' HA ' ' A' ' 42' ' ' ALA . 49.9 mtmt -96.31 120.73 37.14 Favored 'General case' 0 C--N 1.285 -2.225 0 C-N-CA 119.23 -0.988 . . . . 0.0 109.712 179.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -134.05 165.82 24.16 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 106.722 -1.584 . . . . 0.0 106.722 -176.467 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.437 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 38.6 t30 -71.06 138.57 49.92 Favored 'General case' 0 C--N 1.292 -1.934 0 C-N-CA 123.599 0.759 . . . . 0.0 111.564 -176.429 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.4 p30 -65.78 -24.6 66.97 Favored 'General case' 0 N--CA 1.477 0.882 0 CA-C-N 115.147 -0.933 . . . . 0.0 111.575 -178.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.687 HG11 HG11 ' A' ' 36' ' ' VAL . 54.4 t -77.81 -39.36 26.15 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.576 -177.94 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.462 ' HA ' ' CD1' ' A' ' 83' ' ' TYR . 2.9 p -80.97 -54.91 5.16 Favored 'General case' 0 N--CA 1.418 -2.026 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.086 -179.45 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 47.05 89.64 0.01 OUTLIER Glycine 0 C--N 1.349 1.261 0 O-C-N 124.458 1.099 . . . . 0.0 113.979 177.11 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_exo -54.68 -27.84 53.63 Favored 'Trans proline' 0 N--CA 1.488 1.155 0 C-N-CA 123.432 2.755 . . . . 0.0 113.634 -177.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 2.7 p -84.63 -22.86 29.76 Favored 'General case' 0 N--CA 1.433 -1.306 0 C-N-CA 123.463 0.705 . . . . 0.0 112.582 179.372 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 43.8 m -106.46 -75.87 0.62 Allowed 'General case' 0 CA--C 1.541 0.625 0 N-CA-C 112.955 0.724 . . . . 0.0 112.955 -177.04 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 99.3 m-85 -86.55 -37.7 17.91 Favored 'General case' 0 CA--C 1.515 -0.386 0 C-N-CA 121.317 -0.153 . . . . 0.0 110.96 -176.267 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.93 89.8 0.06 Allowed 'General case' 0 N--CA 1.47 0.531 0 C-N-CA 124.767 1.227 . . . . 0.0 113.114 178.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.551 ' HA ' ' O ' ' A' ' 144' ' ' MET . 2.4 m-85 -85.79 111.14 19.88 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 11.1 m -97.24 126.26 42.33 Favored 'General case' 0 C--N 1.295 -1.764 0 CA-C-N 114.902 -1.044 . . . . 0.0 109.947 -175.342 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -76.84 141.26 40.71 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 113.219 0.822 . . . . 0.0 113.219 -175.719 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.3 mmt -137.79 117.01 9.96 Favored Pre-proline 0 C--N 1.307 -1.256 0 C-N-CA 125.935 1.694 . . . . 0.0 107.413 175.692 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 69.6 Cg_endo -82.86 125.16 4.12 Favored 'Trans proline' 0 CA--C 1.54 0.777 0 C-N-CA 121.92 1.746 . . . . 0.0 113.764 -178.306 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.4 m-85 -143.2 130.29 20.73 Favored 'General case' 0 C--N 1.311 -1.065 0 N-CA-C 108.62 -0.881 . . . . 0.0 108.62 176.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 10.2 p -100.68 -61.73 1.33 Allowed 'General case' 0 C--N 1.298 -1.651 0 N-CA-C 108.361 -0.977 . . . . 0.0 108.361 174.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 54.1 p -168.55 78.69 0.14 Allowed 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 114.947 -1.024 . . . . 0.0 108.895 175.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 60.2 tttm -88.64 150.48 23.0 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 115.051 -0.977 . . . . 0.0 109.303 -176.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -59.75 -49.18 81.32 Favored Glycine 0 N--CA 1.467 0.752 0 N-CA-C 114.014 0.366 . . . . 0.0 114.014 -176.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 5.4 tp10 -74.0 -22.1 59.73 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-O 122.306 1.05 . . . . 0.0 109.465 -179.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.437 ' O ' HG23 ' A' ' 98' ' ' VAL . 77.8 t80 -68.9 -32.58 72.32 Favored 'General case' 0 C--N 1.317 -0.826 0 CA-C-N 115.071 -0.968 . . . . 0.0 109.684 174.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.463 ' O ' ' HD3' ' A' ' 99' ' ' LYS . 75.1 mmtt -64.27 -39.16 93.38 Favored 'General case' 0 CA--C 1.52 -0.205 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 175.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 5.5 m -61.16 -39.59 90.69 Favored 'General case' 0 N--CA 1.45 -0.443 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.557 176.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.555 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 90.4 t90 -63.68 -45.27 90.85 Favored 'General case' 0 C--O 1.216 -0.673 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.174 177.034 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.437 HG23 ' O ' ' A' ' 94' ' ' PHE . 99.2 t -55.86 -47.77 79.25 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.883 0 C-N-CA 122.92 0.488 . . . . 0.0 111.123 179.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.463 ' HD3' ' O ' ' A' ' 95' ' ' LYS . 1.7 mptm? -63.99 -45.19 90.12 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.305 -0.407 . . . . 0.0 111.468 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -62.48 -40.8 97.82 Favored 'General case' 0 CA--C 1.508 -0.67 0 N-CA-C 112.125 0.417 . . . . 0.0 112.125 177.452 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.452 ' O ' HG23 ' A' ' 105' ' ' VAL . 77.0 t80 -60.42 -56.0 26.69 Favored 'General case' 0 C--N 1.313 -1.017 0 C-N-CA 123.544 0.737 . . . . 0.0 110.633 -179.859 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 61.6 t -62.42 -33.88 61.62 Favored 'Isoleucine or valine' 0 C--O 1.251 1.157 0 CA-C-O 121.048 0.451 . . . . 0.0 110.764 -178.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -67.74 -47.88 68.02 Favored 'General case' 0 C--O 1.216 -0.71 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.97 178.483 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 27.0 m-80 -63.9 -29.13 70.34 Favored 'General case' 0 N--CA 1.483 1.194 0 N-CA-C 112.012 0.375 . . . . 0.0 112.012 -179.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.452 HG23 ' O ' ' A' ' 101' ' ' TYR . 79.7 t -62.1 -37.89 79.54 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.796 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 174.845 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 4.0 mpt_? -63.43 -33.18 75.0 Favored 'General case' 0 N--CA 1.473 0.711 0 O-C-N 122.24 -0.288 . . . . 0.0 111.436 175.26 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -67.6 -37.38 82.48 Favored 'General case' 0 C--O 1.22 -0.477 0 N-CA-C 110.384 -0.228 . . . . 0.0 110.384 175.977 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -68.26 -36.26 79.17 Favored 'General case' 0 C--O 1.236 0.356 0 CA-C-O 120.826 0.346 . . . . 0.0 110.821 178.388 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.407 HD13 ' O ' ' A' ' 105' ' ' VAL . 9.4 mp -61.58 -42.89 99.51 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-N 115.903 -0.589 . . . . 0.0 111.338 175.542 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 66.8 mttm -78.93 -38.69 36.64 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.011 0.434 . . . . 0.0 111.848 -179.982 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -76.57 -2.12 73.9 Favored Glycine 0 C--N 1.318 -0.439 0 CA-C-N 116.088 -0.506 . . . . 0.0 114.204 -176.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 77.3 p -72.72 -23.34 60.84 Favored 'General case' 0 C--N 1.317 -0.836 0 CA-C-N 117.094 0.447 . . . . 0.0 110.711 -179.506 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 66.57 31.09 77.6 Favored Glycine 0 C--N 1.341 0.837 0 CA-C-N 116.102 -0.499 . . . . 0.0 112.869 178.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 55.7 t -89.37 153.82 3.2 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.015 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -50.01 143.7 7.66 Favored 'General case' 0 N--CA 1.473 0.705 0 C-N-CA 124.557 1.143 . . . . 0.0 111.995 178.709 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.407 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 42.4 t -54.05 -41.73 51.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 C-N-CA 124.565 1.146 . . . . 0.0 112.383 -174.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 18.4 mp0 -62.3 -43.67 98.29 Favored 'General case' 0 C--N 1.308 -1.206 0 C-N-CA 123.331 0.652 . . . . 0.0 110.232 -177.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -69.76 -33.53 72.56 Favored 'General case' 0 C--O 1.211 -0.946 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.723 176.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 39.4 mm -60.81 -37.76 77.18 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.874 0 C-N-CA 122.895 0.478 . . . . 0.0 110.473 176.896 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.407 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 74.7 mmtt -66.3 -35.27 79.95 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-O 120.872 0.368 . . . . 0.0 110.748 178.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.438 ' HA ' ' HD3' ' A' ' 121' ' ' LYS . 71.5 mmtt -75.23 -33.15 61.31 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.209 0.528 . . . . 0.0 110.678 176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -66.67 -35.89 81.22 Favored 'General case' 0 C--N 1.305 -1.343 0 C-N-CA 124.706 1.202 . . . . 0.0 108.009 178.261 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 79.5 mtp -69.39 -26.35 64.6 Favored 'General case' 0 C--O 1.215 -0.749 0 CA-C-N 115.337 -0.847 . . . . 0.0 110.898 175.574 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 51.8 mt-10 -74.47 -28.81 61.19 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-O 121.425 0.631 . . . . 0.0 110.245 176.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 39.9 mt-10 -73.46 -25.18 60.37 Favored 'General case' 0 C--N 1.306 -1.286 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.924 175.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.613 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -55.39 -54.75 47.49 Favored Pre-proline 0 CA--C 1.574 1.898 0 N-CA-C 115.346 1.61 . . . . 0.0 115.346 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_endo -67.6 -23.56 42.78 Favored 'Trans proline' 0 C--N 1.382 2.29 0 C-N-CA 121.549 1.5 . . . . 0.0 111.302 177.232 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 12.3 m -69.93 -36.94 75.71 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-N 115.052 -0.976 . . . . 0.0 109.487 -179.717 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 19.5 m-85 -57.92 -50.07 74.59 Favored 'General case' 0 C--N 1.36 1.064 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 175.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 45.6 t -60.88 -44.94 98.85 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.466 0 CA-C-N 114.328 -1.305 . . . . 0.0 111.551 -177.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt -52.33 -55.67 19.99 Favored 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 123.181 0.592 . . . . 0.0 112.094 -178.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.687 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -68.71 -34.61 75.95 Favored 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.126 -173.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.429 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 98.7 mt -65.28 -40.25 93.64 Favored 'General case' 0 N--CA 1.465 0.289 0 N-CA-C 110.123 -0.325 . . . . 0.0 110.123 176.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.93 -39.38 83.35 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 CA-C-N 116.093 -0.503 . . . . 0.0 111.206 178.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.5 m-20 -68.09 -25.45 65.34 Favored 'General case' 0 N--CA 1.469 0.516 0 N-CA-C 113.521 0.934 . . . . 0.0 113.521 -179.596 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.53 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 74.3 mmtt -100.39 -9.02 22.65 Favored 'General case' 0 C--N 1.314 -0.951 0 C-N-CA 120.656 -0.417 . . . . 0.0 110.936 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 32.7 t80 -45.55 -52.22 10.76 Favored 'General case' 0 N--CA 1.491 1.588 0 C-N-CA 125.609 1.564 . . . . 0.0 114.455 -170.216 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -77.47 1.53 18.95 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 114.322 1.23 . . . . 0.0 114.322 -177.61 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.5 m-20 -115.83 6.12 14.25 Favored 'General case' 0 C--N 1.315 -0.912 0 O-C-N 122.31 -0.244 . . . . 0.0 110.821 176.185 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.53 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 92.9 mt -84.04 130.6 34.87 Favored 'General case' 0 N--CA 1.426 -1.651 0 N-CA-C 114.895 1.443 . . . . 0.0 114.895 -173.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 28.2 mt-10 -110.99 145.77 37.84 Favored 'General case' 0 N--CA 1.422 -1.852 0 N-CA-C 104.775 -2.306 . . . . 0.0 104.775 168.091 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 93.1 m-85 -111.13 140.67 45.49 Favored 'General case' 0 C--N 1.277 -2.553 0 C-N-CA 119.441 -0.903 . . . . 0.0 111.507 -172.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 82.1 m-85 -130.56 169.35 15.69 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-N 115.217 -0.901 . . . . 0.0 109.69 -179.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.551 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 33.9 mtm -145.4 155.64 43.28 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 105.231 -2.137 . . . . 0.0 105.231 176.591 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 58.5 p -85.8 170.29 12.57 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 106.586 -1.635 . . . . 0.0 106.586 171.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 23.2 tptp -59.09 -30.28 67.97 Favored 'General case' 0 C--N 1.314 -0.944 0 C-N-CA 122.903 0.481 . . . . 0.0 111.211 -177.285 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 5.0 p -89.84 -3.62 58.01 Favored 'General case' 0 CA--C 1.562 1.431 0 N-CA-C 114.858 1.429 . . . . 0.0 114.858 -179.456 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.437 ' SD ' ' HA3' ' A' ' 153' ' ' GLY . 72.4 mtm -107.31 -179.52 3.95 Favored 'General case' 0 N--CA 1.478 0.95 0 N-CA-C 113.886 1.069 . . . . 0.0 113.886 -175.734 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . 0.636 ' OD1' ' HD2' ' A' ' 150' ' ' PRO . 64.9 t30 -134.56 155.13 79.86 Favored Pre-proline 0 C--O 1.211 -0.955 0 N-CA-C 106.843 -1.54 . . . . 0.0 106.843 -173.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . 0.636 ' HD2' ' OD1' ' A' ' 149' ' ' ASN . 27.4 Cg_endo -66.1 -18.78 57.04 Favored 'Trans proline' 0 C--N 1.355 0.872 0 C-N-CA 121.587 1.524 . . . . 0.0 112.597 177.528 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -85.89 -24.28 26.7 Favored 'General case' 0 CA--C 1.506 -0.734 0 CA-C-O 120.817 0.342 . . . . 0.0 110.613 177.134 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -143.45 103.73 4.14 Favored 'General case' 0 N--CA 1.424 -1.728 0 CA-C-N 116.018 -0.537 . . . . 0.0 109.999 -174.462 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.437 ' HA3' ' SD ' ' A' ' 148' ' ' MET . . . 95.12 42.77 3.67 Favored Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 120.187 -1.006 . . . . 0.0 112.803 -177.137 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.555 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 39.1 tp -92.49 113.68 26.02 Favored 'General case' 0 N--CA 1.439 -1.003 0 N-CA-C 107.855 -1.165 . . . . 0.0 107.855 177.066 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 83.1 mt -83.89 130.63 35.56 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.891 0 C-N-CA 124.831 1.252 . . . . 0.0 111.053 -173.767 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.579 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -87.6 132.77 33.96 Favored 'General case' 0 C--N 1.314 -0.975 0 N-CA-C 107.087 -1.449 . . . . 0.0 107.087 175.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 140' ' ' LEU . 15.1 m -145.45 150.42 36.47 Favored 'General case' 0 C--N 1.308 -1.232 0 O-C-N 121.568 -0.707 . . . . 0.0 110.413 179.25 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 20.0 p90 -145.76 166.18 26.63 Favored 'General case' 0 C--N 1.315 -0.932 0 N-CA-C 108.263 -1.014 . . . . 0.0 108.263 174.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 5.7 m-30 -100.42 108.46 20.46 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 109.226 -0.657 . . . . 0.0 109.226 179.297 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 41.3 ttmt -76.89 154.17 34.01 Favored 'General case' 0 C--N 1.306 -1.287 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 174.528 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -58.01 120.28 8.27 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-O 121.163 0.506 . . . . 0.0 111.294 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.02 -20.85 48.63 Favored Glycine 0 N--CA 1.442 -0.919 0 CA-C-N 115.599 -0.728 . . . . 0.0 111.69 179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -85.09 125.26 32.63 Favored 'General case' 0 N--CA 1.441 -0.925 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -90.66 -36.3 14.45 Favored 'General case' 0 C--N 1.297 -1.677 0 CA-C-O 121.71 0.767 . . . . 0.0 110.902 -177.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.474 ' HB2' ' HB2' ' A' ' 38' ' ' SER . 85.0 m -97.65 152.26 38.06 Favored Pre-proline 0 C--N 1.284 -2.255 0 N-CA-C 107.848 -1.168 . . . . 0.0 107.848 176.188 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo -50.85 129.46 27.72 Favored 'Trans proline' 0 C--N 1.353 0.79 0 C-N-CA 123.158 2.572 . . . . 0.0 113.418 179.562 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 8.0 m -87.27 122.12 30.63 Favored 'General case' 0 C--N 1.301 -1.535 0 N-CA-C 105.75 -1.945 . . . . 0.0 105.75 176.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.478 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 40.1 m-85 -90.59 136.06 33.3 Favored 'General case' 0 C--N 1.31 -1.131 0 CA-C-O 121.454 0.645 . . . . 0.0 112.06 -170.347 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.687 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 51.8 t -103.39 113.95 41.64 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 C-N-CA 124.858 1.263 . . . . 0.0 108.797 -177.523 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.465 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 29.7 m-85 -130.97 157.47 42.89 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 121.967 0.889 . . . . 0.0 112.923 -177.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.577 ' HA ' HD23 ' A' ' 33' ' ' LEU . 37.0 t -100.19 107.54 21.15 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.168 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.972 179.681 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.441 ' H ' ' HA ' ' A' ' 33' ' ' LEU . 36.8 ttpt -61.35 -56.38 21.03 Favored 'General case' 0 N--CA 1.489 1.478 0 C-N-CA 123.1 0.56 . . . . 0.0 111.658 -174.05 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.6 m -86.88 2.32 49.54 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 115.496 -0.775 . . . . 0.0 111.358 -175.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -92.78 -28.35 12.5 Favored Glycine 0 CA--C 1.488 -1.608 0 C-N-CA 120.144 -1.027 . . . . 0.0 112.258 -175.584 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.419 ' HB3' ' O ' ' A' ' 5' ' ' LYS . 24.0 m-85 -97.09 169.7 9.63 Favored 'General case' 0 CA--C 1.496 -1.105 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.182 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.466 ' HG2' ' O ' ' A' ' 5' ' ' LYS . 16.3 ptpt -88.49 122.88 32.45 Favored 'General case' 0 N--CA 1.425 -1.722 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 -179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 40.2 t -89.09 102.95 13.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 N-CA-C 107.759 -1.2 . . . . 0.0 107.759 179.617 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 39.4 t -105.27 132.83 51.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 -176.687 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -105.16 108.14 19.5 Favored 'General case' 0 N--CA 1.427 -1.609 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 -176.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 82.0 m-85 -89.83 150.14 22.36 Favored 'General case' 0 C--N 1.3 -1.568 0 C-N-CA 120.333 -0.547 . . . . 0.0 111.298 177.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 90.8 mt 81.22 8.94 1.03 Allowed 'General case' 0 N--CA 1.482 1.127 0 C-N-CA 126.018 1.727 . . . . 0.0 110.273 -174.104 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 10.6 mm-40 -90.0 -176.07 4.78 Favored 'General case' 0 N--CA 1.444 -0.757 0 CA-C-N 114.804 -1.089 . . . . 0.0 111.457 176.433 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 95.7 m-70 -94.61 19.65 9.58 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 113.245 0.831 . . . . 0.0 113.245 -170.985 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.6 t-80 -125.42 29.79 5.95 Favored 'General case' 0 C--N 1.307 -1.254 0 N-CA-C 105.906 -1.886 . . . . 0.0 105.906 175.614 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 17.1 t-160 -86.77 74.34 9.82 Favored 'General case' 0 N--CA 1.439 -1.005 0 CA-C-N 114.402 -1.272 . . . . 0.0 111.426 -173.049 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 84.7 t60 -104.48 -2.05 25.82 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 172.294 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 14.7 m-70 -88.4 176.87 7.0 Favored 'General case' 0 C--N 1.312 -1.042 0 CA-C-N 114.316 -1.311 . . . . 0.0 108.676 178.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 75.6 t60 . . . . . 0 C--N 1.311 -1.08 0 N-CA-C 109.362 -0.607 . . . . 0.0 109.362 178.211 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 51.4 ttm . . . . . 0 N--CA 1.449 -0.488 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 64.8 mt -89.6 129.87 39.83 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.713 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 178.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.7 p -130.87 140.32 48.98 Favored 'Isoleucine or valine' 0 N--CA 1.42 -1.947 0 CA-C-O 121.278 0.561 . . . . 0.0 109.825 -179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 40.5 m-85 -95.34 114.51 26.29 Favored 'General case' 0 C--N 1.296 -1.724 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 175.374 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 67.8 mttm -101.24 141.84 33.54 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 178.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -72.98 145.46 46.69 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 115.819 -0.628 . . . . 0.0 110.561 178.843 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 41.8 t -79.86 -29.85 13.03 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.879 -176.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 13.7 mm -81.58 -57.76 4.42 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.067 0 CA-C-O 120.968 0.413 . . . . 0.0 110.688 -174.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.414 ' HB3' ' C ' ' A' ' 152' ' ' ALA . 53.2 p -79.68 -38.01 34.54 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-O 121.219 0.533 . . . . 0.0 111.948 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 87.49 11.14 69.34 Favored Glycine 0 N--CA 1.43 -1.751 0 N-CA-C 110.333 -1.107 . . . . 0.0 110.333 -174.513 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 7.8 t70 -97.39 -176.38 3.49 Favored 'General case' 0 CA--C 1.546 0.79 0 N-CA-C 108.748 -0.834 . . . . 0.0 108.748 -177.98 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 32.4 mt-10 -108.5 126.3 52.76 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 118.543 0.611 . . . . 0.0 111.136 -171.571 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.449 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 35.9 m -95.92 -30.2 3.97 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 N-CA-C 112.9 0.704 . . . . 0.0 112.9 -177.224 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.506 ' HA ' HD12 ' A' ' 18' ' ' LEU . 9.7 p -168.75 159.04 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.547 0.863 0 N-CA-C 109.584 -0.524 . . . . 0.0 109.584 -178.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 33.4 p -143.92 178.76 7.62 Favored 'General case' 0 CA--C 1.542 0.653 0 C-N-CA 123.315 0.646 . . . . 0.0 109.566 179.151 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 39.8 m-20 -56.57 -30.68 63.43 Favored 'General case' 0 N--CA 1.51 2.528 0 C-N-CA 123.125 0.57 . . . . 0.0 112.159 178.826 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -69.31 -15.01 63.25 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.763 -176.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.506 HD12 ' HA ' ' A' ' 14' ' ' VAL . 37.3 mt -109.79 168.12 9.65 Favored 'General case' 0 N--CA 1.43 -1.459 0 N-CA-C 109.324 -0.621 . . . . 0.0 109.324 -176.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.409 ' O ' HG13 ' A' ' 36' ' ' VAL . 13.0 mptt -75.53 107.0 7.37 Favored 'General case' 0 C--N 1.309 -1.17 0 N-CA-C 112.989 0.737 . . . . 0.0 112.989 -179.126 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.438 HG23 ' CD1' ' A' ' 34' ' ' PHE . 75.6 mt -108.05 108.01 24.22 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.19 -1.781 . . . . 0.0 106.19 174.358 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 1.8 p -120.23 157.87 52.24 Favored Pre-proline 0 C--N 1.292 -1.933 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.324 -177.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 3.6 Cg_endo -81.33 166.63 18.05 Favored 'Trans proline' 0 N--CA 1.443 -1.47 0 C-N-CA 121.793 1.662 . . . . 0.0 112.592 178.278 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.52 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 78.1 t -90.63 111.71 23.93 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.763 0 CA-C-N 114.92 -1.036 . . . . 0.0 109.64 177.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 2.3 mpt? -101.85 108.77 20.35 Favored 'General case' 0 C--N 1.303 -1.43 0 C-N-CA 120.293 -0.563 . . . . 0.0 109.738 174.032 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 77.8 mm-40 -122.66 116.06 23.15 Favored 'General case' 0 C--N 1.303 -1.453 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 73.17 12.92 79.7 Favored Glycine 0 C--N 1.311 -0.852 0 C-N-CA 121.154 -0.546 . . . . 0.0 112.113 -178.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 95.47 -8.47 69.06 Favored Glycine 0 N--CA 1.44 -1.036 0 C-N-CA 121.626 -0.321 . . . . 0.0 113.218 -179.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -113.62 168.24 9.93 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-N 117.308 0.554 . . . . 0.0 109.997 -179.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.52 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 6.9 pt-20 -81.78 153.95 26.21 Favored 'General case' 0 N--CA 1.445 -0.701 0 CA-C-O 121.299 0.571 . . . . 0.0 109.903 178.778 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 98.2 t -107.73 110.55 62.62 Favored Pre-proline 0 C--N 1.283 -2.293 0 N-CA-C 106.753 -1.573 . . . . 0.0 106.753 171.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -63.54 132.22 34.71 Favored 'Trans proline' 0 C--O 1.241 0.633 0 C-N-CA 122.911 2.407 . . . . 0.0 114.256 -173.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.51 -4.58 64.22 Favored Glycine 0 CA--C 1.5 -0.849 0 CA-C-N 115.063 -0.971 . . . . 0.0 113.47 174.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.498 HD23 ' HA ' ' A' ' 171' ' ' VAL . 65.6 mt -126.32 160.42 30.44 Favored 'General case' 0 C--N 1.292 -1.891 0 N-CA-C 110.092 -0.336 . . . . 0.0 110.092 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.472 ' HD2' ' HB2' ' A' ' 172' ' ' LYS . 18.7 p90 -147.29 137.91 23.48 Favored 'General case' 0 N--CA 1.432 -1.332 0 N-CA-C 107.753 -1.203 . . . . 0.0 107.753 173.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 44.6 tt0 -104.08 149.78 24.9 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.255 -1.757 . . . . 0.0 106.255 -179.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.522 ' CG1' HG21 ' A' ' 75' ' ' VAL . 77.1 t -110.5 113.14 43.39 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.975 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 178.243 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -81.36 142.34 33.13 Favored 'General case' 0 N--CA 1.426 -1.631 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 178.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 p -98.42 135.98 39.23 Favored 'General case' 0 C--N 1.285 -2.213 0 C-N-CA 119.529 -0.868 . . . . 0.0 111.877 -171.105 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -137.56 129.38 28.69 Favored 'General case' 0 C--O 1.252 1.228 0 CA-C-N 115.23 -0.895 . . . . 0.0 109.414 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 89.5 mtp -83.74 117.02 22.96 Favored 'General case' 0 C--N 1.308 -1.21 0 O-C-N 124.007 0.817 . . . . 0.0 109.63 -177.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.1 m -110.69 168.92 4.07 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.838 0 N-CA-C 109.322 -0.621 . . . . 0.0 109.322 -179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.61 121.81 22.18 Favored 'General case' 0 C--N 1.3 -1.586 0 O-C-N 123.783 0.677 . . . . 0.0 110.839 -178.943 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.7 t -111.37 94.81 3.34 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 175.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -101.25 150.25 18.53 Favored Glycine 0 N--CA 1.42 -2.422 0 N-CA-C 111.324 -0.71 . . . . 0.0 111.324 -178.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -79.7 83.74 1.34 Allowed Glycine 0 C--N 1.309 -0.964 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 177.163 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.19 20.25 26.82 Favored Glycine 0 C--O 1.228 -0.258 0 C-N-CA 121.935 -0.174 . . . . 0.0 113.002 -176.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -56.86 -45.75 82.24 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 124.901 1.28 . . . . 0.0 109.62 177.001 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 44.6 mm -124.12 105.49 15.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.866 -2.272 . . . . 0.0 104.866 173.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 25.1 t70 -144.48 150.02 36.92 Favored 'General case' 0 C--N 1.305 -1.347 0 C-N-CA 121.229 -0.188 . . . . 0.0 110.873 -175.023 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.6 mp -88.21 93.71 4.36 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 -179.107 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -133.51 -120.82 2.14 Favored Glycine 0 N--CA 1.433 -1.561 0 N-CA-C 110.836 -0.905 . . . . 0.0 110.836 178.373 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 40.2 m -114.99 -6.67 12.55 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 179.165 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 87.08 -68.2 3.25 Favored Glycine 0 N--CA 1.443 -0.899 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -175.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 5.1 p-10 -154.45 105.76 2.68 Favored 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 106.483 -1.673 . . . . 0.0 106.483 174.182 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -74.44 -72.8 0.26 Allowed 'General case' 0 C--N 1.315 -0.913 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.483 -177.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -99.58 -7.81 25.35 Favored 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 121.75 0.786 . . . . 0.0 109.09 177.497 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 139.93 -100.77 0.29 Allowed Glycine 0 N--CA 1.426 -1.99 0 N-CA-C 107.439 -2.264 . . . . 0.0 107.439 -177.273 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -86.67 -28.02 27.87 Favored Glycine 0 C--N 1.302 -1.33 0 N-CA-C 109.47 -1.452 . . . . 0.0 109.47 173.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -79.45 133.24 36.53 Favored 'General case' 0 C--O 1.255 1.373 0 CA-C-N 115.29 -0.455 . . . . 0.0 109.838 178.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 165.18 -134.46 3.33 Favored Glycine 0 N--CA 1.424 -2.141 0 N-CA-C 109.704 -1.359 . . . . 0.0 109.704 -178.381 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -148.58 29.03 0.86 Allowed 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 122.685 1.231 . . . . 0.0 109.117 -178.692 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -86.56 74.8 9.82 Favored 'General case' 0 C--N 1.31 -1.127 0 N-CA-C 113.518 0.932 . . . . 0.0 113.518 -176.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 -177.19 68.78 0.02 OUTLIER 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.446 1.499 . . . . 0.0 107.955 173.715 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -97.89 -67.79 0.92 Allowed Glycine 0 N--CA 1.424 -2.113 0 N-CA-C 109.796 -1.322 . . . . 0.0 109.796 175.067 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . 70.37 -57.37 0.58 Allowed 'General case' 0 N--CA 1.483 1.205 0 C-N-CA 126.006 1.723 . . . . 0.0 113.238 178.546 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -168.54 -159.55 0.26 Allowed 'General case' 0 C--N 1.306 -1.299 0 N-CA-C 103.715 -2.698 . . . . 0.0 103.715 -177.261 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -77.62 -28.86 51.54 Favored 'General case' 0 C--N 1.295 -1.787 0 CA-C-N 119.208 0.913 . . . . 0.0 110.086 175.411 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -176.69 140.05 0.33 Allowed 'General case' 0 CA--C 1.507 -0.702 0 O-C-N 124.818 1.324 . . . . 0.0 109.017 175.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 23.9 m -94.25 -71.23 0.67 Allowed 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 105.404 -2.072 . . . . 0.0 105.404 170.586 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 27.7 mp0 -102.79 174.37 5.91 Favored 'General case' 0 C--N 1.314 -0.969 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 168.367 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -132.69 141.3 48.53 Favored 'General case' 0 CA--C 1.486 -1.519 0 N-CA-C 106.352 -1.721 . . . . 0.0 106.352 168.087 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -155.71 165.76 35.56 Favored 'General case' 0 C--N 1.285 -2.232 0 N-CA-C 105.971 -1.863 . . . . 0.0 105.971 179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 41.5 t30 -65.17 130.75 44.49 Favored 'General case' 0 C--N 1.299 -1.616 0 N-CA-C 109.111 -0.699 . . . . 0.0 109.111 178.561 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.5 p30 -57.34 -32.47 66.76 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.182 -0.917 . . . . 0.0 112.123 -177.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.522 HG21 ' CG1' ' A' ' 36' ' ' VAL . 14.7 t -76.38 -33.1 22.7 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.44 -175.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.431 ' HA ' ' CD2' ' A' ' 83' ' ' TYR . 3.4 p -81.67 -46.57 14.15 Favored 'General case' 0 N--CA 1.428 -1.562 0 C-N-CA 120.515 -0.474 . . . . 0.0 110.634 179.22 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 41.52 85.08 0.01 OUTLIER Glycine 0 C--N 1.354 1.567 0 O-C-N 124.651 1.219 . . . . 0.0 114.93 174.849 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 76.3 Cg_exo -55.09 -28.67 61.71 Favored 'Trans proline' 0 N--CA 1.491 1.37 0 C-N-CA 123.69 2.927 . . . . 0.0 114.124 -177.919 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 3.7 p -86.44 -11.34 52.12 Favored 'General case' 0 N--CA 1.434 -1.267 0 C-N-CA 122.873 0.469 . . . . 0.0 112.116 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 16.2 m -117.51 -68.67 0.9 Allowed 'General case' 0 CA--C 1.54 0.585 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -176.728 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.424 ' CZ ' HD11 ' A' ' 18' ' ' LEU . 80.8 m-85 -92.52 -53.45 4.2 Favored 'General case' 0 C--O 1.243 0.72 0 C-N-CA 122.638 0.375 . . . . 0.0 111.062 -175.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 65.27 100.36 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.929 0 C-N-CA 124.963 1.305 . . . . 0.0 112.197 -179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.431 ' CD2' ' HA ' ' A' ' 76' ' ' SER . 63.2 m-85 -102.22 137.96 39.79 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.031 -0.531 . . . . 0.0 111.315 -179.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 31.9 m -111.98 142.55 44.26 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.679 -0.86 . . . . 0.0 108.679 179.114 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -90.37 145.64 24.8 Favored 'General case' 0 N--CA 1.444 -0.754 0 CA-C-O 121.956 0.884 . . . . 0.0 112.902 -176.111 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 65.9 mmm -135.06 108.05 10.48 Favored Pre-proline 0 C--N 1.303 -1.432 0 C-N-CA 125.863 1.665 . . . . 0.0 108.221 175.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -70.69 165.55 31.67 Favored 'Trans proline' 0 C--O 1.252 1.221 0 C-N-CA 122.33 2.02 . . . . 0.0 110.638 175.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 66.3 m-85 -45.46 115.52 0.95 Allowed 'General case' 0 N--CA 1.476 0.837 0 N-CA-C 113.062 0.764 . . . . 0.0 113.062 179.54 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.7 p -88.29 -39.54 14.31 Favored 'General case' 0 N--CA 1.425 -1.718 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 174.47 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 40.6 m 63.82 16.69 9.99 Favored 'General case' 0 CA--C 1.546 0.795 0 C-N-CA 125.292 1.437 . . . . 0.0 114.725 173.017 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -69.63 158.88 34.48 Favored 'General case' 0 N--CA 1.472 0.653 0 O-C-N 122.015 -0.428 . . . . 0.0 110.172 178.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -67.33 -19.27 70.36 Favored Glycine 0 N--CA 1.462 0.396 0 N-CA-C 111.4 -0.68 . . . . 0.0 111.4 177.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 43.2 mt-10 -66.74 -23.79 66.14 Favored 'General case' 0 C--N 1.322 -0.59 0 C-N-CA 124.554 1.142 . . . . 0.0 110.306 176.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.446 ' O ' HG23 ' A' ' 98' ' ' VAL . 80.5 t80 -71.31 -29.97 65.67 Favored 'General case' 0 C--O 1.214 -0.812 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 177.741 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm -73.4 -35.01 65.79 Favored 'General case' 0 C--N 1.327 -0.37 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 176.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.8 m -67.14 -34.84 78.44 Favored 'General case' 0 CA--C 1.541 0.597 0 CA-C-N 115.665 -0.698 . . . . 0.0 109.31 174.53 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.523 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.0 t90 -65.8 -48.57 71.31 Favored 'General case' 0 C--O 1.208 -1.131 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.405 176.464 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 94' ' ' PHE . 86.6 t -59.55 -40.21 81.39 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.157 0 CA-C-O 120.96 0.409 . . . . 0.0 110.132 178.657 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -55.87 -51.29 68.07 Favored 'General case' 0 C--N 1.325 -0.495 0 C-N-CA 124.391 1.077 . . . . 0.0 110.002 176.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.52 -40.54 80.73 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.406 -0.815 . . . . 0.0 112.241 178.791 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 89.3 t80 -57.25 -56.11 26.08 Favored 'General case' 0 C--N 1.313 -0.99 0 C-N-CA 123.946 0.898 . . . . 0.0 110.5 179.305 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . 0.461 ' O ' ' HG3' ' A' ' 106' ' ' ARG . 82.2 t -64.39 -36.76 78.14 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.44 0 CA-C-N 116.504 -0.316 . . . . 0.0 111.106 -178.534 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 36.9 ttp-105 -67.18 -43.7 81.54 Favored 'General case' 0 CA--C 1.536 0.419 0 O-C-N 122.481 -0.137 . . . . 0.0 110.784 -179.737 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 30.1 m-80 -63.96 -36.2 83.18 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 120.807 0.337 . . . . 0.0 110.47 176.813 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.446 HG13 ' HA2' ' A' ' 174' ' ' GLY . 35.4 t -61.06 -43.63 96.6 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.839 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.36 174.463 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . 0.461 ' HG3' ' O ' ' A' ' 102' ' ' VAL . 92.4 mtt180 -57.92 -39.04 77.0 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-O 120.874 0.369 . . . . 0.0 111.269 177.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 2.0 mp0 -75.27 -21.76 58.28 Favored 'General case' 0 C--O 1.215 -0.74 0 N-CA-C 112.111 0.412 . . . . 0.0 112.111 177.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -74.74 -34.51 62.55 Favored 'General case' 0 C--N 1.325 -0.498 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 175.691 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.623 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 10.1 mp -57.71 -41.58 82.02 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.505 0.669 . . . . 0.0 110.171 173.423 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . 0.403 ' HG3' ' O ' ' A' ' 106' ' ' ARG . 27.5 mtpp -81.14 -47.21 13.79 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.622 -177.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -69.99 -14.01 70.26 Favored Glycine 0 C--O 1.228 -0.263 0 N-CA-C 115.293 0.877 . . . . 0.0 115.293 -174.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 12.3 p -77.73 -19.96 54.3 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 117.499 0.65 . . . . 0.0 110.516 176.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 64.95 37.99 94.95 Favored Glycine 0 C--N 1.341 0.844 0 CA-C-N 115.816 -0.629 . . . . 0.0 113.344 177.07 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 39.9 t -73.3 153.5 7.26 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.048 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 179.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -50.47 146.91 4.92 Favored 'General case' 0 N--CA 1.475 0.79 0 C-N-CA 124.461 1.104 . . . . 0.0 112.912 -178.408 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 24.5 t -53.44 -46.05 58.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.772 0 C-N-CA 124.721 1.208 . . . . 0.0 110.942 -175.776 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.1 mm-40 -60.99 -43.88 98.21 Favored 'General case' 0 C--O 1.261 1.661 0 CA-C-N 114.563 -1.198 . . . . 0.0 112.147 -178.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.439 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 2.3 m-20 -66.52 -39.65 88.74 Favored 'General case' 0 C--O 1.193 -1.883 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.858 176.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 34.8 mm -56.23 -37.17 48.73 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 C-N-CA 123.896 0.878 . . . . 0.0 111.809 179.369 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.1 mmtt -60.54 -52.16 66.37 Favored 'General case' 0 N--CA 1.466 0.366 0 N-CA-C 109.45 -0.574 . . . . 0.0 109.45 177.059 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.503 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 2.4 mmmp? -67.34 -32.07 72.76 Favored 'General case' 0 CA--C 1.542 0.672 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.842 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.623 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -68.49 -38.07 80.65 Favored 'General case' 0 C--N 1.312 -1.041 0 C-N-CA 125.55 1.54 . . . . 0.0 109.094 -177.046 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 62.2 mtt -73.66 -20.19 60.63 Favored 'General case' 0 C--N 1.32 -0.717 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.392 178.131 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -76.14 -25.69 55.59 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-O 121.682 0.754 . . . . 0.0 109.203 173.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.503 ' HG3' ' O ' ' A' ' 121' ' ' LYS . 44.3 mt-10 -74.62 -23.42 58.7 Favored 'General case' 0 C--O 1.216 -0.671 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.099 177.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.518 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -53.37 -56.55 23.29 Favored Pre-proline 0 CA--C 1.573 1.827 0 N-CA-C 114.669 1.359 . . . . 0.0 114.669 179.701 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -69.74 -22.2 32.51 Favored 'Trans proline' 0 C--N 1.38 2.227 0 CA-C-N 121.221 1.472 . . . . 0.0 111.311 176.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 49.3 m -67.5 -36.55 81.31 Favored 'General case' 0 N--CA 1.436 -1.139 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.071 178.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.518 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 17.4 m-85 -61.18 -50.98 70.93 Favored 'General case' 0 C--N 1.355 0.83 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.408 ' O ' HG23 ' A' ' 134' ' ' VAL . 60.0 t -56.12 -55.72 16.96 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.245 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.06 -176.221 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 51.8 tttp -60.08 -40.48 89.71 Favored 'General case' 0 CA--C 1.536 0.405 0 N-CA-C 113.631 0.974 . . . . 0.0 113.631 -176.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.633 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 15.0 t90 -71.32 -31.89 67.94 Favored 'General case' 0 C--O 1.246 0.909 0 C-N-CA 119.974 -0.69 . . . . 0.0 111.071 -176.69 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.472 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 93.9 mt -67.89 -36.86 80.95 Favored 'General case' 0 C--O 1.224 -0.258 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 176.227 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.408 HG23 ' O ' ' A' ' 130' ' ' VAL . 91.6 t -69.88 -37.27 72.63 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.58 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.603 177.953 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -66.62 -24.74 66.35 Favored 'General case' 0 N--CA 1.473 0.68 0 N-CA-C 113.6 0.963 . . . . 0.0 113.6 -178.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.599 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 0.8 OUTLIER -109.66 1.47 19.58 Favored 'General case' 0 C--O 1.213 -0.846 0 C-N-CA 120.343 -0.543 . . . . 0.0 112.211 174.782 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 44.2 t80 -45.6 -56.51 5.08 Favored 'General case' 0 N--CA 1.493 1.718 0 C-N-CA 124.656 1.182 . . . . 0.0 113.822 -174.044 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -76.01 2.89 11.51 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 113.489 0.922 . . . . 0.0 113.489 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 23.2 m-20 -111.91 -2.12 15.26 Favored 'General case' 0 C--N 1.302 -1.465 0 CA-C-N 116.649 -0.25 . . . . 0.0 110.465 177.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 96.9 mt -83.82 133.23 34.76 Favored 'General case' 0 N--CA 1.441 -0.908 0 N-CA-C 115.367 1.617 . . . . 0.0 115.367 -171.99 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 1.6 mp0 -104.83 144.93 31.09 Favored 'General case' 0 N--CA 1.416 -2.148 0 N-CA-C 105.329 -2.1 . . . . 0.0 105.329 168.337 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . 0.459 ' HB3' HD11 ' A' ' 154' ' ' LEU . 56.2 m-85 -108.45 140.84 41.2 Favored 'General case' 0 C--N 1.268 -2.973 0 C-N-CA 119.274 -0.971 . . . . 0.0 109.804 -175.176 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.7 m-85 -133.81 154.84 50.72 Favored 'General case' 0 C--N 1.299 -1.607 0 CA-C-N 116.353 -0.385 . . . . 0.0 109.977 -179.192 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 2.3 mpp? -140.56 152.61 45.65 Favored 'General case' 0 C--N 1.298 -1.641 0 N-CA-C 105.426 -2.064 . . . . 0.0 105.426 173.579 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.6 p -79.73 173.75 12.27 Favored 'General case' 0 C--O 1.25 1.119 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 173.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . 0.417 ' HD3' ' O ' ' A' ' 146' ' ' LYS . 7.4 tmtt? -58.1 -40.02 80.12 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-O 120.968 0.413 . . . . 0.0 110.479 -177.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 13.5 p -83.7 -3.53 57.85 Favored 'General case' 0 CA--C 1.557 1.243 0 N-CA-C 113.631 0.975 . . . . 0.0 113.631 -176.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 50.3 mtt -96.04 -178.09 4.22 Favored 'General case' 0 C--N 1.319 -0.733 0 O-C-N 121.865 -0.522 . . . . 0.0 111.852 -178.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.3 m-80 -133.83 158.61 75.06 Favored Pre-proline 0 C--O 1.212 -0.903 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 179.135 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -70.33 -19.92 32.78 Favored 'Trans proline' 0 CA--C 1.546 1.079 0 C-N-CA 121.318 1.345 . . . . 0.0 111.886 175.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -87.37 -21.51 25.62 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.728 -0.669 . . . . 0.0 109.75 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' C ' ' HB3' ' A' ' 9' ' ' SER . . . -146.64 108.09 4.27 Favored 'General case' 0 N--CA 1.436 -1.131 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.637 -175.379 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.76 43.08 3.69 Favored Glycine 0 N--CA 1.439 -1.142 0 C-N-CA 119.764 -1.208 . . . . 0.0 110.81 -175.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.523 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 35.8 tp -98.67 112.4 24.47 Favored 'General case' 0 N--CA 1.432 -1.344 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 178.029 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.9 mp -89.0 134.75 27.55 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.093 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.08 -176.364 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.502 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 57.6 m-85 -87.08 132.98 33.66 Favored 'General case' 0 C--N 1.307 -1.253 0 N-CA-C 106.942 -1.503 . . . . 0.0 106.942 174.201 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 16.5 t -149.56 164.17 35.82 Favored 'General case' 0 C--N 1.291 -1.942 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 177.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 32.0 p90 -155.94 169.36 24.62 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 174.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -94.62 105.67 17.63 Favored 'General case' 0 C--N 1.293 -1.877 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 176.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . 0.412 ' HD2' HG21 ' A' ' 167' ' ' THR . 88.5 tttt -71.71 147.31 47.51 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.653 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 46.6 mt-10 -62.13 114.94 3.71 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.528 0.517 . . . . 0.0 110.789 -177.075 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.82 -16.64 39.67 Favored Glycine 0 N--CA 1.443 -0.861 0 CA-C-N 115.735 -0.666 . . . . 0.0 112.52 -179.288 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -95.19 135.07 37.22 Favored 'General case' 0 C--N 1.313 -0.996 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 -179.05 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 45.1 m80 -96.15 -16.96 21.19 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.559 0.695 . . . . 0.0 110.165 -179.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.69 154.02 42.67 Favored Pre-proline 0 C--N 1.304 -1.406 0 CA-C-N 115.343 -0.844 . . . . 0.0 109.021 179.571 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.5 Cg_endo -54.64 130.24 39.2 Favored 'Trans proline' 0 C--N 1.357 1.017 0 C-N-CA 123.614 2.876 . . . . 0.0 113.622 -179.284 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.412 HG21 ' HD2' ' A' ' 160' ' ' LYS . 39.2 m -95.74 111.5 23.44 Favored 'General case' 0 N--CA 1.423 -1.825 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 177.592 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 90.3 m-85 -83.12 139.55 33.13 Favored 'General case' 0 C--N 1.302 -1.479 0 CA-C-O 121.452 0.644 . . . . 0.0 112.224 -171.61 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.633 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 72.2 t -108.61 110.89 33.71 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.846 0 C-N-CA 124.712 1.205 . . . . 0.0 107.888 -178.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.449 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 28.7 m-85 -125.02 149.5 47.69 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.859 0.838 . . . . 0.0 112.055 -177.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.498 ' HA ' HD23 ' A' ' 33' ' ' LEU . 52.3 t -96.04 101.81 12.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 177.487 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . 0.472 ' HB2' ' HD2' ' A' ' 34' ' ' PHE . 38.1 ttpt -56.6 -56.62 19.06 Favored 'General case' 0 N--CA 1.48 1.036 0 C-N-CA 123.469 0.708 . . . . 0.0 111.882 -173.999 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.607 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 15.3 m -84.37 4.22 32.31 Favored 'General case' 0 C--N 1.288 -2.106 0 CA-C-N 115.025 -0.989 . . . . 0.0 111.57 -175.812 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.446 ' HA2' HG13 ' A' ' 105' ' ' VAL . . . -102.12 -20.09 13.29 Favored Glycine 0 N--CA 1.433 -1.517 0 C-N-CA 120.574 -0.822 . . . . 0.0 112.405 -178.15 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 33.0 m-85 -97.76 171.1 8.53 Favored 'General case' 0 C--N 1.312 -1.051 0 N-CA-C 108.746 -0.835 . . . . 0.0 108.746 177.21 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 19.1 ptpt -94.12 118.75 31.98 Favored 'General case' 0 N--CA 1.427 -1.606 0 CA-C-O 121.606 0.717 . . . . 0.0 109.973 -179.006 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 46.4 t -81.72 106.12 12.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 N-CA-C 107.988 -1.116 . . . . 0.0 107.988 178.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 43.7 t -110.22 113.87 45.45 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 N-CA-C 108.491 -0.929 . . . . 0.0 108.491 -179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 84.6 mttt -95.82 107.34 19.58 Favored 'General case' 0 C--N 1.294 -1.825 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 -178.883 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 47.4 m-85 -86.88 133.9 33.58 Favored 'General case' 0 C--N 1.308 -1.213 0 C-N-CA 120.891 -0.323 . . . . 0.0 110.821 178.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 49.1 tp 55.47 68.3 0.88 Allowed 'General case' 0 C--N 1.325 -0.465 0 O-C-N 124.638 1.211 . . . . 0.0 111.392 178.858 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -73.56 -32.92 64.42 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-O 121.649 0.738 . . . . 0.0 109.487 178.754 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 37.3 p-80 -82.76 76.13 9.62 Favored 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 115.162 -0.926 . . . . 0.0 111.529 178.554 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 23.5 p-80 -126.56 100.57 6.29 Favored 'General case' 0 C--N 1.308 -1.235 0 CA-C-N 115.275 -0.875 . . . . 0.0 108.747 175.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 41.0 m80 -122.01 -84.82 0.66 Allowed 'General case' 0 C--N 1.301 -1.542 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 178.807 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -105.15 -40.68 5.79 Favored 'General case' 0 C--N 1.306 -1.309 0 N-CA-C 107.888 -1.153 . . . . 0.0 107.888 175.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 72.3 t60 -100.65 137.5 38.96 Favored 'General case' 0 N--CA 1.425 -1.722 0 CA-C-N 115.137 -0.938 . . . . 0.0 110.418 -178.312 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 12.0 p80 . . . . . 0 C--N 1.289 -2.051 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 173.439 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 CA--C 1.502 -0.883 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 43.8 mt -89.3 125.16 42.32 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 107.115 -1.439 . . . . 0.0 107.115 -179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.2 p -114.75 145.25 20.77 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.398 0 N-CA-C 109.751 -0.462 . . . . 0.0 109.751 -177.994 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 95.3 m-85 -103.58 112.17 24.97 Favored 'General case' 0 N--CA 1.421 -1.883 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 178.259 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.411 ' HG2' ' HG2' ' A' ' 12' ' ' GLU . 66.6 mttm -100.73 140.52 34.9 Favored 'General case' 0 C--N 1.311 -1.102 0 CA-C-N 115.627 -0.715 . . . . 0.0 109.703 -178.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . 0.401 ' HA ' ' CD1' ' A' ' 175' ' ' TYR . 12.4 t0 -72.48 146.06 47.12 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-O 121.215 0.531 . . . . 0.0 110.876 -179.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.9 t -83.96 -27.92 7.31 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.344 -179.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . 0.417 HD11 ' HA ' ' A' ' 101' ' ' TYR . 28.4 mm -79.29 -59.51 2.91 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.662 0 C-N-CA 120.895 -0.322 . . . . 0.0 110.755 -176.426 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 56.1 p -80.75 -39.67 26.5 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 121.35 0.595 . . . . 0.0 111.151 -178.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.74 7.42 62.99 Favored Glycine 0 N--CA 1.431 -1.693 0 CA-C-N 115.328 -0.851 . . . . 0.0 111.385 -177.974 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -99.1 -175.03 2.91 Favored 'General case' 0 CA--C 1.553 1.082 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 -179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.411 ' HG2' ' HG2' ' A' ' 5' ' ' LYS . 26.9 mt-10 -105.6 141.54 36.89 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-N 118.989 0.813 . . . . 0.0 111.606 -172.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.464 HG23 HG12 ' A' ' 14' ' ' VAL . 18.3 m -106.36 -35.25 3.12 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.575 0 N-CA-C 112.888 0.699 . . . . 0.0 112.888 179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.464 HG12 HG23 ' A' ' 13' ' ' VAL . 9.6 p -169.62 158.56 0.69 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.614 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 -174.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 56.0 p -124.22 167.55 14.13 Favored 'General case' 0 N--CA 1.429 -1.499 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 176.331 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.441 ' HA ' HD12 ' A' ' 20' ' ' ILE . 1.8 p-10 -77.1 0.21 22.36 Favored 'General case' 0 N--CA 1.472 0.629 0 CA-C-O 121.21 0.529 . . . . 0.0 111.388 -178.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -86.05 -15.22 42.0 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 121.808 0.813 . . . . 0.0 109.0 174.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 96.8 mt -97.15 164.63 12.42 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 176.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 30.8 mmtt -62.19 111.97 2.19 Favored 'General case' 0 C--N 1.315 -0.899 0 N-CA-C 114.089 1.144 . . . . 0.0 114.089 -177.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . 0.441 HD12 ' HA ' ' A' ' 16' ' ' ASP . 52.1 mt -126.91 124.51 64.87 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-N 114.624 -1.171 . . . . 0.0 108.021 178.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 5.2 p -122.25 151.37 58.9 Favored Pre-proline 0 C--N 1.288 -2.076 0 CA-C-N 116.326 -0.397 . . . . 0.0 110.244 177.173 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -69.2 145.06 59.18 Favored 'Trans proline' 0 C--O 1.243 0.732 0 C-N-CA 121.654 1.57 . . . . 0.0 109.813 175.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.502 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 75.6 t -78.16 108.89 12.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.023 0 N-CA-C 108.982 -0.748 . . . . 0.0 108.982 178.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.6 mtt -118.89 108.81 15.25 Favored 'General case' 0 C--N 1.291 -1.958 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 28.2 mm-40 -127.39 107.86 10.33 Favored 'General case' 0 C--N 1.304 -1.388 0 CA-C-N 114.844 -1.071 . . . . 0.0 108.731 -176.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 98.7 4.38 57.0 Favored Glycine 0 N--CA 1.438 -1.183 0 N-CA-C 110.954 -0.859 . . . . 0.0 110.954 -178.659 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 113.52 -45.32 1.33 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 111.927 -0.469 . . . . 0.0 111.927 -178.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -99.71 167.9 10.26 Favored 'General case' 0 C--O 1.246 0.888 0 CA-C-O 120.919 0.39 . . . . 0.0 111.647 -178.226 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.502 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 20.8 pt-20 -80.03 154.2 28.32 Favored 'General case' 0 N--CA 1.437 -1.101 0 CA-C-O 121.837 0.827 . . . . 0.0 112.208 -178.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 13.9 t -106.86 116.2 59.08 Favored Pre-proline 0 C--N 1.296 -1.747 0 N-CA-C 103.928 -2.619 . . . . 0.0 103.928 171.137 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . 0.43 ' HB2' ' OE2' ' A' ' 125' ' ' GLU . 61.1 Cg_endo -67.52 143.37 62.68 Favored 'Trans proline' 0 CA--C 1.534 0.486 0 C-N-CA 122.629 2.22 . . . . 0.0 116.222 -168.508 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 73.35 22.04 79.07 Favored Glycine 0 C--N 1.341 0.853 0 CA-C-N 114.507 -1.224 . . . . 0.0 114.064 173.946 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.475 HD13 ' CE3' ' A' ' 132' ' ' TRP . 57.2 mt -136.5 148.15 47.51 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 -175.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -131.27 143.55 50.63 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.507 -0.877 . . . . 0.0 111.159 175.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -101.02 146.66 27.14 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 104.736 -2.32 . . . . 0.0 104.736 -177.503 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.434 HG11 HG21 ' A' ' 75' ' ' VAL . 65.7 t -110.46 115.21 49.19 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.69 0 C-N-CA 118.832 -1.147 . . . . 0.0 112.273 -177.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -81.66 159.06 24.06 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 113.274 -1.785 . . . . 0.0 107.719 178.485 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 30.4 m -104.88 133.93 48.86 Favored 'General case' 0 N--CA 1.414 -2.262 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.764 -178.04 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -121.39 144.78 48.48 Favored 'General case' 0 N--CA 1.431 -1.418 0 N-CA-C 104.877 -2.268 . . . . 0.0 104.877 172.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 79.2 mmm -100.98 119.2 38.39 Favored 'General case' 0 C--N 1.286 -2.183 0 O-C-N 123.483 0.489 . . . . 0.0 110.084 -173.506 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 35.4 m -117.04 141.39 35.58 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.167 0 N-CA-C 109.509 -0.552 . . . . 0.0 109.509 179.352 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -61.54 125.41 23.68 Favored 'General case' 0 C--N 1.314 -0.964 0 CA-C-O 121.102 0.477 . . . . 0.0 111.224 179.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 41.0 t -69.97 -36.29 68.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.704 0 N-CA-C 108.536 -0.912 . . . . 0.0 108.536 178.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -88.6 65.64 3.29 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 178.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . -177.77 35.49 0.08 OUTLIER Glycine 0 N--CA 1.428 -1.874 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 179.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -130.09 19.7 5.14 Favored Glycine 0 N--CA 1.437 -1.256 0 C-N-CA 121.367 -0.444 . . . . 0.0 112.04 -177.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 6.2 m-20 -89.51 86.97 6.89 Favored 'General case' 0 CA--C 1.495 -1.156 0 N-CA-C 108.577 -0.898 . . . . 0.0 108.577 177.367 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 49.6 mm 68.28 110.41 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.476 0.858 0 N-CA-C 107.688 -1.227 . . . . 0.0 107.688 -174.296 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -80.82 73.37 7.82 Favored 'General case' 0 C--O 1.244 0.793 0 N-CA-C 115.177 1.547 . . . . 0.0 115.177 -169.443 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 4.0 mp -136.73 83.67 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 N-CA-C 103.924 -2.621 . . . . 0.0 103.924 166.736 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -143.43 47.4 0.8 Allowed Glycine 0 CA--C 1.493 -1.338 0 N-CA-C 110.357 -1.097 . . . . 0.0 110.357 -177.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . 0.411 ' O ' ' HB2' ' A' ' 56' ' ' PHE . 58.9 m -78.29 -62.55 1.65 Allowed 'General case' 0 C--N 1.3 -1.56 0 CA-C-N 114.642 -0.779 . . . . 0.0 110.069 -178.627 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 102.77 156.61 25.38 Favored Glycine 0 N--CA 1.437 -1.233 0 N-CA-C 109.579 -1.408 . . . . 0.0 109.579 -173.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -71.34 -35.84 71.33 Favored 'General case' 0 C--N 1.308 -1.213 0 CA-C-N 117.256 0.528 . . . . 0.0 112.311 -173.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.95 5.85 50.73 Favored 'General case' 0 C--N 1.311 -1.077 0 CA-C-O 120.936 0.398 . . . . 0.0 111.431 -179.044 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . 0.473 ' CZ ' ' HA2' ' A' ' 64' ' ' GLY . 72.3 m-85 -115.41 74.89 0.91 Allowed 'General case' 0 N--CA 1.439 -0.997 0 C-N-CA 119.736 -0.786 . . . . 0.0 112.518 -176.253 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -121.65 61.57 0.54 Allowed Glycine 0 C--N 1.3 -1.467 0 N-CA-C 108.633 -1.787 . . . . 0.0 108.633 174.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 139.29 -39.61 1.52 Allowed Glycine 0 N--CA 1.439 -1.127 0 N-CA-C 110.713 -0.955 . . . . 0.0 110.713 -176.682 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -68.66 -67.68 0.45 Allowed 'General case' 0 CA--C 1.535 0.397 0 CA-C-O 120.679 0.276 . . . . 0.0 110.554 178.3 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.11 -71.02 1.96 Allowed Glycine 0 N--CA 1.448 -0.502 0 C-N-CA 121.087 -0.578 . . . . 0.0 113.511 175.47 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . 0.453 ' CG ' ' H ' ' A' ' 62' ' ' ASP . 21.8 t70 63.42 -164.29 0.25 Allowed 'General case' 0 N--CA 1.491 1.612 0 C-N-CA 124.085 0.954 . . . . 0.0 108.65 -176.23 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . 0.453 ' H ' ' CG ' ' A' ' 61' ' ' ASP . 37.3 t70 -85.49 -30.28 23.58 Favored 'General case' 0 C--N 1.303 -1.449 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 176.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 41.9 tt0 -163.44 -53.32 0.04 OUTLIER 'General case' 0 C--O 1.236 0.39 0 CA-C-N 114.904 -1.044 . . . . 0.0 109.644 174.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . 0.473 ' HA2' ' CZ ' ' A' ' 56' ' ' PHE . . . -140.38 -66.19 0.04 OUTLIER Glycine 0 N--CA 1.441 -0.977 0 C-N-CA 120.832 -0.699 . . . . 0.0 111.642 -178.292 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -161.51 25.69 0.13 Allowed 'General case' 0 C--N 1.302 -1.497 0 N-CA-C 107.812 -1.181 . . . . 0.0 107.812 178.309 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 11.2 p-10 -151.07 175.57 11.98 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-N 114.868 -1.06 . . . . 0.0 110.296 -168.965 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 17.7 t70 -92.86 112.35 24.28 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 107.225 -1.398 . . . . 0.0 107.225 175.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -84.56 -70.74 0.55 Allowed 'General case' 0 C--N 1.298 -1.668 0 N-CA-C 112.265 0.469 . . . . 0.0 112.265 -175.314 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 17.8 p -134.65 179.99 5.95 Favored 'General case' 0 C--N 1.313 -0.979 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.557 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 -65.69 148.92 50.97 Favored 'General case' 0 CA--C 1.511 -0.53 0 O-C-N 123.27 0.356 . . . . 0.0 110.398 179.496 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 1.9 mptp? -113.72 143.84 43.94 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 109.31 -0.626 . . . . 0.0 109.31 -178.784 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 21.1 mm-40 -132.49 172.39 12.55 Favored 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 123.875 0.87 . . . . 0.0 110.46 178.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.482 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 22.6 t-20 -59.33 122.16 13.22 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 123.958 0.786 . . . . 0.0 110.745 -179.289 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . 0.419 HD22 ' N ' ' A' ' 74' ' ' ASN . 0.1 OUTLIER -51.67 -26.57 9.42 Favored 'General case' 0 N--CA 1.49 1.553 0 N-CA-C 116.141 1.904 . . . . 0.0 116.141 179.482 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.434 HG21 HG11 ' A' ' 36' ' ' VAL . 65.2 t -92.25 -38.38 10.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-N 118.492 0.587 . . . . 0.0 111.21 -175.682 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.482 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 8.7 p -70.86 -42.29 70.29 Favored 'General case' 0 N--CA 1.431 -1.4 0 N-CA-C 109.738 -0.467 . . . . 0.0 109.738 176.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.87 80.42 0.03 OUTLIER Glycine 0 C--N 1.358 1.766 0 O-C-N 125.181 1.551 . . . . 0.0 114.234 174.749 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -60.15 -24.47 77.05 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.897 2.398 . . . . 0.0 113.385 -176.13 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 17.1 t -94.04 5.76 50.69 Favored 'General case' 0 CA--C 1.566 1.579 0 CA-C-O 121.287 0.565 . . . . 0.0 111.03 178.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 18.6 m -140.16 -71.35 0.38 Allowed 'General case' 0 CA--C 1.548 0.89 0 O-C-N 121.014 -1.054 . . . . 0.0 112.648 -177.991 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 96.8 m-85 -83.77 -40.52 18.68 Favored 'General case' 0 C--O 1.244 0.77 0 CA-C-O 120.924 0.392 . . . . 0.0 110.816 -177.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.48 88.63 0.08 Allowed 'General case' 0 C--O 1.237 0.42 0 C-N-CA 125.928 1.691 . . . . 0.0 113.561 179.043 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.534 ' HA ' ' O ' ' A' ' 144' ' ' MET . 3.0 m-85 -86.6 121.09 28.65 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.966 -1.015 . . . . 0.0 113.261 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 26.0 m -91.65 136.26 33.27 Favored 'General case' 0 C--N 1.296 -1.722 0 CA-C-N 113.95 -1.477 . . . . 0.0 108.104 179.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -86.47 137.03 32.86 Favored 'General case' 0 C--N 1.319 -0.73 0 CA-C-O 120.972 0.415 . . . . 0.0 111.606 -178.404 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 83.4 mmm -127.83 134.92 26.74 Favored Pre-proline 0 C--N 1.309 -1.193 0 C-N-CA 124.608 1.163 . . . . 0.0 110.534 179.332 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 98.0 Cg_endo -85.26 167.36 10.64 Favored 'Trans proline' 0 CA--C 1.545 1.075 0 C-N-CA 123.902 3.068 . . . . 0.0 111.978 176.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 69.8 m-85 -54.94 115.96 2.49 Favored 'General case' 0 N--CA 1.476 0.858 0 CA-C-O 121.082 0.468 . . . . 0.0 111.31 177.436 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 6.2 p -85.61 -65.68 0.98 Allowed 'General case' 0 N--CA 1.416 -2.173 0 N-CA-C 108.837 -0.801 . . . . 0.0 108.837 175.492 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 48.9 m 61.85 12.02 4.49 Favored 'General case' 0 CA--C 1.56 1.332 0 N-CA-C 115.08 1.511 . . . . 0.0 115.08 174.343 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -73.85 171.61 13.07 Favored 'General case' 0 N--CA 1.468 0.429 0 O-C-N 122.241 -0.287 . . . . 0.0 110.816 176.244 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -57.11 -40.44 91.48 Favored Glycine 0 N--CA 1.462 0.419 0 O-C-N 123.351 0.407 . . . . 0.0 112.744 -179.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -60.73 -35.32 76.06 Favored 'General case' 0 C--N 1.326 -0.455 0 C-N-CA 122.917 0.487 . . . . 0.0 111.563 176.208 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.459 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.4 t80 -73.73 -35.62 65.08 Favored 'General case' 0 C--O 1.21 -0.984 0 N-CA-C 110.039 -0.356 . . . . 0.0 110.039 178.794 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . 0.416 ' HD3' ' HA ' ' A' ' 95' ' ' LYS . 74.7 mmtt -67.98 -38.4 82.65 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 109.809 -0.441 . . . . 0.0 109.809 177.666 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.5 m -66.2 -35.91 81.67 Favored 'General case' 0 N--CA 1.433 -1.286 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.223 173.677 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.575 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 85.9 t90 -61.37 -43.14 99.38 Favored 'General case' 0 C--O 1.218 -0.586 0 C-N-CA 123.041 0.537 . . . . 0.0 110.198 175.479 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.459 HG23 ' O ' ' A' ' 94' ' ' PHE . 91.1 t -59.28 -44.21 91.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.535 0 C-N-CA 122.954 0.502 . . . . 0.0 110.087 177.907 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . 0.413 ' O ' ' HG3' ' A' ' 103' ' ' ARG . 93.7 mttt -67.87 -39.24 83.76 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.371 178.809 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.94 -41.04 97.5 Favored 'General case' 0 CA--C 1.495 -1.136 0 C-N-CA 123.635 0.774 . . . . 0.0 111.538 175.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.417 ' HA ' HD11 ' A' ' 8' ' ' ILE . 78.2 t80 -59.83 -52.58 64.86 Favored 'General case' 0 N--CA 1.443 -0.811 0 O-C-N 123.999 0.812 . . . . 0.0 109.224 177.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 97.1 t -57.63 -45.31 86.47 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.599 0 O-C-N 123.663 0.602 . . . . 0.0 110.955 179.059 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.413 ' HG3' ' O ' ' A' ' 99' ' ' LYS . 61.2 mtm180 -64.93 -50.33 66.86 Favored 'General case' 0 C--O 1.221 -0.443 0 N-CA-C 112.799 0.666 . . . . 0.0 112.799 -179.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 37.9 m-80 -64.23 -39.69 94.49 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 111.543 0.201 . . . . 0.0 111.543 -179.035 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.445 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.4 t -64.58 -40.5 89.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.981 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.03 176.325 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 53.5 ttt180 -59.65 -39.53 84.69 Favored 'General case' 0 CA--C 1.55 0.962 0 C-N-CA 123.52 0.728 . . . . 0.0 111.076 178.114 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -76.68 -23.76 53.21 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 112.052 0.39 . . . . 0.0 112.052 176.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -72.65 -43.91 62.58 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 175.192 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.635 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 8.5 mp -55.2 -60.63 3.12 Favored 'General case' 0 CA--C 1.513 -0.454 0 C-N-CA 123.707 0.803 . . . . 0.0 111.736 175.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 8.2 mtpm? -71.45 -34.65 70.43 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 115.841 -0.618 . . . . 0.0 112.423 -176.064 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.64 -3.49 83.74 Favored Glycine 0 N--CA 1.438 -1.202 0 C-N-CA 120.569 -0.824 . . . . 0.0 114.806 -175.316 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 60.7 p -71.76 -21.98 61.66 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-N 117.983 0.892 . . . . 0.0 112.029 -177.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.66 29.61 59.28 Favored Glycine 0 N--CA 1.443 -0.865 0 C-N-CA 121.029 -0.605 . . . . 0.0 113.009 178.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 44.5 t -79.16 154.44 4.79 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.073 0 N-CA-C 107.956 -1.128 . . . . 0.0 107.956 175.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -47.11 145.19 2.28 Favored 'General case' 0 CA--C 1.548 0.898 0 C-N-CA 124.707 1.203 . . . . 0.0 113.073 -178.308 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -56.09 -41.91 70.61 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.91 0 C-N-CA 124.473 1.109 . . . . 0.0 113.356 -174.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 50.9 mt-10 -64.44 -33.06 75.0 Favored 'General case' 0 C--O 1.248 0.981 0 CA-C-O 121.009 0.433 . . . . 0.0 111.126 178.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.492 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 12.5 m-20 -70.15 -42.7 72.17 Favored 'General case' 0 C--O 1.197 -1.703 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.417 175.098 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 49.0 mm -54.59 -37.38 38.78 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.199 0 C-N-CA 123.831 0.853 . . . . 0.0 110.869 178.403 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -53.68 -58.14 8.29 Favored 'General case' 0 N--CA 1.48 1.065 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.876 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.418 ' HB3' ' OE1' ' A' ' 125' ' ' GLU . 19.0 mtpp -62.89 -49.53 74.46 Favored 'General case' 0 C--N 1.315 -0.931 0 CA-C-N 113.953 -1.476 . . . . 0.0 111.007 -178.498 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.635 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.6 OUTLIER -54.94 -43.93 73.82 Favored 'General case' 0 C--N 1.306 -1.326 0 C-N-CA 127.027 2.131 . . . . 0.0 109.929 -172.967 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 90.7 mtp -81.29 -27.66 34.97 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 113.028 0.751 . . . . 0.0 113.028 -179.057 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 26.1 mm-40 -82.59 -30.62 29.44 Favored 'General case' 0 N--CA 1.475 0.788 0 C-N-CA 119.849 -0.741 . . . . 0.0 111.185 -179.968 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.43 ' OE2' ' HB2' ' A' ' 31' ' ' PRO . 46.2 mt-10 -78.39 -19.14 53.95 Favored 'General case' 0 C--N 1.306 -1.29 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.43 176.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.54 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -51.94 -52.83 57.82 Favored Pre-proline 0 CA--C 1.563 1.46 0 N-CA-C 114.844 1.424 . . . . 0.0 114.844 178.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -63.94 -24.41 67.45 Favored 'Trans proline' 0 C--N 1.38 2.191 0 C-N-CA 121.532 1.488 . . . . 0.0 112.304 177.372 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 14.4 m -70.91 -31.68 68.38 Favored 'General case' 0 N--CA 1.441 -0.894 0 C-N-CA 122.872 0.469 . . . . 0.0 109.771 179.418 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.54 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 12.4 m-30 -62.99 -49.75 73.45 Favored 'General case' 0 C--N 1.351 0.653 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 176.601 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.426 ' O ' HG23 ' A' ' 134' ' ' VAL . 45.3 t -64.16 -42.66 96.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.382 0 CA-C-N 114.176 -1.375 . . . . 0.0 110.508 -178.428 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 54.3 tttp -61.62 -39.79 92.53 Favored 'General case' 0 C--N 1.323 -0.551 0 C-N-CA 123.248 0.619 . . . . 0.0 111.342 -178.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.569 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 55.5 t90 -68.74 -34.68 76.02 Favored 'General case' 0 C--O 1.24 0.577 0 O-C-N 123.599 0.562 . . . . 0.0 110.615 179.082 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.492 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 88.0 mt -64.25 -39.79 94.68 Favored 'General case' 0 N--CA 1.462 0.15 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 175.871 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.426 HG23 ' O ' ' A' ' 130' ' ' VAL . 92.3 t -65.63 -34.25 69.11 Favored 'Isoleucine or valine' 0 CA--C 1.547 0.865 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.569 177.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 66.9 m-20 -61.6 -39.79 92.51 Favored 'General case' 0 N--CA 1.481 1.092 0 CA-C-O 120.797 0.332 . . . . 0.0 110.987 178.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.612 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 4.7 mptp? -101.81 5.27 41.05 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 113.422 0.897 . . . . 0.0 113.422 -176.182 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 66.2 t80 -48.17 -51.81 23.42 Favored 'General case' 0 N--CA 1.482 1.151 0 N-CA-C 113.8 1.037 . . . . 0.0 113.8 -174.629 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -79.61 1.0 27.74 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 112.545 0.572 . . . . 0.0 112.545 -176.528 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 32.9 m-20 -108.07 -3.0 19.08 Favored 'General case' 0 C--N 1.313 -0.979 0 O-C-N 122.323 -0.235 . . . . 0.0 110.601 177.238 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.612 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.1 mt -83.87 142.4 30.62 Favored 'General case' 0 N--CA 1.43 -1.472 0 CA-C-O 122.128 0.966 . . . . 0.0 113.242 -174.885 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -118.15 142.75 47.11 Favored 'General case' 0 N--CA 1.412 -2.354 0 N-CA-C 104.251 -2.5 . . . . 0.0 104.251 164.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 83.9 m-85 -98.83 144.65 27.8 Favored 'General case' 0 C--N 1.27 -2.862 0 C-N-CA 120.152 -0.619 . . . . 0.0 109.888 -172.883 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 86.8 m-85 -131.85 164.76 25.35 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.155 0.503 . . . . 0.0 110.524 -179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.534 ' O ' ' HA ' ' A' ' 83' ' ' TYR . 45.3 mtp -144.85 146.7 32.18 Favored 'General case' 0 C--N 1.288 -2.088 0 N-CA-C 107.145 -1.428 . . . . 0.0 107.145 179.423 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 38.8 p -88.01 168.48 12.8 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.195 -1.78 . . . . 0.0 106.195 170.215 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 41.0 ttmt -61.26 -30.13 70.27 Favored 'General case' 0 CA--C 1.544 0.728 0 CA-C-N 118.564 0.62 . . . . 0.0 111.999 -178.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 4.7 p -84.36 -2.84 57.76 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.173 0.805 . . . . 0.0 113.173 -178.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 62.2 mtt -111.9 178.4 4.33 Favored 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -176.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 41.1 m-80 -135.85 162.97 53.75 Favored Pre-proline 0 C--N 1.316 -0.884 0 N-CA-C 107.247 -1.39 . . . . 0.0 107.247 -176.37 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -71.62 -21.39 25.61 Favored 'Trans proline' 0 CA--C 1.537 0.632 0 CA-C-N 120.23 1.118 . . . . 0.0 110.356 174.399 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -74.44 -34.92 63.32 Favored 'General case' 0 C--N 1.318 -0.799 0 C-N-CA 125.176 1.391 . . . . 0.0 109.372 177.542 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -146.32 107.34 4.16 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-N 115.17 -0.923 . . . . 0.0 110.052 -173.132 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.42 42.28 3.72 Favored Glycine 0 C--N 1.312 -0.768 0 C-N-CA 120.3 -0.953 . . . . 0.0 112.46 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.575 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 41.1 tp -91.84 112.81 24.89 Favored 'General case' 0 N--CA 1.436 -1.149 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 176.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 95.6 mt -91.7 138.39 19.89 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.216 0 CA-C-N 114.826 -1.079 . . . . 0.0 111.315 -172.474 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 38.8 m-85 -93.85 138.48 31.96 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 178.271 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 25.5 t -150.2 145.79 26.46 Favored 'General case' 0 C--N 1.309 -1.194 0 N-CA-C 108.853 -0.795 . . . . 0.0 108.853 173.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.423 ' HB3' HD23 ' A' ' 140' ' ' LEU . 24.0 p90 -135.21 179.12 6.52 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 175.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -114.53 108.47 16.89 Favored 'General case' 0 C--N 1.285 -2.199 0 N-CA-C 107.723 -1.214 . . . . 0.0 107.723 179.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -99.26 148.82 23.74 Favored 'General case' 0 N--CA 1.425 -1.7 0 C-N-CA 119.943 -0.703 . . . . 0.0 110.061 -179.706 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -52.58 126.55 19.98 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 124.257 1.023 . . . . 0.0 109.294 176.595 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.84 -21.48 31.88 Favored Glycine 0 N--CA 1.443 -0.884 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.595 -178.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -99.36 136.23 39.62 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 177.483 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 58.5 m80 -94.48 -38.06 11.1 Favored 'General case' 0 C--N 1.312 -1.029 0 N-CA-C 108.139 -1.059 . . . . 0.0 108.139 177.552 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 82.3 m -95.32 162.21 25.41 Favored Pre-proline 0 C--N 1.305 -1.342 0 CA-C-N 114.973 -1.012 . . . . 0.0 108.613 177.521 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -51.4 133.06 42.0 Favored 'Trans proline' 0 C--N 1.367 1.519 0 C-N-CA 123.099 2.533 . . . . 0.0 113.145 177.488 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 2.8 m -91.88 108.93 20.28 Favored 'General case' 0 N--CA 1.426 -1.639 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -179.871 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 98.5 m-85 -81.79 139.72 34.63 Favored 'General case' 0 C--N 1.305 -1.332 0 CA-C-O 121.538 0.685 . . . . 0.0 111.989 -173.405 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.569 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 75.5 t -108.05 116.35 51.19 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 CA-C-N 114.258 -1.337 . . . . 0.0 110.072 -174.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 74.3 m-85 -137.95 144.52 41.25 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-O 121.355 0.598 . . . . 0.0 109.935 176.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.415 HG12 ' N ' ' A' ' 174' ' ' GLY . 48.6 t -88.91 113.94 26.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.805 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.276 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -59.04 -48.85 80.09 Favored 'General case' 0 N--CA 1.476 0.839 0 CA-C-O 121.424 0.631 . . . . 0.0 110.514 -175.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.416 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 14.4 m -89.63 0.35 57.0 Favored 'General case' 0 C--N 1.3 -1.556 0 CA-C-N 115.295 -0.866 . . . . 0.0 112.083 -177.564 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.415 ' N ' HG12 ' A' ' 171' ' ' VAL . . . -99.39 -21.72 14.34 Favored Glycine 0 CA--C 1.497 -1.088 0 C-N-CA 120.453 -0.879 . . . . 0.0 112.7 -175.535 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.401 ' CD1' ' HA ' ' A' ' 6' ' ' ASP . 35.5 m-85 -97.27 167.95 10.71 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 177.606 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 41.2 mttp -84.91 115.13 22.61 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 108.741 -0.837 . . . . 0.0 108.741 -177.527 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 57.4 t -84.56 103.55 11.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 O-C-N 124.05 0.843 . . . . 0.0 108.854 -179.605 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 61.8 t -118.5 128.96 75.4 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -178.745 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 2.9 mppt? -96.71 108.13 20.72 Favored 'General case' 0 C--N 1.308 -1.227 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.943 -177.914 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 28.3 m-85 -92.28 138.1 31.8 Favored 'General case' 0 C--N 1.314 -0.977 0 CA-C-N 116.687 -0.233 . . . . 0.0 111.237 177.196 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 37.3 tp 76.14 -18.58 0.46 Allowed 'General case' 0 N--CA 1.477 0.885 0 C-N-CA 126.12 1.768 . . . . 0.0 112.726 177.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . 0.467 ' HA ' ' OE1' ' A' ' 182' ' ' GLU . 2.8 mm-40 -96.31 141.53 29.53 Favored 'General case' 0 N--CA 1.436 -1.154 0 N-CA-C 114.411 1.264 . . . . 0.0 114.411 179.614 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 41.4 m80 -134.21 16.11 3.79 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 176.291 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 29.5 t-80 74.48 -42.24 0.5 Allowed 'General case' 0 N--CA 1.486 1.358 0 C-N-CA 126.539 1.936 . . . . 0.0 110.082 -173.429 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 43.7 t60 -88.39 110.54 20.89 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 106.384 -1.71 . . . . 0.0 106.384 170.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 22.4 t60 -101.08 101.86 12.71 Favored 'General case' 0 C--N 1.3 -1.584 0 CA-C-O 120.936 0.398 . . . . 0.0 110.341 -176.218 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 46.1 t-80 -81.4 109.47 15.92 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 177.509 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 80.1 t60 . . . . . 0 C--N 1.298 -1.67 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.712 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.494 ' HA ' ' OD1' ' A' ' 16' ' ' ASP . 53.9 ttm . . . . . 0 CA--C 1.508 -0.664 0 CA-C-O 120.995 0.426 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.4 mm -102.88 114.16 41.66 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 104.61 -2.367 . . . . 0.0 104.61 175.435 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 13.1 p -124.65 136.83 59.41 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 C-N-CA 119.687 -0.805 . . . . 0.0 111.965 -174.799 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 39.2 m-85 -96.28 111.84 23.78 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 177.264 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -102.31 137.25 40.82 Favored 'General case' 0 C--N 1.293 -1.886 0 CA-C-N 115.598 -0.728 . . . . 0.0 109.726 179.346 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -74.23 147.89 42.05 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.544 -0.753 . . . . 0.0 109.858 178.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 49.9 t -87.47 -27.24 5.73 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 CA-C-O 121.408 0.623 . . . . 0.0 109.446 -177.694 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 34.8 mm -76.8 -53.9 14.13 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.564 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.66 -175.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.6 p -90.8 -36.15 14.41 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-O 121.235 0.541 . . . . 0.0 112.018 179.741 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 83.87 20.23 59.94 Favored Glycine 0 N--CA 1.435 -1.429 0 N-CA-C 109.734 -1.346 . . . . 0.0 109.734 -172.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 5.1 t70 -95.93 -179.16 4.6 Favored 'General case' 0 C--N 1.324 -0.54 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -179.034 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 28.7 mt-10 -110.05 118.1 35.52 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 -175.757 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.55 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 25.8 m -85.35 -30.72 6.61 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 116.138 -0.483 . . . . 0.0 112.04 -175.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.5 p -171.73 161.27 0.44 Allowed 'Isoleucine or valine' 0 C--O 1.241 0.651 0 N-CA-C 108.4 -0.963 . . . . 0.0 108.4 -178.539 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 69.0 p -138.38 176.58 8.58 Favored 'General case' 0 N--CA 1.434 -1.255 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.428 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . 0.494 ' OD1' ' HA ' ' A' ' 1' ' ' MET . 8.3 p-10 -78.23 -1.21 31.77 Favored 'General case' 0 N--CA 1.475 0.824 0 CA-C-O 121.282 0.563 . . . . 0.0 110.844 179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -82.96 -11.73 57.9 Favored 'General case' 0 C--O 1.238 0.483 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 174.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.457 HD11 ' CD2' ' A' ' 81' ' ' PHE . 63.7 mt -113.59 178.15 4.38 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-N 114.487 -1.233 . . . . 0.0 108.437 179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 87.6 tttt -92.34 132.69 36.52 Favored 'General case' 0 C--N 1.313 -1.006 0 CA-C-O 120.968 0.413 . . . . 0.0 110.863 -178.921 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 72.1 mt -128.9 112.8 26.78 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 N-CA-C 108.57 -0.9 . . . . 0.0 108.57 -178.065 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -119.57 154.55 54.6 Favored Pre-proline 0 C--N 1.299 -1.612 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.294 -179.237 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 56.1 Cg_endo -73.65 166.58 29.42 Favored 'Trans proline' 0 C--O 1.241 0.66 0 C-N-CA 121.824 1.683 . . . . 0.0 110.219 174.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.489 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 89.1 t -83.36 108.64 16.17 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.164 -1.05 . . . . 0.0 108.164 177.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 64.8 mtm -109.77 110.98 22.16 Favored 'General case' 0 C--N 1.297 -1.696 0 CA-C-O 121.18 0.514 . . . . 0.0 109.979 -179.439 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 8.7 mm-40 -113.03 104.07 12.02 Favored 'General case' 0 C--N 1.307 -1.251 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.532 -178.617 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 63.61 16.85 59.36 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 114.427 0.531 . . . . 0.0 114.427 177.388 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 116.42 -22.91 10.75 Favored Glycine 0 N--CA 1.444 -0.823 0 C-N-CA 120.233 -0.984 . . . . 0.0 113.163 178.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 14.4 pt-20 -101.09 158.67 15.84 Favored 'General case' 0 C--N 1.314 -0.96 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 7.4 pt-20 -100.58 154.36 18.64 Favored 'General case' 0 N--CA 1.429 -1.495 0 C-N-CA 119.952 -0.699 . . . . 0.0 110.197 177.258 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 47.9 t -107.68 107.03 59.84 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 107.226 -1.398 . . . . 0.0 107.226 174.22 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -68.3 141.65 52.44 Favored 'Trans proline' 0 N--CA 1.482 0.833 0 C-N-CA 123.447 2.764 . . . . 0.0 114.773 -173.692 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 96.11 -12.42 66.89 Favored Glycine 0 N--CA 1.445 -0.746 0 CA-C-N 115.37 -0.832 . . . . 0.0 112.569 176.185 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.588 HD13 ' CE3' ' A' ' 132' ' ' TRP . 50.8 mt -121.12 155.24 34.91 Favored 'General case' 0 C--N 1.29 -2.017 0 N-CA-C 109.041 -0.725 . . . . 0.0 109.041 -176.925 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.1 p90 -137.23 156.99 47.62 Favored 'General case' 0 N--CA 1.431 -1.42 0 N-CA-C 107.805 -1.183 . . . . 0.0 107.805 173.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.473 ' HB2' HG22 ' A' ' 23' ' ' VAL . 45.5 tt0 -132.99 156.14 47.87 Favored 'General case' 0 C--N 1.261 -3.275 0 N-CA-C 106.929 -1.508 . . . . 0.0 106.929 -173.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.469 ' CG1' HG21 ' A' ' 75' ' ' VAL . 78.1 t -111.27 113.48 44.38 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.469 0 C-N-CA 118.987 -1.085 . . . . 0.0 111.23 -179.891 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 27.2 t70 -79.32 159.66 27.1 Favored 'General case' 0 C--N 1.313 -1.021 0 CA-C-N 114.293 -1.322 . . . . 0.0 107.909 174.098 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 6.0 m -97.83 134.33 41.12 Favored 'General case' 0 N--CA 1.414 -2.243 0 C-N-CA 119.663 -0.815 . . . . 0.0 110.156 -173.555 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.488 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.75 123.02 28.29 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 105.399 -2.074 . . . . 0.0 105.399 173.289 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 85.7 mtp -95.29 112.57 24.26 Favored 'General case' 0 C--N 1.293 -1.867 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.523 -172.244 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 33.3 m -111.11 160.33 10.45 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.771 0 CA-C-N 114.726 -1.125 . . . . 0.0 109.073 -179.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -73.91 126.76 31.16 Favored 'General case' 0 C--N 1.294 -1.832 0 N-CA-C 108.53 -0.915 . . . . 0.0 108.53 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -73.97 -37.71 48.1 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 CA-C-O 121.644 0.735 . . . . 0.0 109.155 -179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 107.97 122.71 4.8 Favored Glycine 0 N--CA 1.43 -1.726 0 N-CA-C 110.273 -1.131 . . . . 0.0 110.273 -178.862 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.66 137.62 9.78 Favored Glycine 0 N--CA 1.428 -1.87 0 N-CA-C 110.553 -1.019 . . . . 0.0 110.553 -176.586 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -111.19 174.52 16.91 Favored Glycine 0 N--CA 1.43 -1.725 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 176.405 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . 0.607 ' HA ' ' O ' ' A' ' 50' ' ' ILE . 1.8 m-20 -76.15 0.01 20.45 Favored 'General case' 0 N--CA 1.479 0.986 0 N-CA-C 114.055 1.131 . . . . 0.0 114.055 -174.65 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 59.8 mt -78.81 -22.88 12.91 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.912 0 N-CA-C 107.133 -1.432 . . . . 0.0 107.133 172.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -107.5 -64.93 1.15 Allowed 'General case' 0 C--N 1.327 -0.386 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 176.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . 0.607 ' O ' ' HA ' ' A' ' 47' ' ' ASP . 41.8 mm -94.78 107.22 19.14 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.64 0 N-CA-C 109.681 -0.489 . . . . 0.0 109.681 -178.55 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.63 72.22 2.81 Favored Glycine 0 C--N 1.307 -1.076 0 N-CA-C 110.821 -0.912 . . . . 0.0 110.821 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 42.0 t -82.35 -35.42 27.86 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 -178.153 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -99.67 127.69 9.33 Favored Glycine 0 N--CA 1.42 -2.395 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 49.4 t30 -136.38 98.09 3.74 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 178.209 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -152.99 164.06 38.68 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.171 -1.048 . . . . 0.0 108.171 178.14 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 96.9 m-85 -73.76 117.85 16.01 Favored 'General case' 0 CA--C 1.502 -0.898 0 N-CA-C 107.581 -1.266 . . . . 0.0 107.581 176.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.35 62.22 0.67 Allowed Glycine 0 N--CA 1.42 -2.43 0 N-CA-C 108.571 -1.812 . . . . 0.0 108.571 -173.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -77.83 -29.3 55.03 Favored Glycine 0 N--CA 1.443 -0.85 0 N-CA-C 111.675 -0.57 . . . . 0.0 111.675 -179.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . 64.86 82.69 0.18 Allowed 'General case' 0 C--O 1.249 1.035 0 C-N-CA 125.094 1.358 . . . . 0.0 111.746 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -89.18 89.02 1.54 Allowed Glycine 0 N--CA 1.429 -1.812 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 178.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -69.68 150.13 47.32 Favored 'General case' 0 C--O 1.245 0.834 0 CA-C-O 120.939 0.4 . . . . 0.0 110.132 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -78.44 -38.94 40.1 Favored 'General case' 0 C--N 1.308 -1.196 0 CA-C-N 116.057 -0.52 . . . . 0.0 111.012 -177.163 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 16.8 pt-20 -111.93 139.66 47.24 Favored 'General case' 0 N--CA 1.437 -1.112 0 CA-C-O 121.134 0.492 . . . . 0.0 111.087 -176.665 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 173.13 85.58 0.06 OUTLIER Glycine 0 N--CA 1.422 -2.288 0 N-CA-C 110.347 -1.101 . . . . 0.0 110.347 -178.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -75.55 -22.89 56.65 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 121.505 0.669 . . . . 0.0 109.74 -179.746 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -84.9 100.34 11.54 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 108.345 -0.983 . . . . 0.0 108.345 177.304 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 29.0 m-20 -85.17 68.9 10.68 Favored 'General case' 0 C--N 1.311 -1.091 0 CA-C-O 121.705 0.764 . . . . 0.0 110.683 179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -158.94 73.42 0.61 Allowed 'General case' 0 C--N 1.299 -1.622 0 CA-C-N 114.577 -1.192 . . . . 0.0 107.815 178.618 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 10.9 m -74.92 -24.75 58.56 Favored 'General case' 0 C--N 1.301 -1.506 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.345 -176.918 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 48.7 mt-30 -78.63 124.23 27.95 Favored 'General case' 0 C--O 1.247 0.926 0 CA-C-N 115.68 -0.691 . . . . 0.0 111.674 178.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -126.86 121.2 31.18 Favored 'General case' 0 C--N 1.307 -1.261 0 N-CA-C 108.331 -0.989 . . . . 0.0 108.331 173.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 11.4 tp10 -136.87 159.12 42.81 Favored 'General case' 0 C--N 1.285 -2.215 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 -173.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.564 ' HB3' ' OG ' ' A' ' 76' ' ' SER . 35.0 t30 -66.92 129.37 39.66 Favored 'General case' 0 C--N 1.309 -1.168 0 N-CA-C 107.027 -1.472 . . . . 0.0 107.027 174.516 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 8.3 p30 -52.4 -28.97 21.93 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 123.766 0.827 . . . . 0.0 112.536 -176.041 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.469 HG21 ' CG1' ' A' ' 36' ' ' VAL . 18.2 t -76.14 -52.5 17.53 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.265 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.127 -178.765 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.564 ' OG ' ' HB3' ' A' ' 73' ' ' ASN . 3.6 p -71.45 -18.97 62.29 Favored 'General case' 0 CA--C 1.54 0.573 0 N-CA-C 112.791 0.663 . . . . 0.0 112.791 -177.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.415 ' HA2' ' HD3' ' A' ' 78' ' ' PRO . . . -36.49 122.55 0.77 Allowed Glycine 0 CA--C 1.531 1.09 0 C-N-CA 125.919 1.723 . . . . 0.0 115.547 179.649 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.415 ' HD3' ' HA2' ' A' ' 77' ' ' GLY . 21.4 Cg_exo -70.48 -8.58 23.94 Favored 'Trans proline' 0 C--N 1.353 0.777 0 C-N-CA 123.402 2.735 . . . . 0.0 111.96 178.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 9.3 p -74.82 -28.17 60.6 Favored 'General case' 0 N--CA 1.428 -1.563 0 C-N-CA 123.634 0.773 . . . . 0.0 112.284 -179.078 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 26.4 t -119.8 -81.35 0.63 Allowed 'General case' 0 N--CA 1.434 -1.265 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.994 -177.488 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.457 ' CD2' HD11 ' A' ' 18' ' ' LEU . 54.9 m-85 -82.42 -36.58 26.52 Favored 'General case' 0 C--O 1.237 0.429 0 N-CA-C 113.086 0.773 . . . . 0.0 113.086 -175.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 57.88 94.34 0.03 OUTLIER 'General case' 0 N--CA 1.481 1.112 0 O-C-N 124.076 0.86 . . . . 0.0 112.824 178.658 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 67.9 m-85 -86.72 131.39 34.15 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-O 121.736 0.779 . . . . 0.0 112.133 -177.523 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 20.0 m -94.23 126.52 39.52 Favored 'General case' 0 N--CA 1.42 -1.971 0 CA-C-N 114.165 -1.379 . . . . 0.0 108.649 179.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.37 133.16 34.14 Favored 'General case' 0 C--N 1.313 -0.984 0 N-CA-C 112.389 0.514 . . . . 0.0 112.389 -175.015 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.3 mmt -127.78 143.7 48.57 Favored Pre-proline 0 C--O 1.243 0.755 0 C-N-CA 123.283 0.633 . . . . 0.0 109.611 178.556 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.21 166.47 22.65 Favored 'Trans proline' 0 CA--C 1.551 1.33 0 C-N-CA 123.261 2.641 . . . . 0.0 112.908 177.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 15.9 m-85 -61.26 122.37 14.92 Favored 'General case' 0 N--CA 1.475 0.8 0 C-N-CA 123.005 0.522 . . . . 0.0 110.097 176.319 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.0 p -90.06 -72.84 0.54 Allowed 'General case' 0 N--CA 1.429 -1.491 0 N-CA-C 110.441 -0.207 . . . . 0.0 110.441 178.004 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 38.4 m 62.8 30.67 16.69 Favored 'General case' 0 CA--C 1.547 0.831 0 C-N-CA 124.672 1.189 . . . . 0.0 111.917 179.828 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.428 ' HB3' ' OE1' ' A' ' 93' ' ' GLU . 5.6 mptp? -85.73 169.3 13.55 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-N 116.055 -0.52 . . . . 0.0 111.059 178.758 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.67 -38.87 96.2 Favored Glycine 0 N--CA 1.464 0.563 0 N-CA-C 112.518 -0.233 . . . . 0.0 112.518 -178.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.428 ' OE1' ' HB3' ' A' ' 91' ' ' LYS . 4.3 pm0 -67.32 -19.28 65.44 Favored 'General case' 0 C--N 1.324 -0.508 0 C-N-CA 122.493 0.317 . . . . 0.0 111.439 178.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.43 ' O ' HG23 ' A' ' 98' ' ' VAL . 89.3 t80 -71.95 -33.85 68.54 Favored 'General case' 0 N--CA 1.446 -0.669 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 177.245 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 32.2 mmmt -65.67 -38.16 88.53 Favored 'General case' 0 C--O 1.236 0.369 0 N-CA-C 109.444 -0.576 . . . . 0.0 109.444 177.629 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 10.1 m -65.43 -37.89 88.26 Favored 'General case' 0 N--CA 1.439 -1.004 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.067 177.012 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.493 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 83.8 t90 -61.64 -47.66 84.38 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 122.77 0.428 . . . . 0.0 110.128 176.367 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 94' ' ' PHE . 94.0 t -56.69 -42.23 76.42 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.692 0 C-N-CA 123.122 0.569 . . . . 0.0 111.051 179.921 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 99.0 mttt -66.6 -37.29 84.58 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 113.125 0.787 . . . . 0.0 113.125 -178.347 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -73.72 -40.98 63.17 Favored 'General case' 0 CA--C 1.504 -0.814 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.545 175.036 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 76.5 t80 -55.05 -58.57 7.12 Favored 'General case' 0 N--CA 1.465 0.308 0 C-N-CA 123.838 0.855 . . . . 0.0 110.728 179.619 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 98.9 t -63.38 -37.99 81.0 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.342 0 CA-C-N 116.369 -0.378 . . . . 0.0 111.186 -178.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 71.1 ttt180 -61.67 -54.6 40.49 Favored 'General case' 0 C--N 1.331 -0.209 0 C-N-CA 122.45 0.3 . . . . 0.0 111.343 179.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 85.7 m-20 -65.59 -36.09 82.74 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.165 -0.47 . . . . 0.0 111.233 -176.438 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.409 ' O ' HD13 ' A' ' 109' ' ' LEU . 52.6 t -63.85 -43.24 97.77 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.768 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.087 174.588 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 78.7 ttt180 -61.64 -35.72 78.73 Favored 'General case' 0 CA--C 1.548 0.873 0 C-N-CA 123.341 0.656 . . . . 0.0 111.353 -179.164 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -71.88 -30.5 65.48 Favored 'General case' 0 C--N 1.329 -0.317 0 C-N-CA 120.656 -0.418 . . . . 0.0 111.379 174.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -70.48 -32.09 69.47 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.586 -0.279 . . . . 0.0 110.56 177.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.628 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 8.2 mp -54.37 -59.4 4.73 Favored 'General case' 0 N--CA 1.477 0.881 0 C-N-CA 123.6 0.76 . . . . 0.0 110.985 173.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 21.8 ptmt -82.03 -27.5 33.01 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 113.38 0.882 . . . . 0.0 113.38 -175.133 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -86.83 -2.03 84.59 Favored Glycine 0 C--N 1.321 -0.267 0 N-CA-C 114.929 0.732 . . . . 0.0 114.929 -174.238 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -86.38 -12.99 47.71 Favored 'General case' 0 C--N 1.311 -1.08 0 CA-C-N 117.804 0.802 . . . . 0.0 111.945 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 79.52 38.27 21.44 Favored Glycine 0 N--CA 1.441 -1.013 0 C-N-CA 120.887 -0.673 . . . . 0.0 113.009 177.677 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 21.6 t -77.45 151.71 5.56 Favored 'Isoleucine or valine' 0 C--O 1.246 0.9 0 N-CA-C 107.446 -1.316 . . . . 0.0 107.446 177.109 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -56.9 147.44 23.63 Favored 'General case' 0 N--CA 1.474 0.728 0 C-N-CA 122.763 0.425 . . . . 0.0 111.456 -178.301 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 53.8 t -59.57 -39.65 79.96 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 C-N-CA 123.614 0.766 . . . . 0.0 112.17 -174.161 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -67.09 -33.43 75.48 Favored 'General case' 0 C--O 1.244 0.795 0 CA-C-O 121.101 0.477 . . . . 0.0 110.724 178.809 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.404 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 21.3 m-20 -71.15 -38.91 72.2 Favored 'General case' 0 C--O 1.204 -1.337 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 175.738 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 115' ' ' ALA . 40.2 mm -57.69 -37.19 57.92 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.793 0 C-N-CA 123.841 0.856 . . . . 0.0 110.905 176.863 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -61.39 -48.01 83.19 Favored 'General case' 0 C--O 1.239 0.509 0 CA-C-O 120.928 0.394 . . . . 0.0 110.411 177.172 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 31.6 mmmt -66.42 -33.37 75.54 Favored 'General case' 0 C--O 1.211 -0.961 0 CA-C-N 115.553 -0.749 . . . . 0.0 110.148 178.344 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.628 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.7 OUTLIER -73.03 -28.91 62.62 Favored 'General case' 0 C--N 1.313 -1.004 0 CA-C-N 114.976 -1.011 . . . . 0.0 108.557 -174.985 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 61.9 mtt -81.59 -12.79 58.62 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.837 175.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 39.0 mm-40 -83.33 -39.2 21.07 Favored 'General case' 0 C--N 1.315 -0.902 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 169.567 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . . . . . . . . . 42.8 mt-10 -60.89 -39.02 87.69 Favored 'General case' 0 C--O 1.216 -0.668 0 C-N-CA 124.057 0.943 . . . . 0.0 111.155 175.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.599 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.11 -60.69 5.15 Favored Pre-proline 0 CA--C 1.57 1.742 0 N-CA-C 115.098 1.518 . . . . 0.0 115.098 -177.789 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -67.21 -21.53 48.11 Favored 'Trans proline' 0 C--N 1.378 2.088 0 C-N-CA 121.475 1.45 . . . . 0.0 112.038 177.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 44.7 m -69.73 -38.19 76.77 Favored 'General case' 0 CA--C 1.549 0.905 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.694 177.964 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.599 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 21.0 m-85 -57.24 -57.67 11.58 Favored 'General case' 0 C--N 1.362 1.123 0 N-CA-C 109.085 -0.709 . . . . 0.0 109.085 176.426 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . . . . . . . . . 46.4 t -56.69 -48.38 80.92 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.201 0 CA-C-N 114.393 -1.276 . . . . 0.0 111.943 -175.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 19.1 ttpp -60.44 -54.13 49.31 Favored 'General case' 0 CA--C 1.532 0.272 0 O-C-N 123.515 0.509 . . . . 0.0 111.322 -175.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.588 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.5 t90 -66.56 -31.13 71.64 Favored 'General case' 0 CA--C 1.538 0.482 0 N-CA-C 111.943 0.349 . . . . 0.0 111.943 -175.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.434 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 94.1 mt -65.03 -40.65 95.14 Favored 'General case' 0 C--O 1.222 -0.345 0 C-N-CA 121.068 -0.253 . . . . 0.0 110.512 176.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . . . . . . . . . 61.7 t -74.68 -34.0 33.16 Favored 'Isoleucine or valine' 0 C--O 1.246 0.873 0 CA-C-O 121.204 0.526 . . . . 0.0 110.214 178.973 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 17.7 m-20 -66.39 -43.81 84.82 Favored 'General case' 0 CA--C 1.507 -0.692 0 CA-C-N 116.114 -0.494 . . . . 0.0 112.148 177.721 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.56 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 14.6 tppt? -87.27 -7.95 57.3 Favored 'General case' 0 C--N 1.313 -0.989 0 C-N-CA 120.923 -0.311 . . . . 0.0 111.185 -177.051 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -52.22 -33.95 43.47 Favored 'General case' 0 N--CA 1.482 1.17 0 C-N-CA 124.236 1.014 . . . . 0.0 113.709 -175.096 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 12.1 m-20 -62.63 -21.48 65.69 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-O 121.025 0.441 . . . . 0.0 112.147 178.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 28.0 m-20 -108.76 -8.05 15.44 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.775 178.802 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.56 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 89.8 mt -83.39 118.64 23.85 Favored 'General case' 0 N--CA 1.441 -0.905 0 CA-C-O 122.595 1.188 . . . . 0.0 113.115 -171.917 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -107.73 170.34 8.04 Favored 'General case' 0 N--CA 1.413 -2.298 0 N-CA-C 105.245 -2.131 . . . . 0.0 105.245 178.253 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 78.7 m-85 -116.38 143.26 45.79 Favored 'General case' 0 C--N 1.304 -1.393 0 C-N-CA 119.188 -1.005 . . . . 0.0 113.515 -170.764 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 78.5 m-85 -138.19 169.41 17.84 Favored 'General case' 0 C--N 1.307 -1.279 0 C-N-CA 124.308 1.043 . . . . 0.0 108.918 176.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . 0.537 ' HB3' ' HB2' ' A' ' 148' ' ' MET . 66.8 mtt -151.01 162.01 41.64 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.175 -1.787 . . . . 0.0 106.175 178.331 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 90.3 p -82.31 173.93 11.61 Favored 'General case' 0 C--O 1.255 1.377 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 168.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 33.5 tptt -63.02 -30.18 71.4 Favored 'General case' 0 CA--C 1.558 1.273 0 CA-C-N 118.477 0.58 . . . . 0.0 111.004 -177.186 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 11.8 p -90.01 -4.26 57.53 Favored 'General case' 0 CA--C 1.574 1.899 0 N-CA-C 114.45 1.278 . . . . 0.0 114.45 179.599 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 144' ' ' MET . 54.5 mtt -85.15 163.45 18.74 Favored 'General case' 0 N--CA 1.483 1.217 0 N-CA-C 114.528 1.307 . . . . 0.0 114.528 -175.153 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -122.31 162.15 39.34 Favored Pre-proline 0 C--O 1.215 -0.74 0 CA-C-N 114.827 -1.078 . . . . 0.0 108.966 -175.406 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.18 -26.35 12.75 Favored 'Trans proline' 0 C--N 1.357 0.988 0 C-N-CA 121.701 1.601 . . . . 0.0 111.178 176.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 7.5 m-20 -74.13 -36.9 64.19 Favored 'General case' 0 CA--C 1.506 -0.735 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.047 178.508 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -144.69 117.88 8.94 Favored 'General case' 0 N--CA 1.422 -1.836 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.262 -172.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 94.3 42.61 3.95 Favored Glycine 0 C--N 1.314 -0.671 0 C-N-CA 120.261 -0.971 . . . . 0.0 112.606 -177.314 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.493 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 45.2 tp -98.95 112.29 24.45 Favored 'General case' 0 C--N 1.31 -1.139 0 N-CA-C 107.878 -1.156 . . . . 0.0 107.878 177.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 94.9 mt -92.72 133.42 34.06 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 CA-C-N 115.361 -0.836 . . . . 0.0 111.823 -174.068 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . . . . . . . . . 90.2 m-85 -87.82 139.54 30.42 Favored 'General case' 0 C--N 1.309 -1.155 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 173.463 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 19.7 m -149.81 163.35 38.25 Favored 'General case' 0 C--N 1.31 -1.124 0 O-C-N 121.608 -0.683 . . . . 0.0 110.22 175.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 41.3 p90 -159.22 178.26 10.18 Favored 'General case' 0 C--O 1.198 -1.649 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 176.758 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 49.0 m-85 -102.43 113.53 26.94 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 118.737 0.698 . . . . 0.0 109.442 173.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 29.7 tttp -89.65 152.71 21.22 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 42.5 tt0 -65.29 124.05 21.18 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 175.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.9 -17.98 56.51 Favored Glycine 0 C--N 1.307 -1.039 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -179.006 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -89.24 135.88 33.33 Favored 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 178.148 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 -97.81 -12.46 22.18 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 112.177 0.436 . . . . 0.0 112.177 -173.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.516 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 40.5 m -134.64 168.7 16.48 Favored Pre-proline 0 C--N 1.301 -1.541 0 N-CA-C 106.941 -1.503 . . . . 0.0 106.941 -177.082 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_endo -48.46 121.57 6.51 Favored 'Trans proline' 0 C--N 1.371 1.723 0 C-N-CA 122.779 2.319 . . . . 0.0 111.876 175.082 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 9.1 m -87.16 111.61 21.13 Favored 'General case' 0 C--N 1.293 -1.873 0 N-CA-C 107.167 -1.42 . . . . 0.0 107.167 -178.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . . . . . . . . . 93.8 m-85 -82.0 137.39 35.11 Favored 'General case' 0 C--N 1.308 -1.223 0 CA-C-O 121.043 0.449 . . . . 0.0 110.872 -174.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.434 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 54.5 t -107.55 123.69 63.05 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 C-N-CA 124.335 1.054 . . . . 0.0 109.397 -177.087 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.55 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 53.6 m-85 -138.61 151.36 47.18 Favored 'General case' 0 N--CA 1.441 -0.881 0 CA-C-O 121.765 0.793 . . . . 0.0 112.186 -176.638 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.501 ' HA ' HD23 ' A' ' 33' ' ' LEU . 48.2 t -96.3 97.7 6.82 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.06 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 176.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.4 ttpp -53.31 -56.56 15.62 Favored 'General case' 0 N--CA 1.483 1.181 0 C-N-CA 124.069 0.947 . . . . 0.0 112.193 -173.094 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 15.2 m -82.05 -6.75 59.4 Favored 'General case' 0 C--N 1.292 -1.897 0 CA-C-N 115.012 -0.994 . . . . 0.0 111.763 -174.96 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -85.0 -26.21 38.12 Favored Glycine 0 CA--C 1.493 -1.289 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 -178.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 24.5 m-85 -96.16 171.75 8.4 Favored 'General case' 0 C--N 1.305 -1.335 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 -178.089 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . 0.436 ' HA ' ' HD3' ' A' ' 176' ' ' LYS . 28.8 mmtm -107.37 122.91 47.54 Favored 'General case' 0 C--N 1.289 -2.062 0 CA-C-O 121.313 0.578 . . . . 0.0 111.418 -175.963 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 19.5 t -86.85 103.41 13.1 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 114.427 -1.26 . . . . 0.0 108.735 -176.779 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 66.4 t -101.54 123.51 54.71 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.963 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 178.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 94.8 mttt -106.52 107.22 18.12 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 121.399 0.619 . . . . 0.0 110.036 -176.35 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 89.9 m-85 -93.37 102.67 14.92 Favored 'General case' 0 C--N 1.296 -1.723 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 174.591 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -84.67 -28.14 26.61 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.26 -1.385 . . . . 0.0 107.26 176.638 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -143.59 -179.39 6.41 Favored 'General case' 0 N--CA 1.417 -2.094 0 N-CA-C 106.628 -1.619 . . . . 0.0 106.628 175.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 12.7 t-160 -68.5 -72.92 0.16 Allowed 'General case' 0 C--N 1.314 -0.975 0 CA-C-N 118.421 0.555 . . . . 0.0 110.935 -173.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 25.2 m80 -157.22 131.54 8.46 Favored 'General case' 0 CA--C 1.493 -1.215 0 C-N-CA 124.091 0.956 . . . . 0.0 109.689 178.019 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 33.1 m80 -78.18 120.15 22.57 Favored 'General case' 0 C--N 1.308 -1.232 0 N-CA-C 109.69 -0.485 . . . . 0.0 109.69 177.222 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 38.6 p-80 -77.56 146.49 36.24 Favored 'General case' 0 C--N 1.309 -1.163 0 N-CA-C 107.068 -1.456 . . . . 0.0 107.068 175.607 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 35.2 t-80 -75.39 90.8 2.69 Favored 'General case' 0 C--N 1.308 -1.232 0 C-N-CA 120.364 -0.534 . . . . 0.0 111.989 -174.372 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 33.3 m170 . . . . . 0 CA--C 1.501 -0.921 0 C-N-CA 125.679 1.592 . . . . 0.0 111.441 -179.306 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 56.6 ttp . . . . . 0 CA--C 1.515 -0.387 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.4 mm -85.33 139.69 17.07 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 N-CA-C 107.085 -1.45 . . . . 0.0 107.085 174.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 9.9 p -142.06 152.73 18.53 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 N-CA-C 108.404 -0.961 . . . . 0.0 108.404 177.159 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 64.8 m-85 -112.77 119.4 37.9 Favored 'General case' 0 C--N 1.295 -1.781 0 N-CA-C 109.057 -0.719 . . . . 0.0 109.057 -179.933 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD2' HG21 ' A' ' 178' ' ' VAL . 56.8 mttm -100.86 141.74 33.31 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 115.803 -0.635 . . . . 0.0 111.32 179.063 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -74.87 142.71 44.07 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.428 174.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 38.7 t -77.45 -27.11 15.56 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 CA-C-O 121.13 0.491 . . . . 0.0 110.13 -178.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 21.3 mm -80.8 -53.08 13.24 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.911 0 CA-C-N 116.378 -0.374 . . . . 0.0 110.284 -175.433 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 33.7 p -83.72 -42.33 16.7 Favored 'General case' 0 C--N 1.313 -1.007 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -179.533 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 90.21 12.27 61.85 Favored Glycine 0 N--CA 1.439 -1.154 0 N-CA-C 110.136 -1.186 . . . . 0.0 110.136 -173.526 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 12.2 t70 -105.9 178.91 4.42 Favored 'General case' 0 CA--C 1.548 0.874 0 N-CA-C 109.288 -0.634 . . . . 0.0 109.288 -177.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.3 mp0 -93.06 134.41 35.23 Favored 'General case' 0 C--N 1.314 -0.978 0 C-N-CA 123.052 0.541 . . . . 0.0 111.689 -171.612 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.524 ' HB ' ' CE1' ' A' ' 170' ' ' TYR . 17.4 m -101.05 -35.35 4.29 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.815 0 C-N-CA 120.311 -0.555 . . . . 0.0 112.213 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.406 HG12 HG23 ' A' ' 13' ' ' VAL . 13.7 p -162.15 152.5 3.78 Favored 'Isoleucine or valine' 0 C--O 1.247 0.949 0 N-CA-C 107.773 -1.195 . . . . 0.0 107.773 -177.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 62.5 p -126.74 171.53 11.12 Favored 'General case' 0 N--CA 1.439 -1.014 0 CA-C-O 120.604 0.24 . . . . 0.0 111.142 -177.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -65.04 -15.56 62.48 Favored 'General case' 0 N--CA 1.485 1.319 0 C-N-CA 125.011 1.324 . . . . 0.0 112.343 179.285 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -83.34 -6.51 59.49 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.003 0.43 . . . . 0.0 110.659 179.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 75.9 mt -106.23 170.58 7.83 Favored 'General case' 0 N--CA 1.442 -0.855 0 CA-C-N 116.285 -0.416 . . . . 0.0 109.892 -178.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 36' ' ' VAL . 2.4 tmtp? -79.27 107.01 11.72 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.06 0.457 . . . . 0.0 109.786 -176.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 79.1 mt -110.65 122.78 65.78 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.068 0 CA-C-O 121.004 0.431 . . . . 0.0 110.755 -177.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . 0.439 ' O ' ' HB2' ' A' ' 34' ' ' PHE . 0.6 OUTLIER -131.42 160.32 67.76 Favored Pre-proline 0 C--N 1.308 -1.235 0 C-N-CA 124.146 0.979 . . . . 0.0 110.096 176.614 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -82.63 164.59 16.22 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 121.896 1.73 . . . . 0.0 110.181 172.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.566 HG22 ' HB2' ' A' ' 35' ' ' GLU . 69.0 t -74.96 108.95 7.12 Favored 'Isoleucine or valine' 0 C--O 1.219 -0.506 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 177.034 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 89.0 mtp -115.63 109.26 17.5 Favored 'General case' 0 C--N 1.306 -1.292 0 CA-C-O 121.114 0.483 . . . . 0.0 109.761 177.256 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 38.2 mm-40 -119.53 109.12 15.33 Favored 'General case' 0 C--N 1.305 -1.333 0 CA-C-N 115.117 -0.947 . . . . 0.0 108.967 -178.184 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 87.29 -8.95 74.91 Favored Glycine 0 C--N 1.307 -1.056 0 C-N-CA 121.213 -0.518 . . . . 0.0 111.994 178.91 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 119.63 -19.46 9.73 Favored Glycine 0 N--CA 1.438 -1.202 0 N-CA-C 111.431 -0.668 . . . . 0.0 111.431 -178.236 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 10.8 pt-20 -99.44 156.54 16.97 Favored 'General case' 0 C--O 1.246 0.897 0 N-CA-C 108.501 -0.925 . . . . 0.0 108.501 177.489 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.493 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 10.6 pt-20 -96.29 147.27 23.96 Favored 'General case' 0 N--CA 1.425 -1.687 0 C-N-CA 119.785 -0.766 . . . . 0.0 109.519 178.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 22.0 t -93.75 115.19 64.78 Favored Pre-proline 0 C--N 1.291 -1.965 0 N-CA-C 105.857 -1.905 . . . . 0.0 105.857 174.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -60.17 134.17 54.32 Favored 'Trans proline' 0 C--O 1.238 0.52 0 C-N-CA 123.367 2.711 . . . . 0.0 115.72 -171.551 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 81.87 8.53 86.59 Favored Glycine 0 N--CA 1.442 -0.902 0 CA-C-N 114.309 -1.314 . . . . 0.0 113.9 176.54 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 132' ' ' TRP . 45.5 mt -126.98 146.43 50.34 Favored 'General case' 0 C--N 1.306 -1.287 0 O-C-N 122.56 -0.377 . . . . 0.0 110.503 -177.858 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.439 ' HB2' ' O ' ' A' ' 21' ' ' THR . 15.7 p90 -136.77 146.88 46.27 Favored 'General case' 0 N--CA 1.439 -0.977 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 176.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . 0.566 ' HB2' HG22 ' A' ' 23' ' ' VAL . 41.3 tt0 -120.36 144.24 47.99 Favored 'General case' 0 C--N 1.283 -2.323 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -174.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.45 HG13 ' O ' ' A' ' 19' ' ' LYS . 55.9 t -109.83 114.61 47.45 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.763 0 CA-C-O 121.856 0.836 . . . . 0.0 109.056 -177.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.38 159.83 18.58 Favored 'General case' 0 C--N 1.303 -1.426 0 CA-C-N 113.257 -1.792 . . . . 0.0 110.32 -177.253 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 20.3 m -97.26 135.56 39.01 Favored 'General case' 0 N--CA 1.406 -2.636 0 CA-C-O 121.965 0.888 . . . . 0.0 110.937 -173.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . . . . . . . . . . . -134.93 125.43 26.67 Favored 'General case' 0 C--N 1.296 -1.756 0 N-CA-C 106.572 -1.64 . . . . 0.0 106.572 178.169 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.418 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 60.3 mtt -79.81 129.01 34.12 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 124.16 0.912 . . . . 0.0 110.368 -174.572 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 30.3 m -118.46 144.85 25.48 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.77 0 N-CA-C 109.034 -0.728 . . . . 0.0 109.034 175.901 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -78.98 124.07 27.9 Favored 'General case' 0 C--N 1.3 -1.548 0 N-CA-C 109.122 -0.695 . . . . 0.0 109.122 179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 61.2 t -74.57 96.61 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 CA-C-N 115.526 -0.761 . . . . 0.0 112.345 -175.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -110.66 15.33 29.35 Favored Glycine 0 C--N 1.309 -0.933 0 N-CA-C 108.163 -1.975 . . . . 0.0 108.163 169.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 84.6 -21.2 11.36 Favored Glycine 0 C--N 1.341 0.826 0 CA-C-N 113.88 -1.16 . . . . 0.0 113.376 178.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 101.49 5.33 52.0 Favored Glycine 0 N--CA 1.439 -1.122 0 N-CA-C 108.807 -1.717 . . . . 0.0 108.807 -172.744 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -91.15 76.61 6.08 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 107.159 -1.422 . . . . 0.0 107.159 178.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 50.0 mm 73.68 138.2 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.548 0.886 0 C-N-CA 124.637 1.175 . . . . 0.0 109.879 -175.16 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -87.21 121.16 29.28 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 3.4 mp -84.4 79.65 1.55 Allowed 'Isoleucine or valine' 0 C--O 1.244 0.791 0 CA-C-O 122.572 1.177 . . . . 0.0 110.106 -177.954 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -155.91 112.63 0.53 Allowed Glycine 0 N--CA 1.417 -2.606 0 N-CA-C 108.893 -1.683 . . . . 0.0 108.893 177.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 58.4 m -93.46 11.37 28.74 Favored 'General case' 0 C--N 1.298 -1.653 0 CA-C-O 120.998 0.428 . . . . 0.0 110.611 -178.087 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 172.46 -41.74 0.17 Allowed Glycine 0 N--CA 1.435 -1.421 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.799 -179.58 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -153.59 162.42 41.28 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 -179.352 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -53.97 -40.15 66.62 Favored 'General case' 0 N--CA 1.464 0.238 0 C-N-CA 123.702 0.801 . . . . 0.0 111.187 176.763 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 91.8 m-85 -88.67 98.86 11.91 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 178.958 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -113.64 171.61 13.92 Favored Glycine 0 C--N 1.311 -0.852 0 N-CA-C 110.57 -1.012 . . . . 0.0 110.57 178.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 106.09 123.19 5.1 Favored Glycine 0 C--N 1.309 -0.96 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -178.128 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -98.24 -21.75 16.52 Favored 'General case' 0 C--N 1.304 -1.404 0 CA-C-O 121.326 0.584 . . . . 0.0 110.411 -176.403 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 96.37 37.12 4.92 Favored Glycine 0 N--CA 1.432 -1.631 0 N-CA-C 109.465 -1.454 . . . . 0.0 109.465 -178.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -95.82 -75.01 0.54 Allowed 'General case' 0 C--N 1.317 -0.831 0 CA-C-O 120.891 0.377 . . . . 0.0 111.081 -177.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -108.78 -35.39 6.41 Favored 'General case' 0 C--N 1.306 -1.307 0 CA-C-N 115.7 -0.682 . . . . 0.0 109.462 -178.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . 0.412 ' H ' ' CD ' ' A' ' 63' ' ' GLU . 1.3 mp0 -34.06 89.58 0.0 OUTLIER 'General case' 0 N--CA 1.473 0.718 0 C-N-CA 128.107 2.563 . . . . 0.0 114.142 -174.347 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -101.33 -22.02 10.98 Favored Glycine 0 CA--C 1.494 -1.233 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 178.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -90.64 69.95 6.71 Favored 'General case' 0 N--CA 1.427 -1.577 0 CA-C-O 121.51 0.672 . . . . 0.0 110.127 178.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -103.54 93.35 4.89 Favored 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 106.244 -1.761 . . . . 0.0 106.244 173.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -112.89 154.96 25.52 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 114.738 -1.119 . . . . 0.0 110.211 -170.929 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -68.29 93.35 0.46 Allowed 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.457 0.646 . . . . 0.0 110.661 179.583 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 11.0 m -69.24 145.29 53.27 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-N 115.137 -0.938 . . . . 0.0 109.821 -178.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 78.5 mt-30 -77.65 135.0 38.05 Favored 'General case' 0 C--N 1.31 -1.149 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.418 ' HB3' ' HB3' ' A' ' 40' ' ' MET . 0.4 OUTLIER -120.58 130.74 54.32 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 109.565 -0.531 . . . . 0.0 109.565 175.571 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.4 mt-10 -128.37 160.1 33.29 Favored 'General case' 0 C--N 1.284 -2.254 0 N-CA-C 107.543 -1.281 . . . . 0.0 107.543 175.727 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . . . . . . . . . 28.1 t30 -68.0 132.78 47.91 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 174.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 7.4 p30 -51.25 -30.13 16.71 Favored 'General case' 0 N--CA 1.48 1.067 0 C-N-CA 124.085 0.954 . . . . 0.0 112.457 -178.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.45 HG21 ' CG1' ' A' ' 36' ' ' VAL . 17.5 t -87.19 -67.54 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.771 -178.384 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 7.3 p -69.34 -19.13 63.86 Favored 'General case' 0 C--O 1.238 0.494 0 N-CA-C 114.035 1.124 . . . . 0.0 114.035 -174.002 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.95 122.06 27.45 Favored Glycine 0 N--CA 1.424 -2.103 0 O-C-N 123.791 0.682 . . . . 0.0 111.901 178.969 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . 0.474 ' HA ' ' HA ' ' A' ' 82' ' ' ALA . 53.0 Cg_exo -63.83 -10.28 22.01 Favored 'Trans proline' 0 N--CA 1.475 0.4 0 C-N-CA 123.882 3.055 . . . . 0.0 112.438 177.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 19.3 m -74.46 -13.25 60.68 Favored 'General case' 0 N--CA 1.433 -1.321 0 CA-C-N 115.604 -0.726 . . . . 0.0 110.308 174.069 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.1 m -106.91 -96.96 0.36 Allowed 'General case' 0 N--CA 1.432 -1.334 0 CA-C-N 116.411 -0.358 . . . . 0.0 110.63 176.088 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 81.2 m-85 -92.46 -29.09 16.44 Favored 'General case' 0 CA--C 1.516 -0.337 0 N-CA-C 113.778 1.029 . . . . 0.0 113.778 -177.327 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . 0.474 ' HA ' ' HA ' ' A' ' 78' ' ' PRO . . . 70.95 116.18 0.05 OUTLIER 'General case' 0 N--CA 1.48 1.072 0 C-N-CA 124.287 1.035 . . . . 0.0 111.921 -176.602 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 28.4 m-85 -114.68 148.05 38.76 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.311 -178.037 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 8.9 m -106.39 129.55 54.37 Favored 'General case' 0 C--N 1.289 -2.044 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 178.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -93.03 129.74 38.86 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 120.646 0.26 . . . . 0.0 110.857 -178.311 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 23.6 mmt -134.42 125.78 17.91 Favored Pre-proline 0 C--N 1.313 -1.017 0 C-N-CA 123.45 0.7 . . . . 0.0 110.2 179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.55 130.5 2.78 Favored 'Trans proline' 0 CA--C 1.552 1.417 0 C-N-CA 121.819 1.68 . . . . 0.0 112.451 176.835 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 85.4 m-85 -137.57 115.84 11.82 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 177.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.9 p -105.44 -56.35 2.19 Favored 'General case' 0 N--CA 1.424 -1.767 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 64.2 m -155.81 78.15 0.98 Allowed 'General case' 0 CA--C 1.533 0.316 0 N-CA-C 112.629 0.603 . . . . 0.0 112.629 178.131 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.416 ' HE3' ' OE1' ' A' ' 93' ' ' GLU . 29.5 mtpp -95.49 140.48 30.28 Favored 'General case' 0 C--N 1.307 -1.276 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 168.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -61.58 -38.5 95.94 Favored Glycine 0 C--O 1.224 -0.484 0 N-CA-C 111.497 -0.641 . . . . 0.0 111.497 178.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . 0.416 ' OE1' ' HE3' ' A' ' 91' ' ' LYS . 1.5 mp0 -59.34 -38.44 80.37 Favored 'General case' 0 C--N 1.326 -0.448 0 C-N-CA 124.579 1.152 . . . . 0.0 110.055 177.357 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.469 ' O ' HG23 ' A' ' 98' ' ' VAL . 56.2 t80 -71.37 -37.86 71.58 Favored 'General case' 0 C--O 1.212 -0.882 0 CA-C-N 114.985 -1.007 . . . . 0.0 110.486 179.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -67.45 -34.43 77.17 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.065 0.459 . . . . 0.0 110.418 177.883 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.5 m -67.82 -38.79 83.7 Favored 'General case' 0 N--CA 1.437 -1.108 0 CA-C-N 115.832 -0.622 . . . . 0.0 109.728 174.568 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.445 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -60.13 -45.11 94.11 Favored 'General case' 0 C--O 1.21 -1.022 0 C-N-CA 123.445 0.698 . . . . 0.0 109.901 176.711 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.469 HG23 ' O ' ' A' ' 94' ' ' PHE . 80.5 t -52.47 -47.04 48.18 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.874 0 C-N-CA 123.71 0.804 . . . . 0.0 111.841 179.372 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 1.2 mptm? -67.19 -43.74 81.42 Favored 'General case' 0 N--CA 1.469 0.508 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -68.86 -30.3 68.8 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 116.578 -0.283 . . . . 0.0 111.655 178.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 88.4 t80 -62.56 -54.04 45.69 Favored 'General case' 0 C--N 1.319 -0.754 0 C-N-CA 122.997 0.519 . . . . 0.0 109.958 176.881 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 63.1 t -59.26 -38.62 75.59 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.841 0 O-C-N 123.426 0.454 . . . . 0.0 110.576 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 51.8 ttm-85 -59.03 -55.62 32.79 Favored 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.652 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 36.3 m-80 -66.38 -31.02 71.53 Favored 'General case' 0 CA--C 1.51 -0.558 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.198 -177.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 52.7 t -64.31 -39.09 84.29 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.331 175.508 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 80.8 mtt180 -64.34 -35.68 81.65 Favored 'General case' 0 N--CA 1.461 0.115 0 C-N-CA 120.859 -0.336 . . . . 0.0 111.598 175.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.7 mp0 -68.91 -24.09 64.26 Favored 'General case' 0 C--O 1.235 0.322 0 N-CA-C 111.891 0.33 . . . . 0.0 111.891 176.333 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -76.56 -48.86 17.94 Favored 'General case' 0 C--N 1.321 -0.65 0 N-CA-C 109.092 -0.707 . . . . 0.0 109.092 174.824 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . . . . . . . . . 9.8 mp -56.61 -45.17 81.62 Favored 'General case' 0 N--CA 1.475 0.803 0 O-C-N 123.965 0.791 . . . . 0.0 112.553 178.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 59.5 mtpt -83.29 -22.98 32.81 Favored 'General case' 0 C--N 1.298 -1.673 0 CA-C-N 115.925 -0.58 . . . . 0.0 111.561 -177.396 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.41 -12.9 66.52 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 114.714 0.646 . . . . 0.0 114.714 -178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 11.6 p -74.73 -21.51 59.32 Favored 'General case' 0 CA--C 1.546 0.814 0 N-CA-C 114.568 1.322 . . . . 0.0 114.568 -176.078 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 84.31 38.68 9.73 Favored Glycine 0 C--N 1.319 -0.387 0 C-N-CA 120.549 -0.834 . . . . 0.0 112.627 177.38 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 94.3 t -79.81 147.14 6.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 179.42 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -61.5 150.87 34.46 Favored 'General case' 0 N--CA 1.473 0.693 0 C-N-CA 123.209 0.604 . . . . 0.0 110.974 -179.776 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 60.0 t -53.44 -45.53 57.76 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 C-N-CA 124.023 0.929 . . . . 0.0 113.198 -174.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . 0.481 ' CD ' ' H ' ' A' ' 117' ' ' GLU . 2.1 mp0 -58.66 -46.12 87.86 Favored 'General case' 0 N--CA 1.479 0.98 0 CA-C-O 122.125 0.964 . . . . 0.0 109.447 179.974 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . 0.579 ' O ' ' HB2' ' A' ' 122' ' ' PHE . 31.9 m-20 -72.68 -31.59 65.16 Favored 'General case' 0 C--O 1.192 -1.951 0 CA-C-N 114.493 -1.231 . . . . 0.0 110.962 -177.217 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 20.7 mm -57.91 -38.79 68.27 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.698 0 C-N-CA 123.793 0.837 . . . . 0.0 110.832 174.528 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . . . . . . . . . 75.0 mmtt -57.97 -50.12 74.48 Favored 'General case' 0 C--N 1.326 -0.446 0 N-CA-C 109.289 -0.634 . . . . 0.0 109.289 177.787 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . 0.412 ' O ' ' HG3' ' A' ' 125' ' ' GLU . 74.6 mttt -65.49 -38.51 89.96 Favored 'General case' 0 C--N 1.316 -0.891 0 CA-C-N 114.253 -1.34 . . . . 0.0 109.911 -179.18 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.579 ' HB2' ' O ' ' A' ' 118' ' ' ASP . 3.2 t80 -72.58 -36.55 68.18 Favored 'General case' 0 C--N 1.313 -0.999 0 C-N-CA 126.124 1.769 . . . . 0.0 108.909 -171.091 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 91.9 mtp -77.91 -19.66 54.29 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.124 176.442 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 52.5 mt-10 -78.38 -27.89 46.94 Favored 'General case' 0 N--CA 1.468 0.468 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 173.107 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.416 ' HB2' ' O ' ' A' ' 122' ' ' PHE . 46.3 mt-10 -64.68 -36.67 85.04 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.685 174.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.666 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.71 -56.47 20.87 Favored Pre-proline 0 CA--C 1.57 1.727 0 N-CA-C 115.198 1.555 . . . . 0.0 115.198 -178.636 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 34.1 Cg_endo -67.78 -21.81 44.11 Favored 'Trans proline' 0 C--N 1.381 2.275 0 CA-C-N 121.221 1.472 . . . . 0.0 111.921 176.535 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 27.0 m -71.55 -35.56 70.66 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.666 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 16.4 m-85 -58.93 -53.4 58.79 Favored 'General case' 0 C--N 1.356 0.885 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 175.557 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.471 ' O ' HG23 ' A' ' 134' ' ' VAL . 57.9 t -58.35 -50.38 78.79 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.58 0 CA-C-N 114.571 -1.195 . . . . 0.0 110.824 -178.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 23.4 ttmm -53.68 -54.01 43.98 Favored 'General case' 0 N--CA 1.473 0.696 0 C-N-CA 124.181 0.993 . . . . 0.0 111.199 -178.234 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.553 ' CE3' HD13 ' A' ' 33' ' ' LEU . 77.2 t90 -69.0 -37.26 78.61 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.66 -0.7 . . . . 0.0 111.412 -176.923 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 91.6 mt -64.86 -31.77 73.15 Favored 'General case' 0 C--O 1.212 -0.903 0 O-C-N 122.535 -0.103 . . . . 0.0 111.187 177.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 130' ' ' VAL . 79.2 t -67.84 -38.75 80.67 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.483 0 CA-C-O 120.488 0.185 . . . . 0.0 110.824 177.108 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 21.0 m-20 -72.69 -39.36 67.09 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.292 0.568 . . . . 0.0 111.822 179.072 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 72.9 mmtt -77.4 -17.74 57.9 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.959 -179.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 58.2 t80 -49.45 -37.95 27.77 Favored 'General case' 0 N--CA 1.482 1.14 0 C-N-CA 125.855 1.662 . . . . 0.0 113.462 -175.299 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 8.9 m-20 -62.3 -33.13 74.07 Favored 'General case' 0 N--CA 1.474 0.73 0 O-C-N 123.443 0.464 . . . . 0.0 111.529 -179.053 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 9.9 m-20 -102.5 4.72 38.93 Favored 'General case' 0 C--N 1.313 -1.015 0 CA-C-N 116.095 -0.502 . . . . 0.0 111.969 -176.729 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 76.3 mt -82.35 120.56 25.57 Favored 'General case' 0 N--CA 1.428 -1.554 0 CA-C-O 122.404 1.097 . . . . 0.0 113.137 -173.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 -109.18 134.63 51.49 Favored 'General case' 0 N--CA 1.415 -2.225 0 N-CA-C 104.71 -2.33 . . . . 0.0 104.71 172.8 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -100.88 145.17 28.94 Favored 'General case' 0 C--N 1.282 -2.339 0 C-N-CA 119.941 -0.704 . . . . 0.0 112.214 -169.26 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 84.1 m-85 -129.03 165.19 21.66 Favored 'General case' 0 C--N 1.286 -2.158 0 CA-C-N 114.6 -1.182 . . . . 0.0 109.84 179.387 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 32.1 mtp -141.77 149.49 40.49 Favored 'General case' 0 C--N 1.267 -2.981 0 N-CA-C 104.559 -2.386 . . . . 0.0 104.559 177.351 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 89.3 p -82.26 175.41 10.3 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 107.755 -1.202 . . . . 0.0 107.755 173.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 51.3 tptt -59.9 -35.5 74.99 Favored 'General case' 0 CA--C 1.549 0.925 0 CA-C-O 121.48 0.657 . . . . 0.0 111.477 -175.695 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.0 p -89.48 -3.45 58.37 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 113.865 1.061 . . . . 0.0 113.865 -179.666 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 48.4 mtt -93.67 174.47 7.17 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 114.107 1.151 . . . . 0.0 114.107 -175.462 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -129.72 159.17 71.04 Favored Pre-proline 0 C--N 1.316 -0.866 0 CA-C-N 114.995 -1.002 . . . . 0.0 108.414 -175.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -67.85 -24.69 39.92 Favored 'Trans proline' 0 CA--C 1.54 0.791 0 C-N-CA 121.937 1.758 . . . . 0.0 111.101 176.518 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -84.96 -18.92 33.06 Favored 'General case' 0 CA--C 1.508 -0.647 0 CA-C-N 114.879 -1.055 . . . . 0.0 111.373 179.394 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -154.01 113.4 3.77 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.305 -173.914 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.1 42.32 3.79 Favored Glycine 0 N--CA 1.437 -1.297 0 C-N-CA 120.157 -1.021 . . . . 0.0 111.648 -175.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.445 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 27.3 tp -95.47 112.26 24.01 Favored 'General case' 0 N--CA 1.424 -1.73 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 96.7 mt -94.23 135.78 27.59 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.016 0 CA-C-N 114.602 -1.181 . . . . 0.0 111.312 -173.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.525 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 27.9 m-85 -88.87 135.31 33.6 Favored 'General case' 0 C--N 1.307 -1.272 0 N-CA-C 108.364 -0.976 . . . . 0.0 108.364 177.456 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 14.9 t -150.51 160.29 43.89 Favored 'General case' 0 C--N 1.32 -0.676 0 O-C-N 121.597 -0.689 . . . . 0.0 109.198 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -160.07 174.57 14.11 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 177.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 73.3 m-85 -110.01 112.08 23.86 Favored 'General case' 0 C--N 1.308 -1.2 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 176.158 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 13.8 ptpt -90.94 178.2 6.08 Favored 'General case' 0 C--N 1.305 -1.349 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.936 174.467 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 28.0 mm-40 -69.58 114.96 8.29 Favored 'General case' 0 C--N 1.324 -0.541 0 N-CA-C 110.12 -0.326 . . . . 0.0 110.12 -178.757 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 104.97 -5.86 42.94 Favored Glycine 0 N--CA 1.436 -1.302 0 CA-C-N 115.821 -0.627 . . . . 0.0 112.194 179.549 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -88.98 125.33 34.93 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 116.824 0.312 . . . . 0.0 110.63 -178.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 47.7 m80 -94.08 -11.21 31.1 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.208 0.528 . . . . 0.0 111.251 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . . . . . . . . . 60.8 m -136.7 160.76 65.25 Favored Pre-proline 0 C--N 1.304 -1.387 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 -178.042 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 12.7 Cg_endo -56.35 121.13 9.47 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 122.717 2.278 . . . . 0.0 112.065 177.383 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 11.5 m -89.15 116.65 27.56 Favored 'General case' 0 N--CA 1.422 -1.842 0 N-CA-C 107.123 -1.436 . . . . 0.0 107.123 179.523 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.427 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 96.2 m-85 -82.62 138.6 34.14 Favored 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.56 0.695 . . . . 0.0 112.82 -172.671 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.525 ' HB ' ' HB2' ' A' ' 156' ' ' PHE . 41.9 t -108.03 121.96 61.75 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 114.187 -1.369 . . . . 0.0 109.507 -176.489 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.524 ' CE1' ' HB ' ' A' ' 13' ' ' VAL . 61.9 m-85 -137.45 155.97 48.71 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-O 121.995 0.902 . . . . 0.0 111.247 -179.568 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.49 ' HA ' HD23 ' A' ' 33' ' ' LEU . 25.3 t -100.04 112.69 33.3 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.904 0 N-CA-C 108.183 -1.044 . . . . 0.0 108.183 178.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 35.2 ttpt -63.5 -43.38 97.4 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 124.113 0.965 . . . . 0.0 111.322 -173.582 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.501 ' HB3' ' CE2' ' A' ' 122' ' ' PHE . 18.6 m -89.83 -11.4 42.13 Favored 'General case' 0 C--N 1.292 -1.903 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.218 -179.458 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.403 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -97.03 -23.98 13.85 Favored Glycine 0 C--O 1.212 -1.271 0 CA-C-N 116.044 -0.525 . . . . 0.0 113.19 -173.281 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 69.8 m-85 -97.29 149.22 22.31 Favored 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.605 -1.257 . . . . 0.0 107.605 175.72 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -84.88 112.35 20.47 Favored 'General case' 0 C--N 1.298 -1.632 0 CA-C-O 121.27 0.557 . . . . 0.0 111.35 -174.138 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 26.2 t -73.24 104.36 2.22 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 114.46 -1.246 . . . . 0.0 108.136 176.617 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . 0.417 HG21 ' HD2' ' A' ' 5' ' ' LYS . 70.3 t -115.36 140.29 37.54 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 N-CA-C 107.887 -1.153 . . . . 0.0 107.887 -179.185 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -112.49 121.28 44.38 Favored 'General case' 0 N--CA 1.419 -2.023 0 CA-C-O 121.345 0.593 . . . . 0.0 111.132 179.947 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 64.8 m-85 -103.17 105.42 15.71 Favored 'General case' 0 C--N 1.292 -1.893 0 N-CA-C 108.338 -0.986 . . . . 0.0 108.338 174.357 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 96.4 mt -102.1 37.92 1.77 Allowed 'General case' 0 C--N 1.295 -1.79 0 CA-C-N 115.004 -0.998 . . . . 0.0 109.11 179.822 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 38.0 tt0 -149.47 121.79 8.42 Favored 'General case' 0 N--CA 1.425 -1.694 0 CA-C-N 114.084 -1.417 . . . . 0.0 107.702 179.677 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 77.1 m-70 -82.63 118.88 23.63 Favored 'General case' 0 CA--C 1.49 -1.344 0 N-CA-C 108.32 -0.993 . . . . 0.0 108.32 173.922 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 81.0 m80 -81.0 110.6 16.69 Favored 'General case' 0 C--N 1.287 -2.141 0 CA-C-N 115.597 -0.729 . . . . 0.0 109.736 -177.448 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 57.5 t60 -161.65 -45.14 0.04 OUTLIER 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.526 -0.761 . . . . 0.0 109.998 -174.358 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 58.5 t-80 -99.46 123.29 43.61 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.035 -0.728 . . . . 0.0 109.035 179.622 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 51.2 t-80 -96.3 144.43 26.48 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -178.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 79.7 t60 . . . . . 0 C--N 1.295 -1.778 0 N-CA-C 107.366 -1.346 . . . . 0.0 107.366 174.234 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.241 0.622 0 N-CA-C 109.398 -0.593 . . . . 0.0 109.398 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 35.3 mm -98.35 120.72 48.05 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 105.946 -1.872 . . . . 0.0 105.946 177.284 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 12.0 p -125.53 136.28 61.33 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.755 0 C-N-CA 119.759 -0.776 . . . . 0.0 111.391 -178.813 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 86.0 m-85 -94.28 116.98 29.45 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 177.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 76.3 mttt -106.39 143.25 34.78 Favored 'General case' 0 N--CA 1.421 -1.879 0 C-N-CA 120.176 -0.61 . . . . 0.0 110.29 177.531 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -71.7 148.26 46.61 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.052 -0.976 . . . . 0.0 110.156 179.692 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 93.9 t -87.21 -27.86 5.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.695 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -179.105 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 8.7 mm -75.63 -53.2 16.39 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -175.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 48.0 p -85.98 -42.53 13.93 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-O 121.233 0.54 . . . . 0.0 111.186 178.465 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 100.6 -4.87 56.71 Favored Glycine 0 N--CA 1.437 -1.252 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.763 -179.085 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -101.85 -175.56 2.88 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-N 117.256 0.528 . . . . 0.0 110.887 -174.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 39.1 mt-10 -81.66 130.98 35.25 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 124.499 1.12 . . . . 0.0 112.208 -172.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.435 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 18.8 m -108.67 -28.39 2.74 Favored 'Isoleucine or valine' 0 C--O 1.241 0.617 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.94 176.281 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.6 p -173.23 149.11 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.771 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 17.4 p -123.57 169.28 11.6 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 109.225 -0.657 . . . . 0.0 109.225 176.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 5.9 p-10 -72.95 -9.12 58.37 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-O 121.317 0.579 . . . . 0.0 110.977 -179.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -76.07 -17.44 59.63 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.512 -0.767 . . . . 0.0 109.535 175.538 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . . . . . . . . . 95.5 mt -96.96 -172.74 2.52 Favored 'General case' 0 N--CA 1.439 -0.992 0 N-CA-C 108.782 -0.822 . . . . 0.0 108.782 177.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . 0.49 ' HD2' ' HB3' ' A' ' 37' ' ' ASP . 3.6 tmtp? -88.03 107.81 18.92 Favored 'General case' 0 C--N 1.312 -1.041 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 48.5 mt -115.09 128.31 72.32 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 120.98 0.419 . . . . 0.0 110.848 -179.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 4.0 p -127.97 151.4 75.78 Favored Pre-proline 0 C--N 1.306 -1.297 0 C-N-CA 123.299 0.64 . . . . 0.0 111.085 177.164 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 58.0 Cg_endo -76.53 153.95 35.06 Favored 'Trans proline' 0 C--O 1.245 0.835 0 C-N-CA 121.032 1.155 . . . . 0.0 109.583 172.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.643 ' O ' ' HA ' ' A' ' 29' ' ' GLU . 76.1 t -72.12 116.16 13.61 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.902 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 178.608 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 66.0 mtt -110.59 108.9 19.0 Favored 'General case' 0 C--N 1.302 -1.494 0 CA-C-O 121.158 0.504 . . . . 0.0 110.316 179.86 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 70.8 mm-40 -116.6 107.23 14.45 Favored 'General case' 0 C--N 1.306 -1.322 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 175.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 83.99 4.9 88.21 Favored Glycine 0 C--N 1.31 -0.897 0 C-N-CA 120.88 -0.676 . . . . 0.0 111.664 -178.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.46 -23.26 28.86 Favored Glycine 0 C--O 1.241 0.539 0 C-N-CA 121.563 -0.351 . . . . 0.0 112.354 -179.842 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -99.24 159.24 15.13 Favored 'General case' 0 C--N 1.314 -0.977 0 O-C-N 122.439 -0.448 . . . . 0.0 109.952 -179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . 0.643 ' HA ' ' O ' ' A' ' 23' ' ' VAL . 12.8 pt-20 -86.01 146.73 26.53 Favored 'General case' 0 N--CA 1.43 -1.452 0 CA-C-O 121.35 0.595 . . . . 0.0 111.08 -176.329 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 94.5 t -98.79 116.33 65.38 Favored Pre-proline 0 C--N 1.289 -2.037 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 176.563 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -61.0 136.83 68.03 Favored 'Trans proline' 0 C--O 1.241 0.661 0 C-N-CA 123.49 2.793 . . . . 0.0 114.485 -176.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 91.3 -4.35 80.41 Favored Glycine 0 N--CA 1.431 -1.667 0 CA-C-N 114.506 -1.225 . . . . 0.0 114.14 174.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.474 HD13 ' CE3' ' A' ' 132' ' ' TRP . 42.4 mt -129.7 150.83 50.85 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 116.787 0.294 . . . . 0.0 110.596 -174.561 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 20.6 p90 -141.45 149.66 41.27 Favored 'General case' 0 N--CA 1.435 -1.178 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 176.024 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -113.94 147.42 38.57 Favored 'General case' 0 C--N 1.268 -2.974 0 N-CA-C 108.111 -1.07 . . . . 0.0 108.111 -175.978 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.483 ' CG1' HG21 ' A' ' 75' ' ' VAL . 54.2 t -110.67 112.38 40.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.29 0 N-CA-C 106.517 -1.661 . . . . 0.0 106.517 175.285 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' HB3' ' HD2' ' A' ' 19' ' ' LYS . 31.5 t70 -87.92 161.38 17.49 Favored 'General case' 0 C--N 1.28 -2.429 0 CA-C-N 113.92 -1.491 . . . . 0.0 109.058 -175.697 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 8.2 m -96.42 135.22 38.58 Favored 'General case' 0 N--CA 1.412 -2.334 0 CA-C-O 121.764 0.792 . . . . 0.0 110.65 -168.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.474 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -130.23 124.52 32.67 Favored 'General case' 0 CA--C 1.495 -1.14 0 N-CA-C 106.515 -1.661 . . . . 0.0 106.515 176.745 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . 0.471 ' HB3' ' HB3' ' A' ' 71' ' ' LYS . 89.2 mtp -89.58 123.97 34.13 Favored 'General case' 0 C--N 1.29 -1.992 0 O-C-N 123.622 0.576 . . . . 0.0 111.916 -173.507 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 24.3 m -110.18 155.46 11.43 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.627 178.681 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.492 ' HA ' ' HG2' ' A' ' 71' ' ' LYS . . . -90.46 116.73 28.61 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 113.915 1.08 . . . . 0.0 113.915 -172.474 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 57.8 t -101.99 100.94 11.4 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 172.557 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -100.29 142.71 16.0 Favored Glycine 0 CA--C 1.494 -1.249 0 C-N-CA 120.869 -0.681 . . . . 0.0 112.294 -178.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 92.5 -50.37 2.66 Favored Glycine 0 N--CA 1.436 -1.361 0 N-CA-C 111.503 -0.639 . . . . 0.0 111.503 -179.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 84.23 91.78 0.74 Allowed Glycine 0 CA--C 1.493 -1.339 0 N-CA-C 109.104 -1.598 . . . . 0.0 109.104 -178.812 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 34.5 m-20 -101.14 103.02 14.07 Favored 'General case' 0 C--N 1.29 -2.013 0 N-CA-C 112.897 0.703 . . . . 0.0 112.897 -175.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 45.0 mm -99.97 90.44 1.94 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 N-CA-C 105.152 -2.166 . . . . 0.0 105.152 175.393 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 66.78 34.81 5.36 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 124.034 0.834 . . . . 0.0 110.538 -174.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 2.1 mp 73.6 107.13 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.47 0.557 0 C-N-CA 124.587 1.155 . . . . 0.0 110.203 -177.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . 90.9 169.87 42.77 Favored Glycine 0 N--CA 1.433 -1.527 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.803 -176.888 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 26.1 p -162.98 -45.65 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.222 0 C-N-CA 123.461 0.705 . . . . 0.0 109.167 175.41 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.18 41.9 0.79 Allowed Glycine 0 N--CA 1.435 -1.41 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 178.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 51.0 t-20 -83.69 96.32 8.66 Favored 'General case' 0 C--N 1.313 -1.004 0 N-CA-C 108.895 -0.779 . . . . 0.0 108.895 -179.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.08 89.25 3.08 Favored 'General case' 0 C--N 1.299 -1.599 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 178.236 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 93.4 m-85 63.87 23.63 13.44 Favored 'General case' 0 N--CA 1.476 0.837 0 C-N-CA 124.652 1.181 . . . . 0.0 111.623 -179.587 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 155.41 170.38 20.86 Favored Glycine 0 N--CA 1.432 -1.576 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 -178.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -160.78 -87.52 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.241 -0.981 . . . . 0.0 112.874 -179.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -90.93 157.4 17.33 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.23 0.538 . . . . 0.0 112.054 -175.63 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -149.14 149.68 21.7 Favored Glycine 0 N--CA 1.434 -1.435 0 N-CA-C 108.943 -1.663 . . . . 0.0 108.943 177.912 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -95.58 15.74 19.04 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 117.44 0.62 . . . . 0.0 110.652 -175.273 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.6 p-10 -94.94 15.79 17.79 Favored 'General case' 0 C--N 1.312 -1.058 0 C-N-CA 123.427 0.691 . . . . 0.0 110.532 -179.439 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 37.5 tt0 -139.16 147.67 42.17 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.035 -1.098 . . . . 0.0 108.035 -177.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . 114.48 82.82 1.1 Allowed Glycine 0 N--CA 1.422 -2.264 0 C-N-CA 120.395 -0.907 . . . . 0.0 113.322 175.73 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -69.49 -44.59 70.8 Favored 'General case' 0 C--N 1.319 -0.75 0 N-CA-C 107.985 -1.117 . . . . 0.0 107.985 174.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 16.3 m-20 -88.19 -57.29 2.98 Favored 'General case' 0 C--N 1.317 -0.838 0 N-CA-C 105.879 -1.897 . . . . 0.0 105.879 174.456 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 4.8 p-10 179.18 161.29 0.75 Allowed 'General case' 0 CA--C 1.514 -0.44 0 C-N-CA 125.769 1.628 . . . . 0.0 106.834 177.103 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . -118.6 26.77 9.35 Favored 'General case' 0 C--N 1.309 -1.162 0 CA-C-O 121.594 0.711 . . . . 0.0 109.755 -179.138 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 21.9 p -119.46 177.02 5.08 Favored 'General case' 0 C--N 1.294 -1.834 0 CA-C-N 115.602 -0.726 . . . . 0.0 111.125 -173.853 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 50.0 mt-30 -100.62 117.92 35.72 Favored 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 105.961 -1.866 . . . . 0.0 105.961 170.653 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . 0.492 ' HG2' ' HA ' ' A' ' 42' ' ' ALA . 60.4 mtpt -111.93 121.84 46.14 Favored 'General case' 0 C--N 1.292 -1.926 0 C-N-CA 119.717 -0.793 . . . . 0.0 112.43 -174.856 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HA ' ' SG ' ' A' ' 165' ' ' CYS . 36.6 mt-10 -130.36 171.08 13.34 Favored 'General case' 0 C--N 1.304 -1.397 0 CA-C-N 114.835 -1.075 . . . . 0.0 109.793 179.495 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 39' ' ' ALA . 41.6 t30 -68.85 131.12 44.61 Favored 'General case' 0 C--N 1.31 -1.125 0 CA-C-O 120.934 0.397 . . . . 0.0 111.388 -177.347 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -55.59 -25.64 39.47 Favored 'General case' 0 N--CA 1.487 1.376 0 C-N-CA 124.087 0.955 . . . . 0.0 113.362 177.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.483 HG21 ' CG1' ' A' ' 36' ' ' VAL . 30.7 t -83.83 -37.64 13.37 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 C-N-CA 120.947 -0.301 . . . . 0.0 110.777 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . . . . . . . . . 4.7 p -73.0 -45.72 56.28 Favored 'General case' 0 N--CA 1.441 -0.879 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 178.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 31.76 83.81 0.01 OUTLIER Glycine 0 C--N 1.364 2.139 0 O-C-N 125.843 1.964 . . . . 0.0 115.096 173.649 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_exo -56.94 -31.56 89.95 Favored 'Trans proline' 0 N--CA 1.481 0.793 0 C-N-CA 123.036 2.491 . . . . 0.0 112.674 -178.374 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 11.5 p -84.24 -2.53 57.11 Favored 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 123.206 0.602 . . . . 0.0 111.976 -179.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 14.8 m -130.08 -79.99 0.55 Allowed 'General case' 0 CA--C 1.553 1.073 0 N-CA-C 112.085 0.402 . . . . 0.0 112.085 -174.615 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -82.69 -37.51 24.67 Favored 'General case' 0 C--O 1.242 0.689 0 C-N-CA 122.454 0.301 . . . . 0.0 110.978 -177.286 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 58.35 73.84 0.46 Allowed 'General case' 0 C--O 1.24 0.596 0 C-N-CA 124.789 1.236 . . . . 0.0 112.951 179.018 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . . . . . . . . . 61.5 m-85 -86.4 111.8 20.86 Favored 'General case' 0 C--N 1.306 -1.308 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.779 176.011 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 14.4 m -96.24 136.22 37.01 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.787 -178.154 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -85.27 146.45 27.05 Favored 'General case' 0 C--N 1.313 -1.015 0 O-C-N 123.222 0.326 . . . . 0.0 110.662 -178.351 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 25.9 mmt -129.41 142.9 46.84 Favored Pre-proline 0 C--N 1.306 -1.315 0 N-CA-C 107.81 -1.182 . . . . 0.0 107.81 177.155 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 94.2 Cg_endo -86.73 166.36 8.78 Favored 'Trans proline' 0 C--O 1.253 1.234 0 C-N-CA 122.887 2.391 . . . . 0.0 112.546 -178.932 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 92.7 m-85 -64.2 117.45 7.18 Favored 'General case' 0 CA--C 1.513 -0.471 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 176.849 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 24.4 p -81.87 -24.16 35.91 Favored 'General case' 0 C--N 1.297 -1.694 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 177.185 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 19.7 m 57.86 28.53 16.18 Favored 'General case' 0 C--N 1.362 1.144 0 C-N-CA 124.252 1.021 . . . . 0.0 110.138 -178.868 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -92.17 149.93 21.2 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 114.368 -1.287 . . . . 0.0 109.656 -175.178 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -64.31 -36.1 92.78 Favored Glycine 0 N--CA 1.468 0.806 0 N-CA-C 111.698 -0.561 . . . . 0.0 111.698 178.604 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 41.6 tt0 -62.31 -33.29 74.4 Favored 'General case' 0 C--N 1.32 -0.674 0 C-N-CA 124.191 0.996 . . . . 0.0 110.329 176.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . . . . . . . . . 76.5 t80 -70.81 -36.96 73.19 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 115.743 -0.662 . . . . 0.0 109.363 179.507 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 75.4 mmtt -71.0 -32.14 68.87 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.868 -0.606 . . . . 0.0 109.572 177.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.8 t -61.87 -38.46 88.37 Favored 'General case' 0 N--CA 1.446 -0.659 0 CA-C-N 115.603 -0.726 . . . . 0.0 109.63 175.451 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.582 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 91.5 t90 -61.94 -48.37 80.71 Favored 'General case' 0 C--N 1.347 0.499 0 N-CA-C 109.768 -0.456 . . . . 0.0 109.768 176.515 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . . . . . . . . . 98.9 t -56.3 -42.94 75.55 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.502 0 O-C-N 124.094 0.871 . . . . 0.0 110.873 -179.227 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 27.0 mtpp -72.05 -40.77 68.1 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-N 115.978 -0.555 . . . . 0.0 111.864 179.506 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -68.21 -27.53 66.46 Favored 'General case' 0 N--CA 1.479 0.984 0 N-CA-C 111.899 0.333 . . . . 0.0 111.899 177.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . . . . . . . . . 86.9 t80 -61.64 -50.45 72.48 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.438 -0.949 . . . . 0.0 108.438 175.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 49.5 t -60.33 -38.03 76.15 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.893 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.338 178.276 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.484 ' O ' ' HG2' ' A' ' 107' ' ' GLN . 99.4 mtt180 -58.42 -60.2 4.15 Favored 'General case' 0 N--CA 1.475 0.777 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.973 177.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 45.1 m-80 -60.51 -38.15 83.42 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.88 -0.6 . . . . 0.0 112.139 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . . . . . . . . . 49.3 t -60.71 -50.59 79.85 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.492 0 O-C-N 123.654 0.596 . . . . 0.0 110.312 175.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 48.7 mtt180 -63.17 -25.7 68.46 Favored 'General case' 0 C--O 1.241 0.608 0 N-CA-C 113.126 0.788 . . . . 0.0 113.126 179.404 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . 0.484 ' HG2' ' O ' ' A' ' 103' ' ' ARG . 20.4 mm-40 -74.41 -30.5 61.96 Favored 'General case' 0 C--O 1.219 -0.53 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 178.224 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -73.23 -34.49 65.93 Favored 'General case' 0 C--O 1.216 -0.69 0 N-CA-C 109.562 -0.533 . . . . 0.0 109.562 176.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.581 ' HG ' ' CE1' ' A' ' 122' ' ' PHE . 10.0 mp -57.86 -53.8 54.15 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 116.137 -0.483 . . . . 0.0 112.098 176.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -81.55 -21.2 38.63 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 112.843 0.682 . . . . 0.0 112.843 -178.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -87.5 -1.05 83.88 Favored Glycine 0 C--N 1.311 -0.829 0 CA-C-N 115.835 -0.621 . . . . 0.0 113.803 -179.408 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 57.2 p -71.1 -22.74 62.05 Favored 'General case' 0 C--N 1.316 -0.878 0 N-CA-C 113.264 0.838 . . . . 0.0 113.264 -173.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 75.04 27.38 64.47 Favored Glycine 0 N--CA 1.449 -0.476 0 C-N-CA 120.778 -0.725 . . . . 0.0 111.657 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 61.4 t -92.89 154.21 3.23 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.086 0 N-CA-C 108.524 -0.917 . . . . 0.0 108.524 178.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.454 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -54.02 148.23 11.13 Favored 'General case' 0 N--CA 1.479 1.019 0 C-N-CA 124.201 1.001 . . . . 0.0 112.042 -179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . . . . . . . . . 51.1 t -59.23 -40.12 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.121 0 C-N-CA 123.882 0.873 . . . . 0.0 112.566 -174.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 44.3 mt-10 -66.76 -33.88 76.61 Favored 'General case' 0 C--O 1.25 1.083 0 CA-C-O 121.771 0.796 . . . . 0.0 109.879 -179.141 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -75.47 -32.77 60.72 Favored 'General case' 0 C--N 1.309 -1.175 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.533 177.618 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.454 HG12 ' O ' ' A' ' 115' ' ' ALA . 44.7 mm -63.87 -31.81 54.63 Favored 'Isoleucine or valine' 0 C--O 1.215 -0.745 0 C-N-CA 122.818 0.447 . . . . 0.0 110.109 174.635 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.418 ' O ' ' HG2' ' A' ' 124' ' ' GLU . 34.5 mmtp -60.78 -45.41 94.5 Favored 'General case' 0 N--CA 1.47 0.557 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -66.96 -40.19 87.44 Favored 'General case' 0 N--CA 1.471 0.618 0 CA-C-N 115.717 -0.674 . . . . 0.0 109.695 178.671 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.581 ' CE1' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.03 -38.22 87.85 Favored 'General case' 0 CA--C 1.55 0.948 0 C-N-CA 124.733 1.213 . . . . 0.0 109.316 -176.771 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 69.2 mtm -77.5 -13.37 59.93 Favored 'General case' 0 C--O 1.213 -0.842 0 O-C-N 121.841 -0.537 . . . . 0.0 111.687 177.344 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . 0.418 ' HG2' ' O ' ' A' ' 120' ' ' LYS . 44.3 mm-40 -77.94 -31.54 51.01 Favored 'General case' 0 N--CA 1.469 0.482 0 N-CA-C 108.552 -0.907 . . . . 0.0 108.552 172.781 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.553 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 41.7 mt-10 -67.78 -32.8 73.62 Favored 'General case' 0 C--O 1.214 -0.768 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.68 177.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.556 ' HA ' ' CD1' ' A' ' 129' ' ' PHE . . . -52.28 -57.86 13.77 Favored Pre-proline 0 CA--C 1.564 1.491 0 N-CA-C 115.381 1.623 . . . . 0.0 115.381 -177.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . 0.448 ' O ' ' HB2' ' A' ' 131' ' ' LYS . 29.1 Cg_endo -65.46 -27.5 54.44 Favored 'Trans proline' 0 C--N 1.385 2.465 0 CA-C-N 120.97 1.382 . . . . 0.0 111.233 177.409 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.1 m -65.22 -39.0 92.17 Favored 'General case' 0 CA--C 1.543 0.682 0 C-N-CA 123.344 0.657 . . . . 0.0 110.421 -179.822 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.556 ' CD1' ' HA ' ' A' ' 126' ' ' ALA . 14.6 m-85 -56.12 -57.91 10.15 Favored 'General case' 0 N--CA 1.474 0.772 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 175.765 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.451 ' O ' HG23 ' A' ' 134' ' ' VAL . 25.2 t -57.55 -47.41 85.28 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.372 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.833 -178.133 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . 0.577 ' HE2' ' O ' ' A' ' 131' ' ' LYS . 0.1 OUTLIER -53.99 -55.05 30.75 Favored 'General case' 0 CA--C 1.543 0.701 0 C-N-CA 125.262 1.425 . . . . 0.0 109.885 -178.502 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.474 ' CE3' HD13 ' A' ' 33' ' ' LEU . 56.7 t90 -69.16 -37.09 78.05 Favored 'General case' 0 C--N 1.31 -1.135 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.711 -176.185 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . . . . . . . . . 95.7 mt -64.58 -33.49 76.05 Favored 'General case' 0 N--CA 1.47 0.535 0 N-CA-C 111.5 0.185 . . . . 0.0 111.5 178.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.451 HG23 ' O ' ' A' ' 130' ' ' VAL . 69.0 t -66.26 -42.29 90.63 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.55 0 CA-C-O 120.513 0.196 . . . . 0.0 111.464 178.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -75.78 -26.99 57.82 Favored 'General case' 0 C--N 1.321 -0.632 0 N-CA-C 113.618 0.97 . . . . 0.0 113.618 -178.49 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 75.1 mmtt -85.9 -16.09 39.63 Favored 'General case' 0 C--N 1.313 -1.005 0 C-N-CA 120.842 -0.343 . . . . 0.0 111.054 178.582 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . 0.487 ' HA ' HD12 ' A' ' 140' ' ' LEU . 31.4 t80 -49.11 -41.01 34.38 Favored 'General case' 0 N--CA 1.487 1.384 0 C-N-CA 125.378 1.471 . . . . 0.0 113.814 -171.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -62.57 -34.48 77.05 Favored 'General case' 0 N--CA 1.474 0.729 0 C-N-CA 123.426 0.69 . . . . 0.0 111.553 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -97.17 -1.89 44.1 Favored 'General case' 0 C--N 1.312 -1.063 0 CA-C-N 116.105 -0.498 . . . . 0.0 112.161 -176.434 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 91.2 mt -83.8 129.0 34.94 Favored 'General case' 0 N--CA 1.433 -1.32 0 CA-C-O 121.217 0.532 . . . . 0.0 111.711 -178.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 30.3 mt-10 -105.62 147.97 27.86 Favored 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.673 -2.343 . . . . 0.0 104.673 166.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -101.17 114.76 29.02 Favored 'General case' 0 C--N 1.285 -2.217 0 C-N-CA 120.099 -0.64 . . . . 0.0 110.719 -172.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . 0.432 ' CD1' ' HB3' ' A' ' 157' ' ' SER . 50.1 m-85 -100.29 149.99 23.03 Favored 'General case' 0 C--N 1.29 -2.014 0 CA-C-O 121.495 0.664 . . . . 0.0 111.822 -176.372 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 71.3 mtp -130.48 136.09 48.62 Favored 'General case' 0 C--N 1.281 -2.391 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 175.485 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 44.5 p -81.62 158.38 24.36 Favored 'General case' 0 N--CA 1.424 -1.731 0 N-CA-C 105.776 -1.935 . . . . 0.0 105.776 171.229 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -63.34 -22.99 67.22 Favored 'General case' 0 C--N 1.309 -1.171 0 CA-C-O 121.286 0.565 . . . . 0.0 111.901 -176.731 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 3.2 p -88.02 -3.73 58.87 Favored 'General case' 0 N--CA 1.435 -1.205 0 N-CA-C 113.174 0.805 . . . . 0.0 113.174 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 59.2 mtt -112.93 -178.72 3.46 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 112.907 0.706 . . . . 0.0 112.907 -176.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.4 m-80 -127.71 162.08 51.44 Favored Pre-proline 0 C--O 1.213 -0.839 0 C-N-CA 124.078 0.951 . . . . 0.0 108.898 -175.128 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -71.27 -26.65 20.61 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.426 1.417 . . . . 0.0 111.311 177.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -82.97 -23.96 33.16 Favored 'General case' 0 CA--C 1.506 -0.749 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.662 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -147.37 110.71 4.88 Favored 'General case' 0 N--CA 1.435 -1.218 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.575 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 95.52 43.66 3.37 Favored Glycine 0 N--CA 1.44 -1.061 0 C-N-CA 119.512 -1.328 . . . . 0.0 112.577 -175.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.582 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 40.5 tp -101.19 119.83 39.33 Favored 'General case' 0 N--CA 1.439 -0.988 0 N-CA-C 107.016 -1.476 . . . . 0.0 107.016 174.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 3.6 mp -98.61 141.18 16.77 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.026 0 C-N-CA 123.762 0.825 . . . . 0.0 111.275 -172.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.425 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 75.4 m-85 -93.49 137.14 33.08 Favored 'General case' 0 C--N 1.316 -0.869 0 N-CA-C 108.081 -1.081 . . . . 0.0 108.081 175.472 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . 0.432 ' HB3' ' CD1' ' A' ' 143' ' ' PHE . 32.2 t -150.5 138.41 20.03 Favored 'General case' 0 C--N 1.311 -1.086 0 CA-C-N 118.701 0.682 . . . . 0.0 110.581 175.177 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.403 ' HB3' HD23 ' A' ' 140' ' ' LEU . 19.1 p90 -125.78 179.56 5.12 Favored 'General case' 0 CA--C 1.5 -0.957 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 174.125 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 53.6 m-85 -117.73 124.36 48.29 Favored 'General case' 0 C--N 1.286 -2.194 0 CA-C-N 118.892 0.769 . . . . 0.0 110.819 -176.732 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 31.0 mmtp -56.24 149.75 15.66 Favored 'General case' 0 C--O 1.242 0.659 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.403 171.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 41.0 mt-10 -70.67 107.15 3.79 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.024 -179.093 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 106.89 -1.34 35.85 Favored Glycine 0 N--CA 1.436 -1.308 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.485 -176.55 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -94.09 134.56 36.4 Favored 'General case' 0 N--CA 1.442 -0.866 0 CA-C-O 121.173 0.511 . . . . 0.0 110.442 179.052 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -94.93 -21.11 18.85 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.231 179.281 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.478 ' SG ' ' HA ' ' A' ' 72' ' ' GLU . 58.4 m -103.91 153.13 39.02 Favored Pre-proline 0 N--CA 1.429 -1.479 0 CA-C-N 115.187 -0.915 . . . . 0.0 109.434 -178.317 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -68.35 139.05 44.44 Favored 'Trans proline' 0 C--O 1.253 1.256 0 C-N-CA 122.586 2.19 . . . . 0.0 113.979 -177.129 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . 0.419 HG23 ' HA ' ' A' ' 37' ' ' ASP . 41.2 m -102.81 111.86 24.38 Favored 'General case' 0 C--N 1.306 -1.324 0 N-CA-C 107.192 -1.41 . . . . 0.0 107.192 177.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.438 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 97.1 m-85 -82.44 144.18 30.66 Favored 'General case' 0 C--N 1.3 -1.579 0 CA-C-O 121.895 0.855 . . . . 0.0 113.235 -170.564 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.474 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 53.5 t -117.97 121.61 67.74 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.967 0 CA-C-N 114.557 -1.201 . . . . 0.0 109.678 -174.746 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.435 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 69.0 m-85 -138.74 163.68 31.55 Favored 'General case' 0 N--CA 1.447 -0.604 0 CA-C-O 121.511 0.672 . . . . 0.0 110.389 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.439 HG12 ' H ' ' A' ' 174' ' ' GLY . 55.2 t -100.27 129.05 51.59 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.753 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 177.194 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -74.52 -56.09 5.22 Favored 'General case' 0 CA--C 1.508 -0.656 0 CA-C-O 121.235 0.541 . . . . 0.0 110.821 -175.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . 0.435 ' HB3' ' CE1' ' A' ' 122' ' ' PHE . 15.8 m -87.23 1.49 52.98 Favored 'General case' 0 C--N 1.304 -1.405 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.523 -175.129 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.439 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -101.91 -13.84 30.71 Favored Glycine 0 CA--C 1.496 -1.102 0 C-N-CA 120.639 -0.791 . . . . 0.0 111.852 -179.09 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . . . . . . . . . 3.8 m-85 -105.28 164.13 12.08 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 108.69 -0.856 . . . . 0.0 108.69 178.428 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 55.3 pttt -94.97 109.97 21.93 Favored 'General case' 0 N--CA 1.416 -2.148 0 CA-C-O 121.728 0.775 . . . . 0.0 110.958 -179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 25.6 t -75.74 108.93 8.55 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.124 0 N-CA-C 107.535 -1.283 . . . . 0.0 107.535 178.234 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 38.5 t -110.04 118.35 56.76 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 N-CA-C 108.265 -1.013 . . . . 0.0 108.265 -178.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 60.8 pttt -102.67 114.2 28.24 Favored 'General case' 0 C--N 1.294 -1.847 0 CA-C-O 121.496 0.665 . . . . 0.0 110.844 178.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 53.9 m-85 -95.42 114.41 26.18 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 108.545 -0.909 . . . . 0.0 108.545 176.176 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . . . . . . . . . 2.7 mm? -86.65 178.32 7.08 Favored 'General case' 0 C--N 1.303 -1.431 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 179.447 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -66.02 121.49 15.25 Favored 'General case' 0 C--N 1.318 -0.777 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 179.804 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 2.4 p80 -129.38 98.05 4.75 Favored 'General case' 0 N--CA 1.431 -1.411 0 CA-C-O 121.997 0.903 . . . . 0.0 113.359 -175.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 20.2 m80 -114.96 113.54 24.26 Favored 'General case' 0 C--N 1.295 -1.789 0 N-CA-C 106.782 -1.562 . . . . 0.0 106.782 170.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 28.2 t-80 -82.13 96.79 7.91 Favored 'General case' 0 C--N 1.303 -1.428 0 N-CA-C 109.175 -0.676 . . . . 0.0 109.175 -176.712 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 47.6 t-80 -131.58 -47.62 0.97 Allowed 'General case' 0 C--N 1.297 -1.7 0 CA-C-N 115.351 -0.841 . . . . 0.0 109.9 -177.117 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 45.0 t-80 -109.29 100.83 9.89 Favored 'General case' 0 C--N 1.3 -1.573 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.475 179.34 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 6.8 t60 . . . . . 0 C--N 1.295 -1.773 0 N-CA-C 106.101 -1.815 . . . . 0.0 106.101 174.622 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 59.4 ttp . . . . . 0 CA--C 1.508 -0.642 0 CA-C-O 121.085 0.469 . . . . 0.0 109.775 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 45.1 mt -85.34 128.5 39.04 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 175.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' VAL . . . . . . . . . . . . . 14.9 p -123.8 137.59 56.38 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.615 0 CA-C-O 121.058 0.456 . . . . 0.0 110.332 -179.339 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -103.23 114.69 29.18 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 115.51 -0.768 . . . . 0.0 109.412 179.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 66.1 mttm -105.96 136.58 45.36 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 115.774 -0.648 . . . . 0.0 109.46 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -65.59 145.32 56.22 Favored 'General case' 0 C--N 1.317 -0.809 0 C-N-CA 123.07 0.548 . . . . 0.0 110.437 178.534 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 48.1 t -70.72 -33.94 54.73 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.145 0 C-N-CA 122.962 0.505 . . . . 0.0 112.284 -175.058 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ILE . . . . . . . . . . . . . 28.0 mm -86.23 -48.36 15.89 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 C-N-CA 120.329 -0.548 . . . . 0.0 110.507 -173.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.473 ' HB3' ' HB1' ' A' ' 152' ' ' ALA . 26.8 p -85.38 -42.62 14.37 Favored 'General case' 0 C--N 1.31 -1.128 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.756 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 92.81 0.61 68.73 Favored Glycine 0 N--CA 1.433 -1.519 0 N-CA-C 110.339 -1.104 . . . . 0.0 110.339 -172.096 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -78.22 151.13 33.29 Favored 'General case' 0 CA--C 1.494 -1.206 0 CA-C-O 121.296 0.57 . . . . 0.0 112.017 -178.535 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 40.4 mt-10 -81.12 118.1 22.25 Favored 'General case' 0 C--N 1.3 -1.554 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.05 -176.577 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.432 ' HB ' ' CE2' ' A' ' 170' ' ' TYR . 33.7 m -87.94 -23.47 6.48 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.054 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.338 -177.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 9.8 p -179.39 163.08 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.092 0 N-CA-C 107.481 -1.303 . . . . 0.0 107.481 -179.689 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' SER . . . . . . . . . . . . . 65.5 p -140.77 166.55 24.45 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 176.335 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -59.91 -18.94 48.71 Favored 'General case' 0 N--CA 1.484 1.246 0 C-N-CA 124.469 1.108 . . . . 0.0 112.052 179.238 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' ALA . . . . . . . . . . . . . . . -74.84 -16.74 60.68 Favored 'General case' 0 CA--C 1.538 0.5 0 CA-C-O 121.305 0.574 . . . . 0.0 110.438 178.261 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' LEU . . . . . 0.427 ' HB3' HG22 ' A' ' 75' ' ' VAL . 90.3 mt -100.39 -173.06 2.32 Favored 'General case' 0 N--CA 1.439 -1.011 0 N-CA-C 108.674 -0.861 . . . . 0.0 108.674 177.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' LYS . . . . . . . . . . . . . 3.7 tmtp? -91.19 106.71 18.7 Favored 'General case' 0 C--N 1.313 -1.009 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -175.628 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ILE . . . . . . . . . . . . . 59.4 mt -119.54 126.21 75.11 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-O 121.096 0.475 . . . . 0.0 110.226 179.435 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' THR . . . . . . . . . . . . . 27.6 p -119.15 153.02 52.98 Favored Pre-proline 0 C--N 1.298 -1.671 0 N-CA-C 108.352 -0.981 . . . . 0.0 108.352 174.072 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -77.65 166.84 25.02 Favored 'Trans proline' 0 C--N 1.327 -0.583 0 C-N-CA 121.292 1.328 . . . . 0.0 110.177 175.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . . . . . . . . . 42.5 t -80.92 115.69 23.93 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.977 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 175.279 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' MET . . . . . . . . . . . . . 84.8 mtp -122.55 109.43 14.31 Favored 'General case' 0 N--CA 1.424 -1.766 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.422 179.374 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' GLU . . . . . . . . . . . . . 18.8 mm-40 -123.72 105.0 9.33 Favored 'General case' 0 C--N 1.3 -1.551 0 N-CA-C 107.902 -1.147 . . . . 0.0 107.902 -177.788 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 89.48 25.35 28.36 Favored Glycine 0 C--N 1.309 -0.965 0 C-N-CA 120.683 -0.77 . . . . 0.0 112.726 177.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 92.8 -29.53 7.86 Favored Glycine 0 C--N 1.32 -0.357 0 C-N-CA 121.059 -0.591 . . . . 0.0 113.185 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLU . . . . . . . . . . . . . 13.2 pt-20 -101.98 167.01 10.32 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 179.395 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' GLU . . . . . . . . . . . . . 14.3 pt-20 -87.56 154.16 20.84 Favored 'General case' 0 C--N 1.307 -1.271 0 N-CA-C 109.222 -0.659 . . . . 0.0 109.222 178.334 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' VAL . . . . . . . . . . . . . 61.2 t -101.36 115.49 65.0 Favored Pre-proline 0 C--N 1.281 -2.372 0 N-CA-C 105.121 -2.177 . . . . 0.0 105.121 171.41 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' PRO . . . . . . . . . . . . . 32.7 Cg_endo -61.25 126.79 20.24 Favored 'Trans proline' 0 C--O 1.237 0.463 0 C-N-CA 123.135 2.557 . . . . 0.0 115.35 -170.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' GLY . . . . . . . . . . . . . . . 88.98 15.85 58.71 Favored Glycine 0 N--CA 1.431 -1.671 0 CA-C-N 114.291 -1.322 . . . . 0.0 114.618 174.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' LEU . . . . . 0.462 HD23 ' HA ' ' A' ' 171' ' ' VAL . 75.8 mt -135.88 148.91 48.81 Favored 'General case' 0 C--N 1.312 -1.057 0 CA-C-N 117.315 0.558 . . . . 0.0 111.255 -176.273 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 37.1 p90 -136.9 153.08 50.84 Favored 'General case' 0 N--CA 1.447 -0.585 0 CA-C-O 121.105 0.478 . . . . 0.0 109.989 176.518 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -119.66 145.14 46.74 Favored 'General case' 0 C--N 1.293 -1.884 0 N-CA-C 107.067 -1.457 . . . . 0.0 107.067 -175.874 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' VAL . . . . . 0.464 ' HB ' ' HB2' ' A' ' 168' ' ' PHE . 66.0 t -110.86 114.59 47.54 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.374 0 C-N-CA 119.115 -1.034 . . . . 0.0 110.009 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -88.03 159.92 18.07 Favored 'General case' 0 C--N 1.3 -1.562 0 CA-C-N 114.454 -1.248 . . . . 0.0 107.788 177.889 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' SER . . . . . . . . . . . . . 15.4 m -98.15 141.86 30.56 Favored 'General case' 0 C--N 1.291 -1.972 0 CA-C-O 121.141 0.496 . . . . 0.0 111.143 -172.505 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.435 ' O ' ' HA ' ' A' ' 73' ' ' ASN . . . -141.72 123.16 14.94 Favored 'General case' 0 N--CA 1.427 -1.586 0 N-CA-C 107.181 -1.414 . . . . 0.0 107.181 173.895 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' MET . . . . . . . . . . . . . 59.0 mtt -85.52 136.74 33.29 Favored 'General case' 0 C--N 1.302 -1.459 0 CA-C-O 120.977 0.418 . . . . 0.0 111.354 -178.71 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 28.3 m -123.22 169.31 14.73 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 N-CA-C 108.061 -1.088 . . . . 0.0 108.061 175.458 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -88.19 114.03 24.41 Favored 'General case' 0 C--N 1.306 -1.288 0 CA-C-O 121.247 0.546 . . . . 0.0 109.786 179.088 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . . . . . . . . . 47.4 t -103.47 144.72 13.61 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.644 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 -179.07 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 156.6 -53.05 0.41 Allowed Glycine 0 N--CA 1.432 -1.619 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 178.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.58 -89.21 1.4 Allowed Glycine 0 CA--C 1.495 -1.157 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -157.51 155.73 26.66 Favored Glycine 0 N--CA 1.429 -1.796 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 179.48 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.27 -25.19 29.54 Favored 'General case' 0 C--N 1.31 -1.11 0 CA-C-N 116.784 0.292 . . . . 0.0 110.492 -179.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.2 mt 61.08 51.28 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.9 0 CA-C-O 122.983 1.373 . . . . 0.0 107.934 -178.934 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' ASP . . . . . . . . . . . . . 23.6 t70 70.65 -85.65 0.03 OUTLIER 'General case' 0 CA--C 1.513 -0.468 0 CA-C-N 113.394 -1.73 . . . . 0.0 111.474 -175.651 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ILE . . . . . . . . . . . . . 48.9 mt 38.41 58.31 0.19 Allowed 'Isoleucine or valine' 0 C--O 1.238 0.483 0 C-N-CA 125.344 1.458 . . . . 0.0 111.178 -172.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -81.15 72.53 2.73 Favored Glycine 0 CA--C 1.496 -1.13 0 CA-C-N 114.025 -1.443 . . . . 0.0 110.499 178.772 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' CYS . . . . . . . . . . . . . 80.0 m -110.29 113.62 26.43 Favored 'General case' 0 C--N 1.297 -1.681 0 CA-C-O 120.719 0.295 . . . . 0.0 110.544 -177.231 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -80.96 93.51 1.51 Allowed Glycine 0 N--CA 1.435 -1.377 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 175.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ASN . . . . . . . . . . . . . 33.1 p30 -62.74 152.09 36.68 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 112.894 0.701 . . . . 0.0 112.894 -174.479 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.95 126.84 45.0 Favored 'General case' 0 C--N 1.301 -1.517 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.456 178.603 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PHE . . . . . . . . . . . . . 60.2 m-85 63.94 -74.77 0.04 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 C-N-CA 125.934 1.693 . . . . 0.0 113.836 178.162 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . -173.83 167.31 39.8 Favored Glycine 0 N--CA 1.435 -1.371 0 N-CA-C 109.768 -1.333 . . . . 0.0 109.768 -179.148 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 156.64 -140.11 6.97 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.349 -0.929 . . . . 0.0 112.662 179.09 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' ALA . . . . . . . . . . . . . . . -99.61 106.15 18.08 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-O 121.148 0.499 . . . . 0.0 110.437 -178.625 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . -131.92 25.99 3.86 Favored Glycine 0 N--CA 1.431 -1.688 0 N-CA-C 110.918 -0.873 . . . . 0.0 110.918 178.4 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 67.64 145.1 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.295 0 C-N-CA 125.279 1.432 . . . . 0.0 114.379 -179.329 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ASP . . . . . . . . . . . . . 8.4 m-20 -84.54 -25.41 28.77 Favored 'General case' 0 C--N 1.315 -0.897 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 173.034 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -81.13 99.77 8.7 Favored 'General case' 0 N--CA 1.433 -1.32 0 N-CA-C 107.356 -1.35 . . . . 0.0 107.356 175.006 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLY . . . . . . . . . . . . . . . -149.84 162.99 29.3 Favored Glycine 0 N--CA 1.422 -2.243 0 C-N-CA 119.745 -1.217 . . . . 0.0 112.098 -177.606 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -88.02 24.93 1.68 Allowed 'General case' 0 C--N 1.311 -1.082 0 C-N-CA 123.373 0.669 . . . . 0.0 110.23 179.038 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -57.3 -35.63 70.07 Favored 'General case' 0 N--CA 1.483 1.192 0 C-N-CA 124.84 1.256 . . . . 0.0 111.084 -178.322 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ASP . . . . . . . . . . . . . 6.7 t70 -70.51 -64.53 0.88 Allowed 'General case' 0 N--CA 1.474 0.738 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 173.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ALA . . . . . . . . . . . . . . . 177.58 -51.93 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.778 0 N-CA-C 105.199 -2.148 . . . . 0.0 105.199 179.408 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' THR . . . . . . . . . . . . . 8.5 m -153.64 157.11 39.12 Favored 'General case' 0 N--CA 1.433 -1.276 0 N-CA-C 103.971 -2.603 . . . . 0.0 103.971 174.826 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLN . . . . . . . . . . . . . 62.9 mt-30 -87.62 119.06 27.54 Favored 'General case' 0 C--N 1.311 -1.092 0 CA-C-N 119.221 0.919 . . . . 0.0 109.421 -177.871 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LYS . . . . . . . . . . . . . 84.4 mttt -110.36 121.15 44.61 Favored 'General case' 0 C--N 1.295 -1.791 0 C-N-CA 119.776 -0.77 . . . . 0.0 110.491 173.75 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -150.14 162.21 40.89 Favored 'General case' 0 C--N 1.297 -1.689 0 N-CA-C 105.526 -2.028 . . . . 0.0 105.526 -179.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASN . . . . . 0.488 ' HB2' ' SG ' ' A' ' 165' ' ' CYS . 36.8 t30 -62.43 130.05 43.45 Favored 'General case' 0 C--N 1.31 -1.124 0 C-N-CA 123.056 0.542 . . . . 0.0 111.209 -178.644 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER -58.1 -25.04 60.84 Favored 'General case' 0 N--CA 1.481 1.077 0 N-CA-C 113.542 0.941 . . . . 0.0 113.542 179.231 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' VAL . . . . . 0.427 HG22 ' HB3' ' A' ' 18' ' ' LEU . 38.4 t -78.13 -35.46 20.13 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' SER . . . . . 0.477 ' O ' ' HB2' ' A' ' 81' ' ' PHE . 2.9 p -84.44 -51.45 6.92 Favored 'General case' 0 N--CA 1.424 -1.762 0 CA-C-O 119.192 -0.432 . . . . 0.0 111.241 179.57 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 38.82 87.05 0.01 OUTLIER Glycine 0 C--N 1.352 1.438 0 O-C-N 124.604 1.19 . . . . 0.0 114.687 175.338 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PRO . . . . . . . . . . . . . 71.7 Cg_exo -50.93 -36.15 52.15 Favored 'Trans proline' 0 N--CA 1.494 1.54 0 C-N-CA 123.86 3.04 . . . . 0.0 114.546 -175.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' SER . . . . . . . . . . . . . 10.5 m -84.53 -5.2 59.28 Favored 'General case' 0 CA--C 1.553 1.079 0 N-CA-C 112.006 0.373 . . . . 0.0 112.006 -178.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' SER . . . . . . . . . . . . . 20.4 m -122.86 -67.32 0.96 Allowed 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 112.566 0.58 . . . . 0.0 112.566 -176.379 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' PHE . . . . . 0.477 ' HB2' ' O ' ' A' ' 76' ' ' SER . 99.0 m-85 -91.9 -44.16 9.07 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 117.355 0.07 . . . . 0.0 110.972 -176.807 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . 60.53 99.94 0.03 OUTLIER 'General case' 0 N--CA 1.485 1.309 0 C-N-CA 125.359 1.464 . . . . 0.0 113.624 176.893 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' TYR . . . . . 0.442 ' CD1' ' HA ' ' A' ' 76' ' ' SER . 5.2 m-85 -95.23 111.35 23.2 Favored 'General case' 0 C--N 1.306 -1.317 0 CA-C-O 121.905 0.86 . . . . 0.0 113.053 -176.413 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' THR . . . . . . . . . . . . . 46.5 m -90.68 137.71 32.14 Favored 'General case' 0 C--N 1.308 -1.236 0 CA-C-N 114.121 -1.4 . . . . 0.0 107.918 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ALA . . . . . . . . . . . . . . . -98.24 145.01 27.06 Favored 'General case' 0 C--N 1.316 -0.881 0 N-CA-C 112.073 0.398 . . . . 0.0 112.073 -176.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' MET . . . . . . . . . . . . . 85.1 mtp -138.11 125.85 13.84 Favored Pre-proline 0 C--N 1.323 -0.58 0 C-N-CA 124.169 0.988 . . . . 0.0 108.998 175.225 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -84.77 133.64 5.16 Favored 'Trans proline' 0 N--CA 1.453 -0.907 0 C-N-CA 122.008 1.806 . . . . 0.0 112.942 178.132 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' PHE . . . . . . . . . . . . . 95.8 m-85 -141.28 115.34 9.24 Favored 'General case' 0 C--N 1.312 -1.023 0 N-CA-C 106.822 -1.547 . . . . 0.0 106.822 173.04 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 12.4 p -101.49 -61.55 1.36 Allowed 'General case' 0 C--N 1.302 -1.486 0 CA-C-O 121.056 0.455 . . . . 0.0 111.201 179.449 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 12.8 p -136.13 26.95 3.23 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.425 0.631 . . . . 0.0 110.32 -179.691 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 42.0 mmtt -55.15 125.04 18.91 Favored 'General case' 0 C--O 1.24 0.592 0 CA-C-N 114.539 -1.21 . . . . 0.0 114.158 -178.834 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -68.51 -33.39 76.73 Favored Glycine 0 N--CA 1.441 -0.975 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 176.489 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLU . . . . . . . . . . . . . 44.1 mt-10 -55.47 -44.65 76.63 Favored 'General case' 0 N--CA 1.452 -0.355 0 C-N-CA 123.452 0.701 . . . . 0.0 109.525 173.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' PHE . . . . . 0.468 ' O ' HG23 ' A' ' 98' ' ' VAL . 86.6 t80 -70.06 -39.55 75.58 Favored 'General case' 0 N--CA 1.441 -0.895 0 CA-C-N 115.498 -0.774 . . . . 0.0 111.08 -178.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' LYS . . . . . . . . . . . . . 34.6 mmtp -66.47 -35.37 80.1 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 120.731 0.301 . . . . 0.0 111.192 -179.274 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.0 m -69.92 -36.6 75.48 Favored 'General case' 0 N--CA 1.438 -1.058 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.603 176.26 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' TRP . . . . . 0.48 ' CZ2' ' HB3' ' A' ' 154' ' ' LEU . 89.4 t90 -61.38 -41.62 97.4 Favored 'General case' 0 C--O 1.205 -1.256 0 CA-C-N 115.795 -0.639 . . . . 0.0 109.793 175.312 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' VAL . . . . . 0.468 HG23 ' O ' ' A' ' 94' ' ' PHE . 97.8 t -57.16 -44.82 84.06 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.873 0 C-N-CA 123.118 0.567 . . . . 0.0 110.834 177.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' LYS . . . . . . . . . . . . . 55.0 mtpt -56.96 -56.18 25.01 Favored 'General case' 0 N--CA 1.467 0.387 0 O-C-N 123.683 0.614 . . . . 0.0 109.979 178.658 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -60.55 -40.54 91.92 Favored 'General case' 0 CA--C 1.509 -0.626 0 CA-C-N 115.042 -0.981 . . . . 0.0 112.042 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' TYR . . . . . 0.43 ' O ' HG23 ' A' ' 105' ' ' VAL . 20.4 t80 -63.5 -56.31 17.08 Favored 'General case' 0 N--CA 1.442 -0.855 0 O-C-N 123.454 0.471 . . . . 0.0 110.018 -178.406 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' VAL . . . . . . . . . . . . . 94.5 t -57.51 -41.81 79.66 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 O-C-N 123.561 0.538 . . . . 0.0 111.011 179.596 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 98.6 mtt180 -60.01 -50.68 72.79 Favored 'General case' 0 N--CA 1.468 0.431 0 N-CA-C 111.881 0.326 . . . . 0.0 111.881 178.019 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' ASN . . . . . . . . . . . . . 32.0 m-80 -65.25 -32.99 74.94 Favored 'General case' 0 N--CA 1.477 0.897 0 N-CA-C 111.979 0.363 . . . . 0.0 111.979 179.316 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 101' ' ' TYR . 72.4 t -65.68 -38.67 82.85 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.886 0 N-CA-C 109.912 -0.403 . . . . 0.0 109.912 175.173 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -59.13 -42.7 91.23 Favored 'General case' 0 N--CA 1.477 0.913 0 C-N-CA 122.511 0.324 . . . . 0.0 111.483 176.172 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -68.79 -28.72 67.02 Favored 'General case' 0 CA--C 1.529 0.147 0 CA-C-N 116.575 -0.284 . . . . 0.0 111.248 175.655 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -67.76 -43.61 79.42 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.402 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' LEU . . . . . 0.437 ' HG ' ' CE2' ' A' ' 122' ' ' PHE . 9.5 mp -52.96 -52.32 58.51 Favored 'General case' 0 N--CA 1.471 0.586 0 O-C-N 124.269 0.98 . . . . 0.0 112.756 177.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' LYS . . . . . . . . . . . . . 20.0 pttp -83.41 -21.35 33.03 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.219 0.533 . . . . 0.0 111.759 -177.644 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' GLY . . . . . . . . . . . . . . . -82.74 -1.42 90.56 Favored Glycine 0 C--O 1.226 -0.357 0 CA-C-N 116.044 -0.526 . . . . 0.0 113.026 -177.304 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' SER . . . . . . . . . . . . . 64.3 p -76.27 -17.32 59.52 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 123.11 0.564 . . . . 0.0 111.64 -177.818 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' GLY . . . . . . . . . . . . . . . 78.01 22.22 69.16 Favored Glycine 0 C--N 1.334 0.47 0 N-CA-C 111.669 -0.572 . . . . 0.0 111.669 -178.375 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 54.4 t -80.95 148.51 5.51 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.13 0 C-N-CA 123.257 0.623 . . . . 0.0 110.087 178.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.433 ' O ' HG12 ' A' ' 119' ' ' ILE . . . -62.07 150.5 38.14 Favored 'General case' 0 N--CA 1.467 0.388 0 C-N-CA 123.747 0.819 . . . . 0.0 112.253 -176.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' VAL . . . . . 0.465 ' O ' ' HG2' ' A' ' 120' ' ' LYS . 58.6 t -52.85 -46.02 51.42 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.191 0 C-N-CA 124.39 1.076 . . . . 0.0 113.13 -175.232 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -64.42 -34.34 77.96 Favored 'General case' 0 N--CA 1.475 0.788 0 CA-C-O 121.745 0.783 . . . . 0.0 111.21 179.965 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 54.5 m-20 -76.18 -34.52 59.34 Favored 'General case' 0 C--O 1.209 -1.067 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.068 178.137 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 115' ' ' ALA . 45.6 mm -60.12 -36.51 68.26 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.811 0 C-N-CA 123.05 0.54 . . . . 0.0 110.238 175.457 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' LYS . . . . . 0.465 ' HG2' ' O ' ' A' ' 116' ' ' VAL . 34.9 mmtp -58.88 -48.67 80.57 Favored 'General case' 0 N--CA 1.471 0.619 0 CA-C-O 120.963 0.411 . . . . 0.0 110.042 177.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . . 34.4 mtmm -70.01 -33.85 72.56 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.722 -179.15 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' PHE . . . . . 0.437 ' CE2' ' HG ' ' A' ' 109' ' ' LEU . 0.8 OUTLIER -66.18 -34.21 77.52 Favored 'General case' 0 CA--C 1.551 0.984 0 C-N-CA 124.516 1.126 . . . . 0.0 108.968 179.02 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' MET . . . . . . . . . . . . . 70.7 mtm -80.8 -12.53 59.43 Favored 'General case' 0 C--O 1.208 -1.096 0 CA-C-N 115.79 -0.641 . . . . 0.0 111.852 178.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' GLU . . . . . . . . . . . . . 41.3 mm-40 -74.62 -34.43 62.79 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.416 -0.957 . . . . 0.0 108.416 171.912 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' GLU . . . . . 0.414 ' OE1' ' HA ' ' A' ' 122' ' ' PHE . 38.7 mt-10 -71.39 -34.14 70.13 Favored 'General case' 0 CA--C 1.544 0.724 0 CA-C-N 114.662 -1.154 . . . . 0.0 109.981 178.552 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' ALA . . . . . 0.527 ' HA ' ' CD2' ' A' ' 129' ' ' PHE . . . -51.08 -57.42 13.91 Favored Pre-proline 0 CA--C 1.572 1.798 0 N-CA-C 116.257 1.947 . . . . 0.0 116.257 -175.23 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' PRO . . . . . . . . . . . . . 56.7 Cg_endo -70.37 -23.0 28.5 Favored 'Trans proline' 0 C--N 1.372 1.774 0 CA-C-N 121.04 1.407 . . . . 0.0 111.352 179.16 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' THR . . . . . . . . . . . . . 23.8 m -68.75 -33.72 74.39 Favored 'General case' 0 N--CA 1.429 -1.515 0 CA-C-N 115.45 -0.796 . . . . 0.0 109.48 179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' PHE . . . . . 0.527 ' CD2' ' HA ' ' A' ' 126' ' ' ALA . 13.6 m-85 -60.77 -54.13 48.99 Favored 'General case' 0 C--N 1.358 0.938 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 175.443 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' VAL . . . . . 0.441 ' O ' HG23 ' A' ' 134' ' ' VAL . 48.1 t -56.05 -52.88 45.16 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.218 0 CA-C-N 113.755 -1.566 . . . . 0.0 112.053 -175.282 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -61.37 -41.32 96.89 Favored 'General case' 0 N--CA 1.469 0.501 0 N-CA-C 113.112 0.782 . . . . 0.0 113.112 -178.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' TRP . . . . . 0.52 ' CZ3' HG13 ' A' ' 169' ' ' VAL . 60.9 t90 -69.24 -34.65 75.14 Favored 'General case' 0 C--O 1.246 0.868 0 C-N-CA 121.064 -0.254 . . . . 0.0 111.141 -178.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' LEU . . . . . 0.463 ' HG ' ' O ' ' A' ' 129' ' ' PHE . 95.8 mt -62.7 -38.71 91.52 Favored 'General case' 0 CA--C 1.535 0.387 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 175.21 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' VAL . . . . . 0.441 HG23 ' O ' ' A' ' 130' ' ' VAL . 88.6 t -66.69 -44.11 89.81 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.462 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.697 178.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -60.57 -49.42 77.61 Favored 'General case' 0 N--CA 1.476 0.868 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 179.123 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.577 ' O ' ' HG ' ' A' ' 140' ' ' LEU . 73.9 mmtt -75.95 -15.82 60.11 Favored 'General case' 0 C--N 1.316 -0.864 0 N-CA-C 112.405 0.52 . . . . 0.0 112.405 -177.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' TYR . . . . . . . . . . . . . 77.5 t80 -51.24 -34.55 32.95 Favored 'General case' 0 N--CA 1.485 1.313 0 N-CA-C 114.082 1.142 . . . . 0.0 114.082 -174.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -69.22 -14.58 63.04 Favored 'General case' 0 N--CA 1.472 0.636 0 N-CA-C 112.602 0.593 . . . . 0.0 112.602 -178.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' ASP . . . . . . . . . . . . . 16.7 m-20 -114.44 -6.07 12.88 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.782 178.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' LEU . . . . . 0.577 ' HG ' ' O ' ' A' ' 136' ' ' LYS . 74.6 mt -83.06 129.44 35.03 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 113.714 1.005 . . . . 0.0 113.714 -172.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -114.1 167.92 10.26 Favored 'General case' 0 C--N 1.293 -1.864 0 N-CA-C 104.722 -2.325 . . . . 0.0 104.722 170.531 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' PHE . . . . . . . . . . . . . 88.1 m-85 -125.61 145.73 50.01 Favored 'General case' 0 C--N 1.297 -1.707 0 C-N-CA 118.91 -1.116 . . . . 0.0 112.375 -171.235 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' PHE . . . . . . . . . . . . . 67.8 m-85 -131.66 169.13 16.59 Favored 'General case' 0 C--N 1.303 -1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 111.585 -177.258 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' MET . . . . . . . . . . . . . 61.0 mtp -143.89 142.3 30.73 Favored 'General case' 0 C--N 1.296 -1.748 0 N-CA-C 106.543 -1.651 . . . . 0.0 106.543 176.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' SER . . . . . . . . . . . . . 73.6 p -88.45 172.82 9.08 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 107.461 -1.311 . . . . 0.0 107.461 171.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' LYS . . . . . . . . . . . . . 35.6 ttpt -54.2 -39.17 66.43 Favored 'General case' 0 C--N 1.304 -1.401 0 C-N-CA 124.461 1.104 . . . . 0.0 113.109 -177.611 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 55.0 p -88.87 -3.67 58.68 Favored 'General case' 0 CA--C 1.556 1.183 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -179.111 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' MET . . . . . . . . . . . . . 64.2 mtt -94.74 178.93 5.42 Favored 'General case' 0 N--CA 1.474 0.74 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -174.622 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' ASN . . . . . . . . . . . . . 44.5 m-80 -139.04 160.34 63.04 Favored Pre-proline 0 C--O 1.219 -0.523 0 N-CA-C 108.217 -1.031 . . . . 0.0 108.217 -176.507 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' PRO . . . . . . . . . . . . . 21.4 Cg_endo -65.46 -32.74 48.98 Favored 'Trans proline' 0 CA--C 1.544 1.016 0 C-N-CA 121.826 1.684 . . . . 0.0 112.048 176.434 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -77.67 -38.59 47.31 Favored 'General case' 0 CA--C 1.499 -1.008 0 CA-C-O 121.409 0.623 . . . . 0.0 110.905 178.276 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.473 ' HB1' ' HB3' ' A' ' 9' ' ' SER . . . -126.6 108.28 10.98 Favored 'General case' 0 N--CA 1.424 -1.749 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.594 -172.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 91.15 42.71 4.89 Favored Glycine 0 C--N 1.312 -0.753 0 C-N-CA 120.13 -1.033 . . . . 0.0 113.115 -177.326 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' LEU . . . . . 0.48 ' HB3' ' CZ2' ' A' ' 97' ' ' TRP . 49.5 tp -88.62 114.33 25.13 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 108.058 -1.09 . . . . 0.0 108.058 176.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ILE . . . . . . . . . . . . . 85.1 mt -86.94 130.33 37.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.952 0 CA-C-N 114.807 -1.088 . . . . 0.0 111.809 -172.587 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' PHE . . . . . 0.496 ' HB2' ' HB ' ' A' ' 169' ' ' VAL . 32.4 m-85 -86.65 135.07 33.54 Favored 'General case' 0 C--N 1.313 -1.005 0 N-CA-C 107.125 -1.435 . . . . 0.0 107.125 174.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' SER . . . . . . . . . . . . . 17.9 m -149.7 158.13 43.88 Favored 'General case' 0 C--O 1.212 -0.897 0 O-C-N 121.202 -0.936 . . . . 0.0 111.496 178.457 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' TYR . . . . . 0.4 ' HB3' HD23 ' A' ' 140' ' ' LEU . 9.9 p90 -156.79 178.64 10.12 Favored 'General case' 0 C--O 1.205 -1.252 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 173.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' TYR . . . . . . . . . . . . . 81.4 m-85 -115.66 111.84 21.22 Favored 'General case' 0 C--N 1.301 -1.541 0 CA-C-N 118.572 0.624 . . . . 0.0 109.873 176.774 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' LYS . . . . . . . . . . . . . 22.5 pttp -98.97 164.55 12.14 Favored 'General case' 0 C--O 1.255 1.343 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 175.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 7.8 mm-40 -70.75 141.73 51.45 Favored 'General case' 0 C--N 1.303 -1.448 0 CA-C-O 120.989 0.423 . . . . 0.0 110.669 177.21 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' GLY . . . . . . . . . . . . . . . 99.7 -20.89 47.54 Favored Glycine 0 C--N 1.31 -0.867 0 N-CA-C 111.006 -0.838 . . . . 0.0 111.006 -178.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' ALA . . . . . . . . . . . . . . . -97.11 127.4 43.04 Favored 'General case' 0 N--CA 1.439 -0.984 0 N-CA-C 109.33 -0.618 . . . . 0.0 109.33 -179.316 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' HIS . . . . . . . . . . . . . 17.4 m-70 -87.58 -15.74 36.55 Favored 'General case' 0 C--N 1.312 -1.062 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.094 -179.813 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' CYS . . . . . 0.488 ' SG ' ' HB2' ' A' ' 73' ' ' ASN . 57.7 m -128.1 178.61 1.55 Allowed Pre-proline 0 C--N 1.299 -1.627 0 N-CA-C 107.59 -1.263 . . . . 0.0 107.59 -177.239 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -59.12 131.57 42.14 Favored 'Trans proline' 0 C--N 1.371 1.758 0 C-N-CA 121.636 1.557 . . . . 0.0 112.473 176.918 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' THR . . . . . . . . . . . . . 24.5 m -86.18 113.91 22.59 Favored 'General case' 0 N--CA 1.422 -1.873 0 N-CA-C 106.359 -1.719 . . . . 0.0 106.359 176.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' PHE . . . . . 0.464 ' HB2' ' HB ' ' A' ' 36' ' ' VAL . 49.8 m-85 -86.64 140.01 30.24 Favored 'General case' 0 C--N 1.305 -1.33 0 CA-C-O 121.303 0.573 . . . . 0.0 110.528 -174.203 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' VAL . . . . . 0.52 HG13 ' CZ3' ' A' ' 132' ' ' TRP . 42.6 t -114.03 119.06 60.18 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.243 -175.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.432 ' CE2' ' HB ' ' A' ' 13' ' ' VAL . 57.2 m-85 -138.8 156.74 47.09 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-O 121.481 0.658 . . . . 0.0 110.229 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' VAL . . . . . 0.529 HG12 ' H ' ' A' ' 174' ' ' GLY . 56.8 t -91.26 128.34 43.09 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.855 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 176.824 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' LYS . . . . . . . . . . . . . 24.9 ttpp -75.82 -58.16 3.44 Favored 'General case' 0 C--O 1.216 -0.658 0 CA-C-O 121.152 0.501 . . . . 0.0 111.908 -175.412 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' SER . . . . . . . . . . . . . 13.2 m -84.59 -14.87 47.52 Favored 'General case' 0 C--N 1.305 -1.335 0 CA-C-N 115.666 -0.697 . . . . 0.0 112.126 -171.333 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.529 ' H ' HG12 ' A' ' 171' ' ' VAL . . . -85.93 -12.82 70.59 Favored Glycine 0 C--O 1.21 -1.348 0 C-N-CA 120.919 -0.658 . . . . 0.0 112.809 -176.387 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' TYR . . . . . 0.503 ' CE2' ' HB ' ' A' ' 171' ' ' VAL . 4.1 m-30 -97.52 172.46 7.72 Favored 'General case' 0 CA--C 1.501 -0.923 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -177.805 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' LYS . . . . . . . . . . . . . 75.3 mmtt -85.24 99.66 11.26 Favored 'General case' 0 N--CA 1.427 -1.608 0 CA-C-O 121.792 0.806 . . . . 0.0 108.943 178.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' VAL . . . . . . . . . . . . . 21.3 t -86.57 116.85 29.92 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.935 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 -179.169 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' VAL . . . . . . . . . . . . . 12.4 t -124.84 136.26 61.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' LYS . . . . . . . . . . . . . 62.0 mttp -107.37 118.24 36.2 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 110.024 -0.361 . . . . 0.0 110.024 -178.445 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' PHE . . . . . . . . . . . . . 78.1 m-85 -115.75 161.47 18.68 Favored 'General case' 0 C--N 1.306 -1.312 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.401 177.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' LEU . . . . . 0.479 HD12 ' O ' ' A' ' 181' ' ' LEU . 3.9 pp -110.5 114.17 27.37 Favored 'General case' 0 C--N 1.299 -1.588 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 174.454 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -90.45 119.26 30.58 Favored 'General case' 0 C--N 1.301 -1.541 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 -177.708 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' HIS . . . . . . . . . . . . . 3.8 t60 -127.63 11.59 6.77 Favored 'General case' 0 C--N 1.305 -1.348 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.588 -174.664 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' HIS . . . . . . . . . . . . . 77.9 m80 -88.34 104.65 16.96 Favored 'General case' 0 C--N 1.321 -0.671 0 O-C-N 121.865 -0.522 . . . . 0.0 110.144 -178.652 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' HIS . . . . . . . . . . . . . 61.5 m-70 59.22 77.52 0.3 Allowed 'General case' 0 N--CA 1.487 1.382 0 C-N-CA 124.392 1.077 . . . . 0.0 112.867 -179.702 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' HIS . . . . . . . . . . . . . 98.5 m-70 -148.71 117.06 6.49 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 176.771 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' HIS . . . . . . . . . . . . . 56.7 t-80 -77.08 94.59 4.06 Favored 'General case' 0 C--N 1.306 -1.285 0 N-CA-C 109.522 -0.547 . . . . 0.0 109.522 178.692 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' HIS . . . . . . . . . . . . . 52.4 t-80 . . . . . 0 N--CA 1.422 -1.858 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.642 . . . . . . . . 0 0 . 1 stop_ save_